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A B S T R A C T
Background
Despite evidence supporting the effectiveness of diabetic retinopathy screening (DRS) in reducing the risk of sight loss, attendance for
screening is consistently below recommended levels.
Objectives
The primary objective of the review was to assess the effectiveness of quality improvement (QI) interventions that seek to increase
attendance for DRS in people with type 1 and type 2 diabetes.
Secondary objectives were:
To use validated taxonomies of QI intervention strategies and behaviour change techniques (BCTs) to code the description of interven-
tions in the included studies and determine whether interventions that include particular QI strategies or component BCTs are more
effective in increasing screening attendance;
To explore heterogeneity in effect size within and between studies to identify potential explanatory factors for variability in effect size;
To explore differential effects in subgroups to provide information on how equity of screening attendance could be improved;
To critically appraise and summarise current evidence on the resource use, costs and cost effectiveness.
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Search methods
We searched the Cochrane Library, MEDLINE, Embase, PsycINFO, Web of Science, ProQuest Family Health, OpenGrey, the
ISRCTN, ClinicalTrials.gov, and the WHO ICTRP to identify randomised controlled trials (RCTs) that were designed to improve
attendance for DRS or were evaluating general quality improvement (QI) strategies for diabetes care and reported the effect of the
intervention on DRS attendance. We searched the resources on 13 February 2017. We did not use any date or language restrictions in
the searches.
Selection criteria
We included RCTs that compared any QI intervention to usual care or a more intensive (stepped) intervention versus a less intensive
intervention.
Data collection and analysis
We coded the QI strategy using a modification of the taxonomy developed by Cochrane Effective Practice and Organisation of Care
(EPOC) and BCTs using the BCT Taxonomy version 1 (BCTTv1). We used Place of residence, Race/ethnicity/culture/language,
Occupation, Gender/sex, Religion, Education, Socioeconomic status, and Social capital (PROGRESS) elements to describe the char-
acteristics of participants in the included studies that could have an impact on equity of access to health services.
Two review authors independently extracted data. One review author entered the data into Review Manager 5 and a second review
author checked them. Two review authors independently assessed risks of bias in the included studies and extracted data. We rated
certainty of evidence using GRADE.
Main results
We included 66 RCTs conducted predominantly (62%) in the USA. Overall we judged the trials to be at low or unclear risk of bias. QI
strategies were multifaceted and targeted patients, healthcare professionals or healthcare systems. Fifty-six studies (329,164 participants)
compared intervention versus usual care (median duration of follow-up 12 months). Overall, DRS attendance increased by 12% (risk
difference (RD) 0.12, 95% confidence interval (CI) 0.10 to 0.14; low-certainty evidence) compared with usual care, with substantial
heterogeneity in effect size. Both DRS-targeted (RD 0.17, 95% CI 0.11 to 0.22) and general QI interventions (RD 0.12, 95% CI 0.09
to 0.15) were effective, particularly where baseline DRS attendance was low. All BCT combinations were associated with significant
improvements, particularly in those with poor attendance. We found higher effect estimates in subgroup analyses for the BCTs ‘goal
setting (outcome)’ (RD 0.26, 95% CI 0.16 to 0.36) and ‘feedback on outcomes of behaviour’ (RD 0.22, 95% CI 0.15 to 0.29) in
interventions targeting patients, and ‘restructuring the social environment’ (RD 0.19, 95% CI 0.12 to 0.26) and ‘credible source’ (RD
0.16, 95% CI 0.08 to 0.24) in interventions targeting healthcare professionals.
Ten studies (23,715 participants) compared a more intensive (stepped) intervention versus a less intensive intervention. In these studies
DRS attendance increased by 5% (RD 0.05, 95% CI 0.02 to 0.09; moderate-certainty evidence).
Fourteen studies reporting any QI intervention compared to usual care included economic outcomes. However, only five of these
were full economic evaluations. Overall, we found that there is insufficient evidence to draw robust conclusions about the relative cost
effectiveness of the interventions compared to each other or against usual care.
With the exception of gender and ethnicity, the characteristics of participants were poorly described in terms of PROGRESS elements.
Seventeen studies (25.8%) were conducted in disadvantaged populations. No studies were carried out in low- or middle-income
countries.
Authors’ conclusions
The results of this review provide evidence that QI interventions targeting patients, healthcare professionals or the healthcare system are
associated with meaningful improvements in DRS attendance compared to usual care. There was no statistically significant difference
between interventions specifically aimed at DRS and those which were part of a general QI strategy for improving diabetes care. This
is a significant finding, due to the additional benefits of general QI interventions in terms of improving glycaemic control, vascular
risk management and screening for other microvascular complications. It is likely that further (but smaller) improvements in DRS
attendance can also be achieved by increasing the intensity of a particular QI component or adding further components.
P L A I N L A N G U A G E S U M M A R Y
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Interventions to increase attendance for diabetic retinopathy screening
What is the aim of this review?
The aim of this review was to find out if interventions used to improve attendance for diabetic retinopathy screening are effective.
Key messages
The results of this review found evidence that interventions that target patients, healthcare professionals or the healthcare system
are likely to be effective for improving attendance for diabetic retinopathy screening compared to usual care. We found benefits for
interventions that were specifically aimed at diabetic retinopathy screening, as well as those which were part of a general strategy to
improve diabetes care. This is important, since more general strategies are associated with additional benefits, such as improving blood
glucose control and increasing the detection of other diabetes-related complications.
What was studied in the review?
People with diabetes may lose vision as a result of the damaging effects of the disease on small blood vessels at the back of the eye
(diabetic retinopathy). Screening for diabetic retinopathy to detect and treat early signs can prevent sight loss. However, screening
attendance is variable and sight-threatening changes may not be detected in good time.
This review looked at a variety of interventions to improve diabetic retinopathy screening.
What are the main results of the review?
The Cochrane review authors found 66 relevant studies. Forty-one studies were from the USA, 14 from Europe, three from Canada,
three from Australia and five from elsewhere. Fifty-six studies compared the intervention to improve screening attendance with usual
care and 10 compared a more intensive to a less intensive intervention.
We found that interventions aimed at patients or healthcare professionals or both, or at the healthcare systemwere effective at improving
screening attendance. Interventions aimed at improving the general quality of diabetes care worked as well as those specifically aimed
at improving screening for retinopathy. On average, attendance increased by 12% compared with no intervention.
How up-to-date is this review?
The Cochrane review authors searched for studies that had been published up to 13 February 2017.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Any quality improvement intervention compared to usual care for diabetic retinopathy screening
Patient or population: pat ients with type 1 or 2 diabetes eligible for diabet ic ret inopathy screening
Setting: primary, secondary or tert iary
Intervention: any quality improvement intervent ion
Comparison: usual care
Outcomes Illustrative comparative risks Risk Difference
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
(95% CI)
Attendance with usual
care
Attendance with any QI
Intervention
Proport ion of part ici-
pants attending screen-
ing
(median follow-up 12
months post-interven-
t ion)
472 per 1000 580 per 1000
(557 to 604)
RD 12%
(95%CI 10% to 14%)
329,164
(56 RCTs)
⊕⊕©©
LOW1
There was substan-
t ial unexplained hetero-
geneity between stud-
ies (I2 = 93%, P < 0.001)
. The ef fect appears to
be larger when baseline
performance is low
Ongoing adherence to
screening
- - - - - Not reported
Economic Outcomes
Resources used (staf f
t ime, equipment, con-
sumables)
Wide variat ion in resources used for each study,
hence dif f icult to collate the resource used as a
single output
- 85 - 20,000 (13 RCTs) ⊕⊕©©
LOW2
-
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Staf f / personnel costs;
costs of treatment and
care; cost of primary
care; lost wages and
lost product ivity
Wide variat ion in resources used f rom dif ferent
intervent ions also made it dif f icult to derive av-
erage costs compared with usual care
- 85 - 20,000
(10 RCTs)
Incremental Cost ef -
fect iveness of interven-
t ions
GBP 13,154 for promotion of self -management;
GBP 73,683 for 5 years for face-to-face meeting,
GBP 18.77 for phone call
- 85 - 603
(3 RCTs)
CI: Conf idence interval; RD: Risk dif ference
GRADE Working Group grades of evidence
High-quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate-quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low-quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low-quality: We are very uncertain about the est imate.
1We downgraded the certainty of the evidence by two levels f rom high to low for inconsistency, due to wide variat ion in the
ef fect est imates across studies that could not be explained.
2We downgraded the certainty of the evidence for the economic outcomes by two levels f rom high to low due to inconsistency
across dif ferent elements of the economic outcomes (see Table 7).
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B A C K G R O U N D
Description of the condition
Diabetic retinopathy is the most common microvascular com-
plication of diabetes mellitus and a leading cause of blindness
amongst the working-age adult population in the Western world
(Sivaprasad 2012). The duration of diabetes is the strongest pre-
dictor for the development and progression of retinopathy.Within
20 years of diagnosis, nearly all patients with type 1 diabetes and
more than 60% of patients with type 2 have retinopathy (Fong
2004). A higher prevalence of diabetic retinopathy is found in
people of South Asian, African and Latin American descent, com-
pared to white populations (Sivaprasad 2012). Further risk factors
for the development and progression of diabetic retinopathy in-
clude: poor glycaemic control, hypertension and hyperlipidaemia
(Yau 2012). It has been estimated that globally approximately 93
million individuals may have some form of diabetic retinopathy,
with 28 million suffering from the sight-threatening end points of
the disease (Yau 2012). There is limited evidence on the economic
burden of diabetic retinopathy. One recent estimate for healthcare
costs in Sweden was EUR 106,000 per 100,000 population a year,
based upon a prevalence of diabetes of 4.8% (95% confidence in-
terval 4.7 to 4.9) (Heintz 2010). These costs exclude cost impacts
on those with diabetic retinopathy and their families.
Although effective treatments are available for sight-threatening
diabetic retinopathy in the form of laser photocoagulation (Evans
2014) and more recently the use of anti-vascular endothelial
growth factor inhibitors (Virgili 2014), the success of these inter-
ventions is dependent on early detection and timely referral for
treatment. Diabetic retinopathy screening (DRS) fulfils theWorld
Health Organization (WHO) criteria for a screening programme
(Scanlon 2008): namely, diabetes-associated visual impairment is
an important public health problem; potentially sight-threatening
retinopathy has a recognisable latent stage; a universally accepted
and effective treatment is available; and screening has been shown
to be cost-effective in terms of sight years preserved compared
with no screening (Jones 2010). Annual or biennial DRS is recom-
mended in many countries using a variety of screening modalities,
including: ophthalmoscopy performed by a number of healthcare
professionals (including ophthalmologists, optometrists, diabetic
physicians) or using standard retinal photography or digital fundus
imaging (American Diabetes Association 2015; Kristinsson 1995;
Scanlon 2008). Recently, mathematical algorithms have been de-
veloped that provide individualised risk assessment for diabetic
retinopathy and optimisation of screening intervals based on type
and duration of diabetes, HbA1c, systolic blood pressure, gender
and the presence and grade of retinopathy (Lund 2016).
Relatively few countries have introduced a national population-
based DRS programme, and in most parts of the world screening
remains non-systematic.
The reference standard for the detection of diabetic retinopathy
consists of seven standard 35-degree colour photographic fields
as described by the Early Treatment Diabetic Retinopathy Study
(EDTRS) research group (EDTRS 1991).However this technique
is impractical for widespread retinopathy screening. Although
ophthalmoscopy through dilated pupils has traditionally been
the method of choice for opportunistic screening, the procedure
varies in diagnostic accuracy depending on the particular tech-
nique used (direct or indirect ophthalmoscopy) or the experience
of the healthcare professional performing the test (Hutchinson
2000). Recent developments in digital retinal photography have
facilitated the rapid acquisition of high-quality fundus images that
can be stored and subsequently graded. Digital imaging combined
with trained graders has been shown to be an effective screening
tool to identify sight-threatening retinopathy (Williams 2004),
and is increasingly gaining acceptance for population screening
(Kirkizlar 2013; Sharp 2003; Silva 2009; Taylor 2007).
Despite evidence supporting the effectiveness of DRS in reducing
the risk of sight loss, screening coverage is consistently below rec-
ommended levels (Millett 2006; Paz 2006; Saadine 2008). The
high rates of non-attendance have major financial consequences.
For example, the North and East Devon Diabetic Retinal Screen-
ing Service in the UK invited 22,651 people to participate in reti-
nal screening between April 2009 and March 2010. Of those in-
vited, 2137 (9.4%) failed to attend for their appointment after
three reminders. With each appointment costing GBP 34 in 2009
and GBP 37 in 2010, the total cost of non-attendance was GBP
78,259 (2009/2010GBP) (Waqar 2012). Several factors have been
shown to affect access and attendance for DRS, including eth-
nicity, younger age (less than 40 years), a longer duration of dia-
betes, and living in areas of high social deprivation (Byun 2013;
Gulliford 2010; Hwang 2015; Kliner 2012).
Description of the intervention
Several interventions specifically aimed at improvingDRS, includ-
ing those targeting patients, health professionals or the healthcare
system, have been shown to be effective in improving attendance
across a range of retinopathy screening models (Zhang 2007). Ex-
amples of patient-focused interventions include: (1) educational
programmes to increase awareness of diabetic retinopathy and pro-
mote self-management, and (2) the use of prompts/reminders.
Provider-focused interventions include: (1) clinician education,
and (2) audit and performance feedback. System interventions
include: (1) team changes; (2) establishing electronic registration
and recall, and (3) the use of telemedicine.
In addition to strategies that specifically target DRS, general qual-
ity improvement (QI) implementation strategies for diabetes care
may also be effective in improving screening coverage. A recent
systematic review and meta-analysis of trials assessing a number
of predefined QI strategies to improve diabetes care reported that
these were associated with a significant increase in DRS compared
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to usual care (risk ratio 1.22, 95% confidence interval 1.13 to
1.32) (Tricco 2012). However, this review did not include studies
where interventions were solely targeted at patients, and the au-
thors were unable to distinguish the effectiveness of individual QI
components or identify potential effect modifiers. Furthermore,
the review did not include an economic perspective.
How the intervention might work
Most studies assessing the effectiveness of interventions to im-
prove diabetes care (including those delivered specifically to im-
prove DRS) often involve multicomponent interventions that at-
tempt to change the behaviour of healthcare professionals (e.g. ad-
vising patients to attendDRS) or patients (e.g. actually attending),
or both. As there is no consistent association between the num-
ber of intervention components and their effectiveness (Grimshaw
2004), the ‘ideal’ number of components in such programmes
is unknown. Furthermore, given the complexity of interventions
tested to date, it is not always clear which specific components are
the effective elements of these interventions (i.e. the ’active ingre-
dients’). Hence, the content of complex behaviour change inter-
ventions has been referred to as a ’black box’ (Grimshaw 2014).
There is evidence that the more clearly the ’active’ components
of a complex intervention are described, the more readily the in-
tervention may be delivered in an effective, consistent and cost-
effective manner (Michie 2009). Therefore, identification of the
effective interventions for increasing attendance for DRS first re-
quires clarity about intervention content and the functional rela-
tionship between components of interventions and the intended
outcome. Cochrane Effective Practice and Organisation of Care
(EPOC) have developed a taxonomy that can be used to clas-
sify intervention content in systematic reviews (EPOC 2015). Al-
though the EPOC taxonomy provides a common language and
a useful summary description of the intervention, the taxonomy
may not be sufficiently detailed to specify the components of the
intervention clearly (Presseau 2015). A complementary approach
is to provide a comprehensive categorisation of the ingredients
of the intervention in terms of the behaviour change techniques
(BCTs) used. BCTs are defined as the ‘observable, replicable and ir-
reducible components of an intervention that are designed to alter
or redirect causal processes regulating behaviour’ (Michie 2013).
Recently, a reliable taxonomy of 93 BCTs has been published (co-
developed by team member JF) to provide a common, consistent
terminology (BCTTaxonomy version 1 (BCTTv1)), by which the
component BCTs in complex interventions may be identified and
described. Examples of BCT labels in this taxonomy include: ‘goal
setting,’ ‘self monitoring,’ ‘providing feedback on behaviour’ and
‘problem solving’. Review team members (JP, NI and JG) have
successfully demonstrated the feasibility of using the BCT taxon-
omy within trials of QI interventions for diabetes care (Presseau
2015).
Why it is important to do this review
Given the value of screening for reducing the risk of sight loss
amongst people with diabetes, it is essential that attendance for
DRS is maximised as far as available resources allow. Wide ge-
ographical variation in screening coverage has been reported,
with associated inequalities in outcomes. Given the incremental
costs (resource use) and benefits (effects) associated with interven-
tions to improve attendance for DRS, it is important to consider
whether such strategies are worthwhile.
By identifying the active components of interventions that in-
crease attendance for screening, this review will contribute to the
identification of implementation strategies for early detection of
sight-threatening retinopathy. Furthermore, by exploring the dif-
ferential effects of interventions in particular subgroups the results
may provide clues to help to reduce inequalities in screening at-
tendance and determine the impact of inequity on intervention
effectiveness and efficiency. Although there have been a number
of systematic reviews on interventions to optimise adult screening
programmes (Everett 2011; Holden 2010), it is likely that this ev-
idence is not directly transferable to DRS. Screening for diabetic
retinopathy differs from other forms of screening in that the target
group already has significant contact with the healthcare system
due to their underlying diabetes, and screening has to be life-long
(i.e. annual or biennial surveillance is necessary).
O B J E C T I V E S
The primary objective of the review was to assess the effectiveness
of QI interventions that seek to increase attendance for DRS in
people with type 1 and type 2 diabetes.
Secondary objectives:
• To use validated taxonomies of QI intervention strategies
and behaviour change techniques (BCTs) to code the description
of interventions in the included studies and determine whether
interventions that include particular QI strategies or component
BCTs are more effective in increasing screening attendance;
• To explore heterogeneity in effect size within and between
studies to identify potential explanatory factors for variability in
effect size;
• To explore differential effects in subgroups to provide
information on how equity of screening attendance could be
improved;
• To critically appraise and summarise current evidence on
the resource use, costs and cost effectiveness.
M E T H O D S
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Criteria for considering studies for this review
Types of studies
We considered randomised controlled trials (RCTs), both indi-
vidually randomised and cluster-RCTs, conducted in a primary
or secondary care setting, that were either specifically designed to
improve attendance for DRS or were evaluating general strate-
gies to improve diabetes care. Most commonly, the latter group
of studies referred to ’quality improvement targets’ or ’diabetes
processes of care measures’ as primary or secondary outcomes. We
only included these studies if they reported on the effect of the
intervention on DRS attendance.
To investigate cost effectiveness we included full economic eval-
uations (cost-effectiveness analyses, cost-utility analyses and cost-
benefit analyses), cost analyses and comparative resource-utilisa-
tion studies conducted alongside or as part of an included RCT.
Types of participants
We included people with type 1 and type 2 diabetes mellitus who
were eligible for DRS.
Types of interventions
We included RCTs that used any planned strategy or combina-
tion of strategies to improve attendance for diabetic DRS targeted
at individuals with diabetes (e.g. reminders, promotion of self-
management), healthcare professionals (e.g. education, audit and
feedback) or the healthcare system (e.g. electronic registries, team
changes). Interventions included those specifically targeting DRS,
as well as those that were part of a general strategy to improve pro-
cesses of diabetes care. Comparator interventions were as specified
in the included studies.
Types of outcome measures
Primary outcomes
The primary outcome was the difference in DRS attendance (one
or more visits) within a two-year period following implementation
of the intervention. This could be based on self-reports, medical
insurance claims databases or health-record audits (hospital, pri-
mary care physician or screening administration system record).
Secondary outcomes
We considered the following secondary outcomes:
• Ongoing adherence to screening based on attendance for
screening following the initial screening post-intervention.
• Economic outcomes:
i) Resources (staff time, equipment, consumables)
required to deliver interventions to increase attendance for
screening
ii) Costs of staff used to provide interventions; costs of
treatment and care; cost of primary care; lost wages and lost
productivity (work output)
iii) Cost effectiveness (incremental cost-effectiveness
ratios (ICERs); incremental cost per quality-adjusted life year
(QALY); incremental cost per disability-adjusted life year
(DALY); incremental cost-benefit ratios; net benefits).
Search methods for identification of studies
Electronic searches
The Cochrane Eyes and Vision Information Specialist conducted
systematic searches in the following databases for RCTs and con-
trolled clinical trials. There were no language or publication year
restrictions. The date of the search was 13 February 2017.
• Cochrane Central Register of Controlled Trials
(CENTRAL; 2017, Issue 2) (which contains the Cochrane Eyes
and Vision Trials Register) in the Cochrane Library (searched 13
February 2017) (Appendix 1);
• MEDLINE Ovid (1946 to 13 February 2017) (Appendix
2);
• Embase Ovid (1980 to 13 February 2017) (Appendix 3);
• PsycINFO (1967 to 13 February 2017) (Appendix 4);
• Web of Science Conference Proceedings Citation Index-
Science (CPCI-S) and Emerging Sources Citation Index (ESCI)
(1990 to 13 February 2017) (Appendix 5);
• ProQuest Family Health (1990 to 13 February 2017)
(Appendix 6);
• OpenGrey (1980 to 13 February 2017) (Appendix 7);
• ISRCTN registry (www.isrctn.com/editAdvancedSearch;
searched 13 February 2017) (Appendix 8);
• US National Institutes of Health Ongoing Trials Register
ClinicalTrials.gov (www.clinicaltrials.gov; searched 13 February
2017) (Appendix 9);
• World Health Organization International Clinical Trials
Registry Platform (www.who.int/ictrp; searched 13 February
2017) (Appendix 10).
Searching other resources
We searched the reference lists of included studies to identify ad-
ditional relevant studies. In particular, we used the reference list
of included and excluded studies of a 2012 systematic review by
members of the current review team (NI and JG) (Tricco 2012),
which investigated the effectiveness of QI strategies on the man-
agement of diabetes. Tricco 2012 identified studies which have
multiple interventions to improve the quality of care in diabetes.
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Some of the studies in this review included attendance for DRS as
one of the outcomes being assessed. However, since the informa-
tion on screening for diabetic retinopathy was not reported in the
abstract or coded in the MeSH or thesaurus headings, the elec-
tronic search strategy used in the current review did not identify
a number of these studies. In addition to searching the reference
list of Tricco 2012, we also obtained additional studies reporting
retinopathy outcomes from the review team currently updating
that review. The protocol for the updated review has been repub-
lished (Ivers 2014), as whilst the scope of the review remains the
same, the update proposes an exploration of heterogeneity using
an innovative meta-analytical approach.
We also contacted experts in the field to request information on
any ongoing or unpublished studies that would be relevant for this
review.
Data collection and analysis
Selection of studies
Two review authors (JGL and JB) independently screened the titles
and abstracts of studies identified by the electronic searches. We
obtained full-text copies of possibly relevant studies, resolving any
differences of opinion regarding inclusion/exclusion by discussion.
We documented reasons for exclusion at this stage.
Data extraction and management
Two review authors (JGL and EGR), working independently, ex-
tracted data from the included studies using a modified version
of the Cochrane Effective and Organisation of Care (EPOC) data
collection form (EPOC 2017), which incorporates information
on study design, type and duration of interventions, participants,
setting, methods, outcomes, and results. We translated studies in
languages other than English and similarly extracted data in du-
plicate. Where numerical data were presented only in figures and
not available from authors, two review authors performed data
extraction by using Plot Digitizer open-source software.
For the extraction of data on the sociodemographic characteristics
of participants that are known to be important from an equity per-
spective, we used the Place, Race, Occupation, Gender, Religion,
Education, Socioeconomic status, Social status (PROGRESS)
framework (O’Neill 2014), and also recorded whether any inter-
ventions were aimed at disadvantaged or low- and middle-income
country populations, using the World Bank Atlas method.
An economics review author (PA) identified and further assessed
studies judged potentially to include economic data. Data from
included economic evaluations were extracted by one review au-
thor (PA) and checked by a second. We adapted data collection
from the format and guidelines used to produce the structured
abstracts of full economic evaluations for inclusion in the NHS
Economic Evaluation Database, and redesigned them to accom-
modate the specific data required for our review (CDC 2012). We
classified economic evaluations based on their analytical frame-
work and coded them appropriately.
Coding of intervention content
We coded extracted intervention descriptions from all of the in-
cluded studies using a validated taxonomy to characterise the con-
stituent components of each intervention. Cochrane EPOC has
developed a comprehensive taxonomy to classify intervention con-
tent in systematic reviews (EPOC 2015). We used a subset of
the EPOC taxonomy that has been previously used by members
of the review team in a review of the effectiveness of general QI
implementation strategies for diabetes care (Tricco 2012). This
adapted taxonomy incorporates 12 components targeting health-
care systems (case-management, team changes, electronic patient
registry, facilitated relay of information to clinicians, continuous
quality improvement), clinicians (audit and feedback, clinician ed-
ucation, clinician reminders, financial incentives) or patients (pa-
tient education, promotion of self-management and reminder sys-
tems). Two review authors (JGL and EGR) independently coded
QI components as ’present’ or ’absent’ for both intervention and
control arms, resolving discrepancies in coding by discussion.
Tobetter characterise the detail of the intervention content, we also
coded extracted intervention descriptions into component BCTs
using the BCT taxonomy (Michie 2013), as a coding framework.
Describing an intervention in terms of BCTs (i.e. ’active ingredi-
ents’) provides a useful level of detail for synthesis and comparison
(Presseau 2015). We coded BCTs for each intended recipient as
’present’ or ’absent’ separately for patient and healthcare profes-
sional recipients. We coded each intervention separately, includ-
ing control arms. We coded system-level interventions as target-
ing either healthcare provider or patient behaviour, or both, un-
less an alternative intervention recipient and their behaviour was
reported (e.g. administrative staff sending reminder letters) (see
Table 1).There is substantial evidence that the content of com-
plex behaviour change interventions is often poorly described in
published reports, rendering it more difficult to clearly specify the
content of interventions on this basis alone and increasing the risk
of misclassification (Lorencatto 2013). We therefore contacted all
authors of included studies to ask for further information on the
content of the intervention (e.g. a trial protocol, letters sent to
patients, written or audio-visual materials) to clarify the BCT cod-
ing. We coded these materials using the BCT taxonomy in the
same manner as for the corresponding published reports.Two re-
view authors (EGR and FL) independently conducted BCT cod-
ing, resolving discrepancies by discussion and if necessary by the
involvement of a third review author (JF).
Coding of resource requirement needed to deliver
interventions
9Interventions to increase attendance for diabetic retinopathy screening (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
We developed an ordered ranking scale to quantify the level of
resource needed to deliver each intervention, based on the descrip-
tion of the intervention components in each included study. To
determine the feasibility of this approach, we initially piloted the
scale on a sample of 10 included studies, using two members of
the review team. We graded each intervention initially between
one (least resource-intensive) and five (most resource-intensive),
or zero (unable to determine), together with a record as to how
the review author graded each study.
We incorporated the following resource components into the al-
gorithm:
• Face-to-face minutes
• Phone calls
• Patient home visits
• Printed materials/software
• Training
The resource categories and levels with their corresponding
weights were as follows:
Face-to-face or
care planning minutes/
patient/6 months
Phone calls to patients Additional outreach
visits to patients (travel
time)
Use of materials/ let-
ters/software
Training of health pro-
fessionals other than
reading material
None (0) No (0) No (0) None (0) None (0)
Low 1 - 40 mins (1) Yes (1) Yes (2) Printed materials (1) Low (1)
Moderate 40 - 100 (2) - - Software (2) High (2)
High > 100 (3) - - - -
We defined a priori a criterion of success of the ranking scale as
review author scores from nine out of 10 studies being within
one grade of each other, following discussion. This criterion was
achieved and we used the notes about how we graded each study
to generate a reproducible description of the resource input as-
sociated with each grade on the ranking scale. We then used the
resource components and their intensity levels to extract resource
use required to deliver the interventions in all included studies.
Two review authors (JGL and EGR) did this independently.
Assessment of risk of bias in included studies
Two review authors (JGL and EGR) independently assessed study
quality using the Cochrane EPOC ’Risk of bias’ tool (EPOC
2012). We based the choice of the EPOC ’Risk of bias’ tool on
the expectation that the included studies would be similar to those
included in EPOC reviews, e.g. a large number of cluster trials,
complex interventions and routine data used to assess outcomes.
The EPOC criteria for assessing risk of bias uses nine standard
criteria:
• Was the allocation sequence adequately generated?
• Was the allocation adequately concealed?
• Were baseline outcome measurements similar?
• Were baseline characteristics similar?
• Were incomplete outcome data adequately addressed?
• Was knowledge of the allocated interventions adequately
prevented during the study?
• Was the study adequately protected against contamination?
• Was the study free from selective outcome reporting?
• Was the study free from other risks of bias?
For cluster-RCTs, we considered particular biases, including: (i)
recruitment bias; (ii) baseline imbalance; (iii) loss of clusters, and
(iv) incorrect analysis; as described in Chapter 16 of the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
For each domain, two review authors performed the ’Risk of bias’
assessment independently and assigned a judgement of ’low risk’
’high risk’ or ’unclear risk’ of bias. The review authors resolved any
discrepancies between them by discussion.
The reliability of data outputs from any full economic evalua-
tion are in part predicated on the reliability of the data for the
estimates of the relative treatment effects (for benefits or harms)
of the alternative courses of action (i.e. intervention(s) and com-
parator(s)) under investigation). As the identified economic stud-
ies were a subset of the studies included in the review, the risk
of bias was already assessed. However, assessment of the overall
methodological quality of the economic component was still re-
quired and was carried out by one review author (PA) using the
Consolidated Health Economic Evaluation Reporting Standard
(CHEERS) statement, together with the Consensus on Health
Economic Criteria (CHEC) (Evers 2005; Husereau 2013). In as-
sessing the methodological quality of economic evaluations, the
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main objective is to assess the applicability of the scope of the
analysis in terms of costs and outcomes. This helps to highlight
the applicability and relevance of each economic evaluation.
Measures of treatment effect
Attendance at screening post-intervention is a dichotomous out-
come and we have reported the intervention effect as the risk dif-
ference (RD), i.e. the actual difference in the observed events be-
tween experimental and control interventions. Our choice of RD
was based on the fact that relative effect sizes (e.g. risk ratios) are
highly dependent on the baseline/control compliance, i.e. a simi-
lar risk ratio if screening attendance increase from 10% to 20% or
from 50% to 100%. During the development of the protocol for
the review, we received advice from the Cochrane EPOC group
who have found that RDs are much more interpretable, and it is
also possible to explore whether baseline compliance is an effect
modifier.
Unit of analysis issues
For individual randomised trials the unit of analysis was the in-
dividual participant. For cluster-RCTs, we analysed data after ad-
justment for clustering. In case of cluster-RCTs, where outcomes
were presented at patient level, we used an established method to
adjust for clustering (Higgins 2011).This involved dividing the
original sample size by the design effect, whichwas calculated from
the average cluster size and the intra-cluster correlation coefficient
(ICC). Where the ICC was not reported, we imputed the most
commonly-reported value from studies where it was reported.
Dealing with missing data
We contacted authors of included studies if important data were
not available. Where we were not able to obtain these data, we
reported the available results and did not impute missing data.
Assessment of heterogeneity
We assessed heterogeneity between studies by visual inspection of
forest plots and by formal statistical tests of heterogeneity (Chi
2 test and the I2 statistic), and explored the possible reasons for
heterogeneity using subgroup and random-effects meta-regression
analyses.
Assessment of reporting biases
We explored publication bias using a funnel plot for the main
comparison of any intervention versus usual care.
Data synthesis
We conducted meta-analyses in Review Manager 5 (Review
Manager 2014), using a random-effects model to estimate the
pooled RD across studies. We included data from RCTs ran-
domised by individual and from cluster-adjusted RCTs in the
same meta-analysis. In the case of multiple intervention groups,
we combined groups to create a single pair-wise comparison as
recommended in the Cochrane Handbook for Systematic Reviews of
Interventions (Higgins 2011).
A summary of the results of included economic evaluations is
available as an additional table (Table 2) and is supplemented by a
narrative description in the Results and Discussion sections. Costs
for each study were adjusted to 2016 British pound value (GBP)
using a web-based conversion tool based on implicit price deflators
for gross domestic product (GDP, a measure of the wealth of a
country) and GDP Purchasing Power Parities. Table 2 presents the
original currency and price year used in each included study. Users
of this review who might want to adjust costs to another currency
and price year suitable for their needs should use costs for each
study presented in Table 2 and not the adjusted costs presented in
the main text of the review.
Subgroup analysis and investigation of heterogeneity
We planned to perform the following prespecified subgroup anal-
yses to investigate whether the presence or absence of a particular
covariant explained the variability in effect size:
• QI intervention components/BCTs
• Resource requirements to deliver the intervention
• Population subgroups: type 1, type 2 diabetes mellitus,
participant characteristics across PROGRESS categories
In our analyses, we assessedQI components (coded using themod-
ified EPOC taxonomy) and BCTs of each intervention separately.
Where a study used multiple QI components or BCTs or both,
we applied the same effect size to each component for the analysis.
We compared effect estimates for subsets of studies that used a
particular QI component/BCT or resource intensity and calcu-
lated a pooled effect size. We included BCTs/QI components in
the analysis when 10 more studies were available for each BCT/
QI component.
We further investigated associations betweenDRS attendance and
effect size by meta-regression for a number of covariates, includ-
ing: type of study design (individual/cluster-RCT), baseline DRS
attendance and QI component/BCT used in the intervention. For
meta-regression we used a prespecified random-effects model and
compared the risk difference of studies containing a particular ex-
planatory variable to studies in which the variable was absent. For
metaregression we followed the guidance in the Cochrane Hand-
book for Systematic Reviews of Interventions (Higgins 2011), and
only included covariates for which 10 or more studies were avail-
able.
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We conducted subgroup analyses and meta-regression using Stata
14, deploying the metan and metareg commands.
Sensitivity analysis
We performed a sensitivity analysis to determine the impact on
the pooled effect estimate of imputing the lower and upper range
values for the ICC.
’Summary of findings’ Tables
We prepared ’Summary of findings’ tables for the main compar-
isons (1. effect of any QI intervention versus usual care on DRS
attendance and 2. effect of a more intensive (stepped) invertion
versus a less intensive intervention). We assessed certainty of ev-
idence (GRADE) for each outcome using customised software
(GRADEpro GTD). One author (JGL) did the initial assessment
which was then checked by other review authors. We considered
risk of bias, inconsistency, indirectness, imprecision and publica-
tion bias when judging the certainty of the evidence.
R E S U L T S
Description of studies
Results of the search
The electronic searches yielded 9030 records (Figure 1). The
Cochrane Information Specialist removed 1786 duplicate records
and we screened the remaining 7244 records plus 33 records iden-
tified from additional sources (Tricco 2012). We rejected 7152
records after reading the abstracts and obtained full-text reports
of 125 references for further assessment. We identified 81 reports
of 66 studies that met the inclusion criteria (see Characteristics
of included studies) and excluded 34 reports of 34 studies (see
Characteristics of excluded studies).We also identifiednine reports
of eight ongoing trials (see Characteristics of ongoing studies), and
will assess these when results become available.
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Figure 1. Study flow diagram.
Included studies
The included studies were conducted between 1988 and 2013.
Thirty-five studies (53%) were parallel-group patient RCTs en-
rolling 237,025 patients, and 31 (47%) were cluster-RCTs in
which the healthcare professional or the healthcare setting was
the unit of randomisation. These included 6126 clusters (range
6 to 4125). Fifty-nine studies (89.4%) had two arms, six studies
(9.1%) had three arms and one study (1.5%) had more than three
arms. For further details see Characteristics of included studies.
Types of participants
Participant characteristics are reported in Table 3. Most of the
studies (57.6%) recruited participants with type 2 diabetes, 15.2%
of studies included those with either type 1 or type 2 diabetes, and
in 12.1% of studies the type of diabetes was not reported.
We used PROGRESS elements to describe the characteristics of
participants in the included studies that could have an impact on
equity of access to health services. With the exception of gender
(reported in 93.9% of studies) and ethnicity (reported in 56.1% of
studies), the characteristics of participants were poorly described,
and the relative effectiveness of the interventions for subgroups
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in terms of PROGRESS elements was never reported. Seventeen
studies (25.8%)were conducted in disadvantaged populations and
none were carried out in low- or middle-income countries.
Types of setting
Details of study location and setting are given in Table 3. Most of
the studies (62.1%) were conducted in the USA, 21.2% in Europe
and 16.7% elsewhere. The setting was primary care in 77.7%,
secondary care in 10.6% and unclear in 12.1%.
Intervention content in terms of QI components
(coded using the modified EPOC taxonomy)
Interventions were either specifically targeted at improving atten-
dance for DRS (N = 16) or were part of a general QI intervention
to improve diabetes care (N = 50). For studies comparing any in-
tervention to usual care, most studies provided no description of
usual care, which precluded coding of the comparator arm.
All 12 QI intervention components, as defined by the modified
EPOC taxonomy, were used in at least one study (Figure 2). Gen-
erally, interventions were multifaceted, with several QI compo-
nents per intervention arm (median 3, range 1 - 7). For interven-
tions specifically targeting DRS attendance, the most commonly
used QI components were ‘Patient reminders (56% of studies)’
and ‘Patient education (75%) (Figure 3). For general QI inter-
ventions, a greater number and range of strategies were used, in-
cluding: ‘Patient education’ (48% of studies), ‘Promotion of self-
management’ (40%), ‘Case management’ (40%), ‘Clinician edu-
cation’ (38%) and ‘Team changes’ (36%).
Figure 2. Quality improvement components used in intervention arm of included studies. (DRS=diabetic
retinopathy screening, GQI=general quality improvement).
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Intervention content in terms of BCTs (coded using
the BCT taxonomy)
Overall, 39 out of the possible 93 BCTs (42%) were identified as
targeting change in patient or healthcare professional behaviour
in at least one trial. Interventions specifically targeting DRS pri-
marily used techniques aimed at patients, particularly ‘Instruction
on how to perform the behaviour’ (75% of studies), ‘Prompts/
cues’ (69%) and ‘Information about consequences’ (56%) (Figure
4). Relatively few of these studies used BCTs that were aimed at
healthcare professionals (Figure 5). By contrast, these healthcare
professional-directed strategies were more widely used in general
QI interventions, in particular: ‘Instruction on how to perform the
behaviour’ (66%), ‘Restructuring the social environment’ (52%)
and ‘Feedback on outcomes of behaviour/Biofeedback’ (36%).
Table 1 provides illustrative quotations for each BCT.
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Figure 4. Behaviour change techniques (BCTs) targeting patients used in intervention arm. of included
studies (DRS=diabetic retinopathy screening, GQI=general quality improvement).
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Figure 5. Behaviour change techniques (BCTs) targeting healthcare professionals used in intervention arm
of included studies (DRS=diabetic retinopathy screening, GQI=general quality improvement).
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For studies comparing any intervention to usual care, most studies
provided no description of usual care, which precluded coding of
the comparator arm.
Outcome measures
In 12 (75%) of the 16 studies where the primary target of the
intervention was to improve attendance for DRS, the outcome
was a dilated fundus examination conducted by an ophthalmol-
ogist or optometrist during the follow-up period post-interven-
tion (median follow-up 12 months). The fundus examination was
confirmed by a medical record audit, health claims database, or
an eye-care professional confirmed examination. In four studies
(25%) DRS consisted of screening of digital retinal images.
Of the 50 studies where DRS attendance was reported as part
of a general QI intervention, DRS was usually listed as part of a
number of processes of care based on diabetes guideline recom-
mendations. DRS was variously described as a dilated fundus ex-
amination/diabetic eye exam/retinal exam/eye exam in 49 studies
(98%) and involved grading of retinal images in one study. DRS
was confirmed by medical record audit, from claims databases or
patient self-reports (both validated and unvalidated by an eye-care
professional). The median duration of follow-up was 12 months
(range 1 - 48 months).
In terms of economic outcomes, five studies reported a full eco-
nomic evaluation (Davis 2010; Eccles 2007; Pizzi 2015; Prezio
2014; Walker 2008).Three of these were cost-effectiveness analy-
ses (Davis 2010; Prezio 2014; Walker 2008) and two were cost-
consequence analyses (Eccles 2007; Pizzi 2015). Nine studies were
partial economic evaluations; five were resource-utilisation stud-
ies, (Clancy 2007; Frei 2014; Krein 2004; McCall 2011; Piette
2001), while four were cost-outcome descriptions (Adair 2013;
Frijling 2002; Litaker 2003;Wagner 2001). We could not retrieve
the full text of one of the cost-effectiveness studies, but the abstract
provided some information required for the review alongside the
clinical-effectiveness report (Davis 2010).
Excluded studies
See Characteristics of excluded studies.
Risk of bias in included studies
We conducted ’Risk of bias’ assessment using theCochrane EPOC
’Risk of bias’ tool. Figure 3 and Figure 6 summarise the risks of
bias. Overall, we judged trials to be at low or unclear risk of bias for
most of the bias domains. We provide support for each judgement
in the Characteristics of included studies tables.
Figure 6. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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The studies that reported economic outcomes are a subset of the
studies included in the review, and the risks of bias of these studies
were very similar to the main body of included studies. With
respect to the economic methodological quality, only five of the
14 included studies reported full economic evaluations (Davis
2010; Eccles 2007; Pizzi 2015; Prezio 2014; Walker 2008). One
of these studies (Davis 2010) was published as an abstract and
lacked important methodological details. Only three of the studies
with full economic evaluations (Pizzi 2015; Prezio 2014; Walker
2008) reported a sensitivity analysis to explore changes in the costs
and outcomes under different scenarios. Discounting in economic
evaluations is necessary to adjust future costs and outcomes of an
intervention to its present value, but was reported in only one
of the full economic outcomes (Prezio 2014). Its use would have
been appropriate in those other studies which had a stated follow-
up of longer than 12 months (Eccles 2007; Frijling 2002; Krein
2004; Wagner 2008). We considered the methodological quality
of the full economic evaluations to be moderate, while the partial
economic evaluations by their nature lacked the methodological
characteristics expected of an economic evaluation. Full details of
the methodological quality assessment for each of the included
economic evaluations are available in Table 4 and Table 5.
Allocation
Thirty-three studies (50%) reported using appropriate methods
for random sequence allocation. Two studies (Gabbay 2006;
McDermott 2001) described a non-random component in the se-
quence generation process and we judged them to be at a high
risk of bias for this domain. The rest of the studies provided in-
sufficient information about the sequence-generation process to
judge risk of bias. We rated allocation concealment as adequate
in 39 studies (59%), either because the unit of allocation was by
institution, team or professional and allocation was performed on
all units at the start of the study, or a suitable method was used to
conceal allocation.
Blinding
We rated four studies at a high risk of bias; Adair 2013, where
retinopathy screening data were extracted from patient records by
unmasked extractors, whose knowledge of allocation could have
influenced outcome; Franco 2007, inwhich the general practition-
ers (GPs) in the intervention group provided the data on retinopa-
thy screening; in Sonnichsen 2010, where masking was not possi-
ble and knowledge of being in the intervention or control group
may have influenced the outcome; and Ward 1996, where one of
the outcome assessors was the research nurse who conducted the
interviews to obtain the outcome data in one arm of the trial, and
was therefore unmasked.
Incomplete outcome data
We judged 15 studies (22.7%) to be at a high risk of attrition
bias, with attrition of 20% or more (Dijkstra 2005; Franco 2007;
Gabbay 2013; Harris 2005; Hermans 2013; Ilag 2003; Jacobs
2012; Jansink 2013; Kirwin 2010; Maljanian 2005; O’Connor
2005; Perria 2007; Sonnichsen 2010; Varney 2014; Wagner
2001).The remaining studies were either at low (N = 40) or un-
clear (N = 11) risk of bias for this domain.
Selective reporting
It was possible to judge if a study was free from selective outcome
reporting in only 17 of the included studies (25.8%), as the out-
comeswere consistent with a prospectively-published clinical trials
registry entry or trial protocol. We were unable to assess selective
reporting in the remainder, due to the lack of a study protocol or
trial register entry, or in the case of studies where trial registration
was performed retrospectively.
Other potential sources of bias
In five studies (7.6%) there was a baseline imbalance in DRS
attendance of 10% or more between intervention and control
groups, and in seven studies (10.6%) it was not possible to control
for the possibility that the control group received the intervention.
Effects of interventions
See: Summary of findings for the main comparisonAny quality
improvement intervention compared to usual care for diabetic
retinopathy screening; Summary of findings 2 Stepped quality
improvement intervention compared to intervention alone for
diabetic retinopathy screening
For details of the GRADE assessments, see Summary of findings
for the main comparison and Summary of findings 2.
Primary outcome
See Summary of findings for the main comparison and Summary
of findings 2.
One or more visits for diabetic retinopathy screening within
a two-year period following implementation of the
intervention
All 66 trials provided data for this outcome. These consisted of
two types of comparison: 56 of the 66 studies (85%) compared an
intervention against “current usual care”, and 10 (15%) compared
a more intensive QI intervention or group of QI interventions
against a less intensive intervention. Since these were addressing
different questions, we conducted separate meta-analyses on the
56 and the 10 studies.
Thirty-one of the 66 trials (47%) were cluster-RCTs. Only nine
of these reported an ICC and the ICC reported typically did not
relate specifically to DRS outcomes. Of the nine reporting an
ICC, themost commonly reported value was 0.05, and so this was
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the value we imputed for studies with no estimates of ICCs. The
smallest value reported was 0.01 and the largest value was 0.2. We
ran a sensitivity analysis to investigate the impact on the computed
effect estimates of using the lower and upper range values (see table
below).
ICC 0.05 0.01 0.2
Model RD LCL UCL RD LCL UCL RD LCL UCL
DRS 0.17 0.11 0.22 0.17 0.11 0.22 0.17 0.11 0.22
General 0.12 0.09 0.15 0.12 0.09 0.16 0.11 0.08 0.15
Com-
bined
0.12 0.10 0.14 0.13 0.11 0.15 0.12 0.10 0.14
Abbreviations: RD: risk difference; LCL: lower limit; UCL: upper
limit
Comparison 1: Any QI intervention versus usual care
Of the 56 studies which compared any intervention against usual
care, 13 (23%) evaluated interventions specifically targeting DRS.
The remaining 43 (77%) evaluated interventions directed towards
improving the general quality of diabetes care (including DRS at-
tendance). Although there was substantial heterogeneity in inter-
vention effects (I2 = 93%), 48 out of the 56 studies showed an
improvement in DRS attendance. Since it may be argued that it
is better to examine clinical differences in a meta-analysis rather
than to use them as a reason for not conducting one, we com-
puted pooled estimates for each of these subgroups. We adopted
a random-effects model, which can accommodate statistical het-
erogeneity between studies by assuming that different studies have
different true effect sizes, but we acknowledge that use of the ran-
dom-effects model does not in it itself deal with heterogeneity.We
assessed whether there was evidence of a subgroup effect and, since
there was not (P = 0.15), we conducted all subsequent statistical
analyses on the 56 studies. Overall, DRS attendance increased by
12% (risk difference (RD) 0.12, 95% confidence interval (CI)
0.10 to 0.14; low-certainty evidence) compared with usual care
(Analysis 1.1 Figure 7).
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Figure 7. Forest plot of comparison: 1 Any quality improvement intervention compared to usual care,
outcome: 1.1 Proportion of participants attending screening.
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There was some evidence of funnel plot asymmetry (Figure 8).
Terrin 2003 has suggested, however, that the funnel plot may
be inappropriate for heterogeneous meta-analyses, so we did not
downgrade our findings because of this.
Figure 8. Funnel plot of comparison: 1 Any quality improvement intervention compared to usual care,
outcome: 1.1 Proportion of patients attending screening.
Comparison 2: More intensive (stepped) intervention versus
less intensive intervention
Examples of studies in this comparison included: a tailored (indi-
vidualised) versus a generic patient education newsletter; a com-
parison of audit and feedback to the healthcare professional com-
pared to audit and feedback combined with a diabetes team out-
reach service. Ten studies contributed to this analysis (Analysis 2.1;
Figure 9). Three (30%) evaluated interventions specifically tar-
geting DRS, while seven (70%) evaluated interventions directed
towards improving the general quality of diabetes care. In these
studies DRS attendance increased by 5% (RD 0.05, 95% CI 0.02
to 0.09; moderate-certainty evidence) (Analysis 2.1).
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Figure 9. Forest plot of comparison: 2 Stepped quality improvement intervention compared to
intervention alone (control), outcome: 2.1 Proportion of participants attending screening.
Secondary outcomes
Ongoing adherence to DRS based on attendance for
screening following the initial screening post-intervention
It was not possible to extract data on ongoing adherence to DRS
(based on attendance for screening following the initial screen-
ing post-intervention), since either it was not possible to identify
unique screening episodes from pooled data reported at two time
points, or in one study due to the intervention being offered to
the comparator arm 18 months post-randomisation (Mansberger
2015).
Economic outcomes
Resources (staff time, equipment, consumables) required to
deliver interventions to increase attendance for DRS
We graded each intervention between one (least resource-inten-
sive) and five (most resource-intensive), or as zero (unable to deter-
mine), with a record of how the review author graded each study
also provided. We developed an algorithm to derive the ordered
rank. This mapped resource components and their intensity to
the ordered rank. We incorporated the following resource com-
ponents into the algorithm: face-to-face minutes; telephone calls;
patient home visits; printed materials/software; training.
We then used the resource components and their intensity levels
to extract the resource use required to deliver the interventions in
all included studies. Two review authors (JL and EGR) conducted
this independently. The percentage of studies for each resource
grouping for the 56 studies comparing any intervention with usual
care was as follows: 1 = 48.2%; 2 = 10.7%; 3 = 8.9%; 4 = 19.6%;
5 = 12.6%.
Costs of staff used to provide interventions; costs of
treatment and care; cost of primary care; lost wages and lost
productivity (work output)
We converted all reported costs to the 2016 British pound, and
summarise them for each study inTable 2.Only two studies (Eccles
2007; Prezio 2014) reported both the direct and indirect costs
(productivity loss) of the interventions. In all other studies, the
costs of the interventions reported covered just the direct costs
of providing that intervention. Five studies (Adair 2013; Clancy
2007; Frijling 2002; Prezio 2014; Pizzi 2015) reported the total
direct costs of the interventions, but the resources they considered
relevant and how they combined them to estimate total cost varied
between studies. We report components of the total cost for each
intervention in Table 2.
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The types of resources included in the cost calculations for each
study varied; hence, it is difficult to compare directly across the
studies. The estimated training cost differed between the few stud-
ies that reported this information. In terms of the costs of treat-
ment and care of diabetes, there was no obvious difference in the
healthcare costs between the interventions and comparators in the
studies that reported these data, primarily reflecting an absence
of evidence. Further details on resources and costs from each in-
cluded studies can be found in Table 2.
Incremental cost-effectiveness ratio (ICER)
Only three studies conducted in the USA (Davis 2010; Prezio
2014; Walker 2008) reported this outcome. Davis 2010 reported
an incremental cost per QALY of GBP 13,154 over one year for a
diabetes telecare intervention compared to no intervention. How-
ever, it is unclear what tool they used to estimate QALYs. Prezio
2014 used an established whole-disease model, the Archimedes
Model simulator, to estimate the incremental cost per QALY. Us-
ing a discount rate of 3% and programme effectiveness at 100%,
the incremental cost per QALY was GBP 73,683 over five years,
and GBP 261 over 20 years for the intervention (a culturally-
tailored diabetes education programme delivered by community
health worker) compared with usual care. Prezio 2014 andWalker
2008 also reported an incremental cost-effectiveness ratio. In this
study, the unit of effectiveness was the number of diabetic fundus
examinations gained, which was associated with the number of
diabetic retinopathies diagnosed. The incremental cost per dilated
fundus examination gained for telephone intervention compared
to the mailed/printed intervention was GBP 333. Pizzi 2015 re-
ported a cost-effectiveness analysis with an incremental cost-ef-
fectiveness ratio for the telephone intervention of GBP 18.77 per
additional patient attending a dilated fundus examination, com-
pared with usual care.We did not calculate the ratio for themailed
intervention because it was dominated by usual care.
Exploration of heterogeneity
We detected substantial heterogeneity (I2 > 90%), which we in-
vestigated by subgroup analysis and meta-regression.
Subgroup analysis
Enough studies were available to investigate the effectiveness of
nine out of the possible 12 QI components. Insufficient data were
available to analyse ‘continuous quality improvement’, ‘financial
incentives’ and ’facilitated relay’ of information to clinicians. In-
terventions incorporating all nine QI components evaluated in
the subgroup analysis were associated with improvements in DRS
attendance, with higher pooled effect estimates for interventions
directed at patients (promotion of self-management and patient
education) or the organisation of the health system (team changes
or the establishment of an electronic patient registry) (Table 6).
Sufficient studies were available to investigate the effectiveness
of interventions containing particular BCTs (including 10 BCTs
aimed at patients and seven aimed at healthcare professionals). In-
terventions incorporating all 17 BCTs included in the subgroup
analysis were all shown to be effective in improving DRS atten-
dance. For BCTs aimed at patients, we found higher pooled effect
estimates for ‘goal setting (outcome)’ and ‘credible source’ and for
healthcare professionals ‘restructuring the social environment’ and
‘credible source’ (Table 6). There were insufficient data to conduct
the planned analysis on the variability of effect size according to
population subgroups, and there were too few studies within each
resource category to conduct a subgroup analysis of the relation-
ship between effect size and resource intensity.
Metaregressions
Metaregression revealed some evidence of an association between
effect size and baseline DRS attendance, with larger effects in stud-
ies with poorer screening attendance (Figure 10). The regression
coefficient was -0.208 (-0.419 to 0.004). The residual I2 was still
very high at 94%. Because of regression to the mean, this associ-
ation might be spurious, so we conducted a permutation test to
allow for this (with 1000 permutations, P = 0.055). A comparison
between the effect sizes from studies at high risk of bias (defined
for this purpose as high risk of bias in one or more domains) was
slightly (but not statistically-significantly) higher than those at low
risk of bias (regression coefficient 0.008 (-0.136 to 0.094)). Sim-
ilarly, we found no association between study design (individual
or cluster-RCT) and effect size (regression coefficient - 0.049 (-
0.136 to 0.039), P = 0.268), nor between resource intensity and
effect size (regression coefficient 0.013 (-0.015 0.042), P = 0.356).
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Figure 10. Bubble plot showing the relationship between the risk difference and baseline percentage
screened
When component QI/BCTs were explored (comparing studies
with the intervention to those studies without), there was some
evidence of an association between the patient-targeted BCT ‘goal
setting (outcome)’, with greater improvement in DRS attendance
observed in studies with compared to those without this BCT
(regression coefficient 0.162 (0.07 to 0.254), P = 0.001). It should
be noted that we made no adjustments for multiplicity in these
investigations, so that results should be observed as hypothesis-
generating rather than confirmatory.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Stepped quality improvement intervention compared to intervention alone for diabetic retinopathy screening
Patient or population: pat ients with type 1 or 2 diabetes eligible for diabet ic ret inopathy screening
Setting: primary, secondary or tert iary
Intervention: stepped quality improvement intervent ion compared to intervent ion alone
Comparison: intervent ion alone
Outcomes Illustrative comparative risks Risk Difference
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk
(95% CI)
Corresponding risk
(95% CI)
Attendance with usual
care
At-
tendance with stepped
QI intervention
Proport ion of part ici-
pants attending screen-
ing
(median follow-up 12
months post-interven-
t ion)
361 per 1000 405 per 1000
(372 to 437)
RD 5% (95% CI 2% to
9%)
23,715
(10 RCTs)
⊕⊕⊕©
MODERATE1
There was unexplained
heterogeneity between
studies (I2 = 56%, P = 0.
02)
Ongoing adherence to
screening
- - - - - -
Economic outcomes - - - - - -
CI: Conf idence interval; RD: Risk dif ference
GRADE Working Group grades of evidence
High-quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate-quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low-quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low-quality: We are very uncertain about the est imate.2
7
In
te
rv
e
n
tio
n
s
to
in
c
re
a
se
a
tte
n
d
a
n
c
e
fo
r
d
ia
b
e
tic
re
tin
o
p
a
th
y
sc
re
e
n
in
g
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
8
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
1We downgraded the certainty of the evidence by one level f rom high to moderate for inconsistency due to variat ion in the
ef fect est imates across studies that could not be explained.
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
2
8
In
te
rv
e
n
tio
n
s
to
in
c
re
a
se
a
tte
n
d
a
n
c
e
fo
r
d
ia
b
e
tic
re
tin
o
p
a
th
y
sc
re
e
n
in
g
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
8
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
D I S C U S S I O N
Summary of main results
This review identified 66 RCTs/cluster-RCTs that investigated
the effectiveness of interventions to improve attendance for DRS.
Fifty-six studies (329,164 participants) compared a variety of QI
interventions to usual care. A meta-analysis of these studies found
that QI intervention components that were aimed at patients,
the healthcare professional or the healthcare system were associ-
ated with a 12% absolute increase in DRS attendance. In 13 of
these studies, the QI intervention specifically targeted DRS and
in 43 studies the intervention consisted of a general QI interven-
tion to improve diabetes care. Although the pooled effect estimate
was larger for DRS-targeted interventions compared to non-tar-
geted interventions (17% increase in DRS attendance compared
to 12%), this difference was not statistically significant.
Ten studies (23,715 participants) compared a less intensive inter-
vention (‘active’ control) to amore intensive intervention. Three of
these studies specifically targeted DRS and seven were general QI
interventions. The aim of these studies was to determine whether
stepping up the intensity of an intervention component, or in-
troducing further components, would increase DRS. The pooled
effect estimate for these studies was smaller, with a 5% increase
in DRS attendance in favour of the more intensive intervention,
suggesting that it is possible to further enhance the effect size by
using more intense interventions.
The main comparison in this review (any QI intervention versus
usual care) was associated with substantial heterogeneity. We ex-
plored this by subgroup analysis and meta-regression. There was
some evidence for larger effect sizes in populationswith lower base-
line DRS attendance; however, much of the observed heterogene-
ity was unexplained. Sufficient studies were available to investigate
the impact of particular QI components or BCTs, to identify the
active ingredients of the interventions. All 12 QI components, as
defined by themodifiedEPOC taxonomy, were used in at least one
study, and interventions were generally multifaceted, with two to
three QI components per intervention arm. QI components tar-
geting patients, healthcare professionals or the healthcare system
were all effective in a subgroup analysis. A meta-regression com-
paring studies using particular QI components to those without
them showed no statistically-significant difference between inter-
vention components.
We were able to further describe interventions in terms of their
component BCTs, which provides a level of granularity that is bet-
ter suited to describing the content of the intervention. In a sub-
group analysis, all frequently-used BCTs were effective in improv-
ing attendance, with pooled RDs ranging from 0.11 to 0.26. A
meta-regression found that interventions containing certain BCTs
weremore effective in improvingDRS attendance, including: ‘goal
setting (outcome)’ (regression coefficient (RC) 0.162, 95% CI
0.070 to 0.254, P = 0.001). There was some evidence for larger
effect sizes in populations with lower baseline DRS attendance,
(RC -0.208, 95% CI -0.419 to 0.004, P = 0.054). However much
of the observed heterogeneity was unexplained.
We found no studies reporting our secondary outcome measure
of ongoing adherence to DRS following the initial screening ap-
pointment post-intervention, and no data on the relative effec-
tiveness of interventions in particular population subgroups, e.g.
socioeconomic characteristics.
Fourteen studies reporting economic outcomes were included in
the review. However, only five of these were full economic evalua-
tions. Overall, we found that there is insufficient evidence to draw
robust conclusions about the relative cost effectiveness of the in-
terventions compared to each other or against usual care. QI com-
ponents aimed at patients directly appeared to be more resource-
intensive compared with those aimed at healthcare professionals,
with the exception of establishing an electronic patient registry,
although there would be economies of scale in that there are high
set-up costs but the ongoing running costs would be compara-
tively low.
Overall completeness and applicability of
evidence
To our knowledge only two countries in the world (UK and
Iceland) have introduced a nationwide systematic screening pro-
gramme for diabetic retinopathy. In all other countries screening
remains opportunistic. Although an annual or biennial retinal ex-
amination is recommended in diabetes clinical practice guidelines
inmany countries, screening attendance is often suboptimal. Most
of the trials included in this review (76%) involved general QI
interventions for diabetes care and enrolled patients not achieving
diabetes-relevant quality indicators, including DRS. The pooled
analysis for any QI intervention compared to usual care showed
that both DRS-targeted and general QI interventions were effec-
tive in improving screening attendance, particularly in populations
with poor baseline screening attendance. However, the presence
of substantial unexplained heterogeneity and the lack of data on
the effect of the intervention on particular population subgroups
means that there remains some uncertainty about the size of the
anticipated increase in screening attendance.
Although potential harms associated with other forms of health
screening are well documented, we did not formally include ad-
verse effects/harms as an outcome in this review, since the risk of
an adverse outcome associated with retinopathy screening is low.
However, none of the included studies reported adverse outcomes.
Quality of the evidence
Overall we judged the certainty of the evidence to be low, using
GRADE.We downgraded the evidence by two levels due to serious
inconsistency of findings. We decided a priori to use a random-
effects model to estimate the pooled RDs across studies, which
weights studies relativelymore equally than in a fixed-effectmodel.
Given there was some evidence for larger effect sizes in smaller
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studies, our random-effects estimate of the intervention effect is
more beneficial thanwould have been obtained using a fixed-effect
model.
For many domains, it was not possible to judge the risk of bias
due to poor reporting. For example, since many of the RCTs did
not have a prospectively-published protocol, it was not possible
to make a judgement as to whether outcomes were selectively
reported. A subgroup analysis found that, although studies at high
risk of bias had slightly higher effect estimates compared to those at
low risk of bias, this difference was not statistically significant. The
consensus of the review team was not to downgrade the certainty
of the evidence for risk of bias.
Of the 22 potential ‘economic’ studies identified by the review
team, 14 were eligible for the review as partial or full economic
evaluations. We judged the certainty of the economic evidence
to be low, using GRADE. We downgraded due to inconsistency
across different elements of the economic outcomes. We also iden-
tified publication bias in two of the eight excluded studies. These
studies failed to report the planned economic evaluations, as they
found no evidence of intervention effectiveness. Such an approach
could be considered as selective outcome reporting, such that po-
tentially negative economic findings are not reported. This phe-
nomenon of a reporting bias has been recognised previously, where
studies with unfavourable effectiveness results are not published
or are published later in low-impact journals. Furthermore, ana-
lytically such an approach is substandard, as these studies conflate
absence of evidence with a finding of evidence of absence (of an
effect). We also found evidence of publication bias by inspection
of a funnel plot, but this was difficult to assess in the presence of
such considerable heterogeneity.
Most of the economic evaluations had limitations in their report-
ing, with few providing a breakdown of the costs associated with
delivering the different components of the intervention. There was
also insufficient evidence to show whether part of the direct costs
of the intervention and care may be offset by reduced productivity
costs. However, it is important to note that an expected finding of
an effective intervention would be gains in health and reductions
in the costs of treating diabetes. The overall methodological qual-
ity of the included economic studies was mixed. The partial eco-
nomic evaluations identified, by their nature lacked the method-
ological characteristics expected of an economic evaluation. We
rated the methodological quality of the full economic evaluations
as moderate.
Many of our studies did not report ICC values. We used the data
that were provided to allow an estimation of an “average ICC”,
which we then applied to the studies not reporting ICCs. Since
this was an imputation, we wished to explore the impact that
using other values of ICC would have, and thus repeated our
analysis using the upper and lower values of ICC that had been
observed. Varying in this fashion did not materially impact upon
our estimates of RD.
Potential biases in the review process
We judged many domains as having an ‘unclear’ risk of bias, due
to poor reporting. Although we contacted all authors to request
further information on intervention content, we did not formally
ask for all of the necessary information to make a more informed
judgement across all bias domains.
Coding of intervention content was challenging, given the paucity
of primary data sources, although in some cases (approximately
17%) this was offset by obtaining further information from re-
searchers on intervention content, who also provided materials
used in delivering the interventions. We were not able to assess the
impact of some QI intervention components due to too few tri-
als being available for our subgroup and meta-regression analyses.
Furthermore, we could not control for all potential confounding
factors. Given the complexity of the interventions which incor-
porated multiple QI components, it is likely that other covariates
may have interacted synergistically or antagonistically with the in-
tervention under investigation. The short duration of the included
RCTs (typically 12 months or less) or the failure to report indi-
vidual screening episodes meant that we were unable to assess the
effect of QI interventions on ongoing DRS attendance.
Agreements and disagreements with other
studies or reviews
Only one previous systematic review (Zhang 2007) has investi-
gated the effectiveness of interventions to increase the uptake of
DRS. Although this review included 48 studies, only 12 of these
were RCTs. The authors similarly concluded that a variety of inter-
ventions canbe effective in improving screening uptake, including;
increasing patient and provider awareness of diabetic retinopathy,
introducing a computer-based registration/reminder programme,
and developing a community-based healthcare system.
Compared to the paucity of systematic reviews of the impact of
interventions to improve DRS outcomes, many reviews have eval-
uated the impact of general QI interventions to improve the over-
all quality of diabetes care (Worswick 2013). A recent systematic
review published by members of the current team (Tricco 2012)
included 48 cluster-RCTs and 94 patient RCTs, and found im-
provements in many important quality outcomes for patients with
diabetes. A meta-analysis of a subset of 23 RCTs reported an in-
creased uptake of retinopathy screening (RR 1.22, 95% CI 1.13
to 1.32).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The results of this review provide evidence that quality improve-
ment (QI) interventions targeting patients, healthcare profession-
als or the healthcare system are associated with meaningful im-
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provements in DRS attendance compared to usual care. There was
no statistically-significant difference between interventions specif-
ically aimed at DRS and those which were part of a general QI
strategy for improving diabetes care. This is an important finding,
because of the additional benefits of general QI interventions in
terms of improving glycaemic control, vascular risk management
and screening for other microvascular complications. It is likely
that further (but smaller) improvements in DRS attendance can
also be achieved by increasing the intensity of a particular QI com-
ponent or adding further components.
One of the main objectives of the review was to identify the ‘ac-
tive’ components of successful interventions by using validated
taxonomies to describe the content of the interventions. All of the
QI components as defined by themodified EPOC taxonomy were
associated with improvements in DRS attendance. To better char-
acterise intervention content we coded the interventions in terms
of patient and provider behaviour change techniques (BCTs). For
BCTs aimed at patients, we found higher effect estimates for inter-
ventions incorporating goal setting, and for healthcare profession-
als, interventions involving environmental restructuring. How-
ever, only 42% of the 93 possible BCTs were reported in the in-
cluded interventions. Although not all BCTs in the BCT taxon-
omy might be appropriate for DRS, the findings of this review
suggest that there may be opportunities to assess the potential of
additional BCTs in future trials of novel interventions to improve
screening attendance.
Implications for research
The review highlighted a number of gaps within the evidence
base. There was limited evidence on the relative effectiveness of
QI interventions in particular population subgroups according to
demographic characteristics that could have an impact on health
equity, e.g. ethnicity, level of education, or socioeconomic status.
Moreover, none of the included studies were carried out in low- or
middle-income countries. Further research is also needed on the
cost effectiveness of QI interventions to improve DRS attendance.
Most of the included studies, whether targeting DRS or general
QI strategies for diabetes care, enrolled patients not achieving di-
abetes-relevant quality indicators. For example, five studies specif-
ically targeting DRS recruited exclusively patients who were not
meeting guideline recommendations for screening. It is not clear
whether the interventions would be as effective in populations
with higher screening attendance (more than 80%). There was
some evidence from our meta-regression analysis that the effec-
tiveness of the intervention is negatively correlated with baseline
DRS attendance.
Although we have been able to show that interventions contain-
ing particular BCTs have a greater likelihood of success, given the
multicomponent nature of interventions it is likely that the pres-
ence of other BCTs or other effect modifiers in the intervention
arm may also be having an impact on effectiveness. The analysis
conducted as part of this review did not attempt to fully isolate
the impact of individual QI/BCT components. Further research
is needed to identify which components of interventions or com-
binations of components can optimally improve DRS attendance
at an acceptable cost.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Adair 2013
Methods Study aim: to test whether patients with chronic disease working with lay “care guides”
would achieve more evidence-based goals than those receiving usual care
Study design: parallel-group RCT
Participants Country: USA
Setting: Six primary care clinics in Minnesota
Total number of participants: 2135 patients with hypertension, diabetes or congestive
heart failure (1366 with diabetes)
Percentage male: 51%
Diabetes type: type 1 and 2
Average age (SD): 60.5 yrs (11.5)
Inclusion criteria: age 18 - 79 yrs and with a primary care office visit during the 6-
month enrolment period
Exclusion criteria: pregnancy
Interventions Intervention (n = 930): participants provided with disease-specific care goals and cul-
turally-matched laypersons acting as ‘care guides’ helped participants to achieve goals.
Care guides met with participants in person and/or were contacted by telephone
Comparator (n = 436): participants were provided with care goals followed by usual
clinical care
Duration: 12 months
Outcomes Primary outcome: change in the % of disease-specific care goals met 12 months after
enrolment compared to baseline
Secondary outcomes: percentage of goals met by participants with each diagnosis and
the achievement of each individual goal determined from electronic patient records
(included ‘retinal examinationwithin 2yrs’); to determine whether the benefit of working
with the care guide could be predicted by participant demographics
Baseline screening attendance (control group): 60.6%
Notes Date conducted: July 2010 to April 2012
Trial registration number: NCT01156974
Sources of funding: Robina Foundation
Declaration of interest: none declared (Quote “Disclosures can be viewed at https://
www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M12-3106”)
Trial investigators confirmed all retinal examinations reported in Table 4 were performed
on patients with diabetes
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Low risk Quote “Research supervisors prepared
sealed opaque envelopes containing either a
purple card (assignment to a care guide) or
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Adair 2013 (Continued)
gold card (assignment to usual care). One
hundred eighty envelopes (120 with purple
cards and 60 with gold cards) were given to
the small clinic, 360 (240 purple and 120
gold cards) were given to themedium-sized
clinics, and 540 (360 purple and 180 gold
cards) were given to the large clinic. Each
clinic’s envelopes were shuffled before de-
livery and daily thereafter.” p 177
Adequate allocation concealement? Low risk Quote “Research supervisors prepared
sealed opaque envelopes…’
Quote ‘Patients who consented to en-
roll received identical written information
about the benefits of meeting disease-spe-
cific goals. They then selected and opened
an envelope to determine treatment assign-
ment.” p 177
Similar baseline outcome measurements? Low risk Judgement comment: similar baseline
retinopathy screening attendance between
arms. Table 3 p 179
Similar baseline characteristics? Low risk Judgement comment: similar baseline
characteristics. Table 2 p 179
Incomplete outcome data addressed? Low risk Judgement comment: low attrition and
missing data balanced across both arms of
the trial
Knowledge of allocated intervention pre-
vented?
High risk Quote “Patients, providers, and persons
performing outcome assessments were not
blinded to treatment assignment.” p 176
Judgement comment: retinopathy screen-
ing data extracted from electronic patient
record and knowledge of allocation could
have influenced outcome
Protected against contamination? Low risk Quote: “Care guides and the research team
did not interact with the usual care pa-
tients after enrollment and randomization.
” p 178
Free from selective outcome reporting? Low risk Judgement comment: re-
ported outcomes consistent with trial reg-
istry NCT01156974
Other risks of bias? Low risk Judgement comment: no evidence of other
sources of bias
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Anderson 2003
Methods Study aim: to evaluate the effectiveness of personalised follow-up compared to reminder
letters, in increasing return rates at urban eye disease screening clinics for African Amer-
icans with diabetes and minimal or no retinopathy
Study design: parallel-group RCT
Participants Country: USA
Setting: 9 free culture-specific (urbanAfricanAmerican) community-based eye screening
clinics
Total number of participants: 132
Percentage male: 38%
Diabetes type: type 2
Average age (SD): 55 yrs (NR)
Inclusion criteria: African-American adults with type 2 diabetes attending community
eye clinic
Exclusion criteria: patients who were not African American
Interventions Intervention (n = 67): single reminder letter including information on the day, time
and location of the eye clinic appointment 1 month prior to the appointment. Follow-
up phone call 10 days after letter sent. Phone call also addressed barriers to attending
and message that diabetes can lead to vision loss
Comparator (n = 65): single reminder letter including information on the day, time
and location of the eye clinic appointment 1 month prior to the appointment
Duration: 12 months
Outcomes Primary outcome: return rate for annual dilated fundus examination
Secondary outcomes: factors predicative of returning for a dilated fundus examination
Baseline screening attendance (control group): 26.2%
Notes Date conducted: 1995 to 1999
Trial registration number: NR
Sources of funding: National Institute of Health/National Institute of Diabetes and
Digestive and Kidney Disease
Declaration of interest: NR
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk Not reported
Adequate allocation concealement? Unclear risk Not reported
Similar baseline outcome measurements? Low risk Judgement comment: similar numbers of
participants in each arm having ever had
an eye examination by an ophthalmologist
with similar numbers screened in last year
(see Table 1 p 43)
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Anderson 2003 (Continued)
Similar baseline characteristics? Low risk Quote “There were no statistically signif-
icant differences between the 2 groups on
any of the variables in this table.” (Footnote
Table 1 p 43)
Incomplete outcome data addressed? Low risk Judgement comment: all outcome data re-
ported. See Table 1 p 42
Knowledge of allocated intervention pre-
vented?
Unclear risk Not reported
Protected against contamination? Low risk Judgement comment: it is unlikely that the
control group received the telephone re-
minder
Free from selective outcome reporting? Unclear risk Judgement comment: no protocol or trial
registry entry available and therefore not
possible to assess
Other risks of bias? Low risk Judgement comment: no evidence of other
risks of bias
Barcelo 2010
Methods Study aim: to assess the impact of integrated care, comprising specialist support, collab-
orative learning and case management, on the quality of diabetes care
Study design: cluster-RCT
Participants Country:Mexico
Setting: 10 urban public health centres
Number of clusters: 10
Number of providers: 43 primary care teams
Total number of patients: 307
Percentage male: NR
Diabetes type: type 1 and 2 (97.4% type 2)
Average age (SD): NR
Inclusion criteria: participants were selected based on “their capacity to communicate,
their advanced knowledge of diabetes, and their willingness to collaborate”
Exclusion criteria: NR
Interventions Intervention (5 clusters, n = 196): diabetes education programme, in-service training
of primary care personnel. specialist support to primary care, case management of par-
ticipants not achieving care goals
Comparator (5 clusters, n = 111): usual care (not specified)
Duration: 3 learning sessions within 18 months
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Barcelo 2010 (Continued)
Outcomes Primary outcome: change in the proportion of participants achieving quality improve-
ment targets (metabolic control, cholesterol, blood pressure, eye and foot examinations)
Secondary outcomes: NR
Baseline screening attendance (control group): 3.6%
Notes Date conducted: November 2002 to May 2004
Trial registration number: NR
Sources of funding: NR
Declaration of interest: none declared
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk Not reported
Adequate allocation concealement? Low risk Judgement comment: unit of allocation by
community health centre and allocation
performed prior to the start of the study
Similar baseline outcome measurements? Low risk Judgement comment: similar baseline at-
tendance for a dilated fundus examination
in each arm (see Table 6 p 151)
Similar baseline characteristics? Low risk Judgement comment: baseline characteris-
tics of participants were similar in each arm
(seeTable 1 and 2 p 148 - 9)
Incomplete outcome data addressed? Unclear risk Judgement comment: cannot tell whether
an ITT or per-protocol analysis was con-
ducted. No flow diagram provided with
losses to follow-up, do not know whether
losses to follow-up were similar between
both arms
Knowledge of allocated intervention pre-
vented?
Unclear risk Not reported
Protected against contamination? High risk Quote: “… avoiding the “contamination”
of centers that acted as controls (those cen-
ters providing usual diabetes care) was not
possible, because of the visibility and pub-
licity of the intervention at the local level.”
p 151
Free from selective outcome reporting? Unclear risk Judgement comment: no protocol or trial
registry entry available and therefore not
possible to assess
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Barcelo 2010 (Continued)
Other risks of bias? Low risk Judgement comment: no evidence of other
sources of bias
Basch 1999
Methods Study aim: to evaluate the impact of a multicomponent health education intervention
on the rate of ophthalmic examinations in African Americans with diabetes
Study design: parallel-group RCT
Participants Country: USA
Setting: outpatient clinics at 5 sites in the New York metropolitan area with on-site
ophthalmology services (secondary care)
Total number of participants: 280
Percentage male: 34.3%
Diabetes type: NR
Average age (SD): 54.8 yrs (12.9)
Inclusion criteria: African-American patients > 18 yrs with a diagnosis of diabetes with
no record of receiving a dilated eye exam in the preceding 14 months
Exclusion criteria: blindness in both eyes, advanced eye disease, progressive medical
illness, impaired cognitive ability
Interventions Intervention (n = 137):multicomponent educational intervention consisting of a book-
let and motivational video describing the benefits of eye screening, semi-structured tele-
phone outreach education and counselling
Comparator (n = 143):mailed booklet produced by the American Medical Association
on meal planning
Duration: 6 months (or until eye exam recorded)
Outcomes Primary outcome: documented dilated retinal examination within 6 months of ran-
domisation
Secondary outcomes: predictors of examination status
Baseline screening attendance (control group): 0%
Notes Date conducted: 1993 to 1995
Trial registration number: NR
Sources of funding: National Eye Institute, National Institute of Diabetes andDigestive
and Kidney Disease
Declaration of interest: none declared
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Low risk Quote “After research staff confirmed sub-
jects could be reached by telephone, they
were enrolled and randomised within site
and sex groups. We randomized subjects in
pairs by using tables of random permuta-
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Basch 1999 (Continued)
tions.” p 1879
Adequate allocation concealement? Unclear risk Not reported
Similar baseline outcome measurements? Low risk Quote: “Eligibility criteria based on chart
audits included a diagnosis of diabetes mel-
litus, being African American, being 18
years or older, having no documentation of
a dilated retinal examination in the preced-
ing 14months, and having been seen at the
clinic at least 1 other time in the past year.
” p 1879
Similar baseline characteristics? Low risk Quote “There were no significant differ-
ences between groups on any of the avail-
able personal and demographic variables”
(see Table 1 p 1880)
Incomplete outcome data addressed? Unclear risk Judgement comment: attrition not re-
ported for comparator group and not pos-
sible to assess (see Figure 1 p 1880)
Knowledge of allocated intervention pre-
vented?
Low risk Quote “Research staff, unaware of subjects’
group assignment, auditedmedical records.
” p 1879
Protected against contamination? Low risk Judgement comment: it is unlikely that the
control group received the multicompo-
nent health education intervention
Free from selective outcome reporting? Unclear risk Judgement comment: no protocol or trial
registry entry available and therefore not
possible to assess
Other risks of bias? Low risk Judgement comment: no evidence of other
risks of bias
Bush 2014
Methods Study aim: to evaluate the impact of ‘LinkWorkers’ on the uptake of diabetic retinopathy
screening in a hard-to-reach and high-risk population group
Study design: cluster-RCT
Participants Country: UK
Setting: General practices in Coventry with a predominantly South Asian population
Total number of clusters: 10
Number of providers: NR
Number of patients: 2680
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Bush 2014 (Continued)
Percentage male: NR
Diabetes type: NR
Average age (SD): NR
Inclusion criteria: patients eligible for diabetic retinopathy screening service failing to
attend their first screening appointment
Exclusion criteria: NR
Interventions Intervention (5 clusters, n = 988 participants): multilingual ‘Link Worker’ telephone
calls to participants failing to attend their first appointment to remind them of the
screening appointment and encourage attendance
Comparator (5 clusters, n = 1692 participants): usual care (participants who failed to
attend their initial screen date were sent a further appointment date by post)
Duration: phone calls continued until an examination was reported or after 6 months,
whichever came first
Outcomes Primary outcome: attendance for diabetic retinopathy screening within 6 months of
randomisation
Secondary outcomes: none
Baseline screening attendance (control group): NR
Notes Date conducted: 1 January to 31 December 2007
Trial registration number: ISRCTN79653731
Sources of funding: unfunded
Declaration of interest: none declared
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk Not reported
Adequate allocation concealement? Low risk Judgement comment: unit of allocation by
GPpractice and allocation performed prior
to the start of the study
Similar baseline outcome measurements? Low risk Judgement comment: similar baseline
retinopathy screening attendance (see Ta-
ble 1 p 296)
Similar baseline characteristics? Unclear risk Not reported
Incomplete outcome data addressed? Low risk Judgement comment: data reported for all
participants
Knowledge of allocated intervention pre-
vented?
Low risk Quote “Data available for analyses com-
prised routinely collected and collated at-
tendance data from the retinopathy screen-
ing unit.” p 295
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Bush 2014 (Continued)
Protected against contamination? Low risk Quote “Following randomisation and
throughout the study, there was no further
contact with control practices.” p 295
Free from selective outcome reporting? Unclear risk Judgement comment: trial retrospectively
registered and so not possible to assess
Other risks of bias? Low risk Judgement comment: no evidence of other
risks of bias
Choe 2005
Methods Study aim: to evaluate the effect of case management by a clinical pharmacist on gly-
caemic control and preventive measures in patients with type 2 diabetes mellitus
Study design: parallel-group RCT
Participants Country: USA
Setting: university-affiliated primary care internal medicine clinic
Total number of participants: 80
Percentage male: 47.5%
Diabetes type: type 2
Average age (SD): 51.6 yrs (10.1)
Inclusion criteria: high-risk individuals whose most recent HbA1c levels ≥ 8.0%
Exclusion criteria: type 1 diabetes mellitus (based on diagnosis before age 30 years),
if they were > 70 years, or if they were diagnosed as having cancer, renal failure, severe
cirrhosis, malignant hypertension, or a severe concurrent illness that would substantially
limit life expectancy or require extensive systemic treatment
Interventions Intervention (n = 41): on-site clinical pharmacist acting as a case manager, providing
evaluation and modification of pharmacotherapy, self-management diabetes education
(including an emphasis on the importance of self-care, medications, and screening pro-
cesses). Generally, the clinical pharmacist contacted the participants by telephone on a
monthly basis, unless more frequent assessment or recommendations were needed, and
saw the participants in conjunction with routine primary care visits
Comparator (n = 39): usual care (unspecified)
Duration: 12 months
Outcomes Primary outcome: HbA1c level at 12 months
Secondary outcomes:diabetes processmeasures, including low-density lipoproteinmea-
surement, dilated retinal examination, urine microalbumin screening (or use of an-
giotensin-converting enzyme inhibitors), and monofilament testing for diabetic neu-
ropathy within the 2-year time frame of the study
Baseline screening attendance (control group): NR
Notes Date conducted: NR
Trial registration number: NR
Sources of funding: funding for the clinical pharmacist was provided by the University
of Michigan College of Pharmacy
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Choe 2005 (Continued)
Declaration of interest: NR
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Low risk Quote: “Randomization within each stra-
tum was simple: because
the study was small, randomization was
done by hand,drawing numbers from a
container that included “0” for the control
group or “1” for the intervention group.”
p 255
Adequate allocation concealement? Unclear risk Not reported
Similar baseline outcome measurements? Unclear risk Not reported
Similar baseline characteristics? Low risk Judgement comment: baseline characteris-
tics of participants were similar in each arm
(see Table 1 p 256)
Incomplete outcome data addressed? Low risk Judgement comment: attrition not bal-
anced across arms (12% loss to follow-up
in intervention group and 26% in control
group). See CONSORT flow diagram p
255
Knowledge of allocated intervention pre-
vented?
Low risk Judgement comment: data on eye screening
obtained by chart review but not clear if
outcome assessor was masked
Protected against contamination? Unclear risk Judgement comment: control group not
described and not clear if contamination
was prevented
Free from selective outcome reporting? Unclear risk Judgement comment: no protocol or trial
registry entry available and therefore not
possible to assess
Other risks of bias? Low risk Judgement comment: no evidence of other
sources of bias
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Clancy 2007
Methods Study aim: to evaluate the effect of group visits on clinical outcomes concordant with
10 American Diabetes Association (ADA) guideline processes of care
Study design: parallel-group RCT
Participants Country: USA
Setting: adult primary care centre, Medical University of South Carolina
Total number of participants: 186
Percentage male: 28%
Diabetes type: type 2
Average age (SD): 56 yrs (NR)
Inclusion criteria: aged > 18 years with poorly-controlled diabetes mellitus (HbA1c >
8.0%)
Exclusion criteria: primary diagnosis of substance abuse or dependence; current preg-
nancy; dementia; inability to hear, speak English; obtain transportation to the clinic
Interventions Intervention (n = 96): monthly group visits (14 - 17 per group), co-led by an internal
medicine physician and a registered nurse. One-on-one visits were available for care
as needed between scheduled group visits or for specific medical needs not amenable
to group visits. Group visit content consisted of educational topics such as nutrition,
exercise, foot care, medications, complications of diabetes, and the emotional aspects of
diabetes
Comparator (n = 90): control participants received usual care in the clinic, seeing faculty
or resident physicians, physician assistants, nurse practitioners, or medical or physician
assistant students with access to a dietician and diabetes educator
Duration: 12 months
Outcomes Primary outcome: 10 ADA process-of-care indicators ( > 2 yearly HgA1c, at least yearly
cholesterol levels, treatment for LDL cholesterol levels > 100 mg/dl, yearly ophthal-
mologic referrals, influenza vaccinations, foot exams, and checks for microalbuminuria,
ACE-inhibitor or angiotensin receptor blocker use, daily aspirin unless contraindicated,
and at least 1 pneumococcal vaccine)
Secondary outcomes: NR
Baseline screening attendance (control group): NR
Notes Date conducted: September 2002 to February 2003
Trial registration number: NR
Sources of funding: Agency forHealthcareResearch andQuality; RobertWood Johnson
Foundation; National Institutes of Health
Declaration of interest: 2 authors reported receiving grants from Pfizer and Elli Lilly
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Low risk Quote: “Subjects meeting criteria for in-
clusion into the study were randomized
after informed consent and baseline data
collection using randlst software (http:
//odin.mdacc.tmc.edu/anonftp/) allowing
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Clancy 2007 (Continued)
for stratification and blocking. Subjects
were stratified by race and gender using a
block size of 4.” p 621
Adequate allocation concealement? Unclear risk Not reported
Similar baseline outcome measurements? Unclear risk Not reported
Similar baseline characteristics? Low risk Quote: “Demographic variables were well
balanced between patients randomized to
group visits or usual care at baseline (Table
1).” p 622
Quote: “Clinical variables were also well
balanced at baseline (Table 1) ‘with a mean
HgbA1c level at baseline of 9.3% for group
patients and 8.9% for control patients. The
mean total cholesterol level for group pa-
tients was 193.4 and 196.1 mg/dl for con-
trol patients. Blood pressures, triglycerides,
LDL, and HDL levels showed no signif-
icant baseline differences between the 2
groups.” p 622
Incomplete outcome data addressed? Low risk Judgement comment: missing data bal-
anced across 2 arms of study (17% in the
intervention arm and 16% in the compara-
tor arm). Reasons given for missing data
Knowledge of allocated intervention pre-
vented?
Low risk Quote: “Upon study completion, medical
records were blindly abstracted for the 10
ADA process-of-care indicators.” p 621
Protected against contamination? High risk Quote: “These providers also had patients
in the usual care arm as part of the general
pool of clinic patients; thus, it is possible
through contamination that providers may
have adopted some of the group visit strate-
gies (e.g., group visit educational content)
for control patients.” p 623
Free from selective outcome reporting? Unclear risk Judgement comment: no protocol or trial
registry entry available and therefore not
possible to assess
Other risks of bias? Low risk Judgement comment: no evidence of other
sources of bias
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Conlin 2006
Methods Study aim: to study whether non-mydriatic digital retinal imaging in an ambulatory
care setting affected adherence to annual dilated ophthalmic examinations in patients
with diabetes
Study design: parallel-group RCT
Participants Country: USA
Setting: Department of Veterans Affairs (VA) Boston Healthcare System
Total number of participants: 448
Percentage male: 98%
Diabetes type: NR
Average age (SD): 67 yrs (21.2)
Inclusion criteria: adults with diabetes and a VA-based primary care provider
Exclusion criteria: NR
Interventions Intervention (n = 223): teleretinal imaging by trained imager who demonstrated to the
participant using the retinal images, the basic anatomical structures of the ocular fundus.
Acting as a care co-ordinator, the imager later acted on the image reader’s report when
necessary and communicated with the participant to establish an appropriate eye-exam
schedule. The imager also educated the participant about the importance of optimal
blood glucose and blood pressure control
Comparator (n = 225): usual care (not specified)
Duration: 12 months
Outcomes Primary outcome: documented dilated retinal examination within 12 months of ran-
domisation
Secondary outcomes: diabetic retinopathy outcomes and characteristics of participants
with ungradable images
Baseline screening attendance (control group): NR
Notes Date conducted: NR
Trial registration number: NR
Sources of funding: Department of the Army; VA Health Services Research and De-
velopment Service; National Institutes of Health
Declaration of interest: none declared
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Low risk Quote: “Randomization was accomplished
with a random-variables generator and a
series of sealed envelopes.” p 734
Adequate allocation concealement? Unclear risk Quote: “Randomization was accomplished
with a random-variables generator and a
series of sealed envelopes.” p 734
Judgment comment: not clear whether the
envelopewas assigned to the participant be-
fore opening
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Conlin 2006 (Continued)
Similar baseline outcome measurements? Unclear risk Not reported
Similar baseline characteristics? Unclear risk Not reported
Incomplete outcome data addressed? Low risk Judgement comment: data available for all
participants (see Table 2)
Knowledge of allocated intervention pre-
vented?
Unclear risk Not reported
Protected against contamination? Low risk Judgement comment: it is unlikely that the
control group received teleretinal imaging
Free from selective outcome reporting? Unclear risk Comment: no protocol or trial registry en-
try available and therefore not possible to
assess
Other risks of bias? Low risk Judgement comment: no evidence of other
risks of bias
Davis 2003
Methods Study aim: to determine if telemedicine improves eye examination rates in individuals
with diabetes
Study design: parallel-group RCT
Participants Country: USA
Setting: rural, federally funded, primary care practice in South Carolina
Total number of participants: 59
Percentage male: NR
Diabetes type: NR
Average age (SD): NR
Inclusion criteria: > 18 years with physician diagnosis of diabetes of any duration and
on any form of treatment
Exclusion criteria: NR
Interventions Intervention (n = 30): telemedicine retinal screening programme. Ophthalmologist at a
distant site evaluated retinal photographs and consulted with the participant using real-
time videoconferencing
Comparator (n = 29): usual care (reminded to schedule appointments with their usual
eye care provider)
Duration: NR
Outcomes Primary outcome: retinal examination attendance
Secondary outcomes: NR
Baseline screening attendance (control group): NR
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Davis 2003 (Continued)
Notes Date conducted: NR
Trial registration number: NR
Sources of funding: NR
Declaration of interest: NR
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk Not reported
Adequate allocation concealement? Unclear risk Not reported
Similar baseline outcome measurements? Unclear risk Not reported
Similar baseline characteristics? Unclear risk Not reported
Incomplete outcome data addressed? Unclear risk Not reported
Knowledge of allocated intervention pre-
vented?
Unclear risk Not reported
Protected against contamination? Low risk Judgement comment: it is unlikely that the
control group received the intervention
Free from selective outcome reporting? Unclear risk Judgement comment: no protocol or trial
registry entry available and therefore not
possible to assess
Other risks of bias? Unclear risk Judgement comment: not possible to assess
Davis 2010
Methods Study aim: to evaluate a remote comprehensive diabetes self-management education
intervention to improve adherence to American Diabetes Association (ADA) guidelines
Study design: parallel-group RCT
Participants Country: USA
Setting: underserved population in 3 community health centres in South Carolina
Total number of participants: 165
Percentage male: 25.4%
Diabetes type: NR
Average age (SD): 59.6 yrs (9.3)
Inclusion criteria: HbA1c > 7%, aged≥ 35 yrs, seen in the last year in the community
health centre, diagnosis of diabetes and willingness to participate
Exclusion criteria: BMI < 25, pregnancy, acute and chronic illness preventing partici-
pation
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Davis 2010 (Continued)
Interventions Intervention (telehealth) (n = 85): remote diabetes self-management educational inter-
vention consisting of 13 sessions (3 individual and 10 group). Participants were offered
optional retinal imaging in the primary care setting when they were due for their annual
eye exam
Comparator (n = 80): usual care (consisting of 1 x 20-minute diabetes education ses-
sion using ADA materials). Access to existing services at the community health centre
(including care managers and a nurse practitioner)
Duration: 12 months
Outcomes Primary outcome: HbA1c measured at baseline, 6 months, and 12 months
Secon%dary outcomes: LDL cholesterol, blood pressure, albumin to creatinine ratio,
BMI (measured at 6 and 12 months) and uptake of annual eye examinations
Baseline screening attendance (control group): 46.3%
Notes Date conducted: April 2005 to October 2006
Trial registration number: NCT00288132
Sources of funding: National Institutes of Health
Declaration of interest: none declared
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk Not reported
Adequate allocation concealement? Unclear risk Not reported
Similar baseline outcome measurements? Low risk Judgement comment: similar rates of self-
reported annual eye examinations. Table 2
p 1714
Similar baseline characteristics? Low risk Judgement comment: no significant differ-
ences in baseline characteristics. Table 2 p
1714
Incomplete outcome data addressed? Low risk Quote: “Retention rates at 6 and 12
months were 90.9 and 82.4%, respectively.
” p 1716
Knowledge of allocated intervention pre-
vented?
Unclear risk Not reported
Protected against contamination? Low risk Judgement comment: it is unlikely that the
control group received the intervention
Free from selective outcome reporting? Low risk Judgement comment: re-
ported outcomes consistent with trial reg-
istry NCT00288132
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Davis 2010 (Continued)
Other risks of bias? Low risk Judgement comment: no evidence of other
sources of bias
Dickinson 2014
Methods Study aim: to compare the effectiveness of a programme to improve diabetes care by a)
increasing the practice’s organisational capacity to manage change (Reflective Adaptive
Process (RAP)), and b) implementing and sustaining the Chronic CareModel to support
the clinicians’ efforts to improve care for diabetes (Continuous Quality Improvement
(CQI))
Study design: cluster-RCT
Participants Country: USA
Setting: Small to mid-sized community health centres and independent mixed payer
primary care practices in Colorado
Number of clusters: 40
Number of providers: NR
Total number of patients: 822
Percentage male: 48.7%
Diabetes type: NR
Average age (SD): 60.6 yrs (12.7)
Inclusion criteria: diagnosis of diabetes and at least 1 visit to the practice in 18 months
before practice enrolment and at least 1 visit in the 18 months after enrolment
Exclusion criteria: NR
Interventions Intervention (RAP) (15 clusters, n = 312 patient charts reviewed): practice facilitation
using the RAP model (consisting of changing organisational functioning to improve
diabetes care). Practices received training in change management strategies and provided
with audit and feedback
Intervention (CQI) (10 clusters, n = 189 patient charts reviewed): practice facilita-
tion using the ‘Model for Improvement’ (consisting of forming and facilitating practice
improvement teams and provision of audit and feedback)
Comparator (15 practices, n = 321 patients charts reviewed): practices received lim-
ited feedback on baseline work culture and level of implementation of the Chronic Care
Model (CCM). Practices were given access to a website regarding quality improvements
and received audit and feedback as in the other groups
Duration: practice facilitation of 6 months (RAP) or 18 months (CQI)
Outcomes Primary outcome: HbA1c, blood pressure, lipids, process of care measured at baseline,
9 and 18 months (including diabetes-related visits to ophthalmologist)
Secondary outcomes: patient report (by survey) of their primary care experience
Baseline screening attendance (control group): 5.9%
Notes Date conducted: NR
Trial registration number: NCT00414986
Sources of funding:National Institute ofDiabetes andKidneyDiseases and theNational
Institute of Mental Health
Declaration of interest: none declared
57Interventions to increase attendance for diabetic retinopathy screening (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Dickinson 2014 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk Not reported
Adequate allocation concealement? Low risk Judgement comment: unit of allocation by
community health centre and allocation
performed prior to the start of the study
Similar baseline outcome measurements? Low risk Judgement comment: rates of dilated eye
examinationswere not statistically different
between study arms. Table 2 p 13
Similar baseline characteristics? Unclear risk Quote: “…baseline HbA1c level, systolic
blood pressure, and total cholesterol level
differed significantly across groups (all P <.
05), with slightly better baseline control of
each in RAP practices.” p 11
Judgement comment: unclear whether dif-
ferences in baseline characteristics would
have influenced outcome
Incomplete outcome data addressed? Unclear risk Judgement comment: random sample of
participants taken from each cluster but
missing data from some practices in chart
audit
Knowledge of allocated intervention pre-
vented?
Unclear risk Not reported
Protected against contamination? Low risk Judgement comment: allocation was by
practice and it is unlikely that the control
group received the intervention
Free from selective outcome reporting? Low risk Judgement comment: re-
ported outcomes consistent with trial reg-
istry NCT00414986
Other risks of bias? Unclear risk Judgement comment: no evidence of other
sources of bias
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Dijkstra 2005
Methods Study aim: to investigate whether a comprehensive strategy, involving both patients and
professionals, with the introduction of a diabetes passport as a key component, improves
diabetes care
Study design: cluster-RCT
Participants Country: The Netherlands
Setting: 9 general hospitals throughout The Netherlands
Number of clusters: 9
Number of providers: 42
Total number of patients: 1350
Percentage male: 48%
Diabetes type: types 1 and 2
Average age (SD): 58 yrs (15.5)
Inclusion criteria: all patients under the care of an internist for diabetic monitoring
Exclusion criteria: pregnancy; patients with low life expectancy
Interventions Intervention (4 clusters, n = 600 patients): feedback on aggregated patient baseline
data was given to the healthcare professionals. During an educational meeting with a
national diabetes opinion leader, guidelines were issued on the prevention and treatment
of diabetes complications as well as guidance on the use and dissemination of diabetes
passports. The ‘diabetes passport’ is a patient-held booklet with important personal in-
formation that can be used to track results, record treatment targets and give informa-
tion. The passport also records the medications used, results of laboratory and physical
examinations and patient education. For patients additional educational meeting were
organised
Comparator (5 clusters, n = 750 patients): usual care (national diabetes guidelines
issued to all hospitals during the intervention period)
Duration: 12 months
Outcomes Primary outcome: measures consisted of process and outcome indicators taken from
evidence-based Dutch guidelines on the treatment of diabetes and prevention of com-
plications (including yearly examination of HbA1c, creatinine, total cholesterol or total
cholesterol/HDL ratio, urine for microalbuminuria, weight, BMI and blood pressure,
as well as advice on smoking and physical exercise). The guidelines advise an eye exami-
nation every 1 - 2 years (yearly in the case of those at higher risk of retinopathy)
Secondary outcomes: NR
Baseline screening attendance (control group): 84%
Notes Date conducted: November 1999 to March 2000
Trial registration number: NR
Sources of funding: Netherlands Organisation for Health Research and Development
Declaration of interest: NR
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk Not reported
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Dijkstra 2005 (Continued)
Adequate allocation concealement? Low risk Quote: “Random allocation was done by a
person outside the research group and con-
cealed from the investigators until the start
of the intervention.” p 128
Similar baseline outcome measurements? Low risk Judgement comment: similar baseline eye
examinations < 12 months or < 24 months
(see Table 2 p 131)
Similar baseline characteristics? Low risk Judgement comment: baseline characteris-
tics similar across the 2 arms of the study
(see Tables 1 and 2 p 131)
Incomplete outcome data addressed? High risk Judgement comment: high attrition (58.
5% and 55.7% of those randomised to
intervention and control respectively were
analysed)
Knowledge of allocated intervention pre-
vented?
Unclear risk Not reported
Protected against contamination? Low risk Judgement comment: allocation was by
hospital and it is unlikely that the control
group received the intervention
Free from selective outcome reporting? Unclear risk Judgement comment: no protocol or trial
registry entry available and therefore not
possible to assess
Other risks of bias? Low risk Judgement comment: no evidence of other
sources of bias
Dijkstra 2008
Methods Study aim: to investigate whether the introduction of a diabetes passport improves
diabetes care
Study design: cluster-RCT
Participants Country: The Netherlands
Setting: primary care practices in the middle and south regions of The Netherlands
Number of clusters: 40
Number of providers: 61
Total number of patients: 2059
Percentage male: 49.8%
Diabetes type: types 2
Average age (SD): 63.4 yrs (9.6)
Inclusion criteria: all patients with type 2 diabetes < 80 years under the care of a general
practitioner
60Interventions to increase attendance for diabetic retinopathy screening (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Dijkstra 2008 (Continued)
Exclusion criteria: those with a life expectancy < 1 year; patients who received their
diabetes treatment in secondary care
Interventions Intervention (20 clusters, n = 1004 participants): dissemination of diabetes passports.
The ‘diabetes passport’; is a patient-held booklet with important personal information
that can be used to track results, record treatment targets and give information. The
passport also records the medications used, results of laboratory and physical examina-
tions and patient education. Additional patient education meetings were organised
Comparator (20 clusters, n = 1055 participants): usual care (not specified)
Duration: 15 months
Outcomes Primary outcome: self-reported use of the passport by participants
Secondary outcomes: process and outcome diabetes care indicators (including eye ex-
amination within the previous 24 months)
Baseline screening attendance (control group): 72.2%
Notes Date conducted: NR
Sources of funding: Netherlands Organisation for Health Research and Development
Declaration of interest: NR
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk Not reported
Adequate allocation concealement? Low risk Judgement comment: unit of allocation by
community health centre and allocation
performed prior to the start of the study
Similar baseline outcome measurements? Low risk Judgement comment: similar baseline % of
eye examinations within 24 months (see
Table 3 p 75)
Similar baseline characteristics? Unclear risk Quote: “Comparison of the baseline data
from the intervention and control groups
showed that there were some differences.
The patients in the intervention group
were more often women and fewer moni-
tored glucose themselves than in the con-
trol group (Table 1).”
Judgement comment: baseline characteris-
tic differences could have influenced out-
come
Incomplete outcome data addressed? Low risk Judgement comment: eye screening data
available for all participants
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Dijkstra 2008 (Continued)
Knowledge of allocated intervention pre-
vented?
Unclear risk Not reported
Protected against contamination? Low risk Judgement comment: allocation was by
hospital and it is unlikely that the control
group received the intervention
Free from selective outcome reporting? Unclear risk Judgement comment: no protocol or trial
registry entry available and therefore not
possible to assess
Other risks of bias? Unclear risk Quote: “Table 2 shows that, in addition to
the research intervention activities, several
control and intervention practices had ini-
tiated organizational interventions and re-
vision of professional roles during the in-
tervention period.” p 75
Judgement comment: not clear how these
changes impacted on the outcome
Eccles 2007
Methods Study aim: to evaluate the effectiveness and efficiency of a computerised diabetes register
and management system on the quality of diabetes care
Study design: cluster-RCT
Participants Country: UK
Setting: 3 Primary Care Trusts in the northeast of England
Number of clusters: 58
Number of providers: 58
Total number of patients: 3608
Percentage male: 53%
Diabetes type: type 2
Average age (SD): 66 yrs (11.5)
Inclusion criteria: people with type 2 diabetes appearing on the registers, aged > 35 years
and receiving diabetes care exclusively from study general practices or shared between
study general practices (GPs) and hospital
Exclusion criteria: NR
Interventions Intervention (30 clusters, n = 1674 participants): computerised diabetes register in-
corporating a full structured recall and management system, including individualised
patient management prompts to primary care clinicians based on locally-adapted, evi-
dence-based guidelines
Comparator (28 clusters, n = 1934 participants): usual care (not specified)
Duration: 15 months
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Eccles 2007 (Continued)
Outcomes Primary outcomes: clinical process and outcome variables held on the diabetes registers;
patient-reported outcomes (SF36health status profile, theNewcastleDiabetes Symptoms
Questionnaire and the Diabetes Clinic Satisfaction Questionnaire); service and patient
costs
Secondary outcomes: NR
Baseline screening attendance (control group): 49.5%
Notes Date conducted: 1 April 2002 to 30 June 2003
Trial registration number: ISRCTN32042030
Sources of funding: Diabetes UK, and Northern and Yorkshire Regional NHS R&D
Office
Declaration of interest: 1 of the authors was a partner in a software company that
maintained the software used in the study. The remaining authors declared no competing
interests
Study protocol has been published: www.ncbi.nlm.nih.gov/pubmed/11914161
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Low risk Quote: “Randomisationwas performed us-
ing electronically-generated random num-
bers by the study statistician and was strat-
ified by PCT and practice size.” p 3
Adequate allocation concealement? Low risk Judgement comment: unit of allocation by
primary care practice and allocation per-
formed prior to the start of the study
Similar baseline outcome measurements? Low risk Judgement comment: similar % of
recorded fundoscopy at baseline
Similar baseline characteristics? Low risk Quote: “Table 1 shows the baseline charac-
teristics of control and intervention prac-
tices and patients. None of the differences
in these variables between the intervention
and control group are statistically signifi-
cant.” p 5
Incomplete outcome data addressed? Low risk Judgement comment: although there was
a high attrition for patient-reported out-
comes, the register-derived outcomes were
available for all participants
Knowledge of allocated intervention pre-
vented?
Low risk Judgement comment: data on fundoscopy
obtained directly from the registry
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Eccles 2007 (Continued)
Protected against contamination? Low risk Judgement comment: allocation was by
practice and it is unlikely that the control
group received the intervention
Free from selective outcome reporting? Low risk Judgement comment: reported
outcomes consistent with trial registry IS-
RCTN32042030
Other risks of bias? Low risk Judgement comment: no evidence of other
sources of bias
Ellish 2011
Methods Study aim: to compare the effects of a tailored (individualised) and targeted (generic)
print intervention in promoting dilated fundus examinations in older African Americans
Study design: parallel-group RCT
Participants Country: USA
Setting: primary care
Total number of participants: 72 (sub-population with diabetes)
Percentage male: 25%
Diabetes type: NR
Average age (SD): 72.4 yrs (6.3)
Inclusion criteria: African Americans aged ≥ 65 yrs who had not had a dilated fundus
examination in the last 2 years
Exclusion criteria: NR
Interventions Intervention (n = 39): ‘Tailored intervention’. Each participant received a 4-page
newsletter including a testimonial designed to model eye examination behaviour and a
barrier table to convey specific ideas to overcome barriers. The newsletter was specifi-
cally tailored by the addition of specific messages based on his/her responses to selected
questions from a baseline questionnaire which identified barriers to screening and pre-
ventative health behaviours
Comparator (n = 33): ‘Targeted intervention’. Participants received a standard newslet-
ter with the same sections as the intervention group but without the tailored messages
Duration: 6 months
Outcomes Primary outcome: eye doctor confirmed dilated retinal examination at 6 months fol-
lowing randomisation
Secondary outcomes: predictors of retinal examination attendance
Baseline screening attendance (control group): 0%
Notes Date conducted: June 2007 and September 2008
Trial registration number: NCT00649766
Sources of funding: National Institutes of Health
Declaration of interest: none reported
Data on the sub-population with diabetes obtained from the author
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Ellish 2011 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk Not reported
Adequate allocation concealement? Unclear risk Not reported
Similar baseline outcome measurements? Unclear risk Not reported
Similar baseline characteristics? Low risk Quote “As reported in Table 2, at base-
line the intervention groups were compa-
rable for demographic and other variables.
” p 1594
Incomplete outcome data addressed? Low risk Judgement comment: low attrition. All
participants accounted for (Figure 1 p
1594)
Knowledge of allocated intervention pre-
vented?
Unclear risk Not reported
Protected against contamination? Low risk Judgement comment: it is unlikely that the
control group received the tailored inter-
vention
Free from selective outcome reporting? Unclear risk Judgement comment: trial retrospectively
registered and so not possible to assess
Other risks of bias? Low risk Judgement comment: no evidence of other
sources of bias
Franco 2007
Methods Study aim: to study the impact of an outreach visit by a diabetes specialist on general
practitioners management of type 2 diabetes
Study design: cluster-RCT
Participants Country: Réunion (French overseas territory)
Setting: General practices on the island of Réunion
Total number of clusters: 82
Number of providers: 82
Number of patients: 1581
Percentage male: 25%
Diabetes type: type 2
Average age (SD): 59.9 (NR)
Inclusion criteria: GPs were selected if they had been working for 2 years or more and
were likely to be employed for the duration of the study
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Franco 2007 (Continued)
Exclusion criteria: see above
Interventions Intervention (42 clusters, n = 792 participants): 2 outreach visits by visiting GP with
diabetes expertise. First visit consisted of a presentation on guideline recommendations,
provision of teaching materials and clinical tools for diabetes assessment, e.g. esthe-
siometer. Second visit reinforced guideline recommendations and provided feedback on
a questionnaire relating to 3 consecutive participants with diabetes seen following the
first visit
Comparator (40 clusters, n = 789 participants): usual care (not specified)
Duration: 2 outreach visits and outcomes measured within 6 months of the last visit
Outcomes Primary outcome: compliance with processes of care recommendations for the man-
agement of type 2 diabetes including HbA1c, foot and fundus examination, creatinine
clearance and assessment for proteinuria/microalbuminuria which weremeasured within
6 months following delivery of intervention
Secondary outcomes: none
Baseline screening attendance (control group): 35%
Notes Date conducted: NR
Trial registration number: NR
Sources of funding: NR
Declaration of interest: NR
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk Not reported
Adequate allocation concealement? Low risk Judgement comment: unit of allocation by
GPpractice and allocation performed prior
to the start of the study
Similar baseline outcome measurements? Low risk Judgement comment: similar rates of
retinopathy screening attendance at base-
line (see Table 2 p 2)
Similar baseline characteristics? Low risk Quote: “Le nombre, l’âge, le sex-ratio et
le statut vis-à-vis de l’emploi des patients
étaient semblables dans les deux groupes
(tableau I). [The number , age, sex ratio and
employment status of patients were similar
in both groups (Table I)]” p 2
Incomplete outcome data addressed? High risk Judgement comment: high attrition (ap-
prox 30% in both arms)
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Franco 2007 (Continued)
Knowledge of allocated intervention pre-
vented?
High risk Judgement comment: GPs in the interven-
tion group provided the data on retinopa-
thy screening
Protected against contamination? Low risk Quote “Dans le groupe témoin,contacté
seulement à la fin de l’étude…[In the con-
trol group, contacted only at the end of the
study],..” p 2
Judgement comment: allocation by cluster
andunlikely that the control group received
the intervention
Free from selective outcome reporting? Unclear risk Judgement comment: no protocol or trial
registry entry available and therefore not
possible to assess
Other risks of bias? Low risk Judgement comment: no evidence of other
risks of bias
Frei 2014
Methods Study aim: to test whether the implementation of elements of the ‘Chronic Care Model
(CCM)’ by a specially-trained practice nurse leads to an improved cardiovascular risk
profile among type 2 diabetes patients
Study design: cluster-RCT
Participants Country: Switzerland
Setting: Primary care practices
Total number of clusters: 30
Number of providers: 30
Number of patients: 326
Percentage male: 57%
Diabetes type: type 2
Average age (SD): 67 yrs (10.6)
Inclusion criteria: adults (> 18 years) with type 2 diabetes
Exclusion criteria: unable to read and understand the patient information form due
to dementia, illiteracy or language skills. Patients with oncological diseases and/or an
estimated life expectancy of less than six months due to severe diseases
Interventions Intervention (15 clusters, n = 164 participants): implementation of team care using
elements of the Chronic Care Model (CCM) by a specially-trained practice nurse and
using a computerised monitoring tool and decision support
Comparator (15 clusters, n = 162 participants): usual care (not specified)
Duration: 12 months
Outcomes Primary outcome: HbA1c level
Secondary outcomes: guideline adherence (recommended treatment goals) including
receiving at least 1 eye examination a year. Quality of life
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Frei 2014 (Continued)
Baseline screening attendance (control group): 64%
Notes Date conducted: 2010 to 2013
Trial registration number: ISRCTN05947538
Sources of funding: Swiss Academy for Medical Sciences; A. Menari AG, Switzerland
Declaration of interest: none declared
Study propocol has been published: www.ncbi.nlm.nih.gov/pubmed/20550650
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Low risk Quote:“The PCPs who agreed to partici-
pate in the study were alphabetically or-
dered by their family names in a list with
numbers from 1 to 30. An independent re-
search assistant, who was not involved in
the study and was blind to the identity of
the PCPs, randomly allocated by statisti-
cal computer software SPSS (version 18.0)
15 letters A and 15 letters B to numbers
1-30 and to the corresponding PCPs, re-
spectively. The assignment of the letters A
and B to either the intervention or control
group was randomly conducted by a sec-
ond research assistant who drew blinded a
ticket with the letters A or B and a ticket
with the group allocation intervention or
control group from an envelope.” p 1041
Adequate allocation concealement? Low risk Quote: “We informed all PCPs about the
group allocation after the inclusion of pa-
tients and baseline assessments tominimize
selection bias.” p 1041
Similar baseline outcome measurements? High risk Judgement comment: different rates of
retinopathy screening attendance at base-
line (control 64%, intervention 73.5%)
(see supplementary Table 2)
Similar baseline characteristics? Low risk Judgement comment: similar baseline
characteristics (Table 1 p 1009, Table 2 p
1044)
Incomplete outcome data addressed? Low risk Judgement comment: data available for
all providers and low rate of attrition in
outcome data (see CONSORT diagram p
1042)
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Frei 2014 (Continued)
Knowledge of allocated intervention pre-
vented?
Unclear risk Quote: “due to the study design, it was not
possible to blind PCPs and practice nurses
to group allocation, which might have in-
fluenced the results or might have led to
a more pronounced effect of the interven-
tion.” p 1045
Judgement comment: unclear if would
have affected diabetic retinopathy screen-
ing attendance
Protected against contamination? Low risk Judgement comment: allocation was by
practice and it is unlikely that the control
group received the intervention
Free from selective outcome reporting? Low risk Judgement comment: reported outcomes
consistentwith study protocol and trial reg-
istry ISRCTN05947538
Other risks of bias? Low risk Judgement comment: no evidence of other
risks of bias
Frijling 2002
Methods Study aim: to evaluate the effectiveness of amultifaceted intervention to improve clinical
decision-making of general practitioners (GPs) for patients with diabetes
Study design: cluster-RCT
Participants Country: The Netherlands
Setting: primary care practices in the southern part of The Netherlands
Number of clusters: 124
Number of providers: 185
Total number of patients: 1410
Percentage male: 44.6%
Diabetes type: type 2
Average age (SD): 65 yrs (11.5)
Inclusion criteria: patients with type 2 diabetes
Exclusion criteria: NR
Interventions Intervention (62 clusters, n = 703 participants): GPs given feedback reports about
his or her current clinical decision-making about the diabetes guidelines issued by the
Dutch College of General Practitioners and received outreach visits from facilitators. As
part of the visits, the facilitator specifically addressed the clinical decision-making for
patients with type 2 diabetes. The facilitator provided guidance, support, and educational
materials to facilitate improvement
Comparator (62 clusters, n = 707 participants): usual care (not specified)
Duration: 21 months
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Frijling 2002 (Continued)
Outcomes Primary outcome: compliance rates for evidence-based indicators for management of
patients with type 2 diabetes (including eye examination in the past 24 months)
Secondary outcomes: NR
Baseline screening attendance (control group): 67%
Notes Date conducted: 1996 to 1999
Trial registration number: NR
Sources of funding: Netherlands Heart Foundation.
Declaration of interest: NR
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Low risk Quote: “A random-number generator was
used to select permuted blocks with a block
size of four” p 837
Adequate allocation concealement? Low risk Quote: “The practices were numbered and
the person responsible for the randomiza-
tion process was blind to the practice iden-
tities.” p 837
Similar baseline outcome measurements? Low risk Judgement comment: similar % of eye ex-
aminations at baseline
Similar baseline characteristics? Low risk Quote: “The ages of the patients, the pro-
portions of males and the proportions of
patients with uncontrolled blood glucose
were found to be equally distributed across
the intervention and control groups at base-
line and post-intervention measurement
(Table 1)” p 838
Judgement comment: similar baseline clin-
ical characteristics (see Table 2 p 840)
Incomplete outcome data addressed? Low risk Judgement comment: low cluster attrition.
High compliance with completion of en-
counter forms
Knowledge of allocated intervention pre-
vented?
Low risk Judgement comment: although GPs com-
pleting the encounter forms following each
consultation were unmasked, the data were
entered into a computer by personnel blind
to group allocation
Protected against contamination? Low risk Judgement comment: allocation was by
practice and it is unlikely that the control
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Frijling 2002 (Continued)
group received the intervention
Free from selective outcome reporting? Unclear risk Judgement comment: no protocol or trial
registry entry available and therefore not
possible to assess
Other risks of bias? Low risk Judgement comment: no evidence of other
sources of bias
Gabbay 2006
Methods Study aim: to measure the impact of a patient-oriented structured approach to care co-
ordination and patient education and counselling on improvements in BP, glycaemic
control, lipids, complication screening and diabetes-related distress
Study design: parallel-group RCT
Participants Country: USA
Setting: 2 primary care clinics of Penn State Hershey Medical Centre
Total number of participants: 332
Percentage male: 54.5%
Diabetes type: type 2
Average age (SD): 64.5 yrs (16.4)
Inclusion criteria: patients with diabetes, ≥ 18 years, identified by ICD 9 codes; 2 or
more visits for diabetes within the last year
Exclusion criteria: patients unable to speak English; residents of nursing homes
Interventions Intervention (n = 150): nurse case manager implementing diabetes management using
algorithms under the supervision of the participant’s primary care physician (PCP) (a
family physician or an internist). Goals were based on the ADA recommendations. The
nurse case manager used behavioural goal-setting, established individualised care plan,
provided participant self-management education and surveillance of participants, in-
cluding phone calls to participants, referred patrticipants to a certified diabetes nurse ed-
ucator or a dietitian where appropriate, ordered protocol-driven laboratory tests, tracked
the outcomes using the computerised data registry and made therapeutic recommenda-
tions based on ADA diabetes guidelines with approval of the PCP
Comparator (n = 182): usual care by their PCP, and had no interaction with the nurse
case manager
Duration: 12 months
Outcomes Primary outcome: changes in BP, HbA1c, lipids and complication screening process
measures (including annual retinal screening)
Secondary outcomes: diabetes-related distress, as measured by the PAID questionnaire
at 6 and 12months. The PAID scale is a 20-itemmeasure of emotional adjustment to life
with diabetes, with lower scores indicating better adjustment and coping with diabetes
Baseline screening attendance (control group): NR
Notes Date conducted: NR
Trial registration number: NCT00308386
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Gabbay 2006 (Continued)
Sources of funding: NR
Declaration of interest: NR
Study protocol has been published: www.ncbi.nlm.nih.gov/pubmed/19328244
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? High risk Quote: “A total of 332 patients were ran-
domized (bymethod of odd and even num-
bers) to either NCM intervention (inter-
vention group), or a usual routine care
(control group).” p 30
Judgement comment: inappropriate
method of sequence generation
Adequate allocation concealement? Unclear risk Not reported
Similar baseline outcome measurements? Unclear risk Not reported
Similar baseline characteristics? Low risk Quote: “The intervention group (n =150)
and the control/ usual care group (n =182)
were statistically equivalent on baseline de-
mographic and clinical characteristics.”
p 31
Incomplete outcome data addressed? Unclear risk Judgement comment: attrition not re-
ported
Knowledge of allocated intervention pre-
vented?
Unclear risk Not reported
Protected against contamination? Low risk Judgement comment: it is unlikely that the
control group received the intervention
Free from selective outcome reporting? Unclear risk Judgement comment: no protocol or trial
registry entry available and therefore not
possible to assess
Other risks of bias? Low risk Judgement: although baseline characteris-
tics were balanced across study arms, only
60% of patients randomised to the inter-
vention group agreed to participate
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Gabbay 2013
Methods Study aim: to determine whether the addition of nurse case managers trained in moti-
vational interviewing would result in improved outcomes in type 2 diabetes patients at
high risk of cardiovascular complications
Study design: parallel-group RCT
Participants Country: USA
Setting: 12 primary care clinics within 2 health systems in Central Pennsylvania
Total number of participants: 545
Percentage male: 37.8%
Diabetes type: type 2
Average age (SD): 58 yrs (11)
Inclusion criteria: patients 18 - 75 years with type 2 diabetes were eligible if they had 1
or more of the following: (i) HbA1c > 8.5%; (ii) blood pressure > 140/90 mmHg; and/
or (iii) Low-density lipoprotein (LDL) > 130 mg/dL
Exclusion criteria: could not communicate in either English or Spanish, or if residents
of nursing homes
Interventions Intervention (n = 232 ): bilingual nurse case manager (NCM) met individually with
participants at baseline, 2 and 6 weeks, at 3, 6 and 12 months and at least 6-monthly
thereafter to review clinical laboratory test results, medication adherence and health-
related lifestyle behaviour relating to managing their diabetes. The NCM also checked
whether the participant was due for complications screening and reminded them of
specialist visits
Comparator (n = 313): usual care (not specified)
Duration: 24 months
Outcomes Primary outcome: % of participants reaching the following outcomes 2 years after
enrolment: (1) HbA1C < 7; (2) BP goal < 130/80; (3) LDL at goal < 100
Secondary outcomes:% of participants with yearly ophthalmologic exam ,% of partic-
ipants with yearly foot exam, % of participants with assessment for nephropathy
Baseline screening attendance (control group): NR
Notes Date conducted: August 2006 to March 2008
Trial registration number: NCT00308386
Sources of funding: National Institute of Diabetes and Kidney Diseases
Declaration of interest: none declared
Study protocol has been published: www.ncbi.nlm.nih.gov/pubmed/19328244
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk Not reported
Adequate allocation concealement? Unclear risk Not reported
Similar baseline outcome measurements? Unclear risk Not reported
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Gabbay 2013 (Continued)
Similar baseline characteristics? Low risk Quote: “Baseline characteristics of the
study population are given in Table 1.
There were no significant differences in
study measures between the two groups.”
Table 1 p 353
Incomplete outcome data addressed? High risk Judgement comment: high attrition and
missing data unbalanced across 2 arms
of study (intervention 19%, comparator
26%)
Knowledge of allocated intervention pre-
vented?
Unclear risk Not reported
Protected against contamination? Low risk Judgement comment: it is unlikely that the
control group received the telephone re-
minder
Free from selective outcome reporting? Low risk Judgement comment: re-
ported outcomes consistent with trial reg-
istry NCT00308386
Other risks of bias? High risk Judgement comment: per-protocol anal-
ysis. N = 42 participants originally ran-
domised to the intervention arm were
moved to the control group since they did
not receive the nurseMI. Analysis andbase-
line data presented following the switch
Glasgow 2005
Methods Study aim: to evaluate the effectiveness of a computer-assisted patient-centred interven-
tion to improve the quality of diabetes care in primary care
Study design: cluster-RCT
Participants Country: USA
Setting: family physicians and general internists insured by Sopic Insurance Co in Col-
orado
Number of clusters: 52
Number of providers: 52
Total number of patients: 886
Percentage male: 48%
Diabetes type: type 2
Average age (SD): 62.9 yrs (12.7)
Inclusion criteria: adult patients≥ 25 years with type 2 diabetes and able to read English
Exclusion criteria: NR
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Glasgow 2005 (Continued)
Interventions Intervention (24 clusters, n = 469 participants): interactive computer programme
recording when participant last received 11 items on theNational Committee onQuality
Assurance/American Diabetes Association Provider Recognition Program (PRP) mea-
sures, followed by a printout of a self-management action plan. This was overseen by a
designated ‘care manager’ who met with the participant and reinforced self-management
strategies by telephone
Comparator (28 clusters, n = 417 participants): interactive computer programme
recording when last received 11 items on theNational Committee onQuality Assurance/
AmericanDiabetes Association Provider Recognition Program (PRP)measures, followed
by a printout of a self-management action plan. Control participants did not meet or
receive calls from the care manager
Duration: 12 months
Outcomes Primary outcome: participant reports of provision of receiving the 11 items in the PRP
measures (included dilated eye examination)
Secondary outcomes: Quality of life assessed using the revised ‘Problem Areas in Di-
abetes Scale (PAID-2) and the Patient Health Questionnaire (PHQ); HbA1c and ratio
of total cholesterol to HDL cholesterol levels
Baseline screening attendance (control group): 66.6%
Notes Date conducted: NR
Trial registration number: NR
Sources of funding: Agency for Health Research and Quality
Declaration of interest: NR
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk Not reported
Adequate allocation concealement? Low risk Judgement comment: unit of allocation by
primary care practice and allocation per-
formed prior to the start of the study
Similar baseline outcome measurements? Low risk Judgement comment: similar compliance
with dilated eye examination attendance at
baseline (see Table 2 p 36)
Similar baseline characteristics? Low risk Quote “Initial analysis failed to show base-
line differences between conditions in any
socioeconomic or baseline measures.” p 36
Incomplete outcome data addressed? Unclear risk Judgement comment: high attrition (19%
intervention, 13% control). Reasons for
missing data not given. Unclear if missing
data would impact on outcome
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Glasgow 2005 (Continued)
Knowledge of allocated intervention pre-
vented?
Unclear risk Judgement comment: eye-screening out-
come data based on self-reports and not
clear if outcome assessor was unmasked
Protected against contamination? Low risk Judgement comment: it is unlikely that the
control group received the intervention
Free from selective outcome reporting? Unclear risk Judgement comment: no protocol or trial
registry entry available and therefore not
possible to assess
Other risks of bias? Low risk Judgement comment: no evidence of other
sources of bias
Guldberg 2011
Methods Study aim: to evaluate the effect of an electronically-delivered feedback system on the
quality of care for people with type 2 diabetes
Study design: cluster-RCT
Participants Country: Denmark
Setting: 86 general practices in Vejle country Denmark
Number of clusters: 86
Number of providers: 160
Total number of patients: 2716
Percentage male: 46.1%
Diabetes type: type 2
Average age (SD): NR
Inclusion criteria: patients aged 40 - 70 diagnosed with type 2 diabetes prior to the
intervention
Exclusion criteria: death during intervention, moved out of geographic area during
intervention, GP retired during intervention
Interventions Intervention (43 clusters, n = 1453 participants): electronic feedback system present-
ing register data on patients with type 2 diabetes
Comparator (43 clusters, n = 1263 patients): usual care (not specified)
Duration: 15 months
Outcomes Primary outcome: ophthalmologist-conducted eye examination, redeemed prescrip-
tions, results of blood tests (HbA1c, serum cholesterol)
Secondary outcomes: qualitative study of how the intervention was used and received
by the GPs
Baseline screening attendance (control group): NR
Notes Date conducted: March 2007 to May 2008
Trial registration number: NCT01009528
Sources of funding: Vejle County Quality Committee; Central Region Denmark Qual-
ity Committee; Danish Council for Independent Research; Tryg Foundation; Vissings
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Guldberg 2011 (Continued)
Foundation; Danielsens Foundation; A. P.Moellers Foundation Promoting Medical Sci-
ence
Declaration of interest: none declared
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Low risk Quote: “Randomization was unrestricted
and was done using Stata software..” p 326
Adequate allocation concealement? Low risk Judgement comment: unit of allocation by
GPpractice and allocation performed prior
to the start of the study
Similar baseline outcome measurements? Unclear risk Not reported
Similar baseline characteristics? Low risk Quote: “There were no statistically signifi-
cantly differences concerning the quality of
treatment between the people with Type 2
diabetes in the control and the intervention
groups at baseline” Table 2 p 328
Incomplete outcome data addressed? Low risk Judgement comment: low attrition and
missing data balanced across 2 arms of
study
Knowledge of allocated intervention pre-
vented?
Low risk Quote:“In this study, most tasks were per-
formed by one researcher. Therefore, and
because a very visible tool like the electronic
feedback system was tested, both blinding
and allocation concealment were impossi-
ble in the study design.” p 328
Judgement comment: data on annual eye
examinations obtained from national reg-
istry and therefore unlikely to be influenced
by knowledge of allocation
Protected against contamination? Low risk Judgement comment: allocation was by
practice and it is unlikely that the control
group received the intervention
Free from selective outcome reporting? Unclear risk Judgement comment: trial retrospectively
registered and therefore not possible to as-
sess
Other risks of bias? High risk Judgement comment: selection bias of
providers as only 59%ofGPs accepted invi-
tation, and these may have been more will-
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Guldberg 2011 (Continued)
ing to change according to guidelines, or
already had a high quality of care
Gutierrez 2011
Methods Study aim: to assess the impact of shared medical appointments on the quality of care
for Hispanic patients with type 2 diabetes attending a family medicine residency clinic
Study design: parallel-group RCT
Participants Country: USA
Setting: single family medicine residency clinic
Total number of patients: 103
Percentage male: NR
Diabetes type: type 2
Average age (SD): NR
Inclusion criteria: Hispanic race/ethnicity, aged 18 years and older, diagnosis of type 2
diabetes with HbA1c ≥ 7%
Exclusion criteria: dementia, current pregnancy or mothers who were breast-feeding
Interventions Intervention (n = 50): shared medical appointments with a mean of 9 participants
per group. Clinical team consisted of a resident or fellow researcher, faculty member,
pharmacist, lead nurse, medical assistant, registration clerk, and social worker
Comparator (n = 53): usual care (not specified)
Duration: 17 months
Outcomes Primary outcome: HbA1c, immunisations, aspirin use, eye and foot examinations
Secondary outcomes: quality of life (Diabetes Quality of Life Brief Clinical Inventory)
and diabetes knowledge (Diabetes Knowledge Questionnaire)
Baseline screening attendance (control group): 67.9%
Notes Date conducted: September 2006 to August 2007
Trial registration number: NR
Sources of funding: Department of Family and Community Medicine, University of
Texas; Community Action Research Experience project funded by grant D58HP08301
from the Department of Health and Human Services Health Resources and Services
Administration; foundation grant from the Texas Academy of Family Physicians
Declaration of interest: none declared
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Low risk Quote: “We assigned participants to an
SMA group or a control group using a table
of random numbers.”
Adequate allocation concealement? Unclear risk Not reported
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Gutierrez 2011 (Continued)
Similar baseline outcome measurements? Unclear risk Not reported
Similar baseline characteristics? Low risk Quote: “The SMA and control patients
did not differ significantly by demographic,
clinical, or other characteristics” p 213
Incomplete outcome data addressed? Unclear risk Not reported
Knowledge of allocated intervention pre-
vented?
Unclear risk Not reported
Protected against contamination? Unclear risk Quote: “…the possibility of a “halo effect”
exists, where providers participating in the
SMAs could have gained new knowledge
and insight that allowed them tobetter treat
patients in the control group. For example,
a patient in the control group could have
been advised by the pharmacist to ask his or
her physician about switching to a different
medication because a patient with similar
clinical status in the SMA group was re-
cently switched to that medication.” p 214
Judgement comment: unclear if potential
for contamination would have influenced
retinopathy screening attendance
Free from selective outcome reporting? Unclear risk Judgement comment: no protocol or trial
registry entry available and therefore not
possible to assess
Other risks of bias? Low risk Judgement comment: no evidence of other
sources of bias
Halbert 1999
Methods Study aim: to determine whether multiple mailed patient reminders can produce an
increase in attendance for diabetic retinal examinations over that seen with a single
reminder
Study design: parallel-group RCT
Participants Country: USA
Setting: large network-based health maintenance organisation in California
Total number of participants: 23,740
Percentage male: 46.6%
Diabetes type: NR
Average age (SD): NR
Inclusion criteria: all diabetic members ≥ 18 years with no claim for a dilated fundus
examinationwhowere enrolled inHealthNet, a large network-based healthmaintenance
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Halbert 1999 (Continued)
organisation (HMO) in California, during the study period
Exclusion criteria: NR
Interventions Intervention (n = 11,992): at baseline, participating medical groups in the HMO
network received a letter explaining the programme, the current American Diabetes
Association (ADA) guidelines for retinal examinations, a sample physician letter, and
lists of their patients with diabetes and their diabetic retinopathy screening exam status.
The intervention group received reminders at 3 months, 6 months or 9 months after
baseline if they had not had a dilated retinal examination according to the HMO claims
database. Mailing of reminders was verified by postal receipt
Comparator (n=11,748): at baseline, the diabetic members and their medical groups
received the material described above. In addition, diabetic members who did not have
a record of a diabetic retinopathy exam received educational materials and a report of
their current retinopathy screening status directly from the HMO 2 weeks later
Duration: 12 months
Outcomes Primary outcome: claims from either an ophthalmologist or optometrist using proce-
dural terminology codes
Secondary outcomes: NR
Baseline screening attendance (control group): 0%
Notes Date conducted: August 1996 to July 1997
Trial registration number: NR
Sources of funding: NR
Declaration of interest: NR
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk Not reported
Adequate allocation concealement? Unclear risk Not reported
Similar baseline outcome measurements? Unclear risk Not reported
Similar baseline characteristics? Low risk Quote: “Table 1 describes the demograph-
ics of the eligible diabetic members by sex
and by age-group. There were no differ-
ences in sex and age-group distribution be-
tween the single and multiple intervention
groups (P values were 0.225 and 0.063, re-
spectively)” p 753
Incomplete outcome data addressed? Unclear risk Judgement comment: members who dis-
enrolled from the HMO during the study
period were excluded from the analysis.
These were balanced across both arms of
the study (18% single reminder, 17%mul-
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Halbert 1999 (Continued)
tiple reminder group). Unclear if missing
data would impact on outcome
Knowledge of allocated intervention pre-
vented?
Low risk Judgement comment: outcome data ob-
tained from procedural codes and therefore
unlikely to be influenced by blinding
Protected against contamination? Low risk Comparator group unlikely to receive the
intervention
Free from selective outcome reporting? Unclear risk Judgement comment: no protocol or trial
registry entry available and therefore not
possible to assess
Other risks of bias? Low risk Judgement comment: no evidence of other
sources of bias
Harris 2005
Methods Study aim: to evaluate the effects of a continuing medical education intervention using
teleconferencing on glycaemic control (HbA1c) and family physician adherence to na-
tional diabetes guidelines
Study design: cluster-RCT
Participants Country: Canada
Setting: family physician clinics from 8 geographic regions in Canada
Number of clusters: 90
Number of providers: 90
Total number of patients: 660
Percentage male: 56%
Diabetes type: type 2
Average age (SD): NR
Inclusion criteria: type 2 diabetes of at least 2 years’ duration; aged ≥ 18 years; a
physician visit within the past year and competent to consent
Exclusion criteria: participating in the REACT2 study; pregnancy in previous 2 years
Interventions Intervention (43 clusters, n = 347): 8 x 1-hour small-group educational sessions, each
covering a module related to the management of type 2 diabetes based on national
guidelines. Participants received an educational manual with defined learning objectives
for each module, guideline recommendations, detailed clinical cases, and pertinent re-
search articles. Flow sheets listing the recommended screening tests and clinical targets,
designed to serve as reminders in participants’ medical records, were also provided
Comparator (47 clusters, n = 313): usual care (unspecified)
Duration: 3 months
Outcomes Primary outcome: glycaemic control as measured by glycated haemoglobin (Hb A1c)
Secondary outcomes:medicationmanagement andphysician adherence to clinical prac-
tice guideline complication screening recommendations (including eye examinations)
Baseline screening attendance (control group): NR
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Notes Date conducted: NR
Trial registration number: NR
Sources of funding: GlaxoSmithKline
Declaration of interest: 2 authors had been consultants and received honoraria for
CME-related speaking engagements and research support from GlaxoSmithKline
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk Not reported
Adequate allocation concealement? Low risk Judgement comment: unit of allocation by
primary care practice and allocation per-
formed prior to the start of the study
Similar baseline outcome measurements? Unclear risk Not reported
Similar baseline characteristics? Low risk Judgement comment: gender balance, sim-
ilar mean age at diagnosis and disease du-
ration at baseline
Incomplete outcome data addressed? High risk Quote: “Of the 90 physicians randomly as-
signed, 29 (32%) withdrew or were unable
to identify patients for audit.” p 90
Quote: “Patient consent per physician
ranged from 17% to 100%” p 90
Knowledge of allocated intervention pre-
vented?
Low risk Quote: “Medical record auditors were
blind to physician randomization.” p 89
Protected against contamination? Low risk Judgement comment: allocation was by
practice and it is unlikely that the control
group received the intervention
Free from selective outcome reporting? Unclear risk Judgement comment: no protocol or trial
registry entry available and therefore not
possible to assess
Other risks of bias? Low risk Judgement comment: no evidence of other
sources of bias
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Hayashino 2016
Methods Study aim: to evaluate the effect of a multifaceted intervention using the ‘Achievable
Benchmark of Care (ABC)’ method for improving the technical quality of diabetes care
in primary care settings
Study design: cluster-RCT
Participants Country: Japan
Setting: primary care physicians within District Medical Associations
Total number of clusters: 22
Number of providers: 192
Number of patients: 2236
Percentage male: 63%
Diabetes type: type 2
Average age (SD): 56.5 yrs (5.9)
Inclusion criteria: type 2 diagnosis of diabetes prior to registration, aged 40 - 64 years
and care provided by a single medical doctor in charge of the patient’s diabetes treatment
Exclusion criteria: history of haemodialysis, hospitalisation, bed confinement, resident
in a nursing home, blindness, history of lower limb amputation, history of diagnosis
with a malignant tumour within the last 5 years, pregnancy or potential pregnancy
Interventions Intervention (11 clusters, n = 971 participants): physicians assigned to the interven-
tion group were able to use a disease management system of monitoring and provided
feedback on the quality of diabetes care, which was evaluated in terms of adherence to
the 8 clinical indicators. Other intervention components included lifestyle advisors that
provide reminders for regular visits and advice on lifestyle modifications by telephone or
face-to-face
Comparator (11, n = 1265 participants): usual medical care (not specified)
Duration: 12 months
Outcomes Primary outcome: quality of diabetes care score calculated on the outcomes of 8 quality
indicators (including fundoscopy at least every 12 months)
Secondary outcomes: the effect of intervention on participant outcomes comprising
HbA1c, systolic and diastolic blood pressure, and BMI
Baseline screening attendance (control group): 12.2%
Notes Date conducted: NR
Trial registration number: umin.ac.jp/ctr UMIN000002186
Sources of funding: Japan Agency for Medical Research and Development; Ministry of
Health Labour and Welfare
Declaration of interest: none declared
Study propocol has beenpublished: Izumi,K.,Hayashino, Y., Yamazaki, K. et al.Diabetol
Int (2010) 1: 83. doi:10.1007/s13340-010-0015-6
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Low risk Quote: ‘’The statistician, blind to the iden-
tities of the clusters, randomly allocated 0
(control) or 1 (intervention) codes gener-
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ated by statistical software, to 22 clusters
stratified by each DMA.” p 2
Adequate allocation concealement? Low risk Judgement comment: unit of allocation by
cluster and allocation performed prior to
the start of the study
Similar baseline outcome measurements? Low risk Judgement comment: similar rates of
retinopathy screening attendance at base-
line (Table 3 p 7)
Similar baseline characteristics? Low risk Quote: “There was no statistical difference
in baseline characteristics other than the
type of diabetes therapy between the IG
and the CG; patients in the IG were more
likely to receive diabetes medication (P = 0.
049).” p 5
Incomplete outcome data addressed? Low risk Judgement comment: data available for
100% providers and low rate of attrition in
outcome data (see CONSORT diagram p
5)
Knowledge of allocated intervention pre-
vented?
Unclear risk Not reported
Protected against contamination? Low risk Judgement comment: allocation by cluster
and it is unlikely that the control group
received the intervention
Free from selective outcome reporting? Low risk Judgement comment: reported outcomes
consistent with protocol (see Izumi 2010)
Other risks of bias? Low risk Judgement comment: no evidence of other
risks of bias
Hermans 2013
Methods Study aim: to assess the effect of ’benchmarking’ on quality of primary care for patients
with type 2 diabetes
Study design: cluster-RCT
Participants Country: Belgium, Greece, Luxembourg, Portugal, Spain and the UK
Setting: general practitioner or hospital-based outpatient clinics to represent country-
specific diabetes management practices
Number of clusters: 477
Number of providers: 477
Total number of patients: 4027
Percentage male: 55%
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Diabetes type: type 2
Average age (SD): 65.6 yrs (10.8)
Inclusion criteria: outpatients previously diagnosed with type 2 diabetes and≥ 18 years
of age
Exclusion criteria: patients with gestational diabetes, patients with type 1 diabetes, those
who were hospitalised as a result of their diabetes, participants in other clinical trials,
and members of the Belgian Diabetes Convention (a quality assurance programme with
benchmarked feedback)
Interventions Intervention (293 clusters, n = 2509 participants): usual care consisting of routine
monitoring, treatment and counselling of patients with type 2 diabetes with feedback
benchmarked against other centres in each country
Comparator (184 clusters, n = 1518 participants): usual care (as intervention but
without feedback)
Duration: 12 months
Outcomes Primary outcome: HbA1c, LDL cholesterol, and systolic BP at 12 months
Secondary outcomes: % of participants achieving targets in comparison with baseline
of preventive screening, such as retinopathy, neuropathy; dietary counselling, microal-
buminuria; smoking habits; BMI and physical activity
Baseline screening attendance (control group): 53%
Notes Date conducted: 2010
Trial registration number: NCT00681850
Sources of funding: editorial assistance and assistance with manuscript preparation and
co-ordination was funded by AstraZeneca Belgium
Declaration of interest: HV is a full-time employee of AstraZeneca, all other authors
declared that they had sat on advisory boards or received honoraria from pharmaceutical
companies
Study protocol has been published: www.ncbi.nlm.nih.gov/pubmed/21939502
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk Not reported
Adequate allocation concealement? Low risk Quote: “Investigators were randomized
by a centralized randomization procedure
(What Health, Brussels, Belgium) to either
a benchmarking group or a control group”
p 3389
Similar baseline outcome measurements? Low risk Judgement comment: similar baseline
retinopathy screening attendance (< 10%
difference in baseline rates of annual oph-
thalmic examinations between arms. Table
2 p 3393)
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Hermans 2013 (Continued)
Similar baseline characteristics? Low risk Quote: “Baseline demographic and dis-
ease characteristics were similar between
groups” p 3390
Incomplete outcome data addressed? High risk Judgement comment: 23% of clusters en-
rolled did not contribute to the final anal-
ysis
Knowledge of allocated intervention pre-
vented?
Low risk Quote: “The sequence was concealed until
the intervention was assigned, and investi-
gators were blinded to group assignment.
Because randomization was at the investi-
gator level, blinding of patients was not ap-
plicable.” p 3389
Protected against contamination? Low risk Judgement comment: allocation was by
centre and it is unlikely that the control
group received the intervention
Free from selective outcome reporting? Low risk Judgement comment: re-
ported outcomes consistent with trial reg-
istry NCT00681850
Other risks of bias? High risk Judgement comment: all authors had links
to pharmaceutical companies
Herrin 2006
Methods Study aim: to assess the effectiveness of diabetes resource nurse case management and
physician profiling in improving diabetes care
Study design: cluster-RCT
Participants Country: USA
Setting: Family Medicine and Internal Medicine practices within the HealthTexas
Provider Network (HTPN) - physician component of the Baylor Health Care System-
Dallas-Fort Worth, Texas. HTPN- fee for service setting
Number of clusters: 22
Number of providers: 92
Total number of patients: 2155
Percentage male: 49.8%
Diabetes type: NR
Average age (SD): 72.9 yrs (NR)
Inclusion criteria: patients aged ≥ 65 years on 1 January 2000, with a physician visit
related to diabetes in 2000 and Medicare insurance coverage
Exclusion criteria: Patients who did not fulfil National Diabetes Quality Improvement
Alliance criteria for diagnosis of diabetesmellitus; patientswhose chartswere not available
for abstraction
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Interventions Intervention (claims plus MR group) (7 clusters, n = 849 participants) Medicare
claims feedback plus feedback on clinical measures frommedical record (MR) abstraction
Intervention (claims plus MR plus DRS group) (8 clusters, n = 654 participants):
both types of feedback plus diabetes resource nurse (DRN)
Comparator (claims-only group) (7 clusters, n = 652 participants):Medicare claims
feedback only
Duration: 24 months
Outcomes Primary outcome: HbA1c level; LDL level; diastolic and systolic blood pressures as
dichotomous outcomes based on the ADA and National Diabetes Quality Improvement
Alliance guidelines
Secondary outcomes: HbA1c, LDL, and diastolic and systolic blood pressures as con-
tinuous measures; processes of care measures including annual HbA1c assessment, an-
nual lipid assessment, annual blood pressure measurement, annual eye exam, annual foot
exam, and annual renal assessment
Baseline screening attendance (control group): 10.8%
Notes Date conducted: 2001
Trial registration number: NR
Sources of funding: American Diabetes Association; Pfizer, Inc; and the Baylor Health
Care System
Declaration of interest: NR
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk Quote: “practices were stratified … to
ensure even distribution across arms….
Within each stratum practices were sam-
pled and randomized triplets to ensure even
distribution” p 97
Judgement comment: not clear if method
for sequence generation was appropriate
Adequate allocation concealement? Low risk Judgement comment: unit of allocation by
cluster and allocation performed prior to
the start of the study
Similar baseline outcome measurements? Low risk Judgement comment: similar attendance
for annual eye examination based onMedi-
care claims Table 3 p 99
Similar baseline characteristics? Low risk Quote: “There were no differences in base-
line clinical measures or in the data miss-
ing across study arms. There were no miss-
ing values for process measures, as patients
were assumed to have failed the criteria if
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Herrin 2006 (Continued)
no record was found in the medical record
or Medicare data.” p 99
Incomplete outcome data addressed? Low risk Quote: “There were no missing values for
process measures, as patients were assumed
to have failed the criteria if no record was
found in the medical record or Medicare
data.” p 98
Knowledge of allocated intervention pre-
vented?
Low risk Quote: “Bothmedical record andMedicare
claims data were, however, collected by in-
dividuals blinded to patients’ study arm as-
signments.” p 101
Protected against contamination? Low risk Judgement comment: allocation was by
cluster and it is unlikely that the control
group received the intervention
Free from selective outcome reporting? Unclear risk Judgement comment: no protocol or trial
registry entry available and therefore not
possible to assess
Other risks of bias? Low risk Judgement comment: part-funded by
pharmaceutical company, but states that
the company had no involvement in study
design, data collection, data analysis, or in-
terpretation of data or asked to approve the
final version of the manuscript
Hurwitz 1993
Methods Study aim: to evaluate the effectiveness and acceptability of centrally-organised prompt-
ing for co-ordinating community care of non-insulin-dependent diabetic patients
Study design: parallel-group RCT
Participants Country: UK
Setting: 2 hospital outpatient clinics, 38 general practices, and 11 optometrists in the
catchment area of a District General Hospital in Islington, London, UK
Total number of participants: 181
Percentage male: 58%
Diabetes type: type 2
Average age (SD): 62.6 yrs (10)
Inclusion criteria: mobile non-insulin-dependent diabetic patients under the age of 80
who had attended the District General Hospital diabetic clinics in the previous 2 years
Exclusion criteria: women of childbearing age; patients with 1 or more of 3 estab-
lished significant diabetic complications, i.e. nephropathy with creatinine concentration
> 150 µmol/l; ischaemia severe enough to have resulted in gangrene or amputation, and
retinopathy worse than background in 1 eye
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Interventions Intervention (n = 89): prompting system using a database which sends requests to par-
ticipants to provide blood and urine samples for testing at 6-monthly intervals. Results
were incorporated within personalised medical records which were sent to participants
with a request to take them to their general practitioner within 10 days. General practi-
tioner clinical assessments paralleled those of the hospital clinic. Participants not already
under the care of a hospital eye clinic also received an annual eye test prompt and a map
identifying local optometrists who performed dilated fundoscopy. Copies of optometry
feedback are sent to the participant’s general practitioner, who is thereby kept informed
of eye assessments
Comparator (n = 92): usual care (hospital diabetes clinic review)
Duration: 6 months
Outcomes Primary outcome: number of diabetic reviews; glycaemic control; recording of processes
of care (including random plasma glucose, HbA1c, eye screening)
Secondary outcomes: views of participants, participating GPs and optometrists
Baseline screening attendance (control group): 23.9%
Notes Date conducted: April 1988 to October 1990
Trial registration number: NR
Sources of funding: NR
Declaration of interest: NR
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Low risk Quote: “were randomised (by using Cam-
bridge tables of random numbers).” p 624
Adequate allocation concealement? Unclear risk Not reported
Similar baseline outcome measurements? Unclear risk Not reported
Similar baseline characteristics? Low risk Quote: “Comparisons of control and
prompted patient groups at the start of the
study are shown in table II. The groups
were well matched for demographic vari-
ables and also for most important diabetic
attributes, although mean systolic blood
pressure was recorded as 9 mm Hg greater
in the control group (95% confidence in-
terval 2.1 to 16.0mmHg; p=0.011) and 14
patients in the prompted group were doc-
umented as having signs of leg ischaemia
compared with only four controls χ2=5.7,
df=1; p=0.017).” p 624
Judgement comment: differences in base-
line characteristics unlikely to influence
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Hurwitz 1993 (Continued)
outcome
Incomplete outcome data addressed? Low risk Quote: “At the end of October 1990, 94%
(170/181) of the general practitioner notes
for the study patients were traced.” p 624
Knowledge of allocated intervention pre-
vented?
Unclear risk Not reported
Protected against contamination? Low risk Judgement comment: control participants
unlikely to receive the intervention
Free from selective outcome reporting? Unclear risk Judgement comment: no protocol or trial
registry entry available and therefore not
possible to assess
Other risks of bias? Low risk Judgement comment: no evidence of other
sources of bias
Ilag 2003
Methods Study aim: to evaluate the impact of a systematic patient evaluation and patient and
provider feedback on the processes and outcomes of diabetes care
Study design: cluster RCT
Participants Country: USA
Setting: university primary care internal medicine practices affiliated with a managed
care organisation
Number of clusters: 9
Number of providers: 44
Total number of patients: 284
Percentage male: 47%
Diabetes type: type 1 and 2
Average age (SD): 59 yrs (13.1)
Inclusion criteria: members of the managed care organisation with diabetes aged ≥ 18
years
Exclusion criteria: NR
Interventions Intervention (5 clusters, n = 173 participants): ADAP visits in years 1 and 2. This
consisted of a 1-hour focused encounter with non-physician providers within the pri-
mary care centre assessing key diabetes and cardiovascular health parameters measured
(including fundus photography) and discussed with the participant by a certified diabetes
educator. A tailored report with guideline-driven recommendations for care was sent
to the participant’s primary care provider and incorporated into the electronic patient
record)
Comparator (4 clusters, n = 111 participants): usual care in year 1, ADAP programme
visits delivered in year 2
Duration: 24 months
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Ilag 2003 (Continued)
Outcomes Primary outcome: diabetes processes of care measures including: frequency of dilated
retinal examinations, urine microalbumin measurements, foot examination, measure-
ment of blood pressure HbA1c and LDL cholesterol
Secondary outcomes: participant and provider views of the ADAP programme
Baseline screening attendance (control group): 60.6%
Notes Date conducted: October 1999 to September 2016
Trial registration number: NR
Sources of funding: National Institutes of Health
Declaration of interest: NR
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk Method for cluster randomisation not re-
ported
Adequate allocation concealement? Low risk Judgement comment: unit of allocation by
primary care practice and allocation per-
formed prior to the start of the study
Similar baseline outcome measurements? Unclear risk Not reported
Similar baseline characteristics? Low risk Judgement comment: baseline characteris-
tics balanced across the two arms of the
study (see Table 1 p 2724)
Incomplete outcome data addressed? High risk Judgement comment: high attrition (re-
sults reported for 47% of intervention par-
ticipants and 64% of comparison partici-
pants)
Knowledge of allocated intervention pre-
vented?
Unclear risk Not reported
Protected against contamination? Low risk Quote: “We believe it was necessary to ran-
domize by site to avoid within site contam-
ination.”
Free from selective outcome reporting? Unclear risk Judgement comment: no protocol or trial
registry entry available and therefore not
possible to assess
Other risks of bias? Low risk Judgement comment: no evidence of other
sources of bias
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Jacobs 2012
Methods Study aim: to assess whether pharmacists working with physicians and other healthcare
providers in an ambulatory care setting can improve quality of care for patients with type
2 diabetes
Study design: parallel-group RCT
Participants Country: USA
Setting: single ambulatory general internal medicine setting
Total number of patients: 396
Percentage male: NR
Diabetes type: type 2
Average age (SD): 62.9 yrs (11)
Inclusion criteria: > 18 years with a documented HbA1c value > 8% obtained more
than 6 months before the data acquisition date
Exclusion criteria: received primary care outside of the Lahey Clinic Burlington cam-
pus, were diagnosed with type 1 diabetes, had an HbAlc < 8% within 6 months of ran-
domisation, were enrolled in any other pharmacist-run or diabetes management study,
were receiving diabetes management by an outside endocrinologist, or were unable to
adhere to scheduled follow-up
Interventions Intervention (n = 195): pharmacist-participant clinic visits included obtaining a com-
prehensive medication review; performing targeted physical assessment; ordering lab-
oratory tests; reviewing, modifying, and monitoring participants’ medication therapy
and providing detailed counselling on all therapies; facilitating self-monitoring of blood
glucose; and providing reinforcement of dietary guidelines and exercise
Comparator (n = 201): usual care (not specified)
Duration: 12 months
Outcomes Primary outcome: achieving targets for HbAlc (< 7%), LDL cholesterol (<100 mg/dL)
and blood pressure (< 130/80 mmHg)
Secondary outcomes: compliance with microvascular screening parameters including
retinopathy, neuropathy and nephropathy
Baseline screening attendance (control group): NR
Notes Date conducted: 2003
Trial registration number: NCT00541606
Sources of funding: unrestricted medical grant from Pfizer
Declaration of interest: none declared
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Low risk Quote: “Eligible patients were randomized
to either an intervention or control group
using a computer randomized sequence of
ones and zeros” p 615
Adequate allocation concealement? Unclear risk Not report
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Similar baseline outcome measurements? Unclear risk Not reported
Similar baseline characteristics? Low risk Quote: “Baseline characteristics were sim-
ilar between the two groups and reflect an
obese white population of patients with
diabetes, with a large percentage having
comorbid medical conditions and existing
microvascular complications (Table 1).” p
617
Judgement comment: differences in base-
line characteristics unlikely to affect out-
come
Incomplete outcome data addressed? High risk Judgement comment: per-protocol analy-
sis (participants discontinuing intervention
were not included in the analysis). High at-
trition, unbalanced across study arms
Knowledge of allocated intervention pre-
vented?
Unclear risk Not reported
Protected against contamination? Low risk Judgement comment: allocation was by
cluster and it is unlikely that the control
group received the intervention
Free from selective outcome reporting? Unclear risk Judgement comment: trial retrospectively
registered and therefore not possible to as-
sess
Other risks of bias? High risk Judgement comment: risk of selection bias
Quote: “Patients who agreed to participate
in the study were likely more motivated
to adhere to a diabetes treatment program.
Although the control patients had to have
obtained a minimum number of labora-
tory tests to be included, some patients in
this group may not have participated in the
study and may have been a less motivated
group than the intervention group.” p 619
Jansink 2013
Methods Study aim: to assess the effectiveness of a comprehensive diabetes programme in general
practice that integrates patient-centred lifestyle counselling into structured diabetes care
Study design: cluster-RCT
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Participants Country: The Netherlands
Setting: general practices in the south-eastern part of The Netherlands
Number of clusters: 58
Number of providers: 58
Total number of patients: 940
Percentage male: 54.9%
Diabetes type: type 2
Average age (SD): NR
Inclusion criteria: patients aged < 85 years with a HbA1c > 7% and a BMI > 25 kg/m2
Exclusion criteria: complex comorbidity and treatment in hospital
Interventions Intervention (29 clusters, n = 422 participants): nurses in the intervention group
received a programme consisting of (a) training in lifestyle counselling based on moti-
vational interviewing; (b) tools for structuring diabetes care, such as training in agenda
setting, a local diabetes protocol based on the national guidelines and a social map for
lifestyle support; (c) instruction on record-keeping to integrate lifestyle counselling into
general practice; and (d) introduction of tools to sustain improvements including an
instruction chart (reminder), regular telephone follow-ups with the target participants,
a help desk that also enquired proactively about the progress of diabetes management,
and a follow-up meeting for the nurses
Comparator (29 clusters, n = 518 participants): nurses in the comparator group were
advised to administer care consistent with current diabetes guidelines
Duration: 14 months
Outcomes Primary outcome:HbA1c and reported changes in lifestyle related to diet and physical
activity
Secondary outcomes: other diabetes processes of care recommendations (including eye
examination); quality of life (using EQ-5D)
Baseline screening attendance (control group): NR
Notes Date conducted: 2008
Trial registration number: ISRCTN68707773
Sources of funding: ZonMW-the Netherlands Organization for Health Research and
Development
Declaration of interest: none declared
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk Not reported
Adequate allocation concealement? Low risk Judgement comment: unit of allocation by
general practice and allocation performed
prior to the start of the study
Similar baseline outcome measurements? Unclear risk Not reported
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Similar baseline characteristics? Low risk Judgement comment: similar baseline
characteristics. Table 1 p123
Incomplete outcome data addressed? High risk Quote: “A limitation of the study is the loss
to follow-up in the lifestyle measures from
the patient questionnaire” p 125
Judgement comment: large losses to fol-
low-up, reasons not provided. Outcomes
reported on 47.8% of eligible participants
Knowledge of allocated intervention pre-
vented?
Unclear risk Not reported
Protected against contamination? Low risk Judgement comment: allocation was by
cluster and it is unlikely that the control
group received the intervention
Free from selective outcome reporting? Low risk Judgement comment: reported
outcomes consistent with trial registry IS-
RCTN68707773
Other risks of bias? Low risk Judgement comment: no evidence of other
sources of bias
Kirwin 2010
Methods Study aim: to assess whether pharmacists working with primary care physicians can
improve the quality of diabetes care
Study design: cluster-RCT
Participants Country: USA
Setting: single hospital-based primary care practice
Number of clusters: 8
Number of providers: 72
Total number of patients: 346
Percentage male: 34.2%
Diabetes type: types 1 and 2
Average age (SD): 63 yrs (NR)
Inclusion criteria: 18 years or older; diagnosis of diabetes; patient had a primary care
physician practising within the study clinic; seen in the practice at least once during the
2 years prior to the start of the study
Exclusion criteria: NR
Interventions Intervention (4 clusters, n = 171 participants): primary care physicians received a
personalised letter from a pharmacist for participants with upcoming clinic visits. The
letter contained information extracted from the electronic patient record on overdue
testing and drug therapy to achieve diabetes-related treatment targets
Comparator (4 clusters, n = 175 participants): usual care (not specified)
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Kirwin 2010 (Continued)
Duration: recommendation letter sent and outcome determined 30 days after the visit
to the primary care physician
Outcomes Primary outcome: process measure of annual HbA1c testing
Secondary outcomes: 4 processes of care measures (including annual eye examination)
and 3 biomarker measures (HbA1c < 7%, LDL < 100 mg/dL, BP < 130/80)
Baseline screening attendance (control group): 37.1%
Notes Date conducted: 2004
Trial registration number: NCT00122421
Sources of funding: none
Declaration of interest: none declared
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Low risk Quote: “In July 2003, we identified 1,349
patients meeting these criteria and used a
random number generator to randomly se-
lect 560 being cared for by 72 PCPs for in-
clusion in the study (Figure 1).” p 106
Quote: “We randomized the intervention
at the level of clinical suites within the
study practice immediately after patients
were identified in July 2003.” p 106
Adequate allocation concealement? Low risk Judgement comment: unit of allocation at
the level of the cluster and allocation per-
formed prior to the start of the study
Similar baseline outcome measurements? Low risk Judgement comment: similar baseline an-
nual eye examination in intervention and
control (38% vs 37.1%)
Similar baseline characteristics? Low risk Judgement comment: similar baseline
characteristics. Baseline imbalance in an-
nual lipid profile assessment but unlikely
to influence outcome
Incomplete outcome data addressed? High risk Judgement comment: per-protocol analy-
sis, baseline based on those analysed. Rea-
sons for missing data not provided
Knowledge of allocated intervention pre-
vented?
Unclear risk Not reported
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Protected against contamination? Low risk Judgement comment: allocation by cluster
and it is unlikely that the control group
received the intervention
Free from selective outcome reporting? Low risk Judgement comment: re-
ported outcomes consistent with trial reg-
istry NCT00122421
Other risks of bias? Low risk Judgement comment: no evidence of other
sources of bias
Krein 2004
Methods Study aim: to evaluate the effects of a collaborative case management intervention
for patients with poorly-controlled type 2 diabetes on glycaemic control, intermediate
cardiovascular outcomes, satisfaction with care, and resource utilisation
Study design: parallel-group RCT
Participants Country: USA
Setting: Department of Veterans Affairs (VA) Medical Centres
Total number of participants: 246
Percentage male: 96.5%
Diabetes type: type 2
Average age (SD): 61 yrs (10.5)
Inclusion criteria: patients with at least 1 prescription for an oral hypoglycemic agent,
insulin, or blood glucose monitoring supplies filled in the previous 12 months; most
recent (HbA1c) ≥ 8.5% (within the last year); general medicine clinic visit scheduled
between May 1999 and January 2000
Exclusion criteria: < 18 years; type 1 diabetes or were diagnosed before the age of
30 years; had no telephone; did not speak English; were not competent for interview;
reported primary source of diabetes care outside the VA; were being treated for cancer
(other than non-melanoma skin cancer); had kidney failure, symptomatic heart failure,
liver disease, or blindness; spent winter at another residence; or planned to move
Interventions Intervention (n = 123): 2 nurse practitioner acting as case managers working with
participants and their primary care providers, monitoring and co-ordinating care through
the use of telephone contacts, collaborative goal setting, and treatment algorithms
Comparator (n = 123): provision of educational materials and usual care by their
primary care physician
Duration: 18 months
Outcomes Primary outcome: glycaemic control, as measured by HbA1c level; control of LDL
cholesterol; and blood pressure
Secondary outcomes: health status and participant satisfaction were assessed using a
self-administered written survey, which included the Short Form Health Survey for Vet-
erans and the Patient Satisfaction Questionnaire-Form II (general satisfaction subscale);
demographic characteristics, receipt of eye screening, aspirin use, and healthcare services
received outside the VA
97Interventions to increase attendance for diabetic retinopathy screening (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Krein 2004 (Continued)
Baseline screening attendance (control group): 67.5%
Notes Date conducted: 2000
Trial registration number: NR
Sources of funding: Office of Research and Development, Health Services Research
and Development Service, Department of Veterans Affairs; Michigan Diabetes Research
and Training Center Grant; National Institute of Diabetes and Digestive and Kidney
Diseases, National Institutes of Health
Declaration of interest: NR
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Low risk Quote: “One member of a matched pair,
within one of four possible blocks/cells (site
by baseline HbA1C level), was then as-
signed randomly to the case management
group and the other to the control group
by the project manager who had no knowl-
edge about the patients other than site and
baseline HbA1c level.” p 733
Adequate allocation concealement? Low risk Quote: “One member of a matched pair,
within one of four possible blocks/cells (site
by baseline HbA1C level), was then as-
signed randomly to the case management
group and the other to the control group
by the project manager who had no knowl-
edge about the patients other than site and
baseline HbA1c level.” p 733
Similar baseline outcome measurements? Low risk Judgment comment: similar baseline atten-
dance for diabetic retinopathy screening
(9% baseline difference, see Table 1 p 735)
Similar baseline characteristics? Low risk Quote: “The baseline attributes of the in-
tervention and control groups were simi-
lar (Table 1). Except for having a higher
percentage of non white participants, study
enrollees were demographically representa-
tive of VA ambulatory patients.” p 734
Incomplete outcome data addressed? Low risk Judgement comment: low attrition, bal-
anced across the arms of the study andmiss-
ing data accounted for
98Interventions to increase attendance for diabetic retinopathy screening (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Krein 2004 (Continued)
Knowledge of allocated intervention pre-
vented?
Low risk Judgement comment: eye-screening data
obtained fromVAmedical information sys-
tem and therefore unlikely to be influenced
by lack of masking
Protected against contamination? Low risk Judgement comment: control group un-
likely to have received the intervention
Free from selective outcome reporting? Unclear risk Judgement comment: no protocol or trial
registry entry available and therefore not
possible to assess
Other risks of bias? Low risk Judgement comment: no evidence of other
sources of bias
Lafata 2002
Methods Study aim: to evaluate the effectiveness of a mailed intervention for improving diabetes
management
Study design: parallel-group RCT
Participants Country: USA
Setting: multi-specialty primary care group practice
Total number of participants: 3309
Percentage male: 47.8%
Diabetes type: NR
Average age (SD): 59.8 yrs (NR)
Inclusion criteria: patients aged ≥ 18 yrs with diabetes, aligned to a primary care
physician within a multispeciality practice
Exclusion criteria: none
Interventions Intervention (n = 1641): mailed reminder intervention consisting of a letter from
the primary care physician, self-care handbook, preventive care checklist and specific
recommendations regarding receipt of routine monitoring and screening
Comparator (n = 1668): usual care (not specified)
Duration: 12 months
Outcomes Primary outcome: documented receipt of fasting lipid profile, HbA1c measurement,
dilated retinal exam during the period 6 - 12 months following randomisation
Secondary outcomes: HbA1c and cholesterol levels 1 yr after randomisation
Baseline screening attendance (control group): 47.1%
Notes Date conducted: 1999
Trial registration number: NR
Sources of funding: NR
Declaration of interest: NR
Risk of bias
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Lafata 2002 (Continued)
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Low risk Quote: “Using the randomnumber genera-
tor In SAS (Version 8.2: SAS Institute, Inc.
,Cary, NC) each month, each eligible pa-
tient with a birthday on the month was as-
signed to receive either themailed reminder
packet or usual care.” p 522
Adequate allocation concealement? Unclear risk Not reported
Similar baseline outcome measurements? Low risk Judgement comment: baseline retinal ex-
ams reported and balanced across study
arms (Table 2 p 527)
Similar baseline characteristics? Low risk Quote: “Almost 60% of the study popula-
tion received an HbA1c in the 6 months
preceding the mailed reminder program,
and approximately half received a lipid pro-
file and a retinal exam in the 12months pre-
ceding the mailed reminder program, We
found no statistically significant differences
in these and other characteristics listed in
Table 2 between patients randomized to re-
ceive themailed reminder programor usual
care.” p 526
Incomplete outcome data addressed? Low risk Judgement comment: no missing outcome
data (see Table 3 p 528)
Knowledge of allocated intervention pre-
vented?
Low risk Judgement comment: outcomes were ob-
tained from automated clinical administra-
tive databases
Protected against contamination? Low risk Judgement comment: it is unlikely that the
control group received themailed interven-
tion
Free from selective outcome reporting? Unclear risk Judgement comment: trial retrospectively
registered and therefore not possible to as-
sess
Other risks of bias? Low risk Judgement comment: no evidence of other
risks of bias
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Lian 2013
Methods Study aim: to assess whether a small co-payment would impact on uptake of diabetic
retinopthy screening compared to free access
Study design: parallel-group RCT
Participants Country: Hong Kong, China
Setting: 2 public family medicine clinics
Total number of patients: 4644
Percentage male: 45.2%
Diabetes type: type 1 and 2
Average age (SD): 64.1 yrs (11)
Inclusion criteria: patients with type 1 or type 2 diabetes
Exclusion criteria: patients already under the regular care of an ophthalmologist
Interventions Intervention (n = 2319): participants offered screening with small co-payment. A postal
reminder of the appointment was sent to those who accepted screening. Participants not
attending for screening, were called to book a further appointment
Comparator (n = 2325): participants offered screening with no charge. A postal re-
minder of the appointment was sent to those who accepted screening. Participants not
attending for screening were called to book a further appointment
Duration: NR
Outcomes Primary outcome: uptake of screening and severity of diabetic retinopathy detected
Secondary outcomes: NR
Baseline screening attendance (control group): NR
Notes Date conducted: NR
Trial registration number: NR
Sources of funding: Health and Health Services Research Fund of the Hong Kong SAR
Government and the Azalea Endowment Fund
Declaration of interest: none declared
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Low risk Quote: “Randomization was based on the
random allocation of digits 0 or 1 by com-
puter..” p 1248
Adequate allocation concealement? Low risk Quote: “ ..a research assistant generated the
random sequence and assigned the partic-
ipants…Two trained and experienced tele-
phone interviewers were each allocated a
random half of the subjects allocated to the
free and pay groups.” p 1248
Similar baseline outcome measurements? Unclear risk Not reported
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Similar baseline characteristics? Low risk Quote: “There were no differences between
the characteristics of participants allocated
to the free and pay groups (Table 1).” p
1248
Incomplete outcome data addressed? Low risk Judgement comment: the majority of ex-
clusions were due to participants already
being under ophthalmologist care. Low at-
trition with reasons given and balanced
across both arms of the study
Knowledge of allocated intervention pre-
vented?
Unclear risk Not reported
Protected against contamination? Unclear risk Quote : “Two trained and experienced tele-
phone interviewers were each allocated a
random half of the subjects allocated to the
free and pay groups.” p 1248
Judgement comment: not clear how con-
tamination was prevented
Free from selective outcome reporting? Unclear risk Judgement comment: trial retrospectively
registered and therefore not possible to as-
sess
Other risks of bias? Low risk Judgement comment: no evidence of other
sources of bias
Litaker 2003
Methods Study aim: to compare a traditional physician-only model of care with a more collabo-
rative, team-based approach to chronic disease management
Study design: parallel-group RCT
Participants Country: USA
Setting:Department of General Internal Medicine at the Cleveland Clinic Foundation,
Ohio
Total number of participants: 157
Percentage male: 41%
Diabetes type: type 2
Average age (SD): 60.5 yrs (9)
Inclusion criteria: patients with established diagnoses of mild or moderate hypertension
and non-insulin-dependent diabetes mellitus without known end-organ complications
Exclusion criteria:medically complex individuals (Charlson index > 5) or those requir-
ing 3+ medications for blood pressure control
Interventions Intervention (n = 79): clinical practice algorithms, patient education on disease self-
management strategies, and regular monitoring and feedback delivered primarily by
102Interventions to increase attendance for diabetic retinopathy screening (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Litaker 2003 (Continued)
a nurse practitioner. The nurse practitioner acted as the first-line contact for care, in
treatment decisions and to standardise treatment and for assessing treatment adherence
and individual barriers to adherence
Comparator (n = 78): physician-only or ‘usual’ care defined as any form of treatment
offered by an individual’s primary care physician that reflected the practice style prevalent
at the study site prior to the current investigation
Duration: 12 months
Outcomes Primary outcome: measures to reflect the process and quality of care; documented evi-
dence of annual ophthalmologic and foot examinations; HbA1c assessment at least once
during the study year (other than study measures at 0 and 12 months); documentation
of influenza and pneumococcal vaccination status and administration when appropriate
Secondary outcomes: NR
Baseline screening attendance (control group): NR
Notes Date conducted: October 1996 to January 1998
Trial registration number: NR
Sources of funding: Arison Foundation and the I.H. Page Center for Health Outcomes
Research at the Cleveland Clinic Foundation
Declaration of interest: NR
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk Not reported
Adequate allocation concealement? Unclear risk Not reported
Similar baseline outcome measurements? Unclear risk Not reported
Similar baseline characteristics? Low risk Quote: “Members of the two patient
groups did not differ significantly at study
entry with respect to age, gender or racial
composition, years of education com-
pleted, number of comorbid conditions, or
baseline HbA1c and blood pressure con-
trol, total cholesterol or HDL-c values.” p
229
Incomplete outcome data addressed? Low risk Judgement comment: outcome on all par-
ticipants randomised were reported
Knowledge of allocated intervention pre-
vented?
Unclear risk Not reported
Protected against contamination? Low risk Quote: “Routine use of reminder systems,
forms to facilitate documentation of care,
monitored use of clinical guidelines or ac-
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tive collaboration with a nurse practitioner
were not aspects of usual care for physicians
in this practice during the study period.”
p 226
Free from selective outcome reporting? Unclear risk Judgement comment: no protocol or trial
registry entry available and therefore not
possible to assess
Other risks of bias? Low risk Judgement comment: no evidence of other
sources of bias
Maljanian 2005
Methods Study aim: to evaluate an intensive telephone follow-up as an additional component of
a diabetes disease management programme already shown to be effective in improving
glycaemic control, adherence with ADA standards of care, and HRQOL
Study design: parallel-group RCT
Participants Country: USA
Setting: acute care teaching hospital
Total number of participants: 336
Percentage male: 46.7%
Diabetes type: type 1 and 2
Average age (SD): 58 yrs (12.7)
Inclusion criteria: adult patients with type 1 or type 2 diabetes mellitus who were
referred to the hospital-based disease management programme
Exclusion criteria: NR
Interventions Intervention (n = 176): both the intervention and control groups received the standard
of care provided in the diabetes diseasemanagement programme as follows: (1) 3 x 4-hour
educational classes covering topics such as living with diabetes, introduction to diabetes
and the metabolic syndrome, nutrition and exercise, the importance of adherence to the
ADA standards of care (e.g. annual eye exams, foot exams, blood glucose monitoring)
and strategies to enhance self-management skills; (2) individual visits with a Registered
Nurse and a nutritionist; (3) collaborative care management with written evaluations
and recommendations provided to the participant’s primary care provider, and scheduled
follow-up visits. The intervention group also received a series of 12 weekly phone calls to
reinforce education and self-management skills. The first call was 15 - 20 min in length;
subsequent calls were 5 - 7 minutes each
Comparator (n = 160): usual care consisting of the diabetes disease management pro-
gramme as defined above, without the intensive telephone intervention
Duration: 12 months
Outcomes Primary outcome: glycaemic control; general and disease-specific HRQOL; symptoms
of depression; adherence to self-management guidelines, and participant satisfaction
Secondary outcomes: NR
Baseline screening attendance (control group): NR
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Notes Date conducted: March 2000 to August 2001
Trial registration number: NR
Sources of funding: Aetna Quality of Care Research Foundation through the Academic
Medicine and Managed Care Forum
Declaration of interest: NR
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk Not reported
Adequate allocation concealement? Unclear risk Not reported
Similar baseline outcome measurements? Unclear risk Not reported
Similar baseline characteristics? High risk Quote: “A comparison of demographic and
baseline measures indicated that the two
groups differed on age, BMI, when di-
agnosed, language used in the DLC class
attended, ethnicity (Caucasian, non-Cau-
casian dichotomy), HbA1c, PCS, MCS,
and symptoms of depression (CES-D).” p
18
Judgement comment: the reported baseline
imbalance could have influenced retinopa-
thy screening attendance
Incomplete outcome data addressed? High risk Quote: “The 171 participants who did not
return for their two follow-up visits repre-
sent a significant attrition rate (34%).” p
18
Quote: “The fact that individuals with bet-
ter glycemic control were more likely to re-
turnmay explain some of the floor effect on
glycemic control in the total study popula-
tion. Further, that those patientswithworse
glycemic control and larger BMI at enroll-
ment were the ones more likely tomiss later
appointments is concerning because those
are the patients who most need their di-
abetes education reinforced and self-man-
agement encouraged.” p 23
Knowledge of allocated intervention pre-
vented?
Unclear risk Not reported
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Protected against contamination? Low risk Judgement comment: unlikely that control
group received the intervention
Free from selective outcome reporting? Unclear risk Judgement comment: no protocol or trial
registry entry available and therefore not
possible to assess
Other risks of bias? Low risk Judgement comment: no evidence of other
sources of bias
Mansberger 2015
Methods Study aim: to determine the effectiveness of telemedicine for providingdiabetic retinopa-
thy screening examinations compared with traditional surveillance in community health
clinics with a high proportion of ethnic minorities
Study design: parallel-group RCT
Participants Country: USA
Setting: 2 community health clinics
Total number of participants: 567
Percentage male: 48%
Diabetes type: NR
Average age (SD): 51.1 yrs (11.8)
Inclusion criteria: diabetic patients ≥ 18 years with diabeted who were scheduled to
visit their primary care provider
Exclusion criteria: cognitive impairment preventing informed consent; inability to
transfer to a chair to perform non-mydriatic imaging
Interventions Intervention (n = 296): participants in this group had digital images of their retina
captured with a non-mydriatic camera and were encouraged to see an eye care provider
annually for a diabetic eye exam
Comparator (n = 271): participants in this group were encouraged to see an eye care
provider annually for a diabetic eye exam
Duration: 48 months (intervention offered to comparator group after 18 months)
Outcomes Primary outcome: proportion of participants that receive an annual eye exam
Secondary outcomes: health belief factors associated with adherence
Baseline screening attendance (control group): NR
Notes Date conducted: 1 August 2006 to 31 September 2009
Trial registration number: NCT01364129
Sources of funding: National Eye Institute; Centers forDisease Control and Prevention;
Good Samaritan Foundation at Legacy Health
Declaration of interest: none declared
Risk of bias
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Bias Authors’ judgement Support for judgement
Adequate sequence generation? Low risk Quote: “We used a random number gen-
erator to randomly assign participants to
the telemedicine group or the traditional
surveillance group.” p 519
Adequate allocation concealement? Unclear risk Not reported
Similar baseline outcome measurements? Unclear risk Not reported
Similar baseline characteristics? Low risk Quote: “There were no differences in de-
mographic and medical characteristics at
enrolment between the telemedicine (n =
296) and traditional surveillance (n = 271)
groups.” p 521
Incomplete outcome data addressed? Low risk Judgement comment: no missing outcome
data at 12 and 24 months (see CONSORT
flow diagram p 519)
Knowledge of allocated intervention pre-
vented?
Unclear risk Not reported
Protected against contamination? Low risk Judgement comment: it is unlikely that the
control group received the telemedicine in-
tervention
Free from selective outcome reporting? Unclear risk Judgement comment: trial retrospectively
registered and so not possible to assess
Other risks of bias? Low risk Judgement comment: no evidence of other
risks of bias
McCall 2011
Methods Study aim: to evaluate the impact of commercial programmes for disease management
that use nurse-based call centres on the quality of clinical care, acute care utilisation, and
Medicare expenditures for Medicare fee-for-service beneficiaries
Study design: parallel-group RCT
Participants Country: USA
Setting: primary care practices
Total number of participants: 188,169 patients with diabetes
Percentage male: NR
Diabetes type: NR
Average age (SD): NR
Inclusion criteria: Medicare beneficiaries in each of 8 geographic areas who met the
107Interventions to increase attendance for diabetic retinopathy screening (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
McCall 2011 (Continued)
selection criteria for heart failure or diabetes and had a HCC risk score of 1.35
Exclusion criteria: NR
Interventions Intervention (n=126,557participants with diabetes aloneor diabetes andheart fail-
ure): Medicare Health Support Pilot Program consisting of 8 commercial programmes
for disease management that used nurse-based call centres to assess the needs of indi-
vidual beneficiaries and used health coaches to target those beneficiaries at immediate
high risk for adverse events. The goals of the intervention were to improve beneficiaries’
understanding of their disease or diseases, their ability to manage self-care, and their
ability to communicate with providers. Various educational resources including litera-
ture, videos, and Internet resources were provided. A small portion of the intervention
population received intensive case-management services
Comparator (n = 61,612 participants with diabetes alone or diabetes and heart
failure): usual care (not specified)
Duration: 12 months
Outcomes Primary outcome: changes from baseline compared between the intervention and con-
trol groups for the quality of clinical care provided, the use of acute care, and Medi-
care expenditures. 4 annual evidence-based processes of care measures were evaluated for
patients with diabetes: glycated haemoglobin testing, urinary protein screening, retinal
examination and LDL cholesterol testing
Secondary outcomes: none
Baseline screening attendance (control group): 36.1%
Notes Date conducted: 2004 to 2007
Trial registration number: NR
Sources of funding: NR
Declaration of interest: none declared
Outcome data (based on pooled rates per 100 beneficiaries) calculated from Supplemen-
tary Table 1 (supplementary appendix) using the % of participants with diabetes given
in Table 1 (Main report)
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk Not reported
Adequate allocation concealement? Unclear risk Not reported
Similar baseline outcome measurements? Low risk Judgement comment: similar baseline
screening attendance (see Table 1. Online
supplement)
Similar baseline characteristics? Low risk Quote: “The characteristics of the benefi-
ciaries were well balanced between the in-
tervention and control groups at baseline
(Table 1).” p 1707
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Incomplete outcome data addressed? Unclear risk Not reported
Knowledge of allocated intervention pre-
vented?
Low risk Judgement comment: data on retinopa-
thy screening obtained from routinely-col-
lected data
Protected against contamination? Low risk Judgement comment: it is unlikely that
the control group received the Medicare
Health Support Programme
Free from selective outcome reporting? Unclear risk Judgement comment: no protocol or trial
registry entry available and therefore not
possible to assess
Other risks of bias? Low risk Judgement comment: no evidence of other
risks of bias
McClellan 2003
Methods Study aim: to determine if an intervention that includes claims-based feedback about
patterns of HbA1c measurement results in more frequent monitoring of HbA1c in
diabetic Medicare beneficiaries
Study design: cluster-RCT
Participants Country: USA
Setting: primary care physicians in a southern state treating Medicare beneficiaries
Number of clusters: 123
Number of providers: 477
Total number of patients: 22,971
Percentage male: 43%
Diabetes type: type 1 and type 2
Average age (SD): 74 yrs (NR)
Inclusion criteria: diabetes diagnosis based on 2 outpatient claims 30 days apart or
1 inpatient claim for the care of diabetes mellitus (250.xx, 357.2x, 362.0x, 366.41).
Patients had to be aged at least 65, enrolled in Medicare for a minimum of 11 months
in 1996 or 1998
Exclusion criteria: any HMO coverage or a skilled nursing facility stay longer than 60
days
Interventions Intervention (63 clusters, n = 11,904 participants): mailing to physicians at baseline,
2 months, 4 months, and 6months containing clinical practice guidelines, general infor-
mation about patterns of diabetes care in the state, an educational tape, and practice aids
to implement guideline recommendations (chart stickers, pocket guides, wall posters,
etc.). Intervention physicians were provided with fliers to remind participants to have
regular check-ups of their urine, eyes, feet, and blood; an ADA catalogue containing
diabetes-related publications and patient education presentations; and a ’Diabetic Pass-
port’ that allowed a patient to record their diabetic test results. The passport displayed
the ADA recommendations for HbA1c, eye, urine, and lipid monitoring
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Comparator (61 clusters, n = 11,067 participants): newsletter sent to intervention
and comparator groups containing an article devoted to early detection of microvascular
complication and the importance of glycaemic control which opened up to create a poster
showing the tests/screenings that patients with diabetes mellitus require on a regular basis
Duration: 6 months
Outcomes Primary outcome: changes in frequency of measurement of HbA1c, quantitative urine
protein and dilated eye examinations
Secondary outcomes: NR
Baseline screening attendance (control group): 39.3%
Notes Date conducted: 1996 to 1998
Trial registration number: NR
Sources of funding: NR
Declaration of interest: NR
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Low risk Quote: “After assigning patients to physi-
cians and physicians to counties, the coun-
ties were ordered alphabetically and a ran-
dom number table was used to assign a
county to either the intervention or com-
parison group.” p 1212
Adequate allocation concealement? Low risk Quote: “None of the staff involvedwith the
design and implementationof the interven-
tion were involved with the randomization
of counties or selectionof physicianswithin
counties.” p 1212
Similar baseline outcome measurements? Low risk Judgement comment: similar proportionof
baseline eye exams (see Table 2 p 1214)
Similar baseline characteristics? Low risk Quote: “The two groups were comparable
with respect to race, gender, and the mean
age of the diabetic.” p 1213 (see also Table
1 p 1214)
Judgement comment: Similar quality indi-
cators at baseline (see Table 2 p 1214)
Incomplete outcome data addressed? Low risk Quote: “…the dropout rate among prac-
tices in the comparison and intervention
groups was small, 3.6 and 3.0%, respec-
tively, and thus was unlikely to bias our re-
sults.” p 1215
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Knowledge of allocated intervention pre-
vented?
Low risk Judgement comment: eye-screening out-
comes obtained from routinely-collected
claims data
Protected against contamination? Low risk Judgement comment: control group un-
likely to have received the intervention
Free from selective outcome reporting? Unclear risk Judgement comment: no protocol or trial
registry entry available and therefore not
possible to assess
Other risks of bias? Low risk Judgement comment: no evidence of other
sources of bias
McDermott 2001
Methods Study aim: to evaluate a paper-based recall and reminder system and basic diabetes
education of healthcare workers in improving the quality of diabetes care in a remote
indigenous community
Study design: cluster-RCT
Participants Country: Australia
Setting: 21 primary health care centres in Torres Strait and Northern Peninsula Area in
Queensland Australia
Number of clusters: 21
Number of providers: 3
Total number of patients: 555
Percentage male: 38%
Diabetes type: NR
Average age (SD): 52.3 yrs (13.5)
Inclusion criteria: patients with diabetes
Exclusion criteria: patients aged < 15 years diagnosed < 1 year before the audit
Interventions Intervention (8 clusters, n = 250 participants)): intervention and comparator sites
received audit and feedback on patients with diabetes benchmarked against guidelines.
Evidence-based guidelineswere issued and anewdiabetes outreach servicewas established
(comprising a diabetologist, nutritionist, podiatrist, and diabetes healthcare worker).
Intervention and comparator sites were visited by the outreach team who saw individual
patients on a referral basis. A recall system was established in intervention sites and
healthcare workers in these sites received clinical training on the basics of diabetes care
Comparator (13 clusters, n = 305 participants): see above
Duration: 12 months
Outcomes Primary outcome: proportion of participants fulfilling diabetes care indicators (includ-
ing ‘eye check’ or ‘ophthalmologist check’) in the last 12 months
Secondary outcomes: diabetes-related hospital admissions and hospitalisations
Baseline screening attendance (control group): 29.8%
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Notes Date conducted: March 1999 to February 2000
Trial registration number: NR
Sources of funding: National Health and Medical Research Council
Declaration of interest: NR
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? High risk Quote: “..eight intervention sites were cho-
sen randomly by being picked from a hat
containing the names of all 21 clinics” p
498
Judgement comment: inappropriate
method of sequence generation
Adequate allocation concealement? Low risk Judgement comment: unit of allocation by
primary care practice and allocation per-
formed prior to the start of the study
Similar baseline outcome measurements? Low risk Judgement comment: similar rates of eye
checks and ophthalmology visits at baseline
Similar baseline characteristics? Low risk Quote: “There were no significant differ-
ences in age, sex ratio and duration of dia-
betes at baseline…” p 498
Judgement comment; baseline differences
between arms in diabetes processes of care
(Table 2 p 499) but unlikely to influence
outcome
Incomplete outcome data addressed? Low risk Judgement comment: low attrition andbal-
anced across arms
Knowledge of allocated intervention pre-
vented?
Unclear risk Not reported
Protected against contamination? Low risk Judgement comment: control group un-
likely to have received the intervention
Free from selective outcome reporting? Unclear risk Judgement comment: no protocol or trial
registry entry available and therefore not
possible to assess
Other risks of bias? Low risk Judgement comment: no evidence of other
sources of bias
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Methods Study aim: to evaluate effects of a web-based decision-support tool, the diabetes ‘Disease
Management Application (DMA)’, to improve evidence-based management of type 2
diabetes
Study design: cluster-RCT
Participants Country: USA
Setting: Adult Medicine Clinic (AMC) in Harvard Medical School in Boston Mas-
sachusetts USA
Number of clusters: 26
Number of providers: 26
Total number of patients: 598
Percentage male: 48.1%
Diabetes type: type 2
Average age (SD): 67.5 yrs (12)
Inclusion criteria: patients with at least 1 visit to the AMC during the pre-intervention
year (May 1997 to April 1998) were identified by billing claims, and patients with type
2 diabetes were identified by ICD-9 codes 250.00 - 250.90
Exclusion criteria: type 1 diabetes
Interventions Intervention (12 clusters, n = 307 participants):web-based information management/
clinical decision-support tool providing a single-screen view of patient-specific informa-
tion, enabling decision support at the time of patient contact. The decision-support tool
generated patient-specific recommendations based on evidence-based guidelines
Comparator (14 clusters, n = 291 participants): usual care (not specified)
Duration: 12 months
Outcomes Primary outcome: change in rates of annual HbA1c, LDL cholesterol, BP, and eye and
foot screening and change in the absolute values of HbA1c, LDL cholesterol, and blood
pressure
Secondary outcomes: NR
Baseline screening attendance (control group): 41.2%
Notes Date conducted: May 1998 to April 1999
Trial registration number: NR
Sources of funding: National Pharmaceutical Council; MGH Primary Care Operations
Improvement and Clinical Research Programs
Declaration of interest: NR
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Low risk Quote: “A coin was tossed to select an in-
tervention group and a control group.” p
751
Adequate allocation concealement? Low risk Judgement comment: unit of allocation by
primary care practice and allocation per-
formed prior to the start of the study
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Similar baseline outcome measurements? High risk Quote: “..rates of eye and foot screening
were lower in the intervention group.” p
793
Judgement comment: baseline imbalance
in diabetic retinopathy screening
Similar baseline characteristics? Low risk Quote: “Baseline staff provider and patient
characteristics were similar comparing the
intervention group with the control group
(Table 1).” p 793
Incomplete outcome data addressed? Low risk Judgement comment: data from all partic-
ipants reported
Knowledge of allocated intervention pre-
vented?
Low risk Quote: “Clinical data from paper and
electronic charts were abstracted by three
nurses blinded to group status of providers
and patients.” p 752
Protected against contamination? Low risk Judgement comment: control group un-
likely to have received the intervention
Free from selective outcome reporting? Unclear risk Judgement comment: no protocol or trial
registry entry available and therefore not
possible to assess
Other risks of bias? Low risk Judgement comment: no evidence of other
sources of bias
O’Connor 2005
Methods Study aim: to evaluate the impact of a QI intervention on the quality of diabetes care
Study design: cluster-RCT
Participants Country: USA
Setting: primary care medical practices in Minnesota
Number of clusters: 12
Number of providers: 329
Total number of patients: 754
Percentage male: 54.3%
Diabetes type: NR
Average age (SD): 57.8 yrs (NR)
Inclusion criteria: aged > 19 years who had 2+ ICD-9 diagnostic codes for diabetes in
a defined 12-month period
Exclusion criteria: NR
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Interventions Intervention (6 clusters, n = 428 participants): IDEAL (Improving Care for Diabetes
Through Empowerment Active Collaboration and Leadership) model consisting of fa-
cilitation of leadership actions in support of change, training for the leader and facilitator
of an intra-clinic multidisciplinary continuous quality improvement (CQI) team, and
consultative and networking support of the change process
Comparator (6 clusters, n = 326 participants): usual care (not specified)
Duration: 18 months
Outcomes Primary outcome: % of participants with annual tests of HbA1c, LDL and BP; % of
participants with annual screening for foot, eye or kidney complications
Secondary outcomes: NR
Baseline screening attendance (control group): 39%
Notes Date conducted: NR
Trial registration number: NR
Sources of funding: Centres for Disease Control and Prevention; HealthPartners Re-
search Foundation
Declaration of interest: 1 author reported being a member of advisory boards and
receiving honoraria from LifeScan, NovoNordisk and AmerisourceBergen
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk Not reported
Adequate allocation concealement? Low risk Judgement comment: unit of allocation by
primary care practice and allocation per-
formed prior to the start of the study
Similar baseline outcome measurements? Low risk Judgement comment: similar attendance
for annual eye exams at baseline
Similar baseline characteristics? Low risk Quote: “Table 1 shows that the clinics and
patients in the intervention and control
group were similar in size and in patient
mix…” p 1892
Incomplete outcome data addressed? High risk Judgement comment: reported data was
based on those 754 participants who com-
pleted the pre- and post-intervention sur-
veys and consented to have their medical
record reviewed. Response rates to the sur-
vey averaged 55% - 65% across study sites
Knowledge of allocated intervention pre-
vented?
Unclear risk Not reported
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O’Connor 2005 (Continued)
Protected against contamination? Low risk Judgement comment: control group un-
likely to have received the intervention
Free from selective outcome reporting? Unclear risk Judgement comment: no protocol or trial
registry entry available and therefore not
possible to assess
Other risks of bias? Low risk Judgement comment: no evidence of other
sources of bias
Perria 2007
Methods Study aim: to assess the effectiveness of different strategies for the implementation of
an evidence-based guideline for the management of non-complicated type 2 diabetes
mellitus
Study design: cluster-RCT
Participants Country: Italy
Setting: primary care setting of Italian National Health Service in Lazio region of Central
Italy
Number of clusters: 252
Number of providers: 252
Total number of patients: 6290
Percentage male: 52%
Diabetes type: type 2
Average age (SD): 65 yrs (10)
Inclusion criteria: patients with uncomplicated type 2 diabetes
Exclusion criteria: NR
Interventions Intervention (active implementation)(84 clusters, n = 1952 participants): 2-day
training
module and consequent administration of a diabetes guideline
Intervention (passive implementation) (85 clusters, n = 2106 participants): GPs
received the guideline without any training but with a written request to implement the
guideline
Comparator (83 clusters, n = 2232 participants): usual care (not specified)
Duration: 1 month
Outcomes Primary outcome: GPs’ adherence to guideline recommendations for diabetes manage-
ment (including proportion of participants who were prescribed all microvascular com-
plications assessment tests: eye examination or fundus and blood creatinine or creatinine
clearance and microalbuminuria) per year
Secondary outcomes: GPs’ drug-prescribing behaviour
Baseline screening attendance (control group): 22.9%
Notes Date conducted: December 2003 to December 2004
Trial registration number: ISRCTN80116232
Sources of funding: Italian Ministry of Health
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Perria 2007 (Continued)
Declaration of interest: None declared
Study protocol has been published: www.ncbi.nlm.nih.gov/pubmed/15196307
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Low risk Quote: “Our randomisation sequences was
computer-generated. GPs who accepted to
take part in the study, were assigned by
simple random allocation by the REXSCO
software…” p 4
Adequate allocation concealement? Low risk Quote: “Randomisation was performed by
a researcher not involved in the study and
who was blind to the identity of the prac-
tices.” p 4
Similar baseline outcome measurements? Low risk Judgement comment: similar retinal
screening attendance at baseline (see Table
3 p 6)
Similar baseline characteristics? Low risk Judgement comment: similar baseline de-
mographic and clinical characteristics
Incomplete outcome data addressed? High risk Judgement comment: high attrition and
missingdata not balanced across study arms
Knowledge of allocated intervention pre-
vented?
Unclear risk Not reported
Protected against contamination? Unclear risk Quote: “Our randomisation sequences was
computer-generated. GPs who accepted to
take part in the study, were assigned by
simple random allocation by the REXSCO
software, which assigns to same-practice
partners a nil probability of being ran-
domised, thus minimising the chances of
participant contamination.” p 4
Free from selective outcome reporting? Low risk Judgement comment: reported
outcomes consistent with trial registry IS-
RCTN80116232
Other risks of bias? High risk Judgement comment: only 25% of eligible
GPs agreed to take part
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Peterson 2008
Methods Study aim: to determine whether implementation of a multicomponent organisational
intervention can produce significant change in diabetes care and outcomes in community
primary care practices
Study design: cluster-RCT
Participants Country: USA
Setting: 24 community care practices in Minnesota
Number of clusters: 24
Number of providers: 238
Total number of patients: 7101
Percentage male: 50.3%
Diabetes type: type 2
Average age (SD): 62.8 yrs (0.9)
Inclusion criteria: all type 2 diabetic patients in each practice aged 18 - 89 years
Exclusion criteria: documented as not receiving diabetes care at the practice (referred
care); deceased; no longer in the practice (documented transfer or no contact or 24
months); permanently residing in a long-term care facility
Interventions Intervention (12 clusters, n = 3970 participants): multicomponent intervention
(TRANSLATE) consisting of implementation of an electronic diabetes registry, visit
reminders, and patient-specific physician alerts. A site co-ordinator facilitated pre-visit
planning and a monthly review of performance with a local physician champion
Comparator (12 clusters, n = 3131 participants): usual care (practices were provided
with a report of their process and outcome measures at baseline and were encouraged to
continue usual quality improvement)
Duration: 12 months
Outcomes Primary outcome: % of participants achieving target values for the composite of SBP
< 130 mmHg, LDL cholesterol < 100 mg/dl, and HbA1c < 7.0% at baseline and 12
months
Secondary outcomes: 6 diabetes care process measures (including annual eye examina-
tion)
Baseline screening attendance (control group): 24.8%
Notes Date conducted: NR
Trial registration number: NCT00108927
Sources of funding: National Institute of Diabetes, Digestive, and Kidney Disorders,
National Institutes of Health
Declaration of interest: NR
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk Not reported
Adequate allocation concealement? Low risk Quote: “Practices were randomized in
blocks of four using six sets of opaque
envelopes to ensure that equal numbers
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of control and intervention clinics were
abstracted simultaneously. Envelopes were
prepared by the statistician, assigned in or-
der of postmark, and opened under obser-
vation.” p 2239
Similar baseline outcome measurements? High risk Judgement comment: higher attendance
for eye examination in intervention clinics
at baseline (35.5% versus 24.8%, Table 3
p 2241) and baseline imbalance in diabetic
retinopathy (Table 2 p 2240)
Similar baseline characteristics? Low risk Quote: “No statistically significant differ-
ences existed between intervention and
control practices in patient demographics,
total number of diabetes complications, or
relevant clinical measures.” p 2240
Judgement comment: with the exception
diabetic retinopathy, all other baseline clin-
ical characteristics were similar (Table 2 p
2240)
Incomplete outcome data addressed? Low risk Judgement comment: data from all partic-
ipants included in the analysis
Knowledge of allocated intervention pre-
vented?
Unclear risk Not reported
Protected against contamination? Low risk Judgement comment: control group un-
likely to have received the intervention
Free from selective outcome reporting? Low risk Judgement comment: re-
ported outcomes consistent with trial reg-
istry NCT00108927
Other risks of bias? Low risk Judgement comment: no evidence of other
sources of bias
Piette 2001
Methods Study aim: to evaluated automated telephone disease management (ATDM) with tele-
phone nurse follow-up as a strategy for improving diabetes treatment processes and out-
comes in Department of Veterans Affairs (VA) clinics
Study design: parallel-group RCT
Participants Country: USA
Setting: 4 university-affiliated VA clinics in northern California
Total number of participants: 292
Percentage male: 97%
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Piette 2001 (Continued)
Diabetes type: NR
Average age (SD): 60.5 yrs (10)
Inclusion criteria: adults with a diagnosis of diabetes and an active prescription for a
hypoglycaemic agent
Exclusion criteria: > 75 years of age; mentally ill; a life expectancy of < 12 months; were
newly diagnosed; planned to discontinue receiving services from the clinic within the
12-month follow-up period; did not have a touch-tone telephone
Interventions Intervention (n = 146): bi-weekly automated telephone disease management (ATDM)
health assessment and self-care education calls, and a nurse educator follow-up with
participants based on their ATDM assessment reports
Comparator (n = 146): usual care (not specified)
Duration: 12 months
Outcomes Primary outcome: impact on processes of care (including use of ophthalmology services)
; glycaemic control
Secondary outcomes: participants’ self-care activities and satisfaction with care
Baseline screening attendance (control group): 29.3%
Notes Date conducted: NR
Trial registration number: NR
Sources of funding: Health Services Research and Development Service, Mental Health
Strategic Health Care Group, Quality Enhancement Research Initiative, Department of
Veterans Affairs; American Diabetes Association
Declaration of interest: NR
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Low risk Quote: “Patients were randomized using
sealed envelopes containing group assign-
ments and a sequence generated using a ta-
ble of random numbers.” p 203
Adequate allocation concealement? Low risk Quote: “Patients, their clinicians, and re-
search staff were not aware of patients’
group assignment until after they con-
sented to participate and the envelope was
opened.” p 203
Similar baseline outcome measurements? High risk Judgement comment: large baseline imbal-
ance in the use of ophthalmology services
(intervention 69%, comparator 41%). See
Table 2 p 205
Similar baseline characteristics? Low risk Quote: “Intervention and control groups
had similar characteristics at baseline.” p
204
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Piette 2001 (Continued)
Incomplete outcome data addressed? Low risk Judgement comment: approx. 90% follow-
up and missing data balanced across study
arms
Knowledge of allocated intervention pre-
vented?
Low risk Quote: “Data on patients’ use of specialty
outpatient services were obtained from
electronic utilization databases and survey
self-reports.” p 204
Judgement comment: although blinding of
outcome assessor not reported, unlikely to
influence outcome
Protected against contamination? Low risk Judgement comment: control group un-
likely to have received the intervention
Free from selective outcome reporting? Unclear risk Judgement comment: no protocol or trial
registry entry available and therefore not
possible to assess
Other risks of bias? Low risk Judgement comment: no evidence of other
sources of bias
Pizzi 2015
Methods Study aim: to investigates the outcomes and costs of an educational and telephone in-
tervention on dilated fundus examination follow-up adherence in patients with diabetes
Study design: parallel-group RCT
Participants Country: USA
Setting: tertiary eye-care centre
Total number of participants: 356
Percentage male: 42%
Diabetes type: NR
Average age (SD): 60.7 yrs (12.6)
Inclusion criteria: adults (≥ 18 years old) with diabetes who had been previously eval-
uated in the eye clinic, and had been recommended for a follow-up dilated fundus ex-
amination
Exclusion criteria: NR
Interventions Intervention arm 1 (mailed intervention) (n = 117): personalised letter encouraging
scheduling a dilated fundus examination and a brochure about diabetic eye disease and
reminder card and automatic reminder call the day before the scheduled appointment
Intervention arm 2 (telephone intervention) (n = 120): standard reminder letter 1
month prior to exam due date followed by a personal telephone call offering assistance
in scheduling an appointment and a reminder letter 3 weeks prior to appointment and
automatic reminder call the day before the scheduled appointment
Comparator (n = 119): usual care (standard reminder letter 1 month prior to exam due
date and automatic reminder call the day before the scheduled appointment)
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Duration: 3 months
Outcomes Primary outcome: obtaining a dilated fundus examination within 90 days of the rec-
ommended follow-up date
Secondary outcomes: costs of delivering the intervention
Baseline screening attendance (control group): NR
Notes Date conducted: November 2012 to February 2013
Trial registration number: NR
Sources of funding: US Centers for Disease Control and Prevention
Declaration of interest: NR
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Low risk Quote: “...randomized within age strata
(<65 and>65 -years) using the method of
random permuted block” p 254
Adequate allocation concealement? Low risk Quote: “The study personnel in charge of
randomization did not participate in the
interventions.” p 254
Similar baseline outcome measurements? Unclear risk Not reported
Similar baseline characteristics? Low risk Quote: “There were no statistically signif-
icant differences in demographics among
the three study groups (Table 1)” p 257
Incomplete outcome data addressed? Low risk Judgement comment: all outcome data re-
ported (see Table 2 p 258)
Knowledge of allocated intervention pre-
vented?
Unclear risk Not reported
Protected against contamination? Low risk Judgement comment: it is unlikely that the
control group received the active interven-
tions
Free from selective outcome reporting? Unclear risk Judgement comment: no protocol or trial
registry entry available and therefore not
possible to assess
Other risks of bias? Low risk Judgement comment: no evidence of other
risks of bias
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Prela 2000
Methods Study aim: to evaluate the use of a single direct mailed reminder on rate of annual eye
examinations in people with diabetes
Study design: parallel-group RCT
Participants Country: USA
Setting: Medicare beneficiaries
Total number of participants: 6546
Percentage male: NR
Diabetes type: NR
Average age (SD): NR
Inclusion criteria: Medicare beneficiaries with diabetes (defined by International Clas-
sification of Diseases 9th revision. Clinical Modification ICD-9-CM codes of 250.XX)
Exclusion criteria: NR
Interventions Intervention (n = 4092):mailed intervention reinforcing the importance of annual eye
examinations
Comparator (n = 2454): usual care (not specified)
Duration: 6 months
Outcomes Primary outcome: claims for eye examinations; defined by Physicians Current Proce-
dural Terminology, 4th Edition (CPT-4) codes 99201 - 99205
Secondary outcomes: none
Baseline screening attendance (control group): 48.4%
Notes Date conducted: 1994 to 1995
Trial registration number: NR
Sources of funding: US Centers for Disease Control and Prevention
Declaration of interest: NR
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk Not reported
Adequate allocation concealement? Unclear risk Not reported
Similar baseline outcome measurements? Low risk Judgement comment: baseline retinal ex-
ams reported and balanced across study
arms (see Table 2 p259)
Similar baseline characteristics? Low risk Quote: “The groups were comparable with
regard to age, gender and use of preventa-
tive health services” p 259 (see Table 2)
Incomplete outcome data addressed? Low risk Judgement comment: low attrition, out-
come data reported on >90% (see Table 4
p 260)
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Prela 2000 (Continued)
Knowledge of allocated intervention pre-
vented?
Low risk Judgement comment: outcome data were
obtained from Medicare claims databases
Protected against contamination? Low risk Judgement comment: it is unlikely that the
control group received themailed interven-
tion
Free from selective outcome reporting? Unclear risk Judgement comment: no protocol or trial
registry entry available and therefore not
possible to assess
Other risks of bias? Low risk Judgement comment: no evidence of other
risks of bias
Prezio 2014
Methods Study aim: to determine the impact of a culturally-tailored diabetes education pro-
gramme led by a community health worker (CHW) on the HbA1c, blood pressure, BMI
and lipid status of uninsured Mexican Americans with diabetes
Study design: parallel-group RCT
Participants Country: USA
Setting: primary care (faith-based urban health services clinic serving exclusively unin-
sured patients of largely Mexican American origin)
Total number of participants: 180
Percentage male: 39.5%
Diabetes type: type 2
Average age (SD): 46.8 yrs (10.9)
Inclusion criteria: eligible patients were uninsured, had no previous exposure to the
Community Diabetes Education (CoDE) programme, were 18 to 75 years of age, had
type 2 diabetes either treated with anti-diabetic medications or diet-controlled
Exclusion criteria: advanced complications from diabetes; pregnancy
Interventions Intervention (n = 90): community diabetes educational programme delivered by CHW.
3 educational modules were delivered during individual 1-hour sessions over the first 8
weeks. These sessions covered areas recommended by the ADA. The CHW facilitated
immediate physician contact to address acute problems, assisted with pharmacy refills,
and arranged specialty visits such as dental care and dilated retinal exams. Participants
were provided with a blood glucose monitor and testing strips free of charge and in-
structed in correct use of the device by medical assistants
Comparator (n = 90): usual medical care at the discretion of the clinic physicians.
Participants in this group were provided with a blood glucose monitor and testing strips
free of charge and instructed in correct use of the device by medical assistants. Culturally-
tailored printed diabetes education materials were provided by physicians and clinic staff
Duration: 6 months
Outcomes Primary outcome: impact of the intervention on HbA1c, lipid status, blood pressure
and BMI
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Prezio 2014 (Continued)
Secondary outcomes: participants’ attitudes and knowledge about diabetes self-man-
agement, ADA standards of care (including annual dilated fundus examination)
Baseline screening attendance (control group): 6.7%
Notes Date conducted: 2006
Trial registration number: NCT00151190
Sources of funding: University of Texas School of Public Health, Institute for Faith-
Health Research, Dallas
Declaration of interest: none declared
Study protocol has been published: www.ncbi.nlm.nih.gov/pubmed/17431443
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Low risk Quote: “All patients were given informed
consent in the preferred language of the
study subject followed by (1:1) assignment
to either the intervention or control groups
using a computer generated randomization
schedule.” see Prezio 2013 p 20
Adequate allocation concealement? Unclear risk Not reported
Similar baseline outcome measurements? Low risk Judgement comment: baseline retinal ex-
ams reported and similar across study arms
(see Table 3 p 129)
Similar baseline characteristics? Low risk Quote: “No significant differences in base-
line clinical, demographic, and behavioral
characteristics were found between the in-
tervention and control groups, with the
exception that significantly more control
group participants were employed at study
entry (P = .02; Table 2).” Table 2 p 127
Judgement comment: employment sta-
tus may have influenced attendance for
retinopathy screening
Incomplete outcome data addressed? Low risk Judgement comment: intention-to-treat
analysis. All participants accounted for.
See CONSORT flow diagram p 21 Prezio
2013
Knowledge of allocated intervention pre-
vented?
Unclear risk Not reported
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Prezio 2014 (Continued)
Protected against contamination? High risk Judgement comment: all participants were
from the same faith-based community ser-
vices clinic and no evidence that the study
was protected from contamination
Free from selective outcome reporting? Low risk Judgement comment: re-
ported outcomes consistent with trial reg-
istry NCT00151190
Other risks of bias? Low risk Judgment comment: no evidence of other
risks of bias
Rosenkranz 1996
Methods Study aim: to study whether polaroid fundus photography during a patient consultation
would influence future screening behaviour for diabetic retinopathy
Study design: parallel-group RCT
Participants Country: Germany
Setting: Diabetes clinic within the University of Düsseldorf
Total number of participants: 103
Percentage male: 61.1%
Diabetes type: type 1 and 2 (87% type 2)
Average age (SD): NR
Inclusion criteria: patients with diabetes living within a 100 Km radius of the clinic
Exclusion criteria: diabetic retinopathy or treatment for diabetic retinopathy; patients
with glaucoma or cataract
Interventions Intervention arm 1 (n = 35): Group B. Polaroid photograph taken, shown and ex-
plained to the participant. The photograph was then given to the participant to take
home. Results of all clinical investigations explained to participant and also included in
a subsequent letter which contained a recommendation for an eye exam performed by
an ophthalmologist and the time frame for this exam
Intervention arm2 (n = 31):GroupC. Polaroid photograph taken, shownand explained
to the participant. The photograph was then retained in the participant’s file. Results of
all clinical investigations explained to participant and also included in a subsequent letter
which contained a recommendation for an eye exam performed by an ophthalmologist
and the time frame for this exam
Comparator (n = 37):Group A. Polaroid photograph of fundus taken but not shown to
participant. Results of all clinical investigations explained to participant and also included
in a subsequent letter which contained a recommendation for an eye exam performed
by an ophthalmologist and the time frame for this exam
Duration: 12 months
Outcomes Primary outcome: attendance for diabetic retinopathy screening
Secondary outcomes: factors affecting screening attendance
Baseline screening attendance (control group): NR
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Notes Date conducted: NR
Trial registration number: NR
Sources of funding: NR
Declaration of interest: NR
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk Not reported
Adequate allocation concealement? Unclear risk Not reported
Similar baseline outcome measurements? Unclear risk Not reported
Similar baseline characteristics? Low risk Judgement comment: similar demographic
characteristics across the 3 arms of the study
for age, gender and socioeconomic status
(see Table 1 p 70)
Incomplete outcome data addressed? Low risk Judgement comment: all participants were
followed up and reported (see Table 2 p 71)
Knowledge of allocated intervention pre-
vented?
Unclear risk Not reported
Protected against contamination? High risk Judgement comment: given the nature of
the intervention it is possible that the con-
trol group received the intervention
Free from selective outcome reporting? Unclear risk Judgement comment: no protocol or trial
registry entry available and therefore not
possible to assess
Other risks of bias? High risk Judgement comment: patients with ex-
isting diabetic retinopathy or previously
treated for diabetic retinopathy were ex-
cluded
Schnipper 2010
Methods Study aim: to evaluate whether a new document-based clinical decision-support system
is effective in improving the quality of care in coronary artery disease and diabetes
Study design: cluster-RCT
Participants Country: USA
Setting: Primary care practices at Brigham and Women’s Hospital and Massachusetts
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Schnipper 2010 (Continued)
General Hospital
Number of clusters: 10
Number of providers: 239
Total number of patients: 7009 (71.5% with diabetes)
Percentage male: NR
Diabetes type: type 1 and 2
Average age (SD): NR
Inclusion criteria: patients with type 1 or type 2 diabetes
Exclusion criteria: patients already under the regular care of an ophthalmologist
Interventions Intervention (5 clusters, n = 3431): ‘smart form’ with reminders. Document-based
clinical support system built into an electronic heath record. The system highlights
missing and ‘requests’ missing data
Comparator (5 clusters, n = 3578): usual care (not specified)
Duration: 9 months
Outcomes Primary outcome: mean % of deficiencies in disease management within 1 month of a
clinic visit (including eye examination documentation-diabetes patients only)
Secondary outcomes: NR
Baseline screening attendance (control group): NR
Notes Date conducted: 2008
Trial registration number: NR
Sources of funding: Agency for Healthcare and Quality
Declaration of interest: none declared
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Low risk Quote: “Primary care physicians were as-
signed to receive the Smart Form or usual
care on the basis of random number gener-
ation in Microsoft Excel (Redmond, WA).
”
p SP73
Adequate allocation concealement? Low risk Judgement comment: unit of allocation at
the level of the primary care practice and
allocation performed prior to the start of
the study
Similar baseline outcome measurements? Unclear risk Not reported
Similar baseline characteristics? High risk Judgement comment: a number of baseline
differences in characteristics including: fe-
male (P < 0.001), number of problems on
problem list (P < 0.001), race (P < 0.001)
, primary insurance (P = 0.002), median
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household income (P = 0.01)
Incomplete outcome data addressed? Unclear risk Not reported
Knowledge of allocated intervention pre-
vented?
Unclear risk Not reported
Protected against contamination? Low risk Judgement comment: allocation by pri-
mary care practice; it is unlikely that the
control group received the intervention
Free from selective outcome reporting? Unclear risk Judgement comment: no protocol or trial
registry entry available and therefore not
possible to assess
Other risks of bias? Low risk Judgement comment: no evidence of other
sources of bias
Simon 2010
Methods Study aim: to assess the effects of automated telephone outreach with speech recognition
on diabetes-related testing
Study design: parallel-group RCT
Participants Country: USA
Setting: Harvard Pilgrim Healthcare Institute
Total number of participants: 1200
Percentage male: 61.6%
Diabetes type: 95% type 2
Average age (SD): 51.1 yrs (10.9)
Inclusion criteria: adult health plan members with diabetes overdue for routine testing
(sample limited to individuals with no insurance claim for a dilated eye examination in
the prior year and no claim for 1 or more of the following tests: HbA1c, LDL cholesterol,
or microalbumin)
Exclusion criteria: NR
Interventions Intervention (n=600): a computerised telephone systemplaced 3 calls to the participant’s
home, encouraging the participant to fulfil recommended testing. The automated system
offered a live telephone call back to assist in scheduling tests and also offered to send
participants the following items: 1) a voucher that would allow the provider to waive
the co-payment for a dilated eye examination; 2) an educational nutrition video; 3) a
cookbook; or 4) a pill box
Comparator (n = 600): usual care (not specified)
Duration: 12 months
Outcomes Primary outcome: attendance for a dilated fundus examination
Secondary outcomes: tests for glycaemia, hyperlipidaemia, and nephropathy
Baseline screening attendance (control group): 0%
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Notes Date conducted: 2006
Trial registration number: NCT00790530
Sources of funding: ADA, Harvard Pilgrim Health Care Institute
Declaration of interest: none declared
Outcome data obtained from Supplementary Figure 2 (online supplementary appendix)
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk Not reported
Adequate allocation concealement? Unclear risk Not reported
Similar baseline outcome measurements? Unclear risk Not reported
Similar baseline characteristics? Low risk Quote: “Compared with the usual care
group, the intervention group was younger
(50 vs. 52 years, P=0.02) and had a greater
proportion of men (64 vs.41%, P=0.04);
the groups were comparable on other so-
cio-demographic measures and clinical in-
dicators as shown in supplementary Table
2.” p 1453
Judgement comment: baseline differences
unlikely to influence outcome
Incomplete outcome data addressed? Low risk Judgement comment: no missing data
Knowledge of allocated intervention pre-
vented?
Low risk Judgement comment: outcomes were ob-
tained from automated clinical administra-
tive databases
Protected against contamination? Low risk Judgement comment: it is unlikely that the
control group received telephone interven-
tion
Free from selective outcome reporting? Unclear risk Judgement comment: trial retrospectively
registered and not possible to assess
Other risks of bias? Low risk Judgement comment: no evidence of other
risks of bias
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Methods Study aim: to evaluate the effect of adding pharmacists to the primary care team on the
management of patients with type 2 diabetes
Study design: parallel-group RCT
Participants Country: Canada
Setting: 2 public family medicine clinics (primary care)
Total number of patients: 260
Percentage male: 42.7%
Diabetes type: type 2
Average age (SD): 59.1 yrs (11.6)
Inclusion criteria: patients were eligible if they had type 2 diabetes, were regularly seen
by the primary care team, and did not qualify for urgent specialist referral and assessment
Exclusion criteria: patients who were followed in specialty clinics for diabetes, hyper-
tension, or dyslipidaemia; who were cognitively impaired; who were not responsible for
their own medication administration; or who were unable to communicate in English
Interventions Intervention (n = 131): pharmacists performed medication assessments and limited
history and physical examinations and provided guideline-concordant recommendations
to optimise medication management
Comparator (n = 129): usual care (not specified)
Duration: 12 months
Outcomes Primary outcome: achievement of a clinically-important reduction in blood pressure,
defined as a 10% decrease in systolic blood pressure at 1 year
Secondary outcomes: absolute change in SBP from baseline to 1 year, achievement of
recommended blood pressure targets (< 130/80 mmHg), and antihypertensive medica-
tion changes. Healthcare-related contacts during the study period (including visits to an
ophthalmologist or optometrist)
Baseline screening attendance (control group): NR
Notes Date conducted: 2009
Trial registration number: ISRCTN97121854
Sources of funding: Canadian Diabetes Association, the Institute of Health Economics,
and the Alberta Heritage Foundation for Medical Research
Declaration of interest: none declared
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Low risk Quote: “A central randomization service
(www.epicore.ualberta.ca) provided com-
puter generated random sequences strati-
fied by the primary care clinic for treatment
allocation.” p 21
Adequate allocation concealement? Low risk Quote: “Pharmacists, analysts, and investi-
gators were unaware of the block size and
allocation sequence to preserve allocation
131Interventions to increase attendance for diabetic retinopathy screening (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Simpson 2011 (Continued)
concealment.” p 21
Similar baseline outcome measurements? Unclear risk Not reported
Similar baseline characteristics? Low risk Quote: “Baseline characteristics were well
balanced between the groups (Table 1).” p
23
Incomplete outcome data addressed? Low risk Quote: “There were no differences in age,
sex, diabetes duration, or baseline blood
pressure between the patients who did or
did not complete the study.” p 22
Judgement comment: intention-to-treat
analysis analysis and reasons for losses to
follow-up provided and balanced across
study arms
Knowledge of allocated intervention pre-
vented?
Unclear risk Judgement comment: not clear whether
eye-screening outcome assessors were
masked
Protected against contamination? High risk Quote : “.. there was the possibility of “con-
tamination” or “cointervention” because
both intervention and control patientswere
drawn from the same primary care team.”
p 25
Free from selective outcome reporting? Low risk Judgement comment: reported
outcomes consistent with trial registry IS-
RCTN97121854
Other risks of bias? Low risk Judgement comment: no evidence of other
sources of bias
Sonnichsen 2010
Methods Study aim: to evaluate whether a disease management programme consisting of physi-
cian and patient education, standardised documentation and therapeutic goals improves
metabolic control (HbA1c) and quality of care for adults with type 2 diabetes managed
in primary care
Study design: cluster-RCT
Participants Country: Austria
Setting: primary care practices with a contract with the public health insurance in Austria
(province of Salzburg)
Number of clusters: 6
Number of providers: 92
Total number of patients: 1494
Percentage male: 52.2%
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Diabetes type: type 2
Average age (SD): 65.5 yrs (10.4)
Inclusion criteria: all patients with type 2 diabetes willing to participate in the study
Exclusion criteria: dementia/psychiatric illness with inability to participate or to give
informed consent
Interventions Intervention (3 clusters, n = 654):DiseaseManagement Programme (DMP) containing
the following modules:
• standardised documentation of physical examination, laboratory findings, and
diabetes complications in a DMP-form once a year
• structured interdisciplinary care according to the guidelines of the Austrian
Diabetes Association
• agreement on therapeutic goals in a shared patient-physician decision-making
process at 3-monthly intervals
Comparator (3 clusters, n = 840): usual care (not specified)
Duration: 12 months
Outcomes Primary outcome: change in HbA1c from baseline to 12 months
Secondary outcomes: improvement in systolic or diastolic blood pressure, lipids, and
BMI; measures of process quality including the frequency of HbA1c measurements, eye
and foot examinations; participation in patient education
Baseline screening attendance (control group): NR
Notes Date conducted: 2008
Trial registration number: ISCTN27414162
Sources of funding: ParacelsusMedical University, Public Health Insurance of Salzburg,
Salzburg Savings Bank, Roche Diagnostics
Declaration of interest: none declared
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Low risk Quote: “…cluster-randomisation at the
level of the districts was performed with
computerised sequence generation.” p 4
Adequate allocation concealement? Low risk Quote: “To assure concealment of alloca-
tion at the physician level, GPs and in-
ternists were not told whether they would
be in the intervention or the control group
until after obtaining their consent to par-
ticipate.” p 4
Similar baseline outcome measurements? Unclear risk Not reported
Similar baseline characteristics? Low risk Quote: “Baseline data are shown in table
2. There were no significant differences
between the intervention and the control
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group except for BMI and cholesterol, with
intervention patients being slightly heavier
and having higher cholesterol levels than
controls.” p 4
Judgement comment: baseline differences
unlikely to influence outcome
Incomplete outcome data addressed? High risk Judgement comment: intention-to-treat
(ITT) and per-protocol analysis. For ITT,
after randomisation, 6 GP practices with-
drew before recruiting participants, and 5
in intervention group were excluded since
they withdrew consent and did not provide
baseline values. The trialists excluded these
values and considered it an ITT
Knowledge of allocated intervention pre-
vented?
High risk Quote: “As typical for pragmatic trials,
blinding was not possible and the knowl-
edge of being in the intervention or control
group may have influenced the result.” p 8
Protected against contamination? Low risk Judgement comment: allocation by pri-
mary care practice and it is unlikely that the
control group received the intervention
Free from selective outcome reporting? Low risk Judgement comment: re-
ported outcomes consistent with trial reg-
istry ISCTN27414162
Other risks of bias? Low risk Judgement comment: no evidence of other
sources of bias
Steyn 2013
Methods Study aim: to evaluate the effect introducing a structured clinical record (with embedded
national guideline recommendations) and training of healthcare providers in its use, on
the quality of care for diabetes and hypertension
Study design: cluster-RCT
Participants Country: South Africa
Setting: public sector primary healthcare clinics (Community Health Centres) in work-
ing class residential area in Cape Town
Number of clusters: 18
Number of providers: NR
Total number of patients: 456
Percentage male: 26.1%
Diabetes type: types 1 and 2 (92% type 2)
Average age (SD): 58.3 yrs (10.9)
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Steyn 2013 (Continued)
Inclusion criteria: ≥ 15 years; a documented attendance at the particular community
health clinic with at least 4 visits during the previous year for hypertension or diabetes;
and having received treatment for these conditions at each visit
Exclusion criteria: unable to provide answers to a questionnaire
Interventions Intervention (9 clusters, n = 229 participants):multicomponent intervention consist-
ing of:
• structured record, which incorporated the National Guidelines for the
management of patients with diabetes or hypertension
• physician educational package consisted of an outreach visit by a recognised local
diabetes and hypertension expert
Comparator (9 clusters, n = 217 participants): usual care (guidelines passively dissem-
inated by the National Department of Health)
Duration: 12 months
Outcomes Primary outcome: mean level of HbA1c
Secondary outcomes: proportion of participants with diabetes BP < 130/85 mmHg)
; proportion with uncontrolled glycaemia (% with HbA1c > 7%) ; proportions of par-
ticipants with recorded examinations for complications (retinopathy, nephropathy, foot
problems)
Baseline screening attendance (control group): 8.8%
Notes Date conducted: 2000
Trial registration number: Pan African Clinical Trial Registry (www.pactr.org)
PACTR201303000493351
Sources of funding: South African Medical Research Council; unrestricted grant from
Hoechst, Marion, Roussel
Declaration of interest: 1 author (NL) received honoraria from Novartis and travel
support from Novo Nordisk, Eli Lilly Laboratories and Sanofi Aventis; all other authors
reported no conflict of interest
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Low risk Quote: “Study clinics were randomly allo-
cated, by stratum, to intervention or con-
trol using a computer-generated list of ran-
dom numbers.” p 3
Adequate allocation concealement? Low risk Judgement comment: unit of allocation at
the level of the primary care practice and
allocation performed prior to the start of
the study
Similar baseline outcome measurements? Low risk Judgement comment: similar rates of eye
examinations between arms at baseline (in-
tervention 18%, control 9%)
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Steyn 2013 (Continued)
Similar baseline characteristics? Low risk Judgement comment: similar baseline
characteristics (Table 1 p 5)
Incomplete outcome data addressed? Low risk Judgement comment: low attrition and rea-
sons for missing data provided
Knowledge of allocated intervention pre-
vented?
Unclear risk Not reported
Protected against contamination? Low risk Judgement comment: allocation by pri-
mary care practice and it is unlikely that the
control group received the intervention
Free from selective outcome reporting? Unclear risk Judgement comment: trial retrospectively
registered and therefore not possible to as-
sess
Other risks of bias? Low risk Judgement comment: no evidence of other
sources of bias
Taylor 2003
Methods Study aim: to evaluate the efficacy of a nurse-care management system designed to
improve outcomes in patients with complicated diabetes
Study design: parallel-group RCT
Participants Country: USA
Setting: a medical centre in Santa Clara, California
Total number of participants: 169
Percentage male: 53%
Diabetes type: type 1 and type 2
Average age (SD): 55.1 yrs (10.2)
Inclusion criteria: patients with an HbA1c > 10.0% and an ICD-9-based diagnosis of
diabetes and hypertension, dyslipidaemia, or CVD
Exclusion criteria: did not speak English; not willing or able to participate in the group
sessions once a week for 4 weeks; had congestive heart failure as their primary diagnosis;
were < 18 years of age; were pregnant; were enrolled in a diabetes management clinic; or
fell into the “other” category (e.g. living too far away/moving, deceased, or no-show to
baseline appointment)
Interventions Intervention (n = 84): participantsmet with a nurse-caremanager to establish individual
outcome goals, attended group sessions once a week for up to 4 weeks, and received
telephone calls to manage medications and self-care activities
Comparator (n = 85): usual care (under the treatment of their primary care physician.
Each participant received a folder containingdiabetes pamphlets and sheet of instructions
encouraging them tomaintain contact with their personal physician and to attend general
diabetes education classes at their medical centre)
Duration: 12 months
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Outcomes Primary outcome: % of participants meeting process outcome goals at 12 months
(including self-reported dilated eye exam); number of physician visits during the study
period
Secondary outcomes: participant and physician views regarding the intervention
Baseline screening attendance (control group): 71.2%
Notes Date conducted: 2000 to 2001
Trial registration number: NR
Sources of funding: Robert Wood Johnson Foundation
Declaration of interest: NR
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk Not reported
Adequate allocation concealement? Unclear risk Note reported
Similar baseline outcome measurements? Low risk Judgement comment: similar % of re-
ported dilated eye exams across arms
Similar baseline characteristics? Low risk Quote: “The demographics of the 169 pa-
tients enrolled in the study can be seen in
Table 1.There were no differences between
usual care and intervention subjects for any
of these variables.” p 1060
Incomplete outcome data addressed? Unclear risk Judgement comment: missing data approx.
20% in intervention group and 17% for
comparator group (due to dropping out or
being lost to follow-up). Unclear if missing
data would influence outcome
Knowledge of allocated intervention pre-
vented?
Low risk Quote: “All eligible patients met with a re-
search assistant blinded to the subject’s ran-
dom assignment for baseline and follow-up
assessments at 1 year.” p 1059
Protected against contamination? Low risk Judgement comment: control group un-
likely to have received the intervention
Free from selective outcome reporting? Unclear risk Judgement comment: no protocol or trial
registry entry available and therefore not
possible to assess
Other risks of bias? Low risk Judgement comment: no evidence of other
sources of bias
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Varney 2014
Methods Study aim: to measure the effect of a 6-month telephone coaching intervention on
glycaemic control, risk factor status and adherence to diabetes management practices
Study design: parallel-group RCT
Participants Country: Australia
Setting: hospital diabetes clinic
Total number of participants: 94
Percentage male: 68%
Diabetes type: type 2
Average age (SD): 61.5 yrs (NR)
Inclusion criteria: adults with type 2 diabetes with HbA1c >7%
Exclusion criteria: patients who were unable to provide informed consent, non-English
speaking, cognitively impaired, receiving palliative care, severely hearing impaired or
without telephone access
Interventions Intervention (n=47):usual care plus intensive telephone coaching6months durationby
a dietician experienced in type 2 diabetes management. Participants received an average
of 6 sessions
Comparator (n = 47): usual care (consisting of attendance at the diabetes clinic 3 - 6-
monthly with GP visits as required)
Duration: 6 months
Outcomes Primary outcome: HbA1c at 6 months, adjusted for baseline value
Secondary outcomes: adjusted mean HbA1c at 12 months, as well as 6- and 12-month
adjusted mean fasting glucose, lipids, BP, weight, waist circumference, BMI, physical
activity and Kessler Psychological Distress Scale score. Participants were asked researcher-
generated questions to determine adherence to guidelines recommending annual foot
examinations, biennial eye examinations, annual influenza vaccinations, pneumococcal
vaccination every 5 or 10 years and smoking cessation
Baseline screening attendance (control group): 87.2%
Notes Date conducted: NR
Trial registration number: ACTRN12609000075280 (www.anzctr.org.au)
Sources of funding: St Vincent’s Hospital Research Endowment Fund
Declaration of interest: none declared
Additional outcome data obtained from the author
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Low risk Quote: “A researcher, not involved in re-
cruitment, randomised participants into
intervention and control groups. Com-
puter-generated block randomisation was
undertaken to obtain a one-to-one bal-
anced design.” p 891
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Varney 2014 (Continued)
Adequate allocation concealement? Low risk Quote: “Allocation blinding was main-
tained until randomisation, after which
participants and the principal researcher
were informed of randomisation outcome.
” p 891
Similar baseline outcome measurements? Low risk Judgement comment : no differences in
baseline eye examinations (see Table 1 p
893)
Similar baseline characteristics? Low risk Quote: “Study participants differed from
the population attending the diabetes clinic
in the recruitment period, being younger
61.4 (59.2-63.5) versus 64.1 years (63.2-
65.0, P = 0.02), and being less likely to re-
quire an interpreter, 0% versus 29%, P <
0.001, reflecting the study’s inclusion cri-
teria.” p 892
Judgement comment : baseline difference
unlikely to influence outcome
Incomplete outcome data addressed? High risk Judgement comment: approximately 25%
attrition at 12 months which may have bi-
ased the results
Knowledge of allocated intervention pre-
vented?
Unclear risk Not reported
Protected against contamination? Low risk Judgement comment: it is unlikely that
the control group received the telephone
coaching intervention
Free from selective outcome reporting? Unclear risk Judgement comment: trial retrospectively
registered and so not possible to assess
Other risks of bias? Low risk Judgement comment: no evidence of other
risks of bias
Vidal-Pardo 2013
Methods Study aim: to evaluate the effect of an educational intervention among primary care
physicians on several indicators of good clinical practice in diabetes care
Study design: cluster-RCT
Participants Country: Spain
Setting: primary care physicians in Galicia (north-west Spain)
Number of clusters: 108
Number of providers: 108
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Vidal-Pardo 2013 (Continued)
Total number of patients: 2938
Percentage male: 52.4%
Diabetes type: type 2
Average age (SD): NR
Inclusion criteria: patients aged ≥ 40 years with more than 1 year of diagnosis of type
2 diabetes
Exclusion criteria: women with gestational diabetes
Interventions Intervention (58 clusters, n = 1437 participants): educational intervention comprising
(a) distribution of educational materials; (b) physicians’ specific bench-marking infor-
mation (audit and feedback); (c) an on-line course and 3 on-site educational workshops
on diabetes
Comparator (50 clusters, n = 1501 participants): usual care (not specified)
Duration: 6 months
Outcomes Primary outcome:measurement of risk factors (HbA1c ; BP; LDLcholesterol); processes
of care including annual eye examination
Secondary outcomes: NR
Baseline screening attendance (control group): 25.1%
Notes Date conducted: 2009
Trial registration number: NR
Sources of funding: unrestricted grant from Merck Sharp & Dohme (MSD) and the
Fundacion Escola Galega de Administracion Sanitaria (FEGAS)
Declaration of interest: none declared
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk Not reported
Adequate allocation concealement? Low risk Judgement comment: unit of allocation at
the level of the primary care physician and
allocation performed prior to the start of
the study
Similar baseline outcome measurements? Low risk Judgement comment: similar rates of eye
examinations between arms at baseline (Ta-
ble 3 p 755)
Similar baseline characteristics? Low risk Quote: “Table 2 compares the groups of
patients. Differences between the inter-
vention and control groups are slight and
not statistically significant, except for some
variables at baseline such as family history
of ischaemic heart disease, personal history
of prior coronary revascularisation, pres-
ence of neuropathy and insulin use.” p 753
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Vidal-Pardo 2013 (Continued)
Judgement comment: small baseline differ-
ences unlikely to influence outcome
Incomplete outcome data addressed? Low risk Judgement comment: low attrition andbal-
anced between study arms
Knowledge of allocated intervention pre-
vented?
Unclear risk Not reported
Protected against contamination? High risk Judgement comment: possibility of con-
tamination as control and intervention
physicians worked in the same healthcare
system
Free from selective outcome reporting? Unclear risk Judgement comment: no protocol or trial
registry entry available and therefore not
possible to assess
Other risks of bias? Low risk Judgement comment: no evidence of other
sources of bias
Wagner 2001
Methods Study aim: to evaluate the impact of primary care group visits (chronic care clinics) on
the process and outcome of care for diabetic patients
Study design: cluster-RCT
Participants Country: USA
Setting: primary care clinics in the Group Health Cooperative in western Washington
Number of clusters: 35
Number of providers: NR
Total number of patients: 707
Percentage male: 53.4%
Diabetes type: NR
Average age (SD): 60.7 yrs (NR)
Inclusion criteria: all diabetic patients ≥ 30 yrs of age
Exclusion criteria: patients whowere terminally ill, demented or psychotic, or otherwise
not able to participate in the study
Interventions Intervention (14 clusters, n = 278 participants): participants invited to attend a half-
day chronic care clinic at their primary care clinic in groups of approx. 8 diabetic patients
at intervals of 3 - 6 months. Each chronic care clinic group visit consisted of: individ-
ual visits with the primary care physician, nurse, and clinical pharmacist; and a group
educational/ peer support session. Self-management support was also provided through
one-on-one counselling with the practice nurse
Comparator (21 clusters, n = 429 participants): usual care (not specified)
Duration: 24 months
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Wagner 2001 (Continued)
Outcomes Primary outcome: processes of diabetes care and satisfaction of intervention and control
patients at baseline and at 24 months
Secondary outcomes: HRQOL using the SF36
Baseline screening attendance (control group): 62.2%
Notes Date conducted: NR
Trial registration number: NR
Sources of funding: Robert Wood Johnson Foundation
Declaration of interest: NR
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk Not reported
Adequate allocation concealement? Low risk Judgement comment: unit of allocation by
primary care practice and allocation per-
formed prior to the start of the study
Similar baseline outcome measurements? Low risk Judgement comment: similar % of baseline
retinal exams across arms
Similar baseline characteristics? Low risk Quote: “Table 1 shows that there were
no significant demographic, treatment, or
health status differences between groups.”
p 697
Incomplete outcome data addressed? High risk Quote: “Completed follow-up responses
were obtained from 87% of surviving in-
tervention patients and 79% of surviving
control patients.” p 697
Judgement comment: imbalance in miss-
ing data could have influenced outcome
Knowledge of allocated intervention pre-
vented?
Unclear risk Not reported
Protected against contamination? Low risk Judgement comment: control group un-
likely to have received the intervention
Free from selective outcome reporting? Unclear risk Judgement comment: no protocol or trial
registry entry available and therefore not
possible to assess
Other risks of bias? Low risk Judgement comment: no evidence of other
sources of bias
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Walker 2008
Methods Study aim: to study the impact of a tailored telephone intervention compared to a
standard print intervention on screening for diabetic retinopathy in an urban minority
population
Study design: parallel-group RCT
Participants Country: USA
Setting: 3 inner city health centres
Total number of participants: 635
Percentage male: 39.5%
Diabetes type: NR
Average age (SD): 56.6 yrs (12.5)
Inclusion criteria: aged > 18 years, diagnosed with diabetes, able to speak and read (or
be read to in) English or Spanish, capable of providing informed consent, have access to
a telephone, and report not having had a dilated fundus examination in the previous 12
months
Exclusion criteria: no access to a telephone; unable to speak English or Spanish; fundus
examination in the previous 12 months
Interventions Intervention (n = 326): tailored telephone intervention to promote retinopathy screen-
ing (up to 7 calls over a 6-month period). Participants were interviewed to identify issues
and barriers that might either motivate them or prevent them from going for a dilated
fundus examination. Attempts were made to engage all participants with targeted self-
management strategies and dilated fundus examination education, and they were en-
couraged to make a screening appointment if they indicated they were ready to change
Comparator (n = 309): participants were sent a printed booklet on preventing diabetic
eye problems
Duration: 6 months
Outcomes Primary outcome: documentation of a dilated fundus examination within 6 months of
randomisation
Secondary outcomes: factors that contribute to receiving a dilated fundus examination
within 6 months for participants in the tailored telephone intervention. HbA1c results,
from a 1-year period encompassing the participant’s 6-month intervention period
Baseline screening attendance (control group): 0%
Notes Date conducted: 2001 to 2005
Trial registration number: NR
Sources of funding: National Institute of Health, Rockerfeller Foundation
Declaration of interest: none declared
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk Not reported
Adequate allocation concealement? Unclear risk Not reported
Similar baseline outcome measurements? Unclear risk Not reported
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Walker 2008 (Continued)
Similar baseline characteristics? Low risk Quote: “There were no significant differ-
ences between the two study groups on any
characteristics.” p 188
Incomplete outcome data addressed? Low risk Judgement comment: proportion of miss-
ing data low and balanced between inter-
vention and control groups
Knowledge of allocated intervention pre-
vented?
Low risk Quote: “The trained chart auditor was
masked to the subjects’ group assignment.
” p 186
Protected against contamination? Low risk Judgement comment: it is unlikely that the
control group received the tailored tele-
phone intervention
Free from selective outcome reporting? Unclear risk Judgement comment: no protocol or trial
registry entry available and therefore not
possible to assess
Other risks of bias? Low risk Judgement comment: no evidence of other
risks of bias
Ward 1996
Methods Study aim: to evaluate the impact of audit and feedback to general practitioners on the
quality of their management of type 2 diabetes
Study design: cluster-RCT
Participants Country: Australia
Setting: Western Australia metropolitan general practices
Number of clusters: 139
Number of providers: 139
Total number of patients: 386
Percentage male: NR
Diabetes type: type 2
Average age (SD): NR
Inclusion criteria: NR
Exclusion criteria: NR
Interventions Intervention (doctor interview) (clusters NR, n = 130 participants): each doctor was
sent data by post on their management of patients compared to those of all doctors on
the project along with a recommended standard. This was followed by an interview with
an academic general practitioner to discuss their results using an interview proforma
Intervention (nurse interview) (clusters NR, n = 121 participants): in addition to
receiving their postal data, the doctor was interviewed by a state registered nurse to
discuss their results using the same interview proforma
Comparator (no interview)(clusters NR, n = 135 participants): each doctor was sent
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Ward 1996 (Continued)
their data by post only
Duration: 12 months
Outcomes Primary outcome: 21 process outcomes on the Diabetic Healthcare Checklist (DHC),
including eye examination (or referral to an ophthalmologist)
Secondary outcomes: NR
Baseline screening attendance (control group): 29.6%
Notes Date conducted: NR
Trial registration number: NR
Sources of funding: NR
Declaration of interest: NR
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk Not reported
Adequate allocation concealement? Low risk Judgement comment: unit of allocation by
general practice and allocation performed
prior to the start of the study
Similar baseline outcome measurements? High risk Judgement comment: baseline differences
in annual eye exams (29.6% comparator
group, 23.1% doctor interview group, 19.
8%, nurse interview group). See Table 1 p
145
Similar baseline characteristics? Unclear risk Judgement comment: unclear if baseline
differences in process of care influence out-
come
Incomplete outcome data addressed? Low risk Judgement comment: data from all partic-
ipants available for analysis
Knowledge of allocated intervention pre-
vented?
High risk Judgement comment: 1 of the outcome as-
sessors was the research nurse who con-
ducted the nurse interviews in 1 arm of the
trial and was therefore unmasked
Protected against contamination? Low risk Judgement comment: control group un-
likely to have received the intervention
Free from selective outcome reporting? Unclear risk Judgement comment: no protocol or trial
registry entry available and therefore not
possible to assess
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Ward 1996 (Continued)
Other risks of bias? Low risk Judgement comment: no evidence of other
sources of bias
Weiss 2015
Methods Study aim: to test the impact of a home-based behavioural activation programme to
improve rates of dilated fundus examinations in older African Americans with diabetes
Study design: parallel-group RCT
Participants Country: USA
Setting: 2 urban medical centres
Total number of participants: 206
Percentage male: 39.5%
Diabetes type: type 2
Average age (SD): 72.7 yrs (6.2)
Inclusion criteria: aged ≥ 65 years, self-identification as an African-American individ-
ual, diagnosis of type 2 diabetes mellitus, no self-report or medical documentation of a
dilated fundus examination in the past 12 months, and access to a telephone
Exclusion criteria: cognitive impairment (based on an abbreviated version of the Mini-
Mental State Examination), current significant psychiatric disorder, current medical dis-
order limiting life expectancy, need for dialysis, and hearing impairment that precluded
research participation
Interventions Intervention (n = 103): behavioural intervention delivered by specially-trained commu-
nity health worker. Intervention consisted of education, identifying barriers to a dilated
fundus examination and action-planning
Comparator (n = 103): supportive therapy only without educational materials or be-
havioural strategies or goal-setting
Duration: 6 months
Outcomes Primary outcome: medical documentation of a dilated fundus examination by the 6-
month follow-up visit
Secondary outcomes: risk perceptions of diabetes, diabetes self-care behaviours, depres-
sive symptoms
Baseline screening attendance (control group): 0%
Notes Date conducted: October 2010 to May 2013
Trial registration number: NCT01179555
Sources of funding: Pennsylvania Department of Health
Declaration of interest: none declared
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Low risk Quote: “..participants who completed the
baseline assessment were randomized using
random permuted blocks with a 1 to1 allo-
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Weiss 2015 (Continued)
cation ratio to BADRP or supportive ther-
apy (ST).” p 1006
Adequate allocation concealement? Low risk Quote: “Randomization sheets were stored
in sequentially numbered sealed envelopes
that were opened by the project director
after each participant completed baseline
assessment.” p 1006
Similar baseline outcome measurements? Unclear risk Not reported
Similar baseline characteristics? Low risk Quote: “The 2 arms were balanced with
respect to age, education, sex, recruitment
site, and marital status. Differences on the
Risk Perceptions and Risk Knowledge Sur-
vey of Diabetes Mellitus, Diabetes Self-
Care Inventory, Patient Health Question-
naire, Literacy Assessment for Diabetes,
and the NEI-VFQ 25 composite scores
that may have influenced the primary out-
come were not identified. Participants in
the BADRP group had lower HbA1c levels
and chronic disease scores at baseline.”
p 1008
Incomplete outcome data addressed? Low risk Judgement comment: attrition (approx.
10%) balanced across groups and reasons
for exclusion given (see CONSORT dia-
gram p 1008)
Knowledge of allocated intervention pre-
vented?
Low risk Quote: “Follow-up assessments were con-
ducted in participants’ homes at 6 months’
follow-up by community health workers
masked to treatment assignment.” p 1007
Protected against contamination? Low risk Judgement comment: it is unlikely that the
control group received the behavioural in-
tervention
Free from selective outcome reporting? High risk Judgement comment: per-protocol analy-
sis. Participants who had not received the
intervention were excluded from the anal-
ysis
Other risks of bias? Low risk Judgement comment: no evidence of other
risks of bias
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Welch 2011
Methods Study aim: to evaluate the clinical usefulness of a nurse-led diabetes care programme for
poorly-controlled Hispanic type 2 diabetes patients
Study design: parallel-group RCT
Participants Country: USA
Setting: a single urban community healthcare centre in Springfield, Massachusetts
Total number of patients: 46
Percentage male: 33%
Diabetes type: type 2
Average age (SD): 55.8 yrs (10)
Inclusion criteria: duration of type 2 diabetes of at least 1 year based on medical record
review and treatment history; age 30 - 85 years; HbA1c > 7.5% within the past 3months
but not > 14%; Hispanic ethnicity; independently living and ambulatory
Exclusion criteria: severe diabetes complications, severe psychiatric illness, or severe
visual restrictions, or would not be available for the study period (e.g. leaving the area,
pregnant or planning to become pregnant)
Interventions Intervention (n = 25): 7 x 1-hour diabetes care visits over a 12-month period con-
ducted by a bicultural/bilingual diabetes nurse and dietician team (both certified diabetes
educators). Use of CDMP diabetes care management software that provides tools for
continuous care and contact between patients and their providers. Participants in the
intervention group also received diabetes eye screening using the Diabetes Eye Care and
Treatment (DECAT) programme using the clinically-validated Joslin Vision Network
(JVN) protocol
Comparator (‘attention control’)(n = 21): diabetes education interventionconsisting
of 7 x 1-hour visits over a 12-month period conducted by bicultural/bilingual clinic
support staff who also encouraged participants to formulate diabetes-related questions
for discussion with their primary care provider at the next scheduled primary care visit
Duration: 12 months
Outcomes Primary outcome: adherence to national clinical practice guidelines (blood glucose,
blood pressure, foot exam, eye exam), and levels of diabetes distress, depression, and
treatment satisfaction
Secondary outcomes: NR
Baseline screening attendance (control group): NR
Notes Date conducted: NR
Trial registration number: NR
Sources of funding: Baystate Medical Center Academic Affairs Internal Research Grant
Declaration of interest: NR
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Low risk Quote: “Participants were randomly as-
signed to the CDMP intervention group
(IC) or the attention control group (AC)
by a fair coin toss.” p 682
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Welch 2011 (Continued)
Adequate allocation concealement? Unclear risk Not reported
Similar baseline outcome measurements? Unclear risk Not reported
Similar baseline characteristics? Low risk Quote: “There were no differences between
groups at baseline except for marital status
(P = .04) (Table 1).” p 684
Incomplete outcome data addressed? Low risk Judgement comment: low attrition andbal-
anced between study arms
Knowledge of allocated intervention pre-
vented?
Unclear risk Judgement comment: not clear whether
eye-screening outcome assessors were
masked
Protected against contamination? High risk Quote : “the diabetes educators in the inter-
vention condition trained and supervised
the attention control clinical staff.” p 687
Free from selective outcome reporting? Unclear risk Judgement comment: no protocol or trial
registry entry available and therefore not
possible to assess
Other risks of bias? Low risk Judgement comment: no evidence of other
sources of bias
Zangalli 2016
Methods Study aim: to evaluate the effectiveness of a multifaceted intervention with personal
communication to improve dilated fundus examination follow-up adherence among
those who are less likely to adhere
Study design: parallel-group RCT
Participants Country: USA
Setting: tertiary eye clinic
Total number of participants: 522
Percentage male: 34%
Diabetes type: NR
Average age (SD): 61 yrs (13.0)
Inclusion criteria: eligible participants were > 18 years of age; had no, mild, or mod-
erate DR; were recommended for a follow-up dilated fundus examination; and had not
previously scheduled a follow-up visit
Exclusion criteria: NR
Interventions Intervention (n = 262): intervention group received a personalised reminder letter with
a 1-page brochure about diabetic retinopathy 1 month prior to the recommended visit.
2 weeks later, a research assistant called participants to offer personal assistance with
scheduling an appointment. For participants who made an appointment, a reminder
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Zangalli 2016 (Continued)
letter was mailed 3 weeks prior to the scheduled appointment. Participants also received
automated reminder calls the day before the scheduled appointment
Comparator (n = 260): usual care (consisting of participants receiving a reminder letter
1 month prior to the recommended follow-up date. Participants received no active
assistance with scheduling appointments. Participants who made appointments received
automated reminder calls the day before scheduled appointments)
Duration: 6 months
Outcomes Primary outcome: attendance at a follow-up appointment within 3months of suggested
return date
Secondary outcomes: barriers to care use
Baseline screening attendance (control group): NR
Notes Date conducted: April to October 2012
Trial registration number: NR
Sources of funding: Centers for Disease Control and Prevention
Declaration of interest: none declared
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Low risk Quote: “Participants were randomized to
usual care or intervention within age strata
(≥65 and <65 years) using the method of
random permuted blocks with block sizes
of 2, 4, and 6.” p 2
Adequate allocation concealement? Unclear risk Not reported
Similar baseline outcome measurements? Unclear risk Not reported
Similar baseline characteristics? Low risk Quote: “Participants in the intervention
and control groups had similar baseline
characteristics with regard to sex, ethnicity,
and age.” p 3
Incomplete outcome data addressed? Low risk Judgement comment: low attrition andbal-
anced across groups
Knowledge of allocated intervention pre-
vented?
Unclear risk Not reported
Protected against contamination? Low risk Judgement comment: it is unlikely that the
control group received the intervention
Free from selective outcome reporting? Unclear risk Judgement comment: no protocol or trial
registry entry available and therefore not
possible to assess
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Other risks of bias? Low risk Judgement comment: no evidence of other
risks of bias
Zwarenstein 2014
Methods Study aim: to evaluate the effectiveness of printed educational messages aimed at family
doctors on rates of retinal screening attendance amongst patients with diabetes
Study design: cluster-RCT
Participants Country: Canada
Setting: Primary care (family physicians)
Total number of clusters: 4282
Number of providers: 5048
Total number of patients: 179,833
Percentage male: 51.2%
Diabetes type: NR
Average age (SD): 61.7 yrs (13.1)
Inclusion criteria: patients diagnosed with diabetes who were at least 30 years old and
visited 1 of the target family practitioners within 1 year of the intervention mail-out
Exclusion criteria: patients who had already had an eye examination in the 9 months
immediately prior to the office visit
Interventions Alternative printed educational messages (PEM) containing prompts to encourage dia-
betic retinopathy screening were mailed to each family physician in conjunction with a
widely-read professional newsletter (Informed)
Intervention arm 1 (1066 clusters): PEM consisting of a 2-page insert, indistinguish-
able from the rest of Informed in size and style (the ‘insert’). The insert contained a
concise summary of an evidence-based guideline and references
Intervention arm 2 (535 clusters): (PEM) consisting of a short directive message on a
postcard-sized card (‘outsert’) stapled to the front page of Informed
Intervention arm 3 (536 clusters): PEM ‘outsert’ and supplied with a pad of sticky
take-home reminders (aimed at patients, to remind them to make an appointment for
an eye exam), to be given to participants
Intervention arm 4 (535 clusters): PEM ‘insert’ and ‘outsert’
Intervention arm 5 (533 clusters): PEM ‘insert’ and ‘outsert’ and take-home reminders
Comparator (1077 clusters): newsletter without the PEM
Duration: 3 months
Outcomes Primary outcome: whether or not an eligible trial patient received an eye exam within
90 days of their first family practitioner visit
Secondary outcomes: the impact of patient age on the uptake of eye exams
Baseline screening attendance (control group): NR
Notes Date conducted: 2005 to 2006
Trial registration number: NCT00210275
Sources of funding: Canadian Institutes for Health Research, Institute for Clinical
Evaluation Sciences
Declaration of interest: none declared
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Zwarenstein 2014 (Continued)
Study protocol has been published: www.ncbi.nlm.nih.gov/pubmed/18039361
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Low risk Quote: “Practices were randomly assigned
to an intervention groupby the study statis-
tician, using computer generated random
numbers.” p 2
Adequate allocation concealement? Low risk Judgement comment:unit of allocation by
GPpractice and allocation performed prior
to the start of the study
Similar baseline outcome measurements? Unclear risk Not reported
Similar baseline characteristics? Low risk Quote: “There were small, clinically unim-
portant, differences between the demo-
graphics of patients with diabetes who paid
a visit to a study physician and those who
did not, and between those who were and
were not included in the analysis (Table 2)
.” p 5
Incomplete outcome data addressed? Low risk Judgement comment: data from all clusters
reported
Knowledge of allocated intervention pre-
vented?
Low risk Judgement comment: outcomes were ob-
tained from routinely-collected data
Protected against contamination? Low risk Judgment comment: allocation by cluster
andunlikely that the control group received
the intervention
Free from selective outcome reporting? Low risk Judgement comment: re-
ported outcomes consistent with trial reg-
istry NCT00210275
Other risks of bias? Low risk Judgement comment: no evidence of other
risks of bias
ADA: American Diabetes Association
ADAP: Annual Diabetes Assessment Program
BMI: body mass index
BP: blood pressure
CHW: community health worker
DR: diabetic retinopathy
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HbA1c: glycaemic haemoglobin
HCC: hierarchical condition category
HMO: Health Maintenance Organisation
HRQOL: health-related quality of life
LDL: low-density lipoprotein
QI: quality improvement
SBP: systolic blood pressure
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Abraira 2003 No data on retinopathy screening attendance
Aleo 2015 No data on retinopathy screening attendance
Alfadda 2011 Not RCT
Anderson 2003a Not RCT
Anderson 2010 No data on retinopathy screening attendance
Arora 2014 No data on retinopathy screening attendance
Bellazzi 2004 No data on retinopathy screening attendance
Denig 2014 No data on retinopathy screening attendance
Gangwar 2014 No data available on control group (contacted author)
Gary 2004 No data on retinopathy screening attendance
Harris 2013 Not RCT
Hazavehei 2010 Evaluated intentions to attend for retinopathy screening rather than attendance
Hollander 2005 Not RCT
Jones 2006 Not RCT
Kuvaja-Kollner 2013 Not RCT
Lewis 2007 Qualitative study. No data on retinopathy screening attendance
Maberley 2003 Health economic paper. No data on retinopathy screening attendance
Mangione 2006 Not RCT
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(Continued)
Mazzuca 1988 No data on retinopathy screening attendance
McCulloch 1998 Not RCT
Montori 2002 Not RCT
Montori 2004 Not RCT
Peters 1998 Not RCT
Polak 2003 Health economic paper. No data on retinopathy screening attendance
Rees 2013 No data on retinopathy screening attendance
Samoutis 2010 Not RCT
Schectman 2004 Not RCT
Shah 2014 No data on retinopathy screening attendance
Shea 2006 No data on retinopathy screening attendance
Solorio 2015 Not RCT
Thoolen 2008 No data on retinopathy screening attendance
Wagner 2008 Knowledge of diabetic retinopathy rather than attendance
Weston 2008 Used vignettes rather than real patients
Young 2014 No data on retinopathy screening attendance
Characteristics of ongoing studies [ordered by study ID]
ACTRN12614001110673
Trial name or title The diabetes and eye health project: increasing eye examinations for adults newly diagnosed with type 2
diabetes
Methods Parallel-group RCT (Solomon four group design)
Participants Inclusion criteria: diagnosedwith type 2 diabetes in the past 3 years; Australian residents; able to read English;
registered with the National Diabetes Services Scheme (NDSS); 1 of either: young adult (aged 18 - 39 years)
, or live in rural/regional locations of Victoria, Australia
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ACTRN12614001110673 (Continued)
Interventions Intervention: printed materials (leaflet) containing persuasive behaviour change messages designed to raise
awareness of the importance of maintaining optimal blood glucose and blood pressure levels to minimise
the risk of diabetic retinopathy, increase intentions to engage in regular eye examinations and increase self-
reported eye examinations. The leaflet will be mailed on a single occasion to study participants
Comparator: participants randomised to the usual screening group will be advised by their endocrinologist
during their diabetes clinic visit to arrange an eye examination with their usual eye care professional (as in
current standard of care)
Outcomes From www.anzctr.org.au/
Primary outcome: self-reported eye health examinations assessed by response to a single questionnaire item
(“Since you were diagnosed with diabetes, have you had your eye health checked?”). In order to minimise
social desirability bias and any potential confounding influence of question-behaviour effect, the question will
be embedded within a suite of standard self-management questions based on information already provided
to all new National Diabetes Service Scheme registrants
Secondary outcomes: intention to seek eye health examinations assessed by summed response to 3 intention
items designed specifically for this purpose
Starting date September 2014
Contact information Prof Jane Speight, The Australian Centre for Behavioural Research in Diabetes, 206 Queensberry Street,
Melbourne, VIC 3000, Australia. +61 (0)3 8648 1844, jspeight@acbrd.org.au
Notes
ISRCTN31439939
Trial name or title The Kilimanjaro Diabetic Programme: the development of a sustainable regional eye health screening pro-
gramme to prevent blindness among diabetic patients due to diabetic retinopathy
Methods Parallel-group RCT
Participants Inclusion criteria: all known adult diabetic patients resident in Kilimanjaro region and attending a diabetic
clinic at Kilimanjaro Christian Medical Centre (KCMC) or at 1 of the district diabetic clinics in the 6 rural
districts of Kilimanjaro region
Interventions Phase I:
Intervention group: a digital diabetic retinopathy screening camera will be placed in the diabetic clinic at
KCMC
Control group: patients will be advised to go to the eye clinic at KCMC for a dilated screening examination
by an ophthalmologist
All participants will receive 3 information leaflets on diabetic retinopathy and be counselled by the health
workers in the diabetic clinic that they should have screening for diabetic retinopathy. Visual acuity measure-
ment will be performed and dilating drops installed by the screening team
Phase II:
The retinopathy screening camera will go to all district diabetic clinics twice in the 6-month intervention
period. Patients registered at these clinics will all be advised by clinic staff to attend for retinopathy screening.
The intervention group will receive a text message by mobile phone advising them of the date of the screening
and inviting them to come
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ISRCTN31439939 (Continued)
Outcomes From www.isrctn.com/
Primary outcome: uptake of screening for diabetic retinopathy
Secondary outcomes: prevalence of diabetic retinopathy in urban and rural diabetic patients in Kilimanjaro
region; prevalence of cataract in urban and rural diabetic patients in Kilimanjaro region
Starting date 10 December 2010 to 31 July 2011
Contact information Christoffel Blinden, Mission (CBM) e.V., Nibelungenstrasse 124,Bensheim D-64625,
Germany
Notes
ISRCTN87561257
Trial name or title Individual risk-based screening for diabetic retinopathy (ISDR)
Methods Parallel-group RCT
Participants Inclusion criteria: patients aged 12 or above who attend the community clinic for retinal screening
Interventions Intervention: : personalised risk-based screening intervals
Comparator: annual screening intervals (usual care)
Outcomes From www.isrctn.com/
Primary outcome: comparison of attendance rates for follow-up screening in the 2 arms of the study (non-
attendance will be defined as failure to attend 2 appointments for screening (usually within 6 weeks of each
other))
Secondary outcomes: number of cases of STDR detected; retinopathy level at screening (Liverpool and
NDESP grading); maculopathy level at screening (Liverpool and NDESP grading); number of false positive
screening episodes; number of screening appointments; number of dedicated diabetes assessment clinic ap-
pointments; number of other eye appointments for diabetic eye disease; visual acuity (logMAR); new visual
impairment (≥ +0.50 logMAR); new visual impairment due to diabetic retinopathy (≥ +0.50 logMAR);
number of missed appointments to screening; patient acceptability measures (using a questionnaire designed
for the trial); QALYs estimated using EQ-5D-5L and Health Utilities Index Mark 3 (HUI3); cost per QALY
gained
Starting date November 2014 to January 2018
Contact information ISDR Project Manager, Department of Eye and Vision Science, 3rd Floor University Clinical Department,
Royal Liverpool University Hospital, Prescot Street, Liverpool, L7 8XP, UK
Notes
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NCT01212328
Trial name or title Improving diabetes care: multicomponent cardiovascular disease risk reduction strategies for people with
diabetes in South Asia - The CARRS Multi-center Translation Trial
Methods Parallel-group RCT
Participants Inclusion criteria: aged 35 years and older with a confirmed diagnosis of diabetes and poor glycaemic control
(as evidenced by HbA1c ≥ 8.0%) and 1 or both of: dyslipidemia (LDL ≥ 130 mg/dl) or SBP≥ 140 mmHg,
irrespective of lipid- or BP-lowering medication use
Interventions Intervention: the participants will receive integrated diabetes care management consisting of current diabetes
management guidelines andnon-physician care co-ordinator assistance and electronic health records- decision-
support software (EHR-DSS) (The software will generate diabetes management prompts for the treating
physician and reminders for clinic visits for the intervention arm participants)
Comparator: participants will continue with the usual diabetes care with no care co-ordinator assistance and
no decision-support software management prompt
Outcomes From clinicaltrials.gov/
Primary outcome: multiple CVD risk factor control targets (blood glucose and either blood pressure or
cholesterol, or all 3)
Secondary outcomes: single risk factor control of at least 1 target, either HbA1c or blood pressure or LDL-
cholesterol ; process and patient-centered measures; cost-effectiveness analysis of the intervention compared
to usual care; prescriber and patient acceptability of the Digital Support software and care cordinator with
management guidelines
Starting date October 2010 to June 2014
Contact information Kavita Singh, MSc Tel: +91-11-26850118 ext 39 email;kavita@ccdcindia.org
Notes Trial protocol has been published: www.ncbi.nlm.nih.gov/pubmed/23084280
NCT01351857
Trial name or title Diabetes care management compared to standard diabetes care in adolescents and young adults with type 1
diabetes (TransClin)
Methods Parallel-group RCT
Participants Inclusion criteria: patients between the ages of 17 and 20 years with an established type 1 diabetes diagnosis
for a minimum of 1 year
Interventions From clinicaltrials.gov/
Intervention: a certified diabetes educator will act as a ‘Transition Co-ordinator’ to provide transition support
and the link between paediatric and adult diabetes care. The Transition Co-ordinator is central to the inter-
vention and will provide ongoing contact with the medical system as well as education and clinical support
where appropriate
Comparator: current standard of care (participants in the control group will transition to adult care equal to
the intervention group and will differ only by exclusion of Transition Co-ordinator)
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NCT01351857 (Continued)
Outcomes Primary outcome: proportion of participants who fail to attend at least 1 outpatient adult endocrinology
visit during the second year after transition to adult diabetes care
Secondary Outcomes: frequency of HbA1C measurement (in the 2-year transfer to adult care); frequency
of retinal exam, microalbumin to creatinine ratio, fasting lipid profile and foot exam testing; rate of hospital-
isation/ER visits for acute complications of diabetes
Starting date April 2012 to April 2017
Contact information Cheril Clarson, MD, London Health Sciences Centre Children’s Hospital
Notes Trial protocol has been published: www.ncbi.nlm.nih.gov/pubmed/24106787
NCT01837121
Trial name or title A trial of using SMS reminder among diabetic retinopathy patients in rural China (SMS)
Methods Parallel group RCT
Participants Inclusion criteria: patients with diabetes with access to a cell phone
Interventions Intervention: patient will receive a SMS reminder message about the revisit time and venue 1 week and 1
day before the appointment
Comparator: usual care
Outcomes From clinicaltrials.gov/
Primary outcome: non-attendance rate
Secondary outcomes: knowledge about diabetic retinopathy; presenting vision in the better-seeing andworse-
seeing eyes; vision Loss of 2+ lines of presenting vision in better-seeing eye thought due to diabetic retinopathy;
satisfaction with care; number of treatments received for diabetic retinopathy
Starting date April 2013 to June 2015
Contact information Nathan G Congdon MDMPH. Blindness Prevention and Treatment Department, Zhongshan Ophthalmic
Center
Notes
NCT02339909
Trial name or title Incentives in diabetic eye assessment by screening (IDEAS)
Methods Parallel-group RCT
Participants Inclusion criteria: diabetic patients (> 16 years) who were invited to screening in the last 24 months on a
yearly basis and failed to attend or contact the screening service to rearrange an appointment
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NCT02339909 (Continued)
Interventions Intervention (‘Fixed Incentive’): Standard invitation letter from the screening service, with additional text
offering a fixed financial incentive (GBP 10) if they attend screening
Intervention ‘Probabilistic incentive’: invitation letter from the screening service, with additional text
offering a probabilistic financial incentive (entry into a lottery offering at least a 1 in 100 chance to win GBP
1000) if they attend screening
Comparator: standard intervention from the screening service
Outcomes From clinicaltrials.gov/
Primary outcome: attendance at screening appointment at designated appointment date (between 3 months
and 1 year)
Secondary outcome: outcome from diabetic retinopathy screening
Starting date March 2015 to January 2016
Contact information Colin Bicknell, Clinical Senior Lecturer and Consultant Vascular Surgeon, Imperial College London
Notes Trial protocol has been published: bmcophthalmol.biomedcentral.com/articles/10.1186/s12886-016-0206-
4
NCT02579837
Trial name or title CLEAR SIGHT: A trial of non-mydriatic ultra-widefield retinal imaging to screen for diabetic eye disease
Methods Parallel-group RCT
Participants Inclusion criteria: patients with a known diagnosis of Type 1 diabetes for ≥ 5 years or Type 2 diabetes of
any duration with at least a 12-month interval since the last screening for diabetic eye disease by an eye-care
professional
Interventions Intervention: on-site screening. Participants randomised to the on-site screening group will be advised by
their Endocrinologist during their diabetes clinic visit to arrange an eye examination with their usual eye-care
professional (as in current standard of care). In addition they will also undergo:
• non-mydriatic ultra-widefield (UWF) retinal imaging on the same day as their diabetes clinic visit
• half of this group will by random allocation undergo optical coherence tomography (OCT) using the
Zeiss Cirrus OCT, which may or may not be done on the same day (for practical reasons regarding
availability of OCT at the hospital)
Comparator: usual screening. Participants randomised to the usual screening group will be advised by their
endocrinologist during their diabetes clinic visit to arrange an eye examination with their usual eye-care
professional (as in current standard of care)
Outcomes From clinicaltrials.gov/
Primary outcome: proportion of participants with Actionable Eye Disease (AED)
Secondary outcomes: screening adherence, determined by (i) the proportions of participants who have
screening completed within 12 months of randomisation by the primary screening
method, i.e. non-mydriatic UWF images (On-site Screening group) or an eye examination by an eye-care
professional (Usual Screening group); (ii) for participants in the Onsite Screening group, the proportion
who have also had a screening eye examination by an eye-care professional within 1 year of randomisation;
proportion of participants with Diabetic Maculopathy (DME)
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NCT02579837 (Continued)
Starting date February 2016 to January 2019
Contact information Nour Abu-Romeh, St. Joseph’s Hospital, London, Ontario, Canada, N6A 4V2
Tel: 519-646-6100 ext 65593
Notes
LDL: low-density lipoprotein
QALY: quality-adjusted life years
SBP: systolic blood pressure
STDR: sight-threatening diabetic retinopathy
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D A T A A N D A N A L Y S E S
Comparison 1. Any quality improvement intervention compared to usual care
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Proportion of participants
attending screening
56 329164 Risk Difference (M-H, Random, 95% CI) 0.12 [0.10, 0.14]
1.1 Intervention specifically
targeting diabetic retinopathy
screening
13 118938 Risk Difference (M-H, Random, 95% CI) 0.17 [0.11, 0.22]
1.2 General intervention to
improve the quality of diabetes
care
43 210226 Risk Difference (M-H, Random, 95% CI) 0.12 [0.09, 0.15]
Comparison 2. Stepped quality improvement intervention compared to intervention alone
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Proportion of participants
attending screening
10 23715 Risk Difference (M-H, Random, 95% CI) 0.05 [0.02, 0.09]
1.1 Intervention specifically
targeting diabetic retinopathy
screening
3 19698 Risk Difference (M-H, Random, 95% CI) 0.04 [-0.11, 0.19]
1.2 General intervention to
improve the quality of diabetes
care
7 4017 Risk Difference (M-H, Random, 95% CI) 0.06 [0.02, 0.11]
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Analysis 1.1. Comparison 1 Any quality improvement intervention compared to usual care, Outcome 1
Proportion of participants attending screening.
Review: Interventions to increase attendance for diabetic retinopathy screening
Comparison: 1 Any quality improvement intervention compared to usual care
Outcome: 1 Proportion of participants attending screening
Study or subgroup Intervention Usual care
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Intervention specifically targeting diabetic retinopathy screening
Anderson 2003 44/67 23/65 1.0 % 0.30 [ 0.14, 0.47 ]
Basch 1999 75/137 39/143 1.6 % 0.27 [ 0.16, 0.39 ]
Bush 2014 60/69 86/118 1.5 % 0.14 [ 0.03, 0.25 ]
Conlin 2006 194/223 173/225 2.1 % 0.10 [ 0.03, 0.17 ]
Davis 2003 23/30 4/29 0.8 % 0.63 [ 0.43, 0.83 ]
Lian 2013 1165/1316 1052/1227 2.7 % 0.03 [ 0.00, 0.05 ]
Mansberger 2015 157/296 90/271 2.0 % 0.20 [ 0.12, 0.28 ]
Pizzi 2015 99/237 43/119 1.6 % 0.06 [ -0.05, 0.16 ]
Prela 2000 1224/3721 726/2242 2.8 % 0.01 [ -0.02, 0.03 ]
Walker 2008 103/305 57/293 2.2 % 0.14 [ 0.07, 0.21 ]
Weiss 2015 80/91 30/88 1.5 % 0.54 [ 0.42, 0.66 ]
Zangalli 2016 128/262 80/259 2.0 % 0.18 [ 0.10, 0.26 ]
Zwarenstein 2014 24316/79412 8585/27693 2.9 % 0.00 [ -0.01, 0.00 ]
Subtotal (95% CI) 86166 32772 24.6 % 0.17 [ 0.11, 0.22 ]
Total events: 27668 (Intervention), 10988 (Usual care)
Heterogeneity: Tau2 = 0.01; Chi2 = 229.54, df = 12 (P<0.00001); I2 =95%
Test for overall effect: Z = 6.09 (P < 0.00001)
2 General intervention to improve the quality of diabetes care
Adair 2013 654/722 339/435 2.5 % 0.13 [ 0.08, 0.17 ]
Barcelo 2010 58/79 2/45 1.5 % 0.69 [ 0.58, 0.80 ]
Choe 2005 38/39 26/35 1.1 % 0.23 [ 0.08, 0.38 ]
Clancy 2007 72/96 48/90 1.3 % 0.22 [ 0.08, 0.35 ]
Davis 2010 69/85 31/80 1.3 % 0.42 [ 0.29, 0.56 ]
Dijkstra 2005 133/141 149/168 2.3 % 0.06 [ 0.00, 0.12 ]
-1 -0.5 0 0.5 1
Favours usual care Favours intervention
(Continued . . . )
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(. . . Continued)
Study or subgroup Intervention Usual care
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Dijkstra 2008 125/143 116/139 2.0 % 0.04 [ -0.04, 0.12 ]
Eccles 2007 106/175 102/202 1.7 % 0.10 [ 0.00, 0.20 ]
Franco 2007 187/414 167/412 2.2 % 0.05 [ -0.02, 0.11 ]
Frei 2014 90/103 71/111 1.6 % 0.23 [ 0.12, 0.34 ]
Frijling 2002 187/237 152/235 2.0 % 0.14 [ 0.06, 0.22 ]
Gabbay 2006 102/150 47/182 1.7 % 0.42 [ 0.32, 0.52 ]
Gabbay 2013 64/188 56/233 1.9 % 0.10 [ 0.01, 0.19 ]
Guldberg 2011 57/427 44/361 2.5 % 0.01 [ -0.04, 0.06 ]
Gutierrez 2011 46/50 33/53 1.1 % 0.30 [ 0.15, 0.45 ]
Harris 2005 32/264 12/238 2.5 % 0.07 [ 0.02, 0.12 ]
Hayashino 2016 71/158 23/206 1.9 % 0.34 [ 0.25, 0.43 ]
Hermans 2013 558/1548 278/993 2.6 % 0.08 [ 0.04, 0.12 ]
Hurwitz 1993 72/74 58/70 1.8 % 0.14 [ 0.05, 0.24 ]
Ilag 2003 28/33 19/28 0.7 % 0.17 [ -0.04, 0.38 ]
Jacobs 2012 70/72 76/92 1.9 % 0.15 [ 0.06, 0.23 ]
Jansink 2013 35/106 60/149 1.5 % -0.07 [ -0.19, 0.05 ]
Kirwin 2010 29/48 24/49 0.8 % 0.11 [ -0.08, 0.31 ]
Krein 2004 96/110 94/106 1.9 % -0.01 [ -0.10, 0.07 ]
Lafata 2002 719/1641 647/1668 2.7 % 0.05 [ 0.02, 0.08 ]
Litaker 2003 62/79 53/106 1.3 % 0.28 [ 0.15, 0.42 ]
Maljanian 2005 67/176 63/160 1.6 % -0.01 [ -0.12, 0.09 ]
McCall 2011 71572/126557 34443/61612 2.9 % 0.01 [ 0.00, 0.01 ]
Meigs 2003 51/146 60/139 1.5 % -0.08 [ -0.20, 0.03 ]
O’Connor 2005 26/80 20/61 1.1 % 0.00 [ -0.16, 0.15 ]
Perria 2007 477/1894 231/1015 2.7 % 0.02 [ -0.01, 0.06 ]
Peterson 2008 158/252 52/199 1.9 % 0.37 [ 0.28, 0.45 ]
Piette 2001 53/132 53/140 1.5 % 0.02 [ -0.09, 0.14 ]
Prezio 2014 37/90 26/90 1.2 % 0.12 [ -0.02, 0.26 ]
Schnipper 2010 16/138 17/148 2.1 % 0.00 [ -0.07, 0.08 ]
Simon 2010 204/600 210/600 2.4 % -0.01 [ -0.06, 0.04 ]
-1 -0.5 0 0.5 1
Favours usual care Favours intervention
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Study or subgroup Intervention Usual care
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Simpson 2011 61/131 64/129 1.4 % -0.03 [ -0.15, 0.09 ]
Sonnichsen 2010 34/48 32/63 0.9 % 0.20 [ 0.02, 0.38 ]
Steyn 2013 9/62 2/60 1.7 % 0.11 [ 0.01, 0.21 ]
Taylor 2003 49/61 44/66 1.1 % 0.14 [ -0.01, 0.29 ]
Varney 2014 30/36 29/36 0.9 % 0.03 [ -0.15, 0.21 ]
Vidal-Pardo 2013 240/657 171/619 2.4 % 0.09 [ 0.04, 0.14 ]
Wagner 2001 96/142 139/219 1.7 % 0.04 [ -0.06, 0.14 ]
Subtotal (95% CI) 138384 71842 75.4 % 0.12 [ 0.09, 0.15 ]
Total events: 76940 (Intervention), 38383 (Usual care)
Heterogeneity: Tau2 = 0.01; Chi2 = 535.63, df = 42 (P<0.00001); I2 =92%
Test for overall effect: Z = 7.32 (P < 0.00001)
Total (95% CI) 224550 104614 100.0 % 0.12 [ 0.10, 0.14 ]
Total events: 104608 (Intervention), 49371 (Usual care)
Heterogeneity: Tau2 = 0.00; Chi2 = 776.55, df = 55 (P<0.00001); I2 =93%
Test for overall effect: Z = 11.74 (P < 0.00001)
Test for subgroup differences: Chi2 = 2.04, df = 1 (P = 0.15), I2 =51%
-1 -0.5 0 0.5 1
Favours usual care Favours intervention
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Analysis 2.1. Comparison 2 Stepped quality improvement intervention compared to intervention alone,
Outcome 1 Proportion of participants attending screening.
Review: Interventions to increase attendance for diabetic retinopathy screening
Comparison: 2 Stepped quality improvement intervention compared to intervention alone
Outcome: 1 Proportion of participants attending screening
Study or subgroup Stepped intervention Control
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Intervention specifically targeting diabetic retinopathy screening
Ellish 2011 15/39 17/33 2.2 % -0.13 [ -0.36, 0.10 ]
Halbert 1999 3666/9909 3403/9614 24.7 % 0.02 [ 0.00, 0.03 ]
Rosenkranz 1996 49/66 19/37 3.0 % 0.23 [ 0.04, 0.42 ]
Subtotal (95% CI) 10014 9684 29.9 % 0.04 [ -0.11, 0.19 ]
Total events: 3730 (Stepped intervention), 3439 (Control)
Heterogeneity: Tau2 = 0.01; Chi2 = 6.27, df = 2 (P = 0.04); I2 =68%
Test for overall effect: Z = 0.52 (P = 0.60)
2 General intervention to improve the quality of diabetes care
Dickinson 2014 53/253 20/162 12.5 % 0.09 [ 0.01, 0.16 ]
Glasgow 2005 144/186 135/186 9.9 % 0.05 [ -0.04, 0.14 ]
Herrin 2006 40/227 10/97 11.4 % 0.07 [ -0.01, 0.15 ]
McClellan 2003 450/1142 424/1072 19.1 % 0.00 [ -0.04, 0.04 ]
McDermott 2001 74/124 80/174 7.0 % 0.14 [ 0.02, 0.25 ]
Ward 1996 96/231 39/124 8.0 % 0.10 [ 0.00, 0.20 ]
Welch 2011 19/21 14/18 2.2 % 0.13 [ -0.10, 0.36 ]
Subtotal (95% CI) 2184 1833 70.1 % 0.06 [ 0.02, 0.11 ]
Total events: 876 (Stepped intervention), 722 (Control)
Heterogeneity: Tau2 = 0.00; Chi2 = 11.13, df = 6 (P = 0.08); I2 =46%
Test for overall effect: Z = 2.87 (P = 0.0041)
Total (95% CI) 12198 11517 100.0 % 0.05 [ 0.02, 0.09 ]
Total events: 4606 (Stepped intervention), 4161 (Control)
Heterogeneity: Tau2 = 0.00; Chi2 = 20.32, df = 9 (P = 0.02); I2 =56%
Test for overall effect: Z = 2.88 (P = 0.0039)
Test for subgroup differences: Chi2 = 0.08, df = 1 (P = 0.77), I2 =0.0%
-1 -0.5 0 0.5 1
Favours control Favours Intervention
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A D D I T I O N A L T A B L E S
Table 1. Illustrative quotations for BCTs used in the included studies
Behaviour change technique (BCT) and abbreviated defini-
tions
Illustrative quotation
Goals and planning
Goal setting (behaviour)
Set or agree a goal defined in terms of the behaviour to be achieved
e.g. Set targets for how often patients should attend DRS, or gen-
eral diabetes self-management, such as frequency of blood glucose
testing, amount of carbohydrates to consume at each meal
“Practice nurses planned independent consultations with patients.
The monitoring tool guided them through the consultations, and
provided the opportunity to help the patient in selecting ap-
propriate, concrete, behavioural goals…. The monitoring tool
addressed clinical parameters (e.g., HbA1C , BP and LDL choles-
terol levels), examinations (e.g. food control, neurological tests,
and eye examinations), adherence to prescribed drugs, self-care
goals, and other recommendations” (Frei 2014 p 1040-1)
Problem solving
Analyse, or prompt the person to analyse, factors influencing the
behaviour and generate or select strategies that include overcoming
barriers and/or increasing facilitators
e.g. Support patients to identify reasons for wanting or not want-
ing to attend DRS, and helping them select potential strategies
for overcoming these barriers to screening attendance
“Using a semi structured protocol, the health educator (C.J. H.)
offered one-on-one, interactive education and counselling. Hav-
ing established rapport, she worked to identify and understand
each subject’s reasons for and /or barriers to having a dilated
retinal examination. Focused problem-solving then guided the
subject toward making an informed choice about receiving an
ophthalmic examination.” (Basch 1999, p 1879)
Goal setting (outcome)
Set or agree a goal defined in terms of a positive outcome of wanted
behaviour
e.g. Agree with the patient target HbA1c, blood pressure, or
cholesterol level, or target range for blood glucose
“During the case management sessions, patients and providers
set management goals that were reasonable to achieve.” (Barcelo
2010, p 147)
Action planning
Prompt detailed planning of performance of the behaviour
e.g. Support the patient to develop a plan for how often they will
attend DRS, where the DRS will occur, and how they will get to
their appointment
“Behavioural activation for diabetic retinopathy prevention com-
bined the principles of education about diabetes mellitus, be-
havioural therapy, and the health beliefmodel to assist participants
in identifying barriers to obtaining dilated fundus examinations,
problems-solving solutions to surmounting barriers, formulat-
ing action plans to facilitate dilated retinal examinations, and
gauging the success of action plans.” (Weiss 2015, p 1007)
Review behaviour goals
Review behaviour goal(s) jointly with the person and consider
modifying goal(s) or behaviour change strategy in light of achieve-
ment
e.g. During scheduled diabetic review consultations, discuss with
patients how they are progressing with their agreed self-manage-
ment behavioural goals (e.g. frequency of blood glucose testing,
attendance forDRS).Where patients are notmeeting agreed goals,
either discuss how to adjust goals if needed to increase feasibility,
or engage in problem-solving to overcome any barriers to goal
attainment
“Care managers were trained to use a patient-centred self-manage-
ment approach that included review of the medical care needs
and self-care goals that the patient identified and brainstorm-
ing additional strategies that patients could use to overcome bar-
riers to their goals.” (Glasgow 2005, p 35)
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Table 1. Illustrative quotations for BCTs used in the included studies (Continued)
Discrepancy between current and goal
Draw attention to discrepancies between a person’s current be-
haviour and the person’s previously set outcome goals, behaviour
goals or action plans
e.g. Provide feedback tohealthcare professionals on the proportion
of patients who have received DRS in the previous 12 months,
and compare this against a gold standard for clinical practice based
on clinical guidelines
“Physicians in the IG [intervention group] received a monthly
report of their carequalitywith the top10%quality of diabetes
care score for all physicians being the achievable benchmark.
”(Hayashino 2016, p 1)
Review outcome goal(s)
Review outcome goal(s) jointly with the person and considermod-
ifying goal(s) in light of achievement
e.g. Review or alter target blood glucose levels towards a more
feasible/achievable intermediate target
“The telephone call was structured to first review the patient’s
goals, followed by medication use, symptoms, glucose monitor-
ing, blood pressure monitoring and self-management /care ac-
tivities” (Taylor 2003, p 1059)
Behavioural contract
Create a written specification of the behaviour to be performed,
agreed by the person, and witnesses by another
e.g. Ask the person with diabetes to sign a contract in their self-
management plan or diary, undertaking to attend DRS once
Care guides asked patients to sign a contract (which was
scanned into the HHR) agreeing to work toward their disease-
specific goals. (Adair 2013, p 176)
Commitment
Ask the person to affirm or reaffirm statement indicating commit-
ment to change the behaviour
e.g. Ask the person with diabetes to verbally affirm or reaffirm that
they are committed to attending DRS at the agreed frequency and
location
“The initial goal was toelicit a verbal commitment to schedule
an eye examination.” (Basch 1999, p 1879)
Feedback and monitoring
Monitoring of behaviour by others without feedback
Observe or record behaviour with the person’s knowledge as part
of a behaviour change strategy
e.g. Record the proportion of patients who attend for a DRS exam
as part of clinical audit, but the results are not fed back to the
healthcare professionals whose practice has been audited
“Foot examinations, blood pressure, and eye examinations
were recorded on the reminder by clinic staff, collected af-
ter the patient visit and entered manually.” (Peterson 2008, p
2239)
Feedback on behaviour
Monitor and provide information or evaluative feedback on per-
formance of the behaviour (e.g. form, frequency, duration, inten-
sity)
e.g. Provide a feedback report to healthcare professionals, stating
the proportion of their patients who have attended a DRS exam,
had their blood pressure taken, and had a foot examination
“In addition, diabetic members who did not have a record of
a diabetic retinopathy exam received educational materials and
a report of their current DRE status directly from the HMO
2 weeks later.” (Halbert 1999, p 753)
Self-monitoring of behaviour
Establish a method for the person to monitor and record their
behaviour(s) as part of a behaviour change strategy
“We prepared feedback sheets for adherence to these eight indi-
cators using data from thephysicians’ self-report forms, as the
physicians monitored and promoted these indicators to im-
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Table 1. Illustrative quotations for BCTs used in the included studies (Continued)
e.g. A person with diabetes maintains a self-management diary in
which they record their daily food intake and exercise, and tick
off a checklist when they have attended their annual DRS exam
prove adherence.” (Hayashino 2015, p 601)
Self-monitoring of outcomes of behaviour
Establish a method for the person to monitor and record the out-
come(s) of their behaviour as part of a behaviour change strategy
e.g. A person with diabetes records in their self-management diary
the results of their latest HbA1C result and DRS exam
“In general, case managers were directed to encourage pa-
tient self-management, including diet and exercise, provide re-
minders for recommended screening/tests,help with appoint-
ment scheduling;monitoring home glucose and blood pressure
levels…” (Krein 2004, p 734)
Monitoring of outcomes of behaviour by others without feed-
back
Observe or record outcomes of behaviour with the person’s knowl-
edge as part of a behaviour change strategy
e.g. A person attends a DRS exam, but is not provided with the
results of the examination
“The nurse case manager used behavioural goals setting, estab-
lished individualized care plan, provide patient self-management
education and surveillance of patients…ordered protocol-driven
laboratory tests, tracked the outcomes using the computerized
data registry…” (Gabbay 2006, p 30)
Feedback on outcomes of behaviour
Monitor and provide feedback on the outcome of performance of
the behaviour
e.g. Informing the personwith diabetes of the results ofDRS exam
[i.e. presence/absence of retinopathy]
“…all persons who attended the screening clinics received a di-
lated eye exam by a volunteer community-based ophthalmolo-
gist. The eye exam included visual acuity, intraocular pressure,
and a fundus examination through a dilated pupil…immediately
after receiving the dilated eye exam, the patient was told the
results by the examination ophthalmologist.” (Anderson 2003, p
41)
Biofeedback
Provide feedback about the body (e.g. physiological or biochem-
ical state) using an external monitoring device as part of a be-
haviour change strategy
“… immediately after receiving the dilated eye exam, the pa-
tient was told the results by the examination ophthalmologist.”
(Anderson 2003, p 41)
Social Support
Social Support (unspecified)
Advise on, arrange or provide social support (e.g. from friends,
relatives, colleagues, ‘buddies’ or staff ) or non-contingent praise
or reward for performance of the behaviour. In includes encour-
agement and counselling
e.g. Provide general encouragement or reassurance to a person
with diabetes to attend their DRS appointment
“Overall, the intervention included…and self-management sup-
port (provided by the practice nurse).” (Frei 2014, p 1041)
Social Support (practical)
Advise on, arrange, or provide practical help (e.g. from friends,
relatives, colleagues, ‘buddies’ or staff ) for performance of the
behaviour
e.g. Provide practical help for a patient with diabetes to attend
DRS. This can include, for example: arranging a referral to DRS,
arranging or providing transport to the clinic
“Referrals were facilitated to other clinicians when indicated,
including ophthalmology, podiatry, nutrition and primary care
for follow-up of acute or other chronic issues or when requested
by patients.” (Jacobs 2012, p 616)
Shaping knowledge
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Table 1. Illustrative quotations for BCTs used in the included studies (Continued)
Instruction on how to perform behaviour
Advise or agree on how to perform the behaviour (includes ‘skills
training’)
e.g. Provide advice to a person with diabetes on how often guide-
lines recommend attending DRS, where they can obtain a DRS,
and how to schedule an eye exam
“A direct mail reminder was sent to patients to reinforce the im-
portance of annual eye exams and included the following text:
If you don’t have an eye doctor, ask you regular doctor to refer
you to one.” (Prela 2000, p 258)
Natural consequences
Information about health consequences
Provide information (e.g. written, verbal, visual) about health con-
sequences of performing the behaviour
e.g. Provide advice to the person with diabetes, on the negative
health consequences of retinopathy, and the benefits of early de-
tection
“A tailored telephone intervention was delivered by bilingual in-
terventionists and included: Risk communications, such as the
frequency lack of symptoms of retinopathy and that early
treatment for retinopathy decreases the risk of blindness, were
included.” (Walker 2008, p 187)
Salience of consequences
Use methods specifically designed to emphasise the consequences
of performing the behaviour with the aim of making them more
memorable
e.g. Give a person with diabetes a leaflet containing testimonials
from other persons with diabetes who suffer from retinopathy to
emphasise the benefits of attending DRS and early detection
“The videotape used emotional appeals through storytelling to
increase motivation to have a yearly dilated retinal examination.
” (Basch 1999, p 1879)
Information about social & environmental consequences
Provide information (e.g. written, verbal, visual) about social and
environmental consequences of performing the behaviour
e.g. Provide information on the costs of having a DRS exam
“A take-home reminder (aimed at patients, to remind them to
make an appointment for an eye exam), to be given to patients by
their Family Practitioner, included the following text:
OKIP covers annual eye checks for patients with diabetes so
you will not have to pay” (Zwarenstein 2014, p 90)
Information about emotional consequences
Provide information (e.g. written, verbal, visual) about emotional
consequences of performing the behaviour
e.g. Provide a leaflet recognising the potential negative effects on
emotional and mental health of managing a chronic illness, such
as diabetes
“Group visit content, though patient-guided, was physician-
directed to cover educational topics…and the emotional aspects
of diabetes.” (Clancy 2007, p 621)
Comparison of behaviour
Demonstration of the behaviour
Provide an observable sample of the performance of the behaviour,
directly in person or indirectly (e.g. by film, picture, for the person
to aspire to or imitate)
e.g. Play a video demonstrating the DRS procedure
“The newsletter consisted of six sections, including a testimonial
designed to model eye examination behaviour” (Ellish 2011, p
1593)
Social comparison
Draw attention to others’ performance to allow comparison with
the person’s own performance
e.g. Provide healthcare professionals with feedback on the propor-
“The system presented register data on their’ Type 2 diabetes pop-
ulation, giving them the option either to use the data during indi-
vidual diabetes consultations or to gain an overview of the quality
of their diabetes care and compare it with the corresponding
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Table 1. Illustrative quotations for BCTs used in the included studies (Continued)
tion of their patients who have had a DRS exam, and benchmark
this in comparison to other hospitals or healthcare professionals
quality in their colleagues’ practices.” (Guldberg 2011, p 326)
Information about others’ approval
Provide information about what other people think about their
behaviour. The information clarifies whether others will like, ap-
prove or disapprove of what the person is doing or will do
e.g. Tell the person with diabetes that their familymembers would
likely be keen for them to attend their DRS appointment
“One of the message in the targeted newsletter read:
Even though you’ve been thinking about getting a dilated eye
exam, we hope you’ll make the call now”(Ellish 2011, Addi-
tional information provided by the author)
Associations
Prompts/Cues
Introduce or define environmental or social stimulus with the
purpose of prompting or cueing the behaviour
e.g. Phone the person with diabetes to remind them of their up-
coming DRS appointment
“For those who made an appointment, a reminder letter was
mailed 3 weeks prior to the scheduled appointment. Addi-
tionally, there was an automated reminder call the day before
the scheduled appointment” (Pizzi 2015, p 255)
Reduce prompts/cues
Withdraw gradually prompts to perform the behaviour
e.g. Decrease the frequency with which a person with diabetes
is sent a reminder of their DRS attendance (i.e. from weekly, to
fornightly, to monthly, to quarterly reminders)
“Recommendations for regular telephone follow-ups for diabetes
patients, which will be monthly in the 1st half year and then will
probably decrease” (Jansink 2013 (coded from protocol 2009)
Repetition and substitution
Behavioural practice/rehearsal
Prompt practice or rehearsal of the performance of the behaviour
one or more times in a context or at a time when the performance
may not be necessary, in order to increase habit and skill
e.g. Provide an opportunity for trainee healthcare professionals to
practise delivering a DRS exam to an actor role-playing a patient
with diabetes
“During a 2-day training session, case managers received instruc-
tion on collaborative goal setting, with case examples and role-
playing used to familiarize them with the treatment algo-
rithms”( Krein 2004, p 734)
Graded tasks
Set easy-to-perform tasks, making them increasingly difficult, but
achievable, until the behaviour is performed
e.g. Initially allocate a healthcare professional responsibility for
one component of DRS exam and progressively increase their
responsibility
“Theoretically, this form of facilitation should be necessary for
only a relatively short period of time, with the practice improve-
ment team progressively assuming responsibility for the ongo-
ing improvement efforts after the initial facilitation.” (Dickinson
2014, p 10)
Comparison of outcomes
Credible source
Present verbal or visual communication from a credible source in
favour of or against the behaviour
e.g. Include the logos for national health institutes, or cite pub-
lished clinical guidelines, to endorse information provided in
leaflets regarding DRS
“Participants in the print-intervention group received a mailing
of a colourful, 14-page booklet on preventing diabetes eye
problems called Keep Your Eyes Healthy, in English or Spanish,
developed b y theNational Institutes ofHealth.” (Walker 2008,
p 187)
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Table 1. Illustrative quotations for BCTs used in the included studies (Continued)
Reward and threat
Material incentive (behaviour)
Inform that money, vouchers or other valued objects will be de-
livered if and only if there has been effort and/or progress in per-
forming the behaviour
e.g. Advise the person with diabetes that they will receive a shop-
ping voucher if they attend their upcoming DRS appointment
“The automated system offered a live telephone call back to assist
in scheduling test and alsooffered to send participants the fol-
lowing items: 1) a voucher that would allow the provider to
waive the co-payment for a dilated eye examination…” (Simon
2010, p 1452)
Social reward
Arrange verbal or non-verbal reward if and only if there has been
effort and/or progress in performing the behaviour
e.g. Verbally praise the person with diabetes if they attend their
DRS appointment
“When a subject reported having a dilated retinal examination a
congratulatory letter was sent.” (Basch 1999, p 1879)
Non-specific reward
Inform that a reward will be delivered if and only if there has been
effort and/or progress in performing the behaviour
e.g. Inform the healthcare professional that they will be rewarded
for conducting a DRS exam with a target proportion of their
patients
“CME credits were given to the participating physicians in the
workshops” (Vidal-Pardo 2013, p 752)
Antecedents
Restructuring the physical environment
Change or advise to change the physical environment in order to
facilitate performance of the wanted behaviour or create barriers
to the unwanted behaviour
e.g. Introduce mobile DRS vans in geographically remote areas to
increase access to screening facilities
“Care guide workstations were located in the clinic wait-
ing rooms, to facilitate face-to-face interactions with patients,
providers, and nurses.” (Adair 2013, p 177)
Restructuring the social environment
Change or advise to change the social environment in order to
facilitate performance of the wanted behaviour or create barriers
to the unwanted behaviour
e.g. Change a healthcare team and team working, such as intro-
ducing a new specialist diabetes nurse role responsible for moni-
toring screening rates and phoning people with diabetes to remind
them to attend their DRS appointment
“Three multi-lingual Link Workers already employed by Coven-
try Primary Care Trust (PCT) were trained in diabetes manage-
ment and care and assigned to work with specific intervention
GP surgeries” (Bush 2014, p 295)
Adding objects to the environment
Add objects to the environment in order to facilitate performance
of the behaviour
e.g. Introduce new computerised software to a general practice
to help monitor and remind healthcare professionals as to which
patients need to be prompted to attend DRS
“In addition 4500 diabetes passports were made available at
the four hospitals…” (Dijkstra 2005, p 128)
Scheduled consequences
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Table 1. Illustrative quotations for BCTs used in the included studies (Continued)
Behaviour cost
Arrange for withdrawal of something valued if and only if an
unwanted behaviour is performed
e.g. Charging people with diabetes a fee for failing to attend a
DRS exam
“We were interested to find out whether a small copayment
would be an important deterrent to the uptake of screening for
diabetic retinopathy (DR)…We conducted a randomized trial in
which one group was charged a small fee for DR screening and
the other was provided with free access.” (Lian 2013, p 1247)
Self-belief
Verbal persuasion about capability
Tell the person that they can successfully perform the wanted
behaviour, arguing against self-doubts and asserting that they can
and will succeed
e.g. Encourage or reassure the patient to attend a DRS exam,
providing information as needed to address any concerns or self-
doubts they may have about attending for a DRS exam
“Diabetes is a serious, lifelong condition, but there is so much
that you can do to protect your health. Take charge of your
health, not only for today, but also for the years to come” (Lafata
2002, p 523)
Focus on past success
Advise to think about or list previous successes in performing the
behaviour (or parts of it)
e.g. Help the person with diabetes to remember the last time they
attended a DRS exam, and use this as an opportunity to reassure
them of the benefits of attending
A comprehensive programme that integrated lifestyle: counselling
based on motivational interviewing principles was integrated into
structured diabetes care
[In description of motivational interviewing] “Self-efficacy can be
strengthened by affirming past success (i.e. reinforcement)…”
(Jansink 2013 , additional information from protocol)
DRS: diabetic retinopathy screening
Table 2. Summary of reported costs and resources to deliver interventions
QI Component Study DRS or GQI Estimated costs of resources
used
Resources used
Promotion of self-man-
agement
Davis 2010
N = 85 participants
GQI Staff cost per person = GBP
625.25; costs of the other re-
sources used = GBP 476.35
over 12 months
Direct cost per person = GBP
1101
13 x 15-minute sessions (3 in-
dividuals and 10 group ses-
sion) with nurses and 4 hours
with health educator per per-
son
Wagner 2001
N = 14 clinics, 278 par-
ticipants
GQI Not reported 1-hour group session with rel-
evant health professional ev-
ery 3 - 6 months
Team changes Frei 2014
N = 15 practices, 164
participants
GQI Not reported 6-day training for nurses, 2 x
4-hour workshops for physi-
cians and nurses
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Table 2. Summary of reported costs and resources to deliver interventions (Continued)
Wagner 2001
N = 14 clinics, 278 par-
ticipants
GQI Not reported 1-hour group session with rel-
evant health professional ev-
ery 3 - 6 months
Litaker 2003
N = 79 participants
GQI Mean personnel costs for the
intervention per month per
patient = GBP 130.15
Total additional personnel
costs = GBP 10281.97
An average of 180 minutes
with participants
Case management Krein 2004
N = 123 participants
GQI Not reported 2 days training for case man-
agers, 20 hours/week time
spentwith participants.Quar-
terly profiling and subse-
quently every 6 months
Patient education Prezio 2014
N = 90 participants
GQI Physician cost = GBP 48.76/
hour
Community health worker =
GBP 12.91/hour
Cost of intervention over 20
years = GBP 3646.10 per pa-
tient
7 sessions per participants, 1
hour physician supervision for
health workers
Pizzi 2015
N = 117 participants for
mailed intervention, 120
for telephone interven-
tion
DRS Staff time for 120 participants
= GBP 501.13 for telephone
over 1 month
Staff time for 117 participants
= GBP 173.17 for mailed in-
tervention over 1 month
GBP 85.24/hour for the
physician, GBP 29.32/hr for
health services manager, GBP
16.72/hour for medical assis-
tant
Cost of materials for tele-
phone = GBP 30.25, cost of
materials for mailed interven-
tion
Total cost of intervention =
GBP 577.64 for 120 par-
ticipants in telephone group,
GBP 335.48 for 117 partici-
pants in mailed group over a
month
Total cost when appointment
is made and kept per partici-
pant;
1-hour supervision for every
20-hour intervention deliv-
ered
2 x 1-hour meetings with
medical assistants, health ser-
vices manage and ophthal-
mologist
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Telephone intervention =
GBP 9.47
Mailed intervention = GBP 8.
83
Adair 2013
N = 930 participants
GQI Care guide cost for 120 partic-
ipants = GBP 375,917 at the
rate of GBP 11.77/hour over
a year
2 supervisory nurses = GBP
85,847.24
Training cost = GBP 2228.99
modular furniture and equip-
ment for 12 stations = GBP
79,422.81
Total cost = GBP 463,993
Total cost of intervention per
participant = GBP 326
12 care guides, 2 weeks train-
ing, 2 supervisory nurses, 5
visits on average to clinics,
4 contacts with participants,
furniture and modular equip-
ment
McCall 2011
N = approximately 20,
000 participants
GQI Not reported Not reported
Clancy 2007
N = 96 participants
GQI Deposit fee for group visit =
GBP 13.4/visit, for 12 visits =
GBP 160.60
Monthly
meeting for a year for 2 hours
which includes 1 primary care
internalmedicine physician, 1
registered nurse per visit
Training for physicians and
nurses
3- hour training for clinic staff
12 group visits for 1 year
Schechter 2008 (Walker
2008)
N = 305 participants for
telephone intervention,
298 for print interven-
tion
DRS Costs of health educator =
GBP 14,890.83
Training and supervision =
GBP 2756.44
Telephone charges = GBP
679.67 for 305 participants
Costs of printing and mailing
= GBP 465.99 for 298 partic-
ipants
Average of 3.2 calls for about
20 minutes +5 minutes call
preparation per participant
over 6 months
20 hours training, 1 hour su-
pervision by diabetes nurse
educator, telephone calls
Electronic patient reg-
ister
Eccles 2007
N = 30 practices, 1674
participants
GQI Cost of developing the guide-
lines = GBP 10,208
Cost of software development
= GBP 12519.36
Cost of educational activities
= GBP 2148.11
Cost of guidelines and soft-
ware development. Average of
2 follow-up contacts
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Additional cost of running the
system = GBP 9964.46
Annual cost per participant =
GBP 68.21
Patient reminders Schechter 2008 (Walker
2008)
N = 305 participants for
telephone intervention,
298 for print interven-
tion
DRS Costs of health educator =
GBP 14,890.83
Training and supervision =
GBP 2756.44
Telephone charges = GBP
679.67 for 305 participants
Costs of printing and mailing
= GBP 465.99 for 298 partic-
ipants
Average of 3.2 calls for about
20 minutes + 5 minutes call
preparation per participant
over 6 months
20 hours training, 1 hour su-
pervision by diabetes nurse
educator, telephone calls
Pizzi 2015
N = 117 participants for
mailed intervention, 120
for telephone interven-
tion
DRS Staff time for 120 participants
= GBP 501.13 for telephone
over 1 month
Staff time for 117 participants
= GBP 173.17 for mailed in-
tervention over 1 month
GBP 85.24/hour for the
physician, GBP 29.32/hour
for health services manager,
GBP 16.72/hour for medical
assistant
Cost of materials for tele-
phone = GBP 30.25, cost of
materials for mailed interven-
tion
Total cost of intervention =
GBP 577.64 for 120 par-
ticipants in telephone group,
GBP 335.48 for 117 partici-
pants in mailed group over a
month
1 hour supervision for ev-
ery 20-hour intervention de-
livered
2 x 1-hour meetings with
medical assistants, health ser-
vices manager and ophthal-
mologist
Audit and feedback Frijling 2002
N = 62 clusters, 703 par-
ticipants
GQI Cost of clinical decision-mak-
ing per practice = GBP 341.
51
80 hours training for facilita-
tor, 15 x 1-hour visits to prac-
tice clinic, 3 hoursGP time for
implementation of feedback
Clinician reminders Litaker 2003
N = 79 participants
GQI Mean personnel costs for the
intervention per month =
GBP 130.15
Total additional personnel
costs = GBP 10,281.97
An average of 180 min-
utes with participants over 12
months
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Continuous quality
improvements
Piette 2001
N = 146 participants
GQI ApproximatelyGBP14 -GBP
24 per year for automated
calls.
13 nurses spending an average
of 3.8 hours per participant,
15 automated calls
DRS: diabetic retinopathy screening
GQI: general quality improvement
Table 3. Summary of characteristics of included studies
Study characteristics Target: diabetic retinopathy
screening attendance
N = 16
Target: general quality im-
provement in diabetes care
N = 50
TOTAL
N = 66
Study design Individual RCT:
n = 14 (87.5%)
Cluster-RCT:
n = 2 (12.5%)
2 arms n = 13 (81.3%)
3 arms n = 2 (12.5%)
> 3 arms n = 1 (6.3%)
Individual RCT:
n = 21 (42%)
Cluster-RCT:
n = 29 (58%)
2 arms n = 46 (92%)
3 arms n = 4 (8%)
Individual RCT
n = 35 (53%)
Cluster-RCT
n = 31 (47%)
2 arms n = 59 (89.4%)
3 arms n = 6 (9.1%)
> 3 arms n = 1 (1.5%)
Location USA: n = 12 (75%)
Canada: n = 1 (6.3%)
China: n = 1 (6.3%)
Germany: n = 1 (6.3%)
UK: n = 1 (6.3%)
Conducted between 1995 and
2013
USA: n = 29 (58%)
Canada: n = 2 (4%)
Netherlands: n = 4 (8%)
Australia: n = 3 (6%)
UK: n = 2 (4%)
Other n = 10 (20%)
Conducted between 1988 and
2013
USA: n = 41 (62.1%)
Canada: n = 3 (4.6%)
Netherlands: n = 4 (6.1%)
Australia: n = 3 (4.6%)
UK: n = 3 (4.6%)
Other: n = 12 (18.2%)
Conducted between 1988 and
2013
Setting Primary care:
n = 11 (68.8%)
Outpatient clinics:
n = 4 (25%)
Unclear: n = 1 (6.3%)
Primary care:
n = 40 (80%)
Outpatient n = 3 (6%)
Unclear: n = 7 (14%)
Primary care:
n = 51 (77.3%)
Outpatient clinics
n = 7 (10.6%)
Unclear n = 8 (12.1%)
Diabetes type Type 2:
n = 4 (25%)
Type 1 and Type 2:
n = 3 (18.8%)
Not reported:
n = 9 (56.3%)
Type 2:
n = 34 (68%)
Type 1 and Type 2
n = 7 (14%)
Not reported:
n = 9 (18%)
Type 2 :
n = 38 (57.6%)
Type 1 and 2
n = 10 (15.2%)
Not reported
n = 18 (27.3%)
Number of participants re-
cruited
Individual RCT = 38,273
Cluster RCT = 4135 clusters,
182,513 participants
Total: 220,786 participants in-
Individual RCT = 198,752
Cluster RCT = 1991 clusters,
78,276 participants
Total: 277,028 participants in-
Individual RCT = 237,025
Cluster RCT = 6126 clusters,
260,789 participants
Total: 497,814 participants in-
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Table 3. Summary of characteristics of included studies (Continued)
cluded cluded cluded
Median age Median 60.7 yrs (range 51.1 -
72.7)
Number reporting n = 9
Median 60.6 yrs (range 46.8 -
74)
Number reporting n = 34
Median 60.7 yrs (46.8 - 74)
Number reporting n = 43
Gender (% male) Median 38.9% (range 25% -
98%)
Number reporting n = 12
Median 49.8% (range 25% -
97%):
Number reporting n = 35
Median 48% (25% - 98%)
Number reporting n = 47
Type of screening Retinal exam
n = 12 (75%)
Grading of digital retinal im-
ages: n = 4 (25%)
Retinal exam
n = 49 (98%)
Grading of retinal images
n = 1 (2%)
Retinal exam
n = 61 (92.4%)
Grading of retinal images
n = 5 (7.6%)
Baseline screening attendance
(in previous 12 or 24 m)
Median 0% (range 0% - 48.
4%)
Reported in 7 studies
Median 37.1% (range 0% -
88%)
Reported in 36 studies
Median 35.4% (range 0% - 87.
8%)
Reported in 43 studies
Longest duration of follow-up
(median)*
Median 6 months
(range 3 - 48)
Number reporting n = 14
Median 12 months
(range 1 - 30):
Number reporting n = 49
Median 12 months
(range 1 - 48)
Number reporting n = 63
Intervention target (modified
EPOC classification)
Median number of targets in in-
tervention arm = 2
Participant n = 14 (87.5%)
Healthcare professional n = 4
(25%)
Healthcare system n = 4 (25%)
Median number of targets in in-
tervention arm = 3
Participant n = 31 (62%)
Healthcare professional n = 31
(62%)
Healthcare systemn=37 (74%)
Median number of targets in in-
tervention arm = 3
Participant n = 45 (68.2%)
Healthcare professional n = 35
(53%)
Healthcare system n = 41 (62.
1%)
Mansberger 2015 reported follow-up data to 48 months but intervention offered to intervention and control group after 18 months
and data reported at 12 and 24 months.
Table 4. CHEC checklist for methodological quality assessment of economic evaluations
CHEC
cri-
teria
check-
lists
Adair
2013 Clancy
2007
Davis
2011
Eccles
2007
Frei
2014
Fri-
jling
2002
Krein
2004 Litaker
2003
Mc-
Call
2011
Piette
2001
Pizzi
2015 Prezio
2014
Schechter
2008
Wag-
ner
2001
Is the
study
popu-
lation
Y Y Y Y Y Y Y Y Y Y Y Y Y Y
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Table 4. CHEC checklist for methodological quality assessment of economic evaluations (Continued)
clearly
de-
scribed?
Are
com-
pet-
ing
alter-
na-
tives
clearly
de-
scribed?
Y Y Y N N Y Y Y N N Y Y Y N
Is a
well-
de-
fined
re-
search
ques-
tion
posed
in an-
swer-
able
form?
Y Y Y Y Y Y Y Y Y N Y Y Y Y
Is the
eco-
nomic
study
de-
sign
ap-
pro-
priate
to the
stated
objec-
tive?
N N Y N N N N Y N N Y Y Y N
Is the
cho-
sen
time
hori-
zon
ap-
Y N U N N N N Y N N Y Y Y N
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Table 4. CHEC checklist for methodological quality assessment of economic evaluations (Continued)
pro-
priate
to in-
clude
rele-
vant
costs
and
con-
se-
quences?
Is the
actual
per-
spec-
tive
cho-
sen
ap-
pro-
pri-
ate?
Y N Y Y Y Y Y Y Y Y Y Y Y Y
Are
all
im-
por-
tant
and
rele-
vant
costs
for
each
alter-
native
iden-
tified?
Y N Y Y N N N N N N Y Y Y N
Are all
costs
mea-
sured
ap-
pro-
pri-
ately
in
physi-
Y N U Y N Y N Y Y N Y Y Y N
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Table 4. CHEC checklist for methodological quality assessment of economic evaluations (Continued)
cal
units?
Are
costs
val-
ued
ap-
pro-
pri-
ately?
Y N N Y N Y N Y N N Y Y Y N
Are
all
im-
por-
tant
and
rele-
vant
out-
comes
for
each
alter-
native
iden-
tified?
Y N Y Y Y Y N Y N Y Y Y Y N
Are all
out-
comes
mea-
sured
ap-
pro-
pri-
ately?
Y Y Y Y N Y N Y Y N Y Y Y N
Are
out-
comes
val-
ued
ap-
pro-
pri-
ately?
N N N Y N N N N N N Y Y N N
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Table 4. CHEC checklist for methodological quality assessment of economic evaluations (Continued)
Is an
incre-
men-
tal
analy-
sis of
costs
and
out-
comes
of al-
terna-
tives
per-
formed?
N N Y N N N N N N N Y Y Y N
Are
all
future
costs
and
out-
comes
dis-
counted
ap-
pro-
pri-
ately?
N N N N N N N N N N Y Y N N
Are
all
im-
por-
tant
vari-
ables,
whose
values
are
un-
cer-
tain,
ap-
pro-
pri-
ately
sub-
jected
N N N Y N N N N N N Y Y Y N
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Table 4. CHEC checklist for methodological quality assessment of economic evaluations (Continued)
to
sensi-
tivity
analy-
sis?
Do
the
con-
clu-
sions
fol-
low
from
the
data
re-
ported?
Y Y Y N Y Y Y N N Y Y Y Y Y
Does
the
study
dis-
cuss
the
gen-
eraliz-
abil-
ity of
the
re-
sults
to
other
set-
tings
pa-
tient/
client
groups?
Y Y Y Y Y Y Y Y N Y Y Y Y Y
Does
the
article
indi-
cate
that
there
is no
Y Y Y Y Y Y Y Y N Y Y Y Y Y
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Table 4. CHEC checklist for methodological quality assessment of economic evaluations (Continued)
po-
ten-
tial
con-
flict
of
inter-
est of
study
re-
searcher
(s)
and
fun-
der(s)
?
Are
eth-
ical
and
dis-
tribu-
tional
issues
dis-
cussed
ap-
pro-
pri-
ately?
Y Y Y Y Y Y Y Y Y Y Y Y Y Y
N: no
U: unclear
Y: yes
Table 5. CHEERS checklist for methodological quality assessment of economic evaluations
Section of paper Component Reported on page number
Adair 2013
Abstract Provide a structured summary of objec-
tives, perspective, setting,methods (includ-
ing study design and inputs), results (in-
cluding base case and uncertainty analyses)
, and conclusions
Not reported
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Table 5. CHEERS checklist for methodological quality assessment of economic evaluations (Continued)
Introduction -
Background and objectives Provide an explicit statement of the broader
context for the study
176
Present the study question and its relevance
for health policy or practice decisions
176
Methods
Target population and subgroups Describe characteristics of the base case
population and subgroups analysed, in-
cluding why they were chosen
177
Setting and location State relevant aspects of the system(s) in
which the decision(s) need(s) to be made
177
Study perspective Describe the perspective of the study and
relate this to the costs being evaluated
178 - 179
Comparators Describe the interventions or strategies be-
ing compared and state why they were cho-
sen
Not reported
Time horizon State the time horizon(s) over which costs
and consequences are being evaluated and
say why appropriate
Not reported
Discount rate Report the choice of discount rate(s) used
for costs and outcomes and say why appro-
priate
Not reported
Choice of health outcomes Describe what outcomes were used as the
measure(s) of benefit in the evaluation and
their relevance for the type of analysis per-
formed
Not reported
Measurement of effectiveness Single study-based estimates: Describe fully
the design features of the single effective-
ness study and why the single study was
a sufficient source of clinical effectiveness
data
Not reported
Synthesis-based estimates: Describe fully the
methods used for identification of included
studies and synthesis of clinical effective-
ness data
Not reported
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Table 5. CHEERS checklist for methodological quality assessment of economic evaluations (Continued)
Measurement and valuation of prefer-
ence based outcomes
If applicable, describe the population and
methods used to elicit preferences for out-
comes
Not reported
Estimating resources and costs Single study-based economic evaluation: De-
scribe approaches used to estimate resource
use associatedwith the alternative interven-
tions. Describe primary or secondary re-
search methods for valuing each resource
item in terms of its unit cost. Describe any
adjustments made to approximate to op-
portunity costs
179
Currency, price date, and conversion Report the dates of the estimated resource
quantities and unit costs. Describe meth-
ods for adjusting estimated unit costs to the
year of reported costs if necessary. Describe
methods for converting costs into a com-
mon currency base and the exchange rate
179
Choice of model Describe and give reasons for the specific
type of decision-analyticalmodel used. Pro-
viding a figure to show model structure is
strongly recommended
Not reported
Assumptions Describe all structural or other assump-
tions underpinning the decision-analytical
model
Not reported
Analytical methods Describe all analytical methods supporting
the evaluation. This could includemethods
for dealing with skewed, missing, or cen-
sored data; extrapolation methods; meth-
ods for pooling data; approaches to vali-
date or make adjustments (such as half cy-
cle corrections) to a model; and methods
for handling population heterogeneity and
uncertainty
Not reported
Results
Study parameters Report the values, ranges, references, and,
if used, probability distributions for all pa-
rameters. Report reasons or sources for dis-
tributions used to represent uncertainty
where appropriate. Providing a table to
show the input values is strongly recom-
mended
Appendices
w65
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Table 5. CHEERS checklist for methodological quality assessment of economic evaluations (Continued)
Incremental costs and outcomes For each intervention, report mean val-
ues for the main categories of estimated
costs and outcomes of interest, as well as
mean differences between the comparator
groups. If applicable, report incremental
cost-effectiveness ratios
Appendices
w65
Characterising uncertainty Single study-based economic evaluation: De-
scribe the effects of sampling uncertainty
for the estimated incremental cost and
incremental effectiveness parameters, to-
gether with the impact of methodological
assumptions (such as discount rate, study
perspective)
Not reported
Model-based economic evaluation: Describe
the effects on the results of uncertainty for
all input parameters, and uncertainty re-
lated to the structure of the model and as-
sumptions
Not reported
Characterising heterogeneity If applicable, report differences in costs,
outcomes, or cost-effectiveness that can be
explained by variations between subgroups
of patients with different baseline charac-
teristics or other observed variability in ef-
fects that are not reducible by more infor-
mation
Not reported
Discussion
Study findings, limitations, generalis-
ability, and current knowledge
Summarise key study findings and describe
how they support the conclusions reached.
Discuss limitations and the generalisability
of the findings andhow the findings fit with
current knowledge
183
Other
Source of funding Describe how the study was funded and the
role of the funder in the identification, de-
sign, conduct, and reporting of the analy-
sis. Describe other non-monetary sources
of support
183
Conflicts of interest Describe any potential for conflict of in-
terest of study contributors in accordance
with journal policy. In the absence of a jour-
nal policy, we recommend authors comply
183
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Table 5. CHEERS checklist for methodological quality assessment of economic evaluations (Continued)
with International Committee of Medical
Journal Editors recommendations
Clancy 2007
Title Identify the study as an economic evalu-
ation or use more specific terms such as
“cost-effectiveness analysis”, and describe
the interventions compared
Not reported
Abstract Provide a structured summary of objec-
tives, perspective, setting,methods (includ-
ing study design and inputs), results (in-
cluding base case and uncertainty analyses)
, and conclusions
Not reported
Introduction
Background and objectives Provide an explicit statement of the broader
context for the study
Not reported
Present the study question and its relevance
for health policy or practice decisions
620
Methods Not reported
Target population and subgroups Describe characteristics of the base case
population and subgroups analysed, in-
cluding why they were chosen
621
Setting and location State relevant aspects of the system(s) in
which the decision(s) need(s) to be made
Not reported
Study perspective Describe the perspective of the study and
relate this to the costs being evaluated
Not reported
Comparators Describe the interventions or strategies be-
ing compared and state why they were cho-
sen
620 - 621
Time horizon State the time horizon(s) over which costs
and consequences are being evaluated and
say why appropriate
Not reported
Discount rate Report the choice of discount rate(s) used
for costs and outcomes and say why appro-
priate
Not reported
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Table 5. CHEERS checklist for methodological quality assessment of economic evaluations (Continued)
Choice of health outcomes Describe what outcomes were used as the
measure(s) of benefit in the evaluation and
their relevance for the type of analysis per-
formed
Not reported
Measurement of effectiveness Single study-based estimates: Describe fully
the design features of the single effective-
ness study and why the single study was
a sufficient source of clinical effectiveness
data
620
Synthesis-based estimates: Describe fully the
methods used for identification of included
studies and synthesis of clinical effective-
ness data
Not reported
Measurement and valuation of prefer-
ence based outcomes
If applicable, describe the population and
methods used to elicit preferences for out-
comes
Not reported
Estimating resources and costs Single study-based economic evaluation: De-
scribe approaches used to estimate resource
use associatedwith the alternative interven-
tions. Describe primary or secondary re-
search methods for valuing each resource
item in terms of its unit cost. Describe any
adjustments made to approximate to op-
portunity costs
Not reported
Currency, price date, and conversion Report the dates of the estimated resource
quantities and unit costs. Describe meth-
ods for adjusting estimated unit costs to the
year of reported costs if necessary. Describe
methods for converting costs into a com-
mon currency base and the exchange rate
Not reported
Choice of model Describe and give reasons for the specific
type of decision-analyticalmodel used. Pro-
viding a figure to show model structure is
strongly recommended
Not reported
Assumptions Describe all structural or other assump-
tions underpinning the decision-analytical
model
Not reported
Analytical methods Describe all analytical methods supporting
the evaluation. This could includemethods
for dealing with skewed, missing, or cen-
sored data; extrapolation methods; meth-
622
188Interventions to increase attendance for diabetic retinopathy screening (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 5. CHEERS checklist for methodological quality assessment of economic evaluations (Continued)
ods for pooling data; approaches to vali-
date or make adjustments (such as half cy-
cle corrections) to a model; and methods
for handling population heterogeneity and
uncertainty
Results
Study parameters Report the values, ranges, references, and,
if used, probability distributions for all pa-
rameters. Report reasons or sources for dis-
tributions used to represent uncertainty
where appropriate. Providing a table to
show the input values is strongly recom-
mended
Not reported
Incremental costs and outcomes For each intervention, report mean val-
ues for the main categories of estimated
costs and outcomes of interest, as well as
mean differences between the comparator
groups. If applicable, report incremental
cost-effectiveness ratios
Not reported
Characterising uncertainty Single study-based economic evaluation: De-
scribe the effects of sampling uncertainty
for the estimated incremental cost and
incremental effectiveness parameters, to-
gether with the impact of methodological
assumptions (such as discount rate, study
perspective)
Not reported
Model-based economic evaluation: Describe
the effects on the results of uncertainty for
all input parameters, and uncertainty re-
lated to the structure of the model and as-
sumptions
Not reported
Characterising heterogeneity If applicable, report differences in costs,
outcomes, or cost-effectiveness that can be
explained by variations between subgroups
of patients with different baseline charac-
teristics or other observed variability in ef-
fects that are not reducible by more infor-
mation
Not reported
Discussion
Study findings, limitations, generalis-
ability, and current knowledge
Summarise key study findings and describe
how they support the conclusions reached.
Discuss limitations and the generalisability
Not reported
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Table 5. CHEERS checklist for methodological quality assessment of economic evaluations (Continued)
of the findings andhow the findings fit with
current knowledge
Other
Source of funding Describe how the study was funded and the
role of the funder in the identification, de-
sign, conduct, and reporting of the analy-
sis. Describe other non-monetary sources
of support
624
Conflicts of interest Describe any potential for conflict of in-
terest of study contributors in accordance
with journal policy. In the absence of a jour-
nal policy, we recommend authors comply
with International Committee of Medical
Journal Editors recommendations
624
Davis 2010
Title Identify the study as an economic evalu-
ation or use more specific terms such as
“cost-effectiveness analysis”, and describe
the interventions compared
Abstract
A325
Abstract Provide a structured summary of objec-
tives, perspective, setting,methods (includ-
ing study design and inputs), results (in-
cluding base case and uncertainty analyses)
, and conclusions
Abstract
A325
Introduction
Background and objectives Provide an explicit statement of the broader
context for the study
Abstract
A325
Present the study question and its relevance
for health policy or practice decisions
1712 of effectiveness report
Methods
Target population and subgroups Describe characteristics of the base case
population and subgroups analysed, in-
cluding why they were chosen
1714 of effectiveness report
Setting and location State relevant aspects of the system(s) in
which the decision(s) need(s) to be made
Abstract
A325
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Table 5. CHEERS checklist for methodological quality assessment of economic evaluations (Continued)
Study perspective Describe the perspective of the study and
relate this to the costs being evaluated
Not reported
Comparators Describe the interventions or strategies be-
ing compared and state why they were cho-
sen
Abstract
A325
Time horizon State the time horizon(s) over which costs
and consequences are being evaluated and
say why appropriate
Abstract
A325
Discount rate Report the choice of discount rate(s) used
for costs and outcomes and say why appro-
priate
Not reported
Choice of health outcomes Describe what outcomes were used as the
measure(s) of benefit in the evaluation and
their relevance for the type of analysis per-
formed
1713
Measurement of effectiveness Single study-based estimates: Describe fully
the design features of the single effective-
ness study and why the single study was
a sufficient source of clinical effectiveness
data
Abstract
A325
Synthesis-based estimates: Describe fully the
methods used for identification of included
studies and synthesis of clinical effective-
ness data
Not applicable
Measurement and valuation of prefer-
ence based outcomes
If applicable, describe the population and
methods used to elicit preferences for out-
comes
Not reported
Estimating resources and costs Single study-based economic evaluation: De-
scribe approaches used to estimate resource
use associatedwith the alternative interven-
tions. Describe primary or secondary re-
search methods for valuing each resource
item in terms of its unit cost. Describe any
adjustments made to approximate to op-
portunity costs
Not reported
Currency, price date, and conversion Report the dates of the estimated resource
quantities and unit costs. Describe meth-
ods for adjusting estimated unit costs to the
year of reported costs if necessary. Describe
methods for converting costs into a com-
Not reported
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Table 5. CHEERS checklist for methodological quality assessment of economic evaluations (Continued)
mon currency base and the exchange rate
Choice of model Describe and give reasons for the specific
type of decision-analyticalmodel used. Pro-
viding a figure to show model structure is
strongly recommended
Not applicable
Assumptions Describe all structural or other assump-
tions underpinning the decision-analytical
model
Not applicable
Analytical methods Describe all analytical methods supporting
the evaluation. This could includemethods
for dealing with skewed, missing, or cen-
sored data; extrapolation methods; meth-
ods for pooling data; approaches to vali-
date or make adjustments (such as half cy-
cle corrections) to a model; and methods
for handling population heterogeneity and
uncertainty
Not applicable
Results
Study parameters Report the values, ranges, references, and,
if used, probability distributions for all pa-
rameters. Report reasons or sources for dis-
tributions used to represent uncertainty
where appropriate. Providing a table to
show the input values is strongly recom-
mended
Not reported
Incremental costs and outcomes For each intervention, report mean val-
ues for the main categories of estimated
costs and outcomes of interest, as well as
mean differences between the comparator
groups. If applicable, report incremental
cost-effectiveness ratios
Abstract
A325
Characterising uncertainty Single study-based economic evaluation: De-
scribe the effects of sampling uncertainty
for the estimated incremental cost and
incremental effectiveness parameters, to-
gether with the impact of methodological
assumptions (such as discount rate, study
perspective)
Not reported
Model-based economic evaluation: Describe
the effects on the results of uncertainty for
all input parameters, and uncertainty re-
Not applicable
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Table 5. CHEERS checklist for methodological quality assessment of economic evaluations (Continued)
lated to the structure of the model and as-
sumptions
Characterising heterogeneity If applicable, report differences in costs,
outcomes, or cost-effectiveness that can be
explained by variations between subgroups
of patients with different baseline charac-
teristics or other observed variability in ef-
fects that are not reducible by more infor-
mation
Not reported
Discussion
Study findings, limitations, generalis-
ability, and current knowledge
Summarise key study findings and describe
how they support the conclusions reached.
Discuss limitations and the generalisability
of the findings andhow the findings fit with
current knowledge
Not reported
Other
Source of funding Describe how the study was funded and the
role of the funder in the identification, de-
sign, conduct, and reporting of the analy-
sis. Describe other non-monetary sources
of support
1716
Conflicts of interest Describe any potential for conflict of in-
terest of study contributors in accordance
with journal policy. In the absence of a jour-
nal policy, we recommend authors comply
with International Committee of Medical
Journal Editors recommendations
1716
Eccles 2007
Title Identify the study as an economic evalu-
ation or use more specific terms such as
“cost-effectiveness analysis”, and describe
the interventions compared
Not reported
Abstract Provide a structured summary of objec-
tives, perspective, setting,methods (includ-
ing study design and inputs), results (in-
cluding base case and uncertainty analyses)
, and conclusions
Not reported
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Table 5. CHEERS checklist for methodological quality assessment of economic evaluations (Continued)
Introduction
Background and objectives Provide an explicit statement of the broader
context for the study
2
Present the study question and its relevance
for health policy or practice decisions
2
Methods
Target population and subgroups Describe characteristics of the base case
population and subgroups analysed, in-
cluding why they were chosen
2
Setting and location State relevant aspects of the system(s) in
which the decision(s) need(s) to be made
2
Study perspective Describe the perspective of the study and
relate this to the costs being evaluated
4
Comparators Describe the interventions or strategies be-
ing compared and state why they were cho-
sen
4
Time horizon State the time horizon(s) over which costs
and consequences are being evaluated and
say why appropriate
4
Discount rate Report the choice of discount rate(s) used
for costs and outcomes and say why appro-
priate
Choice of health outcomes Describe what outcomes were used as the
measure(s) of benefit in the evaluation and
their relevance for the type of analysis per-
formed
3
Measurement of effectiveness Single study-based estimates: Describe fully
the design features of the single effective-
ness study and why the single study was
a sufficient source of clinical effectiveness
data
Not reported
Synthesis-based estimates: Describe fully the
methods used for identification of included
studies and synthesis of clinical effective-
ness data
Not reported
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Table 5. CHEERS checklist for methodological quality assessment of economic evaluations (Continued)
Measurement and valuation of prefer-
ence based outcomes
If applicable, describe the population and
methods used to elicit preferences for out-
comes
3
Estimating resources and costs Single study-based economic evaluation: De-
scribe approaches used to estimate resource
use associatedwith the alternative interven-
tions. Describe primary or secondary re-
search methods for valuing each resource
item in terms of its unit cost. Describe any
adjustments made to approximate to op-
portunity costs
3
Currency, price date, and conversion Report the dates of the estimated resource
quantities and unit costs. Describe meth-
ods for adjusting estimated unit costs to the
year of reported costs if necessary. Describe
methods for converting costs into a com-
mon currency base and the exchange rate
4
Choice of model Describe and give reasons for the specific
type of decision-analyticalmodel used. Pro-
viding a figure to show model structure is
strongly recommended
Not reported
Assumptions Describe all structural or other assump-
tions underpinning the decision-analytical
model
Not reported
Analytical methods Describe all analytical methods supporting
the evaluation. This could includemethods
for dealing with skewed, missing, or cen-
sored data; extrapolation methods; meth-
ods for pooling data; approaches to vali-
date or make adjustments (such as half cy-
cle corrections) to a model; and methods
for handling population heterogeneity and
uncertainty
Not reported
Results
Study parameters Report the values, ranges, references, and,
if used, probability distributions for all pa-
rameters. Report reasons or sources for dis-
tributions used to represent uncertainty
where appropriate. Providing a table to
show the input values is strongly recom-
mended
Not reportted
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Table 5. CHEERS checklist for methodological quality assessment of economic evaluations (Continued)
Incremental costs and outcomes For each intervention, report mean val-
ues for the main categories of estimated
costs and outcomes of interest, as well as
mean differences between the comparator
groups. If applicable, report incremental
cost-effectiveness ratios
8 - 12
Characterising uncertainty Single study-based economic evaluation: De-
scribe the effects of sampling uncertainty
for the estimated incremental cost and
incremental effectiveness parameters, to-
gether with the impact of methodological
assumptions (such as discount rate, study
perspective)
Not reported
Model-based economic evaluation: Describe
the effects on the results of uncertainty for
all input parameters, and uncertainty re-
lated to the structure of the model and as-
sumptions
Not reported
Characterising heterogeneity If applicable, report differences in costs,
outcomes, or cost-effectiveness that can be
explained by variations between subgroups
of patients with different baseline charac-
teristics or other observed variability in ef-
fects that are not reducible by more infor-
mation
Not reported
Discussion
Study findings, limitations, generalis-
ability, and current knowledge
Summarise key study findings and describe
how they support the conclusions reached.
Discuss limitations and the generalisability
of the findings andhow the findings fit with
current knowledge
6, 10
Other
Source of funding Describe how the study was funded and the
role of the funder in the identification, de-
sign, conduct, and reporting of the analy-
sis. Describe other non-monetary sources
of support
11
Conflicts of interest Describe any potential for conflict of in-
terest of study contributors in accordance
with journal policy. In the absence of a jour-
nal policy, we recommend authors comply
11
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Table 5. CHEERS checklist for methodological quality assessment of economic evaluations (Continued)
with International Committee of Medical
Journal Editors recommendations
Frei 2014
Title Identify the study as an economic evalu-
ation or use more specific terms such as
“cost-effectiveness analysis”, and describe
the interventions compared
Not reported
Abstract Provide a structured summary of objec-
tives, perspective, setting,methods (includ-
ing study design and inputs), results (in-
cluding base case and uncertainty analyses)
, and conclusions
Not reported
Introduction
Background and objectives Provide an explicit statement of the broader
context for the study
1040
Present the study question and its relevance
for health policy or practice decisions
1040
Methods
Target population and subgroups Describe characteristics of the base case
population and subgroups analysed, in-
cluding why they were chosen
1043
Setting and location State relevant aspects of the system(s) in
which the decision(s) need(s) to be made
1040
Study perspective Describe the perspective of the study and
relate this to the costs being evaluated
Not reported
Comparators Describe the interventions or strategies be-
ing compared and state why they were cho-
sen
1040
Time horizon State the time horizon(s) over which costs
and consequences are being evaluated and
say why appropriate
Not reported
Discount rate Report the choice of discount rate(s) used
for costs and outcomes and say why appro-
priate
Not reported
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Table 5. CHEERS checklist for methodological quality assessment of economic evaluations (Continued)
Choice of health outcomes Describe what outcomes were used as the
measure(s) of benefit in the evaluation and
their relevance for the type of analysis per-
formed
Not reported
Measurement of effectiveness Single study-based estimates: Describe fully
the design features of the single effective-
ness study and why the single study was
a sufficient source of clinical effectiveness
data
Not reported
Synthesis-based estimates: Describe fully the
methods used for identification of included
studies and synthesis of clinical effective-
ness data
Not applicable
Measurement and valuation of prefer-
ence based outcomes
If applicable, describe the population and
methods used to elicit preferences for out-
comes
Not reported
Estimating resources and costs Single study-based economic evaluation: De-
scribe approaches used to estimate resource
use associatedwith the alternative interven-
tions. Describe primary or secondary re-
search methods for valuing each resource
item in terms of its unit cost. Describe any
adjustments made to approximate to op-
portunity costs
Not reported
Currency, price date, and conversion Report the dates of the estimated resource
quantities and unit costs. Describe meth-
ods for adjusting estimated unit costs to the
year of reported costs if necessary. Describe
methods for converting costs into a com-
mon currency base and the exchange rate
Not reported
Choice of model Describe and give reasons for the specific
type of decision-analyticalmodel used. Pro-
viding a figure to show model structure is
strongly recommended
Not applicable
Assumptions Describe all structural or other assump-
tions underpinning the decision-analytical
model
Not applicable
Analytical methods Describe all analytical methods supporting
the evaluation. This could includemethods
for dealing with skewed, missing, or cen-
sored data; extrapolation methods; meth-
Not applicable
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Table 5. CHEERS checklist for methodological quality assessment of economic evaluations (Continued)
ods for pooling data; approaches to vali-
date or make adjustments (such as half cy-
cle corrections) to a model; and methods
for handling population heterogeneity and
uncertainty
Results
Study parameters Report the values, ranges, references, and,
if used, probability distributions for all pa-
rameters. Report reasons or sources for dis-
tributions used to represent uncertainty
where appropriate. Providing a table to
show the input values is strongly recom-
mended
Not reported
Incremental costs and outcomes For each intervention, report mean val-
ues for the main categories of estimated
costs and outcomes of interest, as well as
mean differences between the comparator
groups. If applicable, report incremental
cost-effectiveness ratios
Not reported
Characterising uncertainty Single study-based economic evaluation: De-
scribe the effects of sampling uncertainty
for the estimated incremental cost and
incremental effectiveness parameters, to-
gether with the impact of methodological
assumptions (such as discount rate, study
perspective)
Not reported
Model-based economic evaluation: Describe
the effects on the results of uncertainty for
all input parameters, and uncertainty re-
lated to the structure of the model and as-
sumptions
Not applicable
Characterising heterogeneity If applicable, report differences in costs,
outcomes, or cost-effectiveness that can be
explained by variations between subgroups
of patients with different baseline charac-
teristics or other observed variability in ef-
fects that are not reducible by more infor-
mation
Not reported
Discussion
Study findings, limitations, generalis-
ability, and current knowledge
Summarise key study findings and describe
how they support the conclusions reached.
Discuss limitations and the generalisability
1045
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Table 5. CHEERS checklist for methodological quality assessment of economic evaluations (Continued)
of the findings andhow the findings fit with
current knowledge
Other
Source of funding Describe how the study was funded and the
role of the funder in the identification, de-
sign, conduct, and reporting of the analy-
sis. Describe other non-monetary sources
of support
1045
Conflicts of interest Describe any potential for conflict of in-
terest of study contributors in accordance
with journal policy. In the absence of a jour-
nal policy, we recommend authors comply
with International Committee of Medical
Journal Editors recommendations
1045
Frijling 2002
Title Identify the study as an economic evalu-
ation or use more specific terms such as
“cost-effectiveness analysis”, and describe
the interventions compared
Not reported
Abstract Provide a structured summary of objec-
tives, perspective, setting,methods (includ-
ing study design and inputs), results (in-
cluding base case and uncertainty analyses)
, and conclusions
Not reported
Introduction
Background and objectives Provide an explicit statement of the broader
context for the study
837
Present the study question and its relevance
for health policy or practice decisions
837
Methods
Target population and subgroups Describe characteristics of the base case
population and subgroups analysed, in-
cluding why they were chosen
838
Setting and location State relevant aspects of the system(s) in
which the decision(s) need(s) to be made
838
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Table 5. CHEERS checklist for methodological quality assessment of economic evaluations (Continued)
Study perspective Describe the perspective of the study and
relate this to the costs being evaluated
Not reported
Comparators Describe the interventions or strategies be-
ing compared and state why they were cho-
sen
837
Time horizon State the time horizon(s) over which costs
and consequences are being evaluated and
say why appropriate
Not reported
Discount rate Report the choice of discount rate(s) used
for costs and outcomes and say why appro-
priate
Not reported
Choice of health outcomes Describe what outcomes were used as the
measure(s) of benefit in the evaluation and
their relevance for the type of analysis per-
formed
Not reported
Measurement of effectiveness Single study-based estimates: Describe fully
the design features of the single effective-
ness study and why the single study was
a sufficient source of clinical effectiveness
data
Not reported
Synthesis-based estimates: Describe fully the
methods used for identification of included
studies and synthesis of clinical effective-
ness data
Not applicable
Measurement and valuation of prefer-
ence based outcomes
If applicable, describe the population and
methods used to elicit preferences for out-
comes
Not reported
Estimating resources and costs Single study-based economic evaluation: De-
scribe approaches used to estimate resource
use associatedwith the alternative interven-
tions. Describe primary or secondary re-
search methods for valuing each resource
item in terms of its unit cost. Describe any
adjustments made to approximate to op-
portunity costs
Not reported
Currency, price date, and conversion Report the dates of the estimated resource
quantities and unit costs. Describe meth-
ods for adjusting estimated unit costs to the
year of reported costs if necessary. Describe
methods for converting costs into a com-
Not reported
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Table 5. CHEERS checklist for methodological quality assessment of economic evaluations (Continued)
mon currency base and the exchange rate
Choice of model Describe and give reasons for the specific
type of decision-analyticalmodel used. Pro-
viding a figure to show model structure is
strongly recommended
Not applicable
Assumptions Describe all structural or other assump-
tions underpinning the decision-analytical
model
Not applicable
Analytical methods Describe all analytical methods supporting
the evaluation. This could includemethods
for dealing with skewed, missing, or cen-
sored data; extrapolation methods; meth-
ods for pooling data; approaches to vali-
date or make adjustments (such as half cy-
cle corrections) to a model; and methods
for handling population heterogeneity and
uncertainty
Not reported
Results
Study parameters Report the values, ranges, references, and,
if used, probability distributions for all pa-
rameters. Report reasons or sources for dis-
tributions used to represent uncertainty
where appropriate. Providing a table to
show the input values is strongly recom-
mended
Not reported
Incremental costs and outcomes For each intervention, report mean val-
ues for the main categories of estimated
costs and outcomes of interest, as well as
mean differences between the comparator
groups. If applicable, report incremental
cost-effectiveness ratios
Not reported
Characterising uncertainty Single study-based economic evaluation: De-
scribe the effects of sampling uncertainty
for the estimated incremental cost and
incremental effectiveness parameters, to-
gether with the impact of methodological
assumptions (such as discount rate, study
perspective)
Not reported
Model-based economic evaluation: Describe
the effects on the results of uncertainty for
all input parameters, and uncertainty re-
Not applicable
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Table 5. CHEERS checklist for methodological quality assessment of economic evaluations (Continued)
lated to the structure of the model and as-
sumptions
Characterising heterogeneity If applicable, report differences in costs,
outcomes, or cost-effectiveness that can be
explained by variations between subgroups
of patients with different baseline charac-
teristics or other observed variability in ef-
fects that are not reducible by more infor-
mation
Not applicable
Discussion
Study findings, limitations, generalis-
ability, and current knowledge
Summarise key study findings and describe
how they support the conclusions reached.
Discuss limitations and the generalisability
of the findings andhow the findings fit with
current knowledge
841
Other
Source of funding Describe how the study was funded and the
role of the funder in the identification, de-
sign, conduct, and reporting of the analy-
sis. Describe other non-monetary sources
of support
841
Conflicts of interest Describe any potential for conflict of in-
terest of study contributors in accordance
with journal policy. In the absence of a jour-
nal policy, we recommend authors comply
with International Committee of Medical
Journal Editors recommendations
Not reported
Krein 2004
Title Identify the study as an economic evalu-
ation or use more specific terms such as
“cost-effectiveness analysis”, and describe
the interventions compared
Not reported
Abstract Provide a structured summary of objec-
tives, perspective, setting,methods (includ-
ing study design and inputs), results (in-
cluding base case and uncertainty analyses)
, and conclusions
Not reported
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Table 5. CHEERS checklist for methodological quality assessment of economic evaluations (Continued)
Introduction
Background and objectives Provide an explicit statement of the broader
context for the study
732
Present the study question and its relevance
for health policy or practice decisions
732
Methods
Target population and subgroups Describe characteristics of the base case
population and subgroups analysed, in-
cluding why they were chosen
733
Setting and location State relevant aspects of the system(s) in
which the decision(s) need(s) to be made
733
Study perspective Describe the perspective of the study and
relate this to the costs being evaluated
Not reported
Comparators Describe the interventions or strategies be-
ing compared and state why they were cho-
sen
733
Time horizon State the time horizon(s) over which costs
and consequences are being evaluated and
say why appropriate
Not reported
Discount rate Report the choice of discount rate(s) used
for costs and outcomes and say why appro-
priate
Not reported
Choice of health outcomes Describe what outcomes were used as the
measure(s) of benefit in the evaluation and
their relevance for the type of analysis per-
formed
Not reported
Measurement of effectiveness Single study-based estimates: Describe fully
the design features of the single effective-
ness study and why the single study was
a sufficient source of clinical effectiveness
data
Not reported
Synthesis-based estimates: Describe fully the
methods used for identification of included
studies and synthesis of clinical effective-
ness data
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Table 5. CHEERS checklist for methodological quality assessment of economic evaluations (Continued)
Measurement and valuation of prefer-
ence based outcomes
If applicable, describe the population and
methods used to elicit preferences for out-
comes
Not reported
Estimating resources and costs Single study-based economic evaluation: De-
scribe approaches used to estimate resource
use associatedwith the alternative interven-
tions. Describe primary or secondary re-
search methods for valuing each resource
item in terms of its unit cost. Describe any
adjustments made to approximate to op-
portunity costs
Not reported
Currency, price date, and conversion Report the dates of the estimated resource
quantities and unit costs. Describe meth-
ods for adjusting estimated unit costs to the
year of reported costs if necessary. Describe
methods for converting costs into a com-
mon currency base and the exchange rate
Not reported
Choice of model Describe and give reasons for the specific
type of decision-analyticalmodel used. Pro-
viding a figure to show model structure is
strongly recommended
Assumptions Describe all structural or other assump-
tions underpinning the decision-analytical
model
Not reported
Analytical methods Describe all analytical methods supporting
the evaluation. This could includemethods
for dealing with skewed, missing, or cen-
sored data; extrapolation methods; meth-
ods for pooling data; approaches to vali-
date or make adjustments (such as half cy-
cle corrections) to a model; and methods
for handling population heterogeneity and
uncertainty
Not reported
Results
Study parameters Report the values, ranges, references, and,
if used, probability distributions for all pa-
rameters. Report reasons or sources for dis-
tributions used to represent uncertainty
where appropriate. Providing a table to
show the input values is strongly recom-
mended
Not reported
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Table 5. CHEERS checklist for methodological quality assessment of economic evaluations (Continued)
Incremental costs and outcomes For each intervention, report mean val-
ues for the main categories of estimated
costs and outcomes of interest, as well as
mean differences between the comparator
groups. If applicable, report incremental
cost-effectiveness ratios
Not reported
Characterising uncertainty Single study-based economic evaluation: De-
scribe the effects of sampling uncertainty
for the estimated incremental cost and
incremental effectiveness parameters, to-
gether with the impact of methodological
assumptions (such as discount rate, study
perspective)
Not reported
Model-based economic evaluation: Describe
the effects on the results of uncertainty for
all input parameters, and uncertainty re-
lated to the structure of the model and as-
sumptions
Not applicable
Characterising heterogeneity If applicable, report differences in costs,
outcomes, or cost-effectiveness that can be
explained by variations between subgroups
of patients with different baseline charac-
teristics or other observed variability in ef-
fects that are not reducible by more infor-
mation
Not applicable
Discussion
Study findings, limitations, generalis-
ability, and current knowledge
Summarise key study findings and describe
how they support the conclusions reached.
Discuss limitations and the generalisability
of the findings andhow the findings fit with
current knowledge
738
Other
Source of funding Describe how the study was funded and the
role of the funder in the identification, de-
sign, conduct, and reporting of the analy-
sis. Describe other non-monetary sources
of support
732
Conflicts of interest Describe any potential for conflict of in-
terest of study contributors in accordance
with journal policy. In the absence of a jour-
nal policy, we recommend authors comply
Not reported
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Table 5. CHEERS checklist for methodological quality assessment of economic evaluations (Continued)
with International Committee of Medical
Journal Editors recommendations
Litaker 2003
Title Identify the study as an economic evalu-
ation or use more specific terms such as
“cost-effectiveness analysis”, and describe
the interventions compared
front page
Abstract Provide a structured summary of objec-
tives, perspective, setting,methods (includ-
ing study design and inputs), results (in-
cluding base case and uncertainty analyses)
, and conclusions
Not reported
Introduction
Background and objectives Provide an explicit statement of the broader
context for the study
224
Present the study question and its relevance
for health policy or practice decisions
224
Methods
Target population and subgroups Describe characteristics of the base case
population and subgroups analysed, in-
cluding why they were chosen
225
Setting and location State relevant aspects of the system(s) in
which the decision(s) need(s) to be made
225
Study perspective Describe the perspective of the study and
relate this to the costs being evaluated
Not reported
Comparators Describe the interventions or strategies be-
ing compared and state why they were cho-
sen
226
Time horizon State the time horizon(s) over which costs
and consequences are being evaluated and
say why appropriate
Not reported
Discount rate Report the choice of discount rate(s) used
for costs and outcomes and say why appro-
priate
Not reported
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Table 5. CHEERS checklist for methodological quality assessment of economic evaluations (Continued)
Choice of health outcomes Describe what outcomes were used as the
measure(s) of benefit in the evaluation and
their relevance for the type of analysis per-
formed
Not reported
Measurement of effectiveness Single study-based estimates: Describe fully
the design features of the single effective-
ness study and why the single study was
a sufficient source of clinical effectiveness
data
Not reported
Synthesis-based estimates: Describe fully the
methods used for identification of included
studies and synthesis of clinical effective-
ness data
Not reported
Measurement and valuation of prefer-
ence based outcomes
If applicable, describe the population and
methods used to elicit preferences for out-
comes
226
Estimating resources and costs Single study-based economic evaluation: De-
scribe approaches used to estimate resource
use associatedwith the alternative interven-
tions. Describe primary or secondary re-
search methods for valuing each resource
item in terms of its unit cost. Describe any
adjustments made to approximate to op-
portunity costs
Not reported
Currency, price date, and conversion Report the dates of the estimated resource
quantities and unit costs. Describe meth-
ods for adjusting estimated unit costs to the
year of reported costs if necessary. Describe
methods for converting costs into a com-
mon currency base and the exchange rate
Not reported
Choice of model Describe and give reasons for the specific
type of decision-analyticalmodel used. Pro-
viding a figure to show model structure is
strongly recommended
Not applicable
Assumptions Describe all structural or other assump-
tions underpinning the decision-analytical
model
Not applicable
Analytical methods Describe all analytical methods supporting
the evaluation. This could includemethods
for dealing with skewed, missing, or cen-
sored data; extrapolation methods; meth-
Not applicable
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Table 5. CHEERS checklist for methodological quality assessment of economic evaluations (Continued)
ods for pooling data; approaches to vali-
date or make adjustments (such as half cy-
cle corrections) to a model; and methods
for handling population heterogeneity and
uncertainty
Results
Study parameters Report the values, ranges, references, and,
if used, probability distributions for all pa-
rameters. Report reasons or sources for dis-
tributions used to represent uncertainty
where appropriate. Providing a table to
show the input values is strongly recom-
mended
Not reported
Incremental costs and outcomes For each intervention, report mean val-
ues for the main categories of estimated
costs and outcomes of interest, as well as
mean differences between the comparator
groups. If applicable, report incremental
cost-effectiveness ratios
Not reported
Characterising uncertainty Single study-based economic evaluation: De-
scribe the effects of sampling uncertainty
for the estimated incremental cost and
incremental effectiveness parameters, to-
gether with the impact of methodological
assumptions (such as discount rate, study
perspective)
Not reported
Model-based economic evaluation: Describe
the effects on the results of uncertainty for
all input parameters, and uncertainty re-
lated to the structure of the model and as-
sumptions
Not applicable
Characterising heterogeneity If applicable, report differences in costs,
outcomes, or cost-effectiveness that can be
explained by variations between subgroups
of patients with different baseline charac-
teristics or other observed variability in ef-
fects that are not reducible by more infor-
mation
232
Discussion
Study findings, limitations, generalis-
ability, and current knowledge
Summarise key study findings and describe
how they support the conclusions reached.
Discuss limitations and the generalisability
234
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Table 5. CHEERS checklist for methodological quality assessment of economic evaluations (Continued)
of the findings andhow the findings fit with
current knowledge
Other
Source of funding Describe how the study was funded and the
role of the funder in the identification, de-
sign, conduct, and reporting of the analy-
sis. Describe other non-monetary sources
of support
235
Conflicts of interest Describe any potential for conflict of in-
terest of study contributors in accordance
with journal policy. In the absence of a jour-
nal policy, we recommend authors comply
with International Committee of Medical
Journal Editors recommendations
Not reported
McCall 2011
Title Identify the study as an economic evalu-
ation or use more specific terms such as
“cost-effectiveness analysis”, and describe
the interventions compared
Not reported
Abstract Provide a structured summary of objec-
tives, perspective, setting,methods (includ-
ing study design and inputs), results (in-
cluding base case and uncertainty analyses)
, and conclusions
Not reported
Introduction
Background and objectives Provide an explicit statement of the broader
context for the study
1705
Present the study question and its relevance
for health policy or practice decisions
1706
Methods
Target population and subgroups Describe characteristics of the base case
population and subgroups analysed, in-
cluding why they were chosen
1708
Setting and location State relevant aspects of the system(s) in
which the decision(s) need(s) to be made
1705
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Table 5. CHEERS checklist for methodological quality assessment of economic evaluations (Continued)
Study perspective Describe the perspective of the study and
relate this to the costs being evaluated
Not reported
Comparators Describe the interventions or strategies be-
ing compared and state why they were cho-
sen
Not reported
Time horizon State the time horizon(s) over which costs
and consequences are being evaluated and
say why appropriate
Not reported
Discount rate Report the choice of discount rate(s) used
for costs and outcomes and say why appro-
priate
Not reported
Choice of health outcomes Describe what outcomes were used as the
measure(s) of benefit in the evaluation and
their relevance for the type of analysis per-
formed
Not reported
Measurement of effectiveness Single study-based estimates: Describe fully
the design features of the single effective-
ness study and why the single study was
a sufficient source of clinical effectiveness
data
Not reported
Synthesis-based estimates: Describe fully the
methods used for identification of included
studies and synthesis of clinical effective-
ness data
Not applicable
Measurement and valuation of prefer-
ence based outcomes
If applicable, describe the population and
methods used to elicit preferences for out-
comes
Not applicable
Estimating resources and costs Single study-based economic evaluation: De-
scribe approaches used to estimate resource
use associatedwith the alternative interven-
tions. Describe primary or secondary re-
search methods for valuing each resource
item in terms of its unit cost. Describe any
adjustments made to approximate to op-
portunity costs
Not reported
Currency, price date, and conversion Report the dates of the estimated resource
quantities and unit costs. Describe meth-
ods for adjusting estimated unit costs to the
year of reported costs if necessary. Describe
methods for converting costs into a com-
Not reported
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Table 5. CHEERS checklist for methodological quality assessment of economic evaluations (Continued)
mon currency base and the exchange rate
Choice of model Describe and give reasons for the specific
type of decision-analyticalmodel used. Pro-
viding a figure to show model structure is
strongly recommended
Not applicable
Assumptions Describe all structural or other assump-
tions underpinning the decision-analytical
model
Not applicable
Analytical methods Describe all analytical methods supporting
the evaluation. This could includemethods
for dealing with skewed, missing, or cen-
sored data; extrapolation methods; meth-
ods for pooling data; approaches to vali-
date or make adjustments (such as half cy-
cle corrections) to a model; and methods
for handling population heterogeneity and
uncertainty
Not applicable
Results
Study parameters Report the values, ranges, references, and,
if used, probability distributions for all pa-
rameters. Report reasons or sources for dis-
tributions used to represent uncertainty
where appropriate. Providing a table to
show the input values is strongly recom-
mended
Not reported
Incremental costs and outcomes For each intervention, report mean val-
ues for the main categories of estimated
costs and outcomes of interest, as well as
mean differences between the comparator
groups. If applicable, report incremental
cost-effectiveness ratios
Not reported
Characterising uncertainty Single study-based economic evaluation: De-
scribe the effects of sampling uncertainty
for the estimated incremental cost and
incremental effectiveness parameters, to-
gether with the impact of methodological
assumptions (such as discount rate, study
perspective)
Not reported
Model-based economic evaluation: Describe
the effects on the results of uncertainty for
all input parameters, and uncertainty re-
Not applicable
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Table 5. CHEERS checklist for methodological quality assessment of economic evaluations (Continued)
lated to the structure of the model and as-
sumptions
Characterising heterogeneity If applicable, report differences in costs,
outcomes, or cost-effectiveness that can be
explained by variations between subgroups
of patients with different baseline charac-
teristics or other observed variability in ef-
fects that are not reducible by more infor-
mation
Not applicable
Discussion
Study findings, limitations, generalis-
ability, and current knowledge
Summarise key study findings and describe
how they support the conclusions reached.
Discuss limitations and the generalisability
of the findings andhow the findings fit with
current knowledge
1712
Other
Source of funding Describe how the study was funded and the
role of the funder in the identification, de-
sign, conduct, and reporting of the analy-
sis. Describe other non-monetary sources
of support
Not reported
Conflicts of interest Describe any potential for conflict of in-
terest of study contributors in accordance
with journal policy. In the absence of a jour-
nal policy, we recommend authors comply
with International Committee of Medical
Journal Editors recommendations
Not reported
Piette 2001
Title Identify the study as an economic evalu-
ation or use more specific terms such as
“cost-effectiveness analysis”, and describe
the interventions compared
Not reported
Abstract Provide a structured summary of objec-
tives, perspective, setting,methods (includ-
ing study design and inputs), results (in-
cluding base case and uncertainty analyses)
, and conclusions
Not reported
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Table 5. CHEERS checklist for methodological quality assessment of economic evaluations (Continued)
Introduction
Background and objectives Provide an explicit statement of the broader
context for the study
202 - 203
Present the study question and its relevance
for health policy or practice decisions
Not reported
Methods
Target population and subgroups Describe characteristics of the base case
population and subgroups analysed, in-
cluding why they were chosen
204
Setting and location State relevant aspects of the system(s) in
which the decision(s) need(s) to be made
203
Study perspective Describe the perspective of the study and
relate this to the costs being evaluated
Not reported
Comparators Describe the interventions or strategies be-
ing compared and state why they were cho-
sen
177
Time horizon State the time horizon(s) over which costs
and consequences are being evaluated and
say why appropriate
Not reported
Discount rate Report the choice of discount rate(s) used
for costs and outcomes and say why appro-
priate
Not reported
Choice of health outcomes Describe what outcomes were used as the
measure(s) of benefit in the evaluation and
their relevance for the type of analysis per-
formed
Not reported
Measurement of effectiveness Single study-based estimates: Describe fully
the design features of the single effective-
ness study and why the single study was
a sufficient source of clinical effectiveness
data
Not reported
Synthesis-based estimates: Describe fully the
methods used for identification of included
studies and synthesis of clinical effective-
ness data
Not applicable
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Table 5. CHEERS checklist for methodological quality assessment of economic evaluations (Continued)
Measurement and valuation of prefer-
ence based outcomes
If applicable, describe the population and
methods used to elicit preferences for out-
comes
Not applicable
Estimating resources and costs Single study-based economic evaluation: De-
scribe approaches used to estimate resource
use associatedwith the alternative interven-
tions. Describe primary or secondary re-
search methods for valuing each resource
item in terms of its unit cost. Describe any
adjustments made to approximate to op-
portunity costs
Not reported
Currency, price date, and conversion Report the dates of the estimated resource
quantities and unit costs. Describe meth-
ods for adjusting estimated unit costs to the
year of reported costs if necessary. Describe
methods for converting costs into a com-
mon currency base and the exchange rate
Not reported
Choice of model Describe and give reasons for the specific
type of decision-analyticalmodel used. Pro-
viding a figure to show model structure is
strongly recommended
Not applicable
Assumptions Describe all structural or other assump-
tions underpinning the decision-analytical
model
Not applicable
Analytical methods Describe all analytical methods supporting
the evaluation. This could includemethods
for dealing with skewed, missing, or cen-
sored data; extrapolation methods; meth-
ods for pooling data; approaches to vali-
date or make adjustments (such as half cy-
cle corrections) to a model; and methods
for handling population heterogeneity and
uncertainty
Not applicable
Results
Study parameters Report the values, ranges, references, and,
if used, probability distributions for all pa-
rameters. Report reasons or sources for dis-
tributions used to represent uncertainty
where appropriate. Providing a table to
show the input values is strongly recom-
mended
Not reported
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Table 5. CHEERS checklist for methodological quality assessment of economic evaluations (Continued)
Incremental costs and outcomes For each intervention, report mean val-
ues for the main categories of estimated
costs and outcomes of interest, as well as
mean differences between the comparator
groups. If applicable, report incremental
cost-effectiveness ratios
Not reported
Characterising uncertainty Single study-based economic evaluation: De-
scribe the effects of sampling uncertainty
for the estimated incremental cost and
incremental effectiveness parameters, to-
gether with the impact of methodological
assumptions (such as discount rate, study
perspective)
Not reported
Model-based economic evaluation: Describe
the effects on the results of uncertainty for
all input parameters, and uncertainty re-
lated to the structure of the model and as-
sumptions
Not applicable
Characterising heterogeneity If applicable, report differences in costs,
outcomes, or cost-effectiveness that can be
explained by variations between subgroups
of patients with different baseline charac-
teristics or other observed variability in ef-
fects that are not reducible by more infor-
mation
Not reported
Discussion
Study findings, limitations, generalis-
ability, and current knowledge
Summarise key study findings and describe
how they support the conclusions reached.
Discuss limitations and the generalisability
of the findings andhow the findings fit with
current knowledge
207
Other
Source of funding Describe how the study was funded and the
role of the funder in the identification, de-
sign, conduct, and reporting of the analy-
sis. Describe other non-monetary sources
of support
207
Conflicts of interest Describe any potential for conflict of in-
terest of study contributors in accordance
with journal policy. In the absence of a jour-
nal policy, we recommend authors comply
Not reported
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Table 5. CHEERS checklist for methodological quality assessment of economic evaluations (Continued)
with International Committee of Medical
Journal Editors recommendations
Pizzi 2015
Title Identify the study as an economic evalu-
ation or use more specific terms such as
“cost-effectiveness analysis”, and describe
the interventions compared
front page
Abstract Provide a structured summary of objec-
tives, perspective, setting,methods (includ-
ing study design and inputs), results (in-
cluding base case and uncertainty analyses)
, and conclusions
front page
Introduction
Background and objectives Provide an explicit statement of the broader
context for the study
254
Present the study question and its relevance
for health policy or practice decisions
254
Methods
Target population and subgroups Describe characteristics of the base case
population and subgroups analysed, in-
cluding why they were chosen
254
Setting and location State relevant aspects of the system(s) in
which the decision(s) need(s) to be made
254
Study perspective Describe the perspective of the study and
relate this to the costs being evaluated
255
Comparators Describe the interventions or strategies be-
ing compared and state why they were cho-
sen
254
Time horizon State the time horizon(s) over which costs
and consequences are being evaluated and
say why appropriate
256
Discount rate Report the choice of discount rate(s) used
for costs and outcomes and say why appro-
priate
256
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Table 5. CHEERS checklist for methodological quality assessment of economic evaluations (Continued)
Choice of health outcomes Describe what outcomes were used as the
measure(s) of benefit in the evaluation and
their relevance for the type of analysis per-
formed
255
Measurement of effectiveness Single study-based estimates: Describe fully
the design features of the single effective-
ness study and why the single study was
a sufficient source of clinical effectiveness
data
254 - 255
Synthesis-based estimates: Describe fully the
methods used for identification of included
studies and synthesis of clinical effective-
ness data
Not reported
Measurement and valuation of prefer-
ence based outcomes
If applicable, describe the population and
methods used to elicit preferences for out-
comes
Not applicable
Estimating resources and costs Single study-based economic evaluation: De-
scribe approaches used to estimate resource
use associatedwith the alternative interven-
tions. Describe primary or secondary re-
search methods for valuing each resource
item in terms of its unit cost. Describe any
adjustments made to approximate to op-
portunity costs
256
Currency, price date, and conversion Report the dates of the estimated resource
quantities and unit costs. Describe meth-
ods for adjusting estimated unit costs to the
year of reported costs if necessary. Describe
methods for converting costs into a com-
mon currency base and the exchange rate
256
Choice of model Describe and give reasons for the specific
type of decision-analyticalmodel used. Pro-
viding a figure to show model structure is
strongly recommended
256
Assumptions Describe all structural or other assump-
tions underpinning the decision-analytical
model
256 - 257
Analytical methods Describe all analytical methods supporting
the evaluation. This could includemethods
for dealing with skewed, missing, or cen-
sored data; extrapolation methods; meth-
256
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Table 5. CHEERS checklist for methodological quality assessment of economic evaluations (Continued)
ods for pooling data; approaches to vali-
date or make adjustments (such as half cy-
cle corrections) to a model; and methods
for handling population heterogeneity and
uncertainty
Results
Study parameters Report the values, ranges, references, and,
if used, probability distributions for all pa-
rameters. Report reasons or sources for dis-
tributions used to represent uncertainty
where appropriate. Providing a table to
show the input values is strongly recom-
mended
258 - 259
Incremental costs and outcomes For each intervention, report mean val-
ues for the main categories of estimated
costs and outcomes of interest, as well as
mean differences between the comparator
groups. If applicable, report incremental
cost-effectiveness ratios
260
Characterising uncertainty Single study-based economic evaluation: De-
scribe the effects of sampling uncertainty
for the estimated incremental cost and
incremental effectiveness parameters, to-
gether with the impact of methodological
assumptions (such as discount rate, study
perspective)
258 - 260
Model-based economic evaluation: Describe
the effects on the results of uncertainty for
all input parameters, and uncertainty re-
lated to the structure of the model and as-
sumptions
Not reported
Characterising heterogeneity If applicable, report differences in costs,
outcomes, or cost-effectiveness that can be
explained by variations between subgroups
of patients with different baseline charac-
teristics or other observed variability in ef-
fects that are not reducible by more infor-
mation
258 - 260
Discussion
Study findings, limitations, generalis-
ability, and current knowledge
Summarise key study findings and describe
how they support the conclusions reached.
Discuss limitations and the generalisability
261 - 262
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Table 5. CHEERS checklist for methodological quality assessment of economic evaluations (Continued)
of the findings andhow the findings fit with
current knowledge
Other
Source of funding Describe how the study was funded and the
role of the funder in the identification, de-
sign, conduct, and reporting of the analy-
sis. Describe other non-monetary sources
of support
263
Conflicts of interest Describe any potential for conflict of in-
terest of study contributors in accordance
with journal policy. In the absence of a jour-
nal policy, we recommend authors comply
with International Committee of Medical
Journal Editors recommendations
263
Prezio 2014
Title Identify the study as an economic evalu-
ation or use more specific terms such as
“cost-effectiveness analysis”, and describe
the interventions compared
771
Abstract Provide a structured summary of objec-
tives, perspective, setting,methods (includ-
ing study design and inputs), results (in-
cluding base case and uncertainty analyses)
, and conclusions
771
Introduction
Background and objectives Provide an explicit statement of the broader
context for the study
772
Present the study question and its relevance
for health policy or practice decisions
772
Methods
Target population and subgroups Describe characteristics of the base case
population and subgroups analysed, in-
cluding why they were chosen
772
Setting and location State relevant aspects of the system(s) in
which the decision(s) need(s) to be made
772
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Table 5. CHEERS checklist for methodological quality assessment of economic evaluations (Continued)
Study perspective Describe the perspective of the study and
relate this to the costs being evaluated
772
Comparators Describe the interventions or strategies be-
ing compared and state why they were cho-
sen
772
Time horizon State the time horizon(s) over which costs
and consequences are being evaluated and
say why appropriate
772
Discount rate Report the choice of discount rate(s) used
for costs and outcomes and say why appro-
priate
772
Choice of health outcomes Describe what outcomes were used as the
measure(s) of benefit in the evaluation and
their relevance for the type of analysis per-
formed
774
Measurement of effectiveness Single study-based estimates: Describe fully
the design features of the single effective-
ness study and why the single study was
a sufficient source of clinical effectiveness
data
772
Synthesis-based estimates: Describe fully the
methods used for identification of included
studies and synthesis of clinical effective-
ness data
Not reported
Measurement and valuation of prefer-
ence based outcomes
If applicable, describe the population and
methods used to elicit preferences for out-
comes
Not applicable
Estimating resources and costs Single study-based economic evaluation: De-
scribe approaches used to estimate resource
use associatedwith the alternative interven-
tions. Describe primary or secondary re-
search methods for valuing each resource
item in terms of its unit cost. Describe any
adjustments made to approximate to op-
portunity costs
772
Currency, price date, and conversion Report the dates of the estimated resource
quantities and unit costs. Describe meth-
ods for adjusting estimated unit costs to the
year of reported costs if necessary. Describe
methods for converting costs into a com-
772
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Table 5. CHEERS checklist for methodological quality assessment of economic evaluations (Continued)
mon currency base and the exchange rate
Choice of model Describe and give reasons for the specific
type of decision-analyticalmodel used. Pro-
viding a figure to show model structure is
strongly recommended
772
Assumptions Describe all structural or other assump-
tions underpinning the decision-analytical
model
772 - 774
Analytical methods Describe all analytical methods supporting
the evaluation. This could includemethods
for dealing with skewed, missing, or cen-
sored data; extrapolation methods; meth-
ods for pooling data; approaches to vali-
date or make adjustments (such as half cy-
cle corrections) to a model; and methods
for handling population heterogeneity and
uncertainty
774
Results
Study parameters Report the values, ranges, references, and,
if used, probability distributions for all pa-
rameters. Report reasons or sources for dis-
tributions used to represent uncertainty
where appropriate. Providing a table to
show the input values is strongly recom-
mended
774 - 776
Incremental costs and outcomes For each intervention, report mean val-
ues for the main categories of estimated
costs and outcomes of interest, as well as
mean differences between the comparator
groups. If applicable, report incremental
cost-effectiveness ratios
777
Characterising uncertainty Single study-based economic evaluation: De-
scribe the effects of sampling uncertainty
for the estimated incremental cost and
incremental effectiveness parameters, to-
gether with the impact of methodological
assumptions (such as discount rate, study
perspective)
776 - 777
Model-based economic evaluation: Describe
the effects on the results of uncertainty for
all input parameters, and uncertainty re-
Not applicable
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Table 5. CHEERS checklist for methodological quality assessment of economic evaluations (Continued)
lated to the structure of the model and as-
sumptions
Characterising heterogeneity If applicable, report differences in costs,
outcomes, or cost-effectiveness that can be
explained by variations between subgroups
of patients with different baseline charac-
teristics or other observed variability in ef-
fects that are not reducible by more infor-
mation
777
Discussion
Study findings, limitations, generalis-
ability, and current knowledge
Summarise key study findings and describe
how they support the conclusions reached.
Discuss limitations and the generalisability
of the findings andhow the findings fit with
current knowledge
775
Other
Source of funding Describe how the study was funded and the
role of the funder in the identification, de-
sign, conduct, and reporting of the analy-
sis. Describe other non-monetary sources
of support
778
Conflicts of interest Describe any potential for conflict of in-
terest of study contributors in accordance
with journal policy. In the absence of a jour-
nal policy, we recommend authors comply
with International Committee of Medical
Journal Editors recommendations
778
Schechter 2008
Title Identify the study as an economic evalu-
ation or use more specific terms such as
“cost-effectiveness analysis”, and describe
the interventions compared
763
Abstract Provide a structured summary of objec-
tives, perspective, setting,methods (includ-
ing study design and inputs), results (in-
cluding base case and uncertainty analyses)
, and conclusions
763
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Table 5. CHEERS checklist for methodological quality assessment of economic evaluations (Continued)
Introduction
Background and objectives Provide an explicit statement of the broader
context for the study
763 - 764
Present the study question and its relevance
for health policy or practice decisions
764
Methods
Target population and subgroups Describe characteristics of the base case
population and subgroups analysed, in-
cluding why they were chosen
764
Setting and location State relevant aspects of the system(s) in
which the decision(s) need(s) to be made
764
Study perspective Describe the perspective of the study and
relate this to the costs being evaluated
764
Comparators Describe the interventions or strategies be-
ing compared and state why they were cho-
sen
764
Time horizon State the time horizon(s) over which costs
and consequences are being evaluated and
say why appropriate
764
Discount rate Report the choice of discount rate(s) used
for costs and outcomes and say why appro-
priate
765
Choice of health outcomes Describe what outcomes were used as the
measure(s) of benefit in the evaluation and
their relevance for the type of analysis per-
formed
764
Measurement of effectiveness Single study-based estimates: Describe fully
the design features of the single effective-
ness study and why the single study was
a sufficient source of clinical effectiveness
data
764
Synthesis-based estimates: Describe fully the
methods used for identification of included
studies and synthesis of clinical effective-
ness data
Not applicable
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Table 5. CHEERS checklist for methodological quality assessment of economic evaluations (Continued)
Measurement and valuation of prefer-
ence based outcomes
If applicable, describe the population and
methods used to elicit preferences for out-
comes
765
Estimating resources and costs Single study-based economic evaluation: De-
scribe approaches used to estimate resource
use associatedwith the alternative interven-
tions. Describe primary or secondary re-
search methods for valuing each resource
item in terms of its unit cost. Describe any
adjustments made to approximate to op-
portunity costs
764
Currency, price date, and conversion Report the dates of the estimated resource
quantities and unit costs. Describe meth-
ods for adjusting estimated unit costs to the
year of reported costs if necessary. Describe
methods for converting costs into a com-
mon currency base and the exchange rate
764
Choice of model Describe and give reasons for the specific
type of decision-analyticalmodel used. Pro-
viding a figure to show model structure is
strongly recommended
Not applicable
Assumptions Describe all structural or other assump-
tions underpinning the decision-analytical
model
Not applicable
Analytical methods Describe all analytical methods supporting
the evaluation. This could includemethods
for dealing with skewed, missing, or cen-
sored data; extrapolation methods; meth-
ods for pooling data; approaches to vali-
date or make adjustments (such as half cy-
cle corrections) to a model; and methods
for handling population heterogeneity and
uncertainty
765
Results
Study parameters Report the values, ranges, references, and,
if used, probability distributions for all pa-
rameters. Report reasons or sources for dis-
tributions used to represent uncertainty
where appropriate. Providing a table to
show the input values is strongly recom-
mended
766
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Table 5. CHEERS checklist for methodological quality assessment of economic evaluations (Continued)
Incremental costs and outcomes For each intervention, report mean val-
ues for the main categories of estimated
costs and outcomes of interest, as well as
mean differences between the comparator
groups. If applicable, report incremental
cost-effectiveness ratios
765
Characterising uncertainty Single study-based economic evaluation: De-
scribe the effects of sampling uncertainty
for the estimated incremental cost and
incremental effectiveness parameters, to-
gether with the impact of methodological
assumptions (such as discount rate, study
perspective)
766
Model-based economic evaluation: Describe
the effects on the results of uncertainty for
all input parameters, and uncertainty re-
lated to the structure of the model and as-
sumptions
Not applicable
Characterising heterogeneity If applicable, report differences in costs,
outcomes, or cost-effectiveness that can be
explained by variations between subgroups
of patients with different baseline charac-
teristics or other observed variability in ef-
fects that are not reducible by more infor-
mation
765
Discussion
Study findings, limitations, generalis-
ability, and current knowledge
Summarise key study findings and describe
how they support the conclusions reached.
Discuss limitations and the generalisability
of the findings andhow the findings fit with
current knowledge
767
Other
Source of funding Describe how the study was funded and the
role of the funder in the identification, de-
sign, conduct, and reporting of the analy-
sis. Describe other non-monetary sources
of support
767
Conflicts of interest Describe any potential for conflict of in-
terest of study contributors in accordance
with journal policy. In the absence of a jour-
nal policy, we recommend authors comply
768
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Table 5. CHEERS checklist for methodological quality assessment of economic evaluations (Continued)
with International Committee of Medical
Journal Editors recommendations
Wagner 2001
Title Identify the study as an economic evalu-
ation or use more specific terms such as
“cost-effectiveness analysis”, and describe
the interventions compared
Not reported
Abstract Provide a structured summary of objec-
tives, perspective, setting,methods (includ-
ing study design and inputs), results (in-
cluding base case and uncertainty analyses)
, and conclusions
Not reported
Introduction
Background and objectives Provide an explicit statement of the broader
context for the study
695
Present the study question and its relevance
for health policy or practice decisions
695
Methods
Target population and subgroups Describe characteristics of the base case
population and subgroups analysed, in-
cluding why they were chosen
697
Setting and location State relevant aspects of the system(s) in
which the decision(s) need(s) to be made
695 - 696
Study perspective Describe the perspective of the study and
relate this to the costs being evaluated
Not reported
Comparators Describe the interventions or strategies be-
ing compared and state why they were cho-
sen
Not reported
Time horizon State the time horizon(s) over which costs
and consequences are being evaluated and
say why appropriate
Not reported
Discount rate Report the choice of discount rate(s) used
for costs and outcomes and say why appro-
priate
Not reported
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Table 5. CHEERS checklist for methodological quality assessment of economic evaluations (Continued)
Choice of health outcomes Describe what outcomes were used as the
measure(s) of benefit in the evaluation and
their relevance for the type of analysis per-
formed
Not reported
Measurement of effectiveness Single study-based estimates: Describe fully
the design features of the single effective-
ness study and why the single study was
a sufficient source of clinical effectiveness
data
Not reported
Synthesis-based estimates: Describe fully the
methods used for identification of included
studies and synthesis of clinical effective-
ness data
Not applicable
Measurement and valuation of prefer-
ence based outcomes
If applicable, describe the population and
methods used to elicit preferences for out-
comes
Not applicable
Estimating resources and costs Single study-based economic evaluation: De-
scribe approaches used to estimate resource
use associatedwith the alternative interven-
tions. Describe primary or secondary re-
search methods for valuing each resource
item in terms of its unit cost. Describe any
adjustments made to approximate to op-
portunity costs
Not reported
Currency, price date, and conversion Report the dates of the estimated resource
quantities and unit costs. Describe meth-
ods for adjusting estimated unit costs to the
year of reported costs if necessary. Describe
methods for converting costs into a com-
mon currency base and the exchange rate
Not reported
Choice of model Describe and give reasons for the specific
type of decision-analyticalmodel used. Pro-
viding a figure to show model structure is
strongly recommended
Not applicable
Assumptions Describe all structural or other assump-
tions underpinning the decision-analytical
model
Not applicable
Analytical methods Describe all analytical methods supporting
the evaluation. This could includemethods
for dealing with skewed, missing, or cen-
sored data; extrapolation methods; meth-
Not reported
228Interventions to increase attendance for diabetic retinopathy screening (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 5. CHEERS checklist for methodological quality assessment of economic evaluations (Continued)
ods for pooling data; approaches to vali-
date or make adjustments (such as half cy-
cle corrections) to a model; and methods
for handling population heterogeneity and
uncertainty
Results
Study parameters Report the values, ranges, references, and,
if used, probability distributions for all pa-
rameters. Report reasons or sources for dis-
tributions used to represent uncertainty
where appropriate. Providing a table to
show the input values is strongly recom-
mended
697 - 698
Incremental costs and outcomes For each intervention, report mean val-
ues for the main categories of estimated
costs and outcomes of interest, as well as
mean differences between the comparator
groups. If applicable, report incremental
cost-effectiveness ratios
Not reported
Characterising uncertainty Single study-based economic evaluation: De-
scribe the effects of sampling uncertainty
for the estimated incremental cost and
incremental effectiveness parameters, to-
gether with the impact of methodological
assumptions (such as discount rate, study
perspective)
Not reported
Model-based economic evaluation: Describe
the effects on the results of uncertainty for
all input parameters, and uncertainty re-
lated to the structure of the model and as-
sumptions
Not reported
Characterising heterogeneity If applicable, report differences in costs,
outcomes, or cost-effectiveness that can be
explained by variations between subgroups
of patients with different baseline charac-
teristics or other observed variability in ef-
fects that are not reducible by more infor-
mation
Not reported
Discussion
Study findings, limitations, generalis-
ability, and current knowledge
Summarise key study findings and describe
how they support the conclusions reached.
Discuss limitations and the generalisability
698 - 699
229Interventions to increase attendance for diabetic retinopathy screening (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 5. CHEERS checklist for methodological quality assessment of economic evaluations (Continued)
of the findings andhow the findings fit with
current knowledge
Other
Source of funding Describe how the study was funded and the
role of the funder in the identification, de-
sign, conduct, and reporting of the analy-
sis. Describe other non-monetary sources
of support
699
Conflicts of interest Describe any potential for conflict of in-
terest of study contributors in accordance
with journal policy. In the absence of a jour-
nal policy, we recommend authors comply
with International Committee of Medical
Journal Editors recommendations
Not reported
Table 6. Results of subgroup analysis
Subgroup category N
studies
RD (95% CI) I2 %
QI Strategy
Audit and feedback 11 0.12 (0.06 to 0.18) 89
Case management 18 0.14 (0.07 to 0.21) 94
Team changes 19 0.20 (0.13 to 0.26) 88
Electronic patient registry 10 0.18 (0.07 to 0.29) 94
Clinician education 16 0.13 (0.07 to 0.19) 95
Clinician reminders 10 0.13 (0.05 to 0.21) 85
Patient Education 30 0.15 (0.13 to 0.18) 95
Promotion of self-manage-
ment
21 0.19 (0.13 to 0.26) 96
Patient reminders 16 0.11 (0.07 to 0.14) 93
BCT (patients)
Goal setting (Outcome) 14 0.26 (0.16 to 0.36) 93
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Table 6. Results of subgroup analysis (Continued)
Feedback on outcomes of be-
haviour/biofeedback
15 0.19 (0.13 to 0.25) 80
Credible source 10 0.22 (0.06 to 0.38) 95
Prompts/cues 25 0.11 (0.07 to 0.14) 92
Social support (unspecified) 14 0.19 (0.09 to 0.28) 93
Problem solving 10 0.17 (0.08 to 0.27) 89
Restructuring the social envi-
ronment
17 0.17 (0.10 to 0.24) 85
Instruction on how to per-
form behaviour
34 0.13 (0.11 to 0.15) 94
Social support (practical) 20 0.14 (0.09 to 0.20) 90
Information about health
consequences
19 0.12 (0.07 to 0.16) 92
BCT (healthcare professionals)
Restructuring the social envi-
ronment
23 0.19 (0.12 to 0.26) 91
Credible source 13 0.16 (0.08 to 0.24) 95
Adding objects to the envi-
ronment
15 0.14 (0.07 to 0.20) 88
Social support (practical) 10 0.13 (0.03 to 0.22) 87
Instruction on how to per-
form behaviour
30 0.13 (0.08 to 0.17) 93
Prompts/cues 15 0.12 (0.06 to 0.17) 85
Feedback on outcomes of be-
haviour/biofeedback
17 0.11 (0.07 to 0.16) 81
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Table 7. GRADE rating for economic outcomes
Resources and costs
per participant
Eco-
nomic
out-
comes
No
of studies
with evi-
dence for
the
economic
outcomes
Design Limita-
tions/risk
of bias
Inconsis-
tency
Indirect-
ness
Impreci-
sion
Other
factors
No
of partic-
ipants
Any
Quality
Improve-
ment in-
terven-
tion
Usual
care
Overall
quality
Re-
sources
used
(staff
time,
equip-
ment,
consum-
ables)
(13 stud-
ies)
Adair
2013
Clancy
2007
Davis
2010
Eccles
2007
Frei 2014
Frijling
2002
Krein
2004
Litaker
2003
Piette
2001
Pizzi
2015
Prezio
201
Wagner
2001
RCTs Yesa Yes ( there
was justi-
fication
for varia-
tion based
on
setting)
No No Resources
used
varied due
to settings
and inter-
vention
strategy
85 - 20,
000
Wide variation in re-
sources used for each
study, hence difficult
to collate the resource
used as a single output
⊕⊕
LOW
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Table 7. GRADE rating for economic outcomes (Continued)
Walker
2008
Staff/
person-
nel costs;
costs
of treat-
ment and
care; cost
of
primary
care; lost
wages
and
lost pro-
ductivity
(10 stud-
ies)
Adair
2013
Clancy
2007
Davis
2010
Eccles
2007
Frijling
2002
Litaker
2003
Piette
2001
Pizzi
2015
Prezio
2014
Walker
2008
RCTs Yesa Yes ( there
was justi-
fication
for varia-
tion based
on
setting)
No No Costs var-
ied due to
settings,
level
of experi-
ence
and edu-
cational
Back-
ground of
personnel
85 - 20,
000
Wide variation in re-
sources used from dif-
fer-
ent interventions also
made it difficult to de-
rive average costs com-
pared with usual care
⊕⊕
LOW
Incre-
mental
cost
effective-
ness
of inter-
ventions.
(3 stud-
ies)
Davis
RCTs Yesa No No No None 85 - 603 GBP 13,154 for pro-
motion of self-man-
agement
GBP 73,683 for 5
years for face-to-face
meeting
GBP 18.77 for phone
call
⊕⊕⊕
LOW
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Table 7. GRADE rating for economic outcomes (Continued)
2010
Prezio
2014
Walker
2008
a. Unclear risk from adequate masking (blinding), Unclear sequence generation and allocation concealment
A P P E N D I C E S
Appendix 1. CENTRAL and NHS EED search strategy
#1 MeSH descriptor: [Diabetes Mellitus] explode all trees
#2 MeSH descriptor: [Diabetes Complications] explode all trees
#3 MeSH descriptor: [Diabetic Retinopathy] explode all trees
#4 (diabet* or proliferative or non-proliferative) near/4 retinopath*
#5 diabet* near/3 (eye* or vision or visual* or sight*)
#6 retinopath* near/3 (eye* or vision or visual* or sight*)
#7 DR near/3 (eye* or vision or visual* or sight*)
#8 #1 or #2 or #3 or #4 or #5 or #6 or #7
#9 MeSH descriptor: [Mass Screening] explode all trees
#10 MeSH descriptor: [Vision Tests] explode all trees
#11 MeSH descriptor: [Telemedicine] explode all trees
#12 MeSH descriptor: [Photography] explode all trees
#13 MeSH descriptor: [Ophthalmoscopes] explode all trees
#14 MeSH descriptor: [Ophthalmoscopy] explode all trees
#15 ophthalmoscop* or fundoscop* or funduscop*:ti
#16 (exam* or photo* or imag*) near/3 fundus
#17 photography or retinography
#18 (mydriatic or digital or retina* or fundus or steroscopic) near/3 camera*
#19 (mydriatic or digital or retina* or fundus or steroscopic) near/3 imag*
#20 screen$.tw.
#21 (eye* or retina* or ophthalm*) near/4 exam*
#22 (eye* or vision or retinopathy or ophthalmic) near/4 test*
#23 (eye* or retina* or ophthalm*) near/4 visit*
#24 MeSH descriptor: [Office Visits] this term only
#25 (telemedicine* or telemonitor* or telescreen* or telehealth or teleophthalmology)
#26 #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25
#27 MeSH descriptor: [Quality of Health Care] explode all trees
#28 MeSH descriptor: [Quality of Health Care] this term only
#29 MeSH descriptor: [Quality Improvement] this term only
#30 MeSH descriptor: [Delivery of Health Care] this term only
#31 MeSH descriptor: [Delivery of Health Care, Integrated] this term only
#32 service delivery
#33 decision making
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#34 consensus near/3 (process* or discuss)
#35 stakeholder*
#36 MeSH descriptor: [Quality Control] this term only
#37 MeSH descriptor: [Total Quality Management] this term only
#38 MeSH descriptor: [Quality Indicators, Health Care] this term only
#39 MeSH descriptor: [Quality Assurance, Health Care] this term only
#40 quality assurance
#41 quality near/2 improv*
#42 total quality
#43 continuous quality
#44 quality management
#45 (organisation* near/3 cultur*)
#46 MeSH descriptor: [Disease Management] this term only
#47 MeSH descriptor: [Program Evaluation] this term only
#48 (provider* or program*) near/3 (monitor* or evaluate* or modif* or practice)
#49 implement* near/3 (improve* or change* or effort* or issue* or impede* or glossary or tool* or innovation* or outcome* or driv*
or examin* or reexamin* or scale* or strateg* or advis* or expert*)
#50 needs near/3 assess*
#51 (education* or learn*) near/5 (continu* or material* or meeting or collaborat*)
#52 MeSH descriptor: [Medical Audit] explode all trees
#53 audit or feedback or compliance or adherence or training or innovation:ti
#54 guideline* near/3 (clinical or practice or implement* or promot*)
#55 MeSH descriptor: [Health Services Accessibility] explode all trees
#56 outreach near/2 (service$ or visit*)
#57 intervention* near/3 (no or usual or routine or target* or tailor* or mediat*)
#58 usual care
#59 #27 or #28 or #29 or #30 or #31 or #32 or #33 or #34 or #35 or #36 or #37 or #38 or #39 or #40 or #41 or #42 or #43 or #44
or #45 or #46 or #47 or #48 or #49 or #50 or #51 or #52 or #53 or #54 or #55 or #56 or #57 or #58
#60 MeSH descriptor: [Reminder Systems] explode all trees
#61 remind*
#62 improve* near/3 (attend* or visit* or intervention* or adhere*)
#63 increas* near/3 (attend* or visit* or intervention* or adhere*)
#64 appointment* near/3 (miss* or fail* or remind* or follow up)
#65 MeSH descriptor: [Telephone] this term only
#66 telephone*
#67 MeSH descriptor: [Cell Phones] this term only
#68 MeSH descriptor: [Mobile Applications] this term only
#69 MeSH descriptor: [Remote Consultation] this term only
#70 m-health or e-health or g-health or u-health
#71 phone* near/1 (smart or cell)
#72 smartphone* or cellphone*
#73 hand held device*
#74 mobile near/2 (health or healthcare or phone* or device* or monitor* or comput* or app or apps or application)
#75 MeSH descriptor: [Internet] this term only
#76 MeSH descriptor: [Social Networking] this term only
#77 email* or text* or message*
#78 letter or mail or mailed or print* or brochure* or newsletter*
#79 #60 or #61 or #62 or #63 or #64 or #65 or #66 or #67 or #68 or #69 or #70 or #71 or #72 or #73 or #74 or #75 or #76 or #77
or #78
#80 MeSH descriptor: [Primary Health Care] this term only
#81 MeSH descriptor: [General Practitioners] this term only
#82 MeSH descriptor: [Physicians, Family] this term only
#83 MeSH descriptor: [Physicians, Primary Care] this term only
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#84 MeSH descriptor: [Primary Prevention] this term only
#85 MeSH descriptor: [Preventive Health Services] this term only
#86 MeSH descriptor: [Community Health Services] this term only
#87 MeSH descriptor: [Nurses, Community Health] this term only
#88 MeSH descriptor: [Health Services, Indigenous] this term only
#89 MeSH descriptor: [Rural Health Services] explode all trees
#90 MeSH descriptor: [Mobile Health Units] this term only
#91 Ophthalmologist* or Optometrist* or Optician* or Orthopist* or Refractionists
#92 (Ophthalmic or eye) near/3 (surgeon* or nurse* or technician* or officer* or assistant* or staff*)
#93 MeSH descriptor: [Physician’s Practice Patterns] this term only
#94 MeSH descriptor: [Professional Practice] this term only
#95 MeSH descriptor: [Education, Medical, Continuing] this term only
#96 MeSH descriptor: [Nurses] explode all trees
#97 MeSH descriptor: [Specialties, Nursing] this term only
#98 MeSH descriptor: [Nurse’s Role] this term only
#99 MeSH descriptor: [Education, Nursing, Continuing] this term only
#100 nurse or nurses
#101 MeSH descriptor: [Pharmacists] this term only
#102 pharmacist*
#103 (role or roles) near/3 expan*
#104 task* near/3 shift*
#105 MeSH descriptor: [Medical Records Systems, Computerized] explode all trees
#106 MeSH descriptor: [Management Information Systems] this term only
#107 MeSH descriptor: [Database Management Systems] this term only
#108 MeSH descriptor: [Computer Systems] this term only
#109 MeSH descriptor: [Point-of-Care Systems] this term only
#110 MeSH descriptor: [Hospital Information Systems] this term only
#111 (health or healthcare) near/4 (record or management system*)
#112 (decision near/5 support) .ti.
#113 #80 or #81 or #82 or #83 or #84 or #85 or #86 or #87 or #88 or #89 or #90 or #91 or #92 or #93 or #94 or #95 or #96 or #97
or #98 or #99 or #100 or #101 or #102 or #103 or #104 or #105 or #106 or #107 or #108 or #109 or #110 or #111 or #112
#114 MeSH descriptor: [Economics] this term only
#115 MeSH descriptor: [Costs and Cost Analysis] this term only
#116 MeSH descriptor: [Cost Allocation] this term only
#117 MeSH descriptor: [Cost-Benefit Analysis] this term only
#118 MeSH descriptor: [Cost Control] this term only
#119 MeSH descriptor: [Cost Savings] this term only
#120 MeSH descriptor: [Cost of Illness] explode all trees
#121 MeSH descriptor: [Cost Sharing] this term only
#122 MeSH descriptor: [Deductibles and Coinsurance] this term only
#123 MeSH descriptor: [Medical Savings Accounts] this term only
#124 MeSH descriptor: [Health Care Costs] this term only
#125 MeSH descriptor: [Direct Service Costs] this term only
#126 MeSH descriptor: [Drug Costs] this term only
#127 MeSH descriptor: [Employer Health Costs] this term only
#128 MeSH descriptor: [Hospital Costs] this term only
#129 MeSH descriptor: [Health Expenditures] this term only
#130 MeSH descriptor: [Capital Expenditures] this term only
#131 MeSH descriptor: [Economics, Hospital] explode all trees
#132 MeSH descriptor: [Economics, Medical] explode all trees
#133 MeSH descriptor: [Economics, Nursing] this term only
#134 MeSH descriptor: [Economics, Pharmaceutical] this term only
#135 MeSH descriptor: [Fees and Charges] explode all trees
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#136 MeSH descriptor: [Budgets] explode all trees
#137 low* near/2 cost*
#138 high* near/2 cost*
#139 (health care or healthcare) near/2 cost*
#140 fiscal or funding or financial or finance
#141 cost near/2 estimate*
#142 cost near/2 variable*
#143 unit near/2 cost*
#144 economic* or pharmacoeconomic* or price* or pricing
#145 MeSH descriptor: [Uncompensated Care] this term only
#146 MeSH descriptor: [Reimbursement Mechanisms] this term only
#147 MeSH descriptor: [Reimbursement, Incentive] this term only
#148 insurance near/3 (health or scheme*)
#149 financial or economic or pay or payment or copayment or paid or fee or fees or monetary or money or cash or incentiv* or
disincentiv*
#150 #114 or #115 or #116 or #117 or #118 or #119 or #120 or #121 or #122 or #123 or #124 or #125 or #126 or #127 or #128 or
#129 or #130 or #131 or #132 or #133 or #134 or #135 or #136 or #137 or #138 or #139 or #140 or #141 or #142 or #143 or #144
or #145 or #146 or #147 or #148 or #149
#151 #59 or #79 or #113 or #150
#152 MeSH descriptor: [Patient Acceptance of Health Care] explode all trees
#153 MeSH descriptor: [Attitude to Health] explode all trees
#154 MeSH descriptor: [Health Behavior] explode all trees
#155 barrier* or obstacle* or facilitat* or enable*
#156 uptake or takeup or attend* or accept* or adhere* or attitude* or participat* or facilitat* or utilisat* or utilizat*
#157 complie* or comply or compliance* or noncompliance* or non compliance*
#158 encourag* or discourage* or reluctan* or nonrespon* or non respon* or refuse* or refusal
#159 non-attend* or non attend* or dropout or drop out or apath*
#160 MeSH descriptor: [Health Education] this term only
#161 MeSH descriptor: [Patient Education as Topic] explode all trees
#162 MeSH descriptor: [Health Promotion] explode all trees
#163 health near/2 (promotion* or knowledge or belief*)
#164 educat* near/2 (intervention* or information or material or leaflet)
#165 MeSH descriptor: [Socioeconomic Factors] this term only
#166 MeSH descriptor: [Poverty] explode all trees
#167 MeSH descriptor: [Social Class] this term only
#168 MeSH descriptor: [Educational Status] this term only
#169 (school or education*) near/3 (status or level* or attain* or achieve*)
#170 MeSH descriptor: [Employment] this term only
#171 MeSH descriptor: [Healthcare Disparities] this term only
#172 MeSH descriptor: [Health Status Disparities] this term only
#173 MeSH descriptor: [Medically Underserved Area] explode all trees
#174 MeSH descriptor: [Rural Population] this term only
#175 MeSH descriptor: [Urban Population] this term only
#176 MeSH descriptor: [Ethnic Groups] explode all trees
#177 MeSH descriptor: [Minority Groups] this term only
#178 MeSH descriptor: [Vulnerable Populations] this term only
#179 (health* or social* or racial* or ethnic*) near/5 (inequalit* or inequit* or disparit* or equit* or disadvantage* or depriv*)
#180 disadvant* or marginali* or underserved or under served or impoverish* or minorit* or racial* or ethnic*
#181 #152 or #153 or #154 or #155 or #156 or #157 or #158 or #159 or #160 or #161 or #162 or #163 or #164 or #165 or #166 or
#167 or #168 or #169 or #170 or #171 or #172 or #173 or #174 or #175 or #176 or #177 or #178 or #179 or #180
#182 #151 or #181
#183 #8 and #26 and #182
#184 (ranibizumab or bevacizumab or avastin or aflibercept or photocoagulation or coronary or cardiovascular):ti
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#185 blood glucose or blood pressure:ti
#186 macula* near/2 (oedema or edema):ti
#187 #184 or #185 or #186
#188 #183 not #187
Appendix 2. MEDLINE Ovid search strategy
1. randomized controlled trial.pt.
2. random$.ab,ti.
3. placebo.ab,ti.
4. dt.fs.
5. trial.ab,ti.
6. (group or groups).ab,ti.
7. or/1-6
8. exp animals/
9. exp humans/
10. 8 not (8 and 9)
11. 7 not 10
12. exp Randomized Controlled Trials as Topic/
13. 11 or 12
14. exp Diabetes Mellitus/
15. exp Diabetes Complications/
16. exp Diabetic Retinopathy/
17. ((diabet$ or proliferative or non-proliferative) adj4 retinopath$).tw.
18. diabetic retinopathy.kw.
19. (diabet$ adj3 (eye$ or vision or visual$ or sight$)).tw.
20. (retinopath$ adj3 (eye$ or vision or visual$ or sight$)).tw.
21. (DR adj3 (eye$ or vision or visual$ or sight$)).tw.
22. or/14-21
23. exp Mass Screening/
24. exp Vision Tests/
25. exp Telemedicine/
26. exp Photography/
27. exp Ophthalmoscopes/
28. exp Ophthalmoscopy/
29. (ophthalmoscop$ or fundoscop$ or funduscop$).ti.
30. ((exam$ or photo$ or imag$) adj3 fundus).tw.
31. (photography or retinography).tw.
32. ((mydriatic or digital or retina$ or fundus or steroscopic) adj3 camera).tw.
33. ((mydriatic or digital or retina$ or fundus or steroscopic) adj3 imag$).tw.
34. screen$.tw.
35. ((eye$ or retina$ or ophthalm$) adj4 exam$).tw.
36. ((eye or vision or retinopathy or ophthalmic) adj4 test$).tw.
37. ((eye$ or retina$ or ophthalm$) adj4 visit$).tw.
38. Office Visits/
39. (telemedicine$ or telemonitor$ or telescreen$ or telehealth or teleophthalmology).tw.
40. or/23-39
41. “Quality of Health Care”/
42. Quality Improvement/
43. Delivery of Health Care/
44. Delivery of Health Care, Integrated/
45. service delivery.tw.
46. decision making.tw.
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47. (consensus adj3 (process$ or discuss)).tw.
48. stakeholder$.tw.
49. Quality Control/
50. Total Quality Management/
51. Quality Indicators, Health Care/
52. Quality Assurance, Health Care/
53. quality assurance.tw.
54. (quality adj2 improv$).tw.
55. total quality.tw.
56. continuous quality.tw.
57. quality management.tw.
58. (organisation$ adj3 cultur$).tw.
59. Disease Management/
60. Program Evaluation/
61. ((provider$ or program$) adj3 (monitor$ or evaluate$ or modif$ or practice)).tw.
62. (implement$ adj3 (improve$ or change$ or effort$ or issue$ or impede$ or glossary or tool$ or innovation$ or outcome$ or driv$
or examin$ or reexamin$ or scale$ or strateg$ or advis$ or expert$)).tw.
63. (need$ adj3 assess$).tw.
64. ((education$ or learn$) adj5 (continu$ or material$ or meeting or collaborat$)).tw.
65. exp Medical audit/
66. (audit or feedback or compliance or adherence or training or innovation).ti.
67. (guideline$ adj3 (clinical or practice or implement$ or promot$)).tw.
68. exp Health Services Accessibility/
69. (outreach adj2 (service$ or visit$)).tw.
70. (intervention$ adj3 (no or usual or routine or target$ or tailor$ or mediat$)).tw.
71. usual care.tw.
72. exp Reminder Systems/
73. remind$.tw.
74. (improve$ adj3 (attend$ or visit$ or intervention$ or adhere$)).tw.
75. (increas$ adj3 (attend$ or visit$ or intervention$ or adhere$)).tw.
76. (appointment$ adj3 (miss$ or fail$ or remind$ or follow up)).tw.
77. Telephone/
78. telephone.tw.
79. Cell Phones/
80. Mobile Applications/
81. Remote Consultation/
82. (m-health or e-health or g-health or u-health).tw.
83. (phone$ adj1 (smart or cell)).tw.
84. (smartphone$ or cellphone$).tw.
85. (hand adj1 held device$).tw.
86. (mobile adj2 (health or healthcare or phone$ or device$ or monitor$ or comput$ or app or apps or application)).tw.
87. Internet/
88. Social Networking/
89. (email$ or text$ or message$).tw.
90. (letter or mail or mailed or print$ or brochure$ or newsletter$).tw.
91. Primary Health Care/
92. General Practitioners/ or Physicians, Family/ or Physicians, Primary Care/
93. Primary Prevention/
94. Preventive Health Services/
95. Community Health Services/
96. Community Health Nursing/
97. Health Services, Indigenous/
98. Rural Health Services/
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99. Mobile Health Units/
100. (Ophthalmologist$ or Optometrist$ or Optician$ or Orthopist$ or Refractionists).tw.
101. ((Ophthalmic or eye) adj3 (surgeon$ or nurse$ or technician$ or officer$ or assistant$ or staff$)).tw.
102. Physician’s Practice Patterns/
103. Professional Practice/
104. (professional adj3 (practice or develop$ or educat)).tw.
105. Education, Medical, Continuing/
106. exp nurses/
107. Specialties, Nursing/
108. Nurse’s Role/
109. Education, Nursing, Continuing/
110. (nurse or nurses).tw.
111. Pharmacists/
112. pharmacist$.tw.
113. ((role or roles) adj3 expan$).tw.
114. (task$ adj3 shift$).tw.
115. exp Medical Records Systems, Computerized/
116. Management Information Systems/
117. Database Management Systems/
118. Computer Systems/
119. Point-of-Care Systems/
120. Hospital Information Systems/
121. ((health or healthcare) adj4 (record or management system$)).tw.
122. (decision adj5 support).ti.
123. Economics/
124. “costs and cost analysis”/
125. Cost allocation/
126. Cost-benefit analysis/
127. Cost control/
128. Cost savings/
129. Cost of illness/
130. Cost sharing/
131. “deductibles and coinsurance”/
132. Medical savings accounts/
133. Health care costs/
134. Direct service costs/
135. Drug costs/
136. Employer health costs/
137. Hospital costs/
138. Health expenditures/
139. Capital expenditures/
140. Value of life/
141. exp economics, hospital/
142. exp economics, medical/
143. Economics, nursing/
144. Economics, pharmaceutical/
145. exp “fees and charges”/
146. exp budgets/
147. (low adj cost).mp.
148. (high adj cost).mp.
149. (health?care adj cost$).mp.
150. (fiscal or funding or financial or finance).tw.
151. (cost adj estimate$).mp.
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152. (cost adj variable).mp.
153. (unit adj cost$).mp.
154. (economic$ or pharmacoeconomic$ or price$ or pricing).tw.
155. Uncompensated Care/
156. Reimbursement Mechanisms/
157. Reimbursement, Incentive/
158. (insurance adj3 (health$ or scheme$)).tw.
159. (financial or economic or pay or payment or copayment or paid or fee or fees or monetary or money or cash or incentiv$ or
disincentiv$).tw.
160. or/41-159
161. exp Patient Acceptance of health Care/
162. exp Attitude to Health/
163. exp Health Behavior/
164. (barrier$ or obstacle$ or facilitat$ or enable$).tw.
165. (uptake or takeup or attend$ or accept$ or adhere$ or attitude$ or participat$ or facilitat$ or utilisat$ or utilizat$).tw.
166. (complie$ or comply or compliance$ or noncompliance$ or non compliance$).tw.
167. (encourag$ or discourage$ or reluctan$ or nonrespon$ or non respon$ or refuse$).tw.
168. (non-attend$ or non attend$ or dropout or drop out or apath$).tw.
169. Health Education/
170. exp Patient Education as Topic/
171. exp Health Promotion/
172. exp Counseling/
173. “Attitude of Health Personnel”/
174. (health adj2 (promotion$ or knowledge or belief$)).tw.
175. (educat$ adj2 (intervention$ or information or material or leaflet)).tw.
176. Socioeconomic Factors/
177. exp Poverty/
178. Social Class/
179. Educational Status/
180. ((school or education$) adj3 (status or level$ or attain$ or achieve$)).tw.
181. Employment/
182. Healthcare Disparities/
183. Health Status Disparities/
184. exp Medically Underserved Area/
185. Rural Population/
186. Urban Population/
187. exp Ethnic Groups/
188. Minority Groups/
189. Vulnerable Populations/
190. ((health$ or social$ or racial$ or ethnic$) adj5 (inequalit$ or inequit$ or disparit$ or equit$ or disadvantage$ or depriv$)).tw.
191. (disadvant$ or marginali$ or underserved or under served or impoverish$ or minorit$ or racial$ or ethnic$).tw.
192. or/161-191
193. 160 or 192
194. 13 and 22 and 40 and 193
195. (ranibizumab or bevacizumab or avastin or aflibercept or photocoagulation or coronary or cardiovascular).ti.
196. (blood glucose or blood pressure).ti.
197. (macula$ adj2 (oedema or edema)).ti.
198. (cataract or intraocular or glaucoma).ti.
199. macula$ degeneration.ti.
200. nerve fiber layer.ti.
201. or/195-200
202. 194 not 201
The search filter for trials at the beginning of the MEDLINE strategy is from the published paper by Glanville 2006.
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Appendix 3. Embase Ovid search strategy
1. exp randomized controlled trial/
2. exp randomization/
3. exp double blind procedure/
4. exp single blind procedure/
5. or/1-4
6. (animal or animal experiment).sh.
7. human.sh.
8. 6 and 7
9. 6 not 8
10. 5 not 9
11. exp clinical trial/
12. (clin$ adj3 trial$).tw.
13. random$.tw.
14. exp placebo/
15. placebo$.tw.
16. ((singl$ or doubl$ or trebl$ or tripl$) adj3 (blind$ or mask$)).tw.
17. exp experimental design/
18. exp crossover procedure/
19. exp control group/
20. exp latin square design/
21. or/11-20
22. 21 not 9
23. 22 not 10
24. exp comparative study/
25. exp evaluation/
26. exp prospective study/
27. (control$ or prospectiv$ or volunteer$).tw.
28. or/24-27
29. 28 not 9
30. 29 not (10 or 22)
31. 10 or 23 or 30
32. “randomized controlled trial (topic)”/
33. 31 or 32
34. exp diabetes mellitus/
35. exp diabetic retinopathy/
36. ((diabet$ or proliferative or non-proliferative) adj4 retinopath$).tw.
37. diabetic retinopathy.kw.
38. (diabet$ adj3 (eye$ or vision or visual$ or sight$)).tw.
39. (retinopath$ adj3 (eye$ or vision or visual$ or sight$)).tw.
40. (DR adj3 (eye$ or vision or visual$ or sight$)).tw.
41. or/34-40
42. exp Screening/
43. exp Vision Test/
44. Eye Examination/
45. Telemedicine/
46. Photography/
47. Eye Photography/
48. Ophthalmoscopy/
49. (ophthalmoscop$ or fundoscop$ or funduscop$).ti.
50. ((exam$ or photo$ or imag$) adj3 fundus).tw.
51. (photography or retinography).tw.
242Interventions to increase attendance for diabetic retinopathy screening (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
52. ((mydriatic or digital or retina$ or fundus or steroscopic) adj3 camera).tw.
53. ((mydriatic or digital or retina$ or fundus or steroscopic) adj3 imag$).tw.
54. screen$.tw.
55. ((eye$ or retina$ or ophthalm$) adj4 exam$).tw.
56. ((eye or vision or retinopathy or ophthalmic) adj4 test$).tw.
57. ((eye$ or retina$ or ophthalm$) adj4 visit$).tw.
58. (telemedicine$ or telemonitor$ or telescreen$ or telehealth or teleophthalmology).tw.
59. or/42-58
60. Health Care Quality/
61. Quality Improvement/
62. Health Care Delivery/
63. Integrated Health Care System/
64. service delivery.tw.
65. decision making.tw.
66. (consensus adj3 (process$ or discuss)).tw.
67. stakeholder$.tw.
68. Quality Control/
69. Total Quality Management/
70. quality assurance.tw.
71. (quality adj2 improv$).tw.
72. total quality.tw.
73. continuous quality.tw.
74. quality management.tw.
75. (organisation$ adj3 cultur$).tw.
76. disease management/
77. program evaluation/
78. ((provider$ or program$) adj3 (monitor$ or evaluate$ or modif$ or practice)).tw.
79. (implement$ adj3 (improve$ or change$ or effort$ or issue$ or impede$ or glossary or tool$ or innovation$ or outcome$ or driv$
or examin$ or reexamin$ or scale$ or strateg$ or advis$ or expert$)).tw.
80. (need$ adj3 assess$).tw.
81. ((education$ or learn$) adj5 (continu$ or material$ or meeting or collaborat$)).tw.
82. Medical audit/
83. (audit or feedback or compliance or adherence or training or innovation).ti.
84. (guideline$ adj3 (clinical or practice or implement$ or promot$)).tw.
85. (outreach adj2 (service$ or visit$)).tw.
86. (intervention$ adj3 (no or usual or routine or target$ or tailor$ or mediat$)).tw.
87. usual care.tw.
88. reminder system/
89. remind$.tw.
90. (improve$ adj3 (attend$ or visit$ or intervention$ or adhere$)).tw.
91. (increas$ adj3 (attend$ or visit$ or intervention$ or adhere$)).tw.
92. (appointment$ adj3 (miss$ or fail$ or remind$ or follow up)).tw.
93. telephone/
94. telephone.tw.
95. Mobile Phone/
96. Mobile Application/
97. Teleconsultation/
98. (m-health or e-health or g-health or u-health).tw.
99. (phone$ adj1 (smart or cell)).tw.
100. (smartphone$ or cellphone$).tw.
101. (hand adj1 held device$).tw.
102. (mobile adj2 (health or healthcare or phone$ or device$ or monitor$ or comput$ or app or apps or application)).tw.
103. Internet/
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104. Social Network/
105. (email$ or text$ or message$).tw.
106. (letter or mail or mailed or print$ or brochure$ or newsletter$).tw.
107. Primary Health Care/
108. General Practitioner/
109. Primary Prevention/
110. Preventive Health Service/
111. Community Care/
112. Community Health Nursing/
113. exp Transcultural Care/
114. Rural Health Care/
115. Ophthalmologist/
116. (Ophthalmologist$ or Optometrist$ or Optician$ or Orthopist$ or Refractionists).tw.
117. ((Ophthalmic or eye) adj3 (surgeon$ or nurse$ or technician$ or officer$ or assistant$ or staff$)).tw.
118. Clinical Practice/
119. Professional Practice/
120. Continuing Education/
121. (professional adj3 (practice or develop$ or educat)).tw.
122. Nurse/
123. Nursing Discipline/
124. Nurse Attitude/
125. Nursing Education/
126. (nurse or nurses).tw.
127. pharmacist/
128. pharmacist$.tw.
129. ((role or roles) adj3 expan$).tw.
130. (task$ adj3 shift$).tw.
131. Electronic Medical Record/
132. Information System/
133. Data Base/
134. Computer System/
135. Hospital Information System/
136. ((health or healthcare) adj4 (record or management system$)).tw.
137. (decision adj5 support).ti.
138. cost benefit analysis/
139. cost effectiveness analysis/
140. cost of illness/
141. cost control/
142. economic aspect/
143. financial management/
144. health care cost/
145. health care financing/
146. health economics/
147. hospital cost/
148. (fiscal or financial or finance or funding).tw.
149. cost minimization analysis/
150. (cost adj estimate$).mp.
151. (cost adj variable$).mp.
152. (unit adj cost$).mp.
153. (economic$ or pharmacoeconomic$ or price$ or pricing).tw.
154. exp Reimbursement/
155. (financial or economic or pay or payment or copayment or paid or fee or fees or monetary or money or cash or incentiv$ or
disincentiv$).tw.
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156. (insurance adj3 (health$ or scheme$)).tw.
157. or/60-156
158. exp Patient Attitude/
159. exp Health Behaviour/
160. (barrier$ or obstacle$ or facilitat$ or enable$).tw.
161. (uptake or takeup or attend$ or accept$ or adhere$ or attitude$ or participat$ or facilitat$ or utilisat$ or utilizat$).tw.
162. (complie$ or comply or compliance$ or noncompliance$ or non compliance$).tw.
163. (encourag$ or discourage$ or reluctan$ or nonrespon$ or non respons$ or refuse$).tw.
164. (non-attend$ or non attend$ or dropout or drop out or apath$).tw.
165. Health Education/
166. exp Patient Education/
167. Diabetes Education/
168. Help Seeking Behavior/
169. Patient Participation/
170. Patient Decision Making/
171. exp Health Promotion/
172. (health adj2 (promotion$ or knowledge or belief$)).tw.
173. (educat$ adj2 (intervention$ or information or material or leaflet)).tw.
174. exp Socioeconomics/
175. Income/
176. Social Class/
177. Social Status/
178. Educational Status/
179. ((school or education$) adj3 (status or level$ or attain$ or achieve$)).tw.
180. Employment/
181. Health Care Disparity/
182. Health Disparity/
183. Rural Population/
184. Rural Area/
185. Urban Population/
186. Urban Area/
187. exp Ethnic Group/
188. Ethnicity/
189. Race Difference/
190. Minority Groups/
191. Vulnerable Populations/
192. ((health$ or social$ or racial$ or ethnic$) adj5 (inequalit$ or inequit$ or disparit$ or equit$ or disadvantage$ or depriv$)).tw.
193. (disadvant$ or marginali$ or underserved or under served or impoverish$ or minorit$ or racial$ or ethnic$).tw.
194. or/158-193
195. 157 or 194
196. 33 and 41 and 59 and 195
197. (ranibizumab or bevacizumab or avastin or aflibercept or photocoagulation or coronary or cardiovascular).ti.
198. (blood glucose or blood pressure).ti.
199. (macula$ adj2 (oedema or edema)).ti.
200. (cataract or intraocular or glaucoma).ti.
201. macula$ degeneration.ti.
202. nerve fiber layer.ti.
203. or/197-202
204. 196 not 203
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Appendix 4. PsychINFO search strategy
1. exp Treatment Effectiveness Evaluation/
2. exp Clinical Trials/
3. exp Placebo/
4. placebo$.tw.
5. randomly.tw.
6. randomi#ed.tw.
7. trial$.tw.
8. ((singl$ or doubl$ or trebl$ or tripl$) adj3 (blind$ or mask$ or dummy)).tw.
9. (factorial$ or allocat$ or assign$ or volunteer$).tw.
10. (crossover$ or cross over$).tw.
11. (quasi adj (experimental or random$)).tw.
12. (control$ adj3 (trial$ or study or studies or group$)).tw.
13. or/1-12
14. diabetes/
15. ((diabet$ or proliferative or non-proliferative) adj4 retinopath$).tw.
16. (diabet$ adj3 (eye$ or vision or visual$ or sight$)).tw.
17. (retinopath$ adj3 (eye$ or vision or visual$ or sight$)).tw.
18. (DR adj3 (eye$ or vision or visual$ or sight$)).tw.
19. or/14-18
20. exp Screening/
21. ophthalmologic examination/
22. telemedicine/
23. (ophthalmoscop$ or fundoscop$ or funduscop$).ti.
24. ((exam$ or photo$ or imag$) adj3 fundus).tw.
25. (photography or retinography).tw.
26. ((mydriatic or digital or retina$ or fundus or steroscopic) adj3 camera).tw.
27. ((mydriatic or digital or retina$ or fundus or steroscopic) adj3 imag$).tw.
28. screen$.tw.
29. ((eye$ or retina$ or ophthalm$) adj4 exam$).tw.
30. ((eye or vision or retinopathy or ophthalmic) adj4 test$).tw.
31. ((eye$ or retina$ or ophthalm$) adj4 visit$).tw.
32. (telemedicine$ or telemonitor$ or telescreen$ or telehealth or teleophthalmology).tw.
33. or/20-32
34. 13 and 19 and 33
Appendix 5. CPCI-S and ESCI search strategy
#11 #10 AND #2 AND #1
#10 #9 OR #8 OR #7 OR #6 OR #5 OR #4 OR #3
#9 TS = (photography OR retinography OR telemedicine* OR telemonitor* OR telescreen* OR telehealth OR teleophthalmology)
#8 TS = (fundus NEAR/3 exam* OR fundus NEAR/3 photo* OR fundus NEAR/3 imag*)
#7 TS = (imag* NEAR/3 mydriatic OR imag* NEAR/3 digital OR imag* NEAR/3 retina* OR imag* NEAR/3 fundus OR imag*
NEAR/3 steroscopic OR camera NEAR/3 mydriatic OR camera NEAR/3 digital OR camera NEAR/3 retina* OR camera NEAR/3
fundus OR camera NEAR/3 steroscopic)
#6 TI = (ophthalmoscop* OR fundoscop* OR funduscop*)
#5 TS = (visit NEAR/4 eye* OR visit NEAR/4 retina* OR visit NEAR/4 ophthalmic)
#4 TS = (exam* NEAR/4 eye* OR exam* NEAR/4 retina* OR exam* NEAR/4 ophthalmic)
#3 TS = (screen* OR test* NEAR/4 eye OR test* NEAR/4 vision OR test* NEAR/4 retinopathy OR test* NEAR/4 ophthalmic)
#2 TS = (diabetic NEAR/3 retinopath* OR diabetic NEAR/3 eye* OR diabetic NEAR/3 vision OR diabetic NEAR/3 visual* OR
diabetic NEAR/3 sight* OR diabetic NEAR/3 proliferative OR diabetic NEAR/3 “non proliferative”)
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#1 TS =(clinical trial* OR research design OR comparative stud* OR evaluation stud* OR controlled trial* OR follow-up stud* OR
prospective stud* OR random* OR placebo* OR single blind* OR double blind*)
Appendix 6. ProQuest Family Health search strategy
ab(diabetic AND(retinopathyOReyeORvisionORvisualOR sight)) ANDab(screenORscreeningOR testORexamORexamination
OR telemedicine ) AND ab(random OR randomly OR randomised OR randomized )
Appendix 7. OpenGrey search strategy
(screen OR test OR exam OR Ophthalmoscopy OR digital OR imaging OR fundus OR telemedicine OR telemonitor OR telescreen
OR telehealth) AND diabetic retinopathy
Appendix 8. ISRCTN search strategy
(screen OR test OR exam OR ophthalmoscopy OR digital OR imaging OR fundus OR telemedicine OR telemonitor OR telescreen
OR telehealth) within Condition: diabetic retinopathy
Appendix 9. ClinicalTrials.gov search strategy
(screen OR test OR exam OR Ophthalmoscopy OR digital OR imaging OR fundus OR telemedicine OR telemonitor OR telescreen
OR telehealth) | Interventional Studies | diabetic retinopathy
Appendix 10. WHO ICTRP search strategy
Condition = diabetic retinopathy AND Intervention = screen OR test OR exam OR Ophthalmoscopy OR digital OR imaging OR
fundus OR telemedicine OR telemonitor OR telescreen OR telehealth
C O N T R I B U T I O N S O F A U T H O R S
Protocol
All author were involved in the development of the protocol for this review.
Review
JGL and JB screened titles and abstracts.
JGL and EGR extracted data and performed ’risk of bias assessments’.
EGR, FL and JF performed BCT coding.
SR designed and developed the algorithm for resource requirement.
PA conducted the economic evaluation review (with input from LV).
JGL inputted data into Revman. CB checked the data.
CB conducted the statistical analysis (checked by JGL).
JGL produced the first draft of the review and all authors reviewed and commented on the draft.
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
In addition to the prespecified covariates for metaregression we also investigated the effect of study design (individual versus cluster-
RCT) and risk of bias (high versus low). We had originally planned to conduct a sensitivity analysis to compare studies of high versus
low risk of bias.
Only nine of the 30 included cluster-trials reported an ICC. The most commonly-reported value was imputed for studies with no
estimates of ICCs. We therefore conducted an unplanned sensitivity analysis to investigate the impact on the pooled effect estimate of
using the lower and upper range values.
The checklists used for the economic analysis differed from those that were originally stated in our published Cochrane protocol, due
to the recent updates of the methods for the incorporation of economic evidence into Cochrane Intervention Reviews. See Table 4 and
Table 5 for the completed CHEERS and CHEC checklists for each included economic evaluation.
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